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Abstract 
Background 
Abnormal burn scarring can cause physical and psychological distress to children and their 
families. Silicone and pressure garment therapy are common burn scar interventions, used 
either alone or in combination. However, no definitive high quality evidence is available 
regarding these interventions for paediatric burn scar management. Existing evidence 
regarding pressure garment therapy effectiveness is confounded by the unknown level of 
pressure supplied by the pressure garment to the burn scar. 
 
Thesis aim 
The overarching aim of this thesis was to determine the effectiveness of silicone and 
pressure garment therapy for the prevention and management of post-burn scarring in 
children. This comprised of two sub-aims, to determine the: (1) interface pressure in 
paediatric pressure garment therapy; (2) effectiveness of silicone versus pressure garment 
therapy for preventing and managing paediatric post-burn scarring.  
 
Methodology  
Aim one was achieved via a pilot longitudinal cohort study. Aim two was addressed via a 
systematic review and randomised controlled trial (RCT). The study methods and results 
are presented in the order they will appear in the thesis. 
 
Systematic review 
Searches of six electronic databases, grey literature and hand searches of relevant journals 
were completed. Eligible studies included RCT’s if they assessed the effectiveness of 
silicone and pressure garment therapy (alone or combined) for preventing and managing 
post-burn scarring in children and adults. Risk of bias was determined using the Cochrane 
risk of bias tool and Grading of Recommendations Assessment, Development and 
Evaluation. Meta-analyses were completed. The protocol was registered in PROSPERO. 
 
Pilot longitudinal cohort study  
A pilot longitudinal cohort study was completed with children aged less than 18 years 
receiving pressure garment therapy post-burn. Test-retest reliability of the Pliance X was 
investigated at baseline and analysed using an Intra-Class Correlation Coefficient (ICC). 
Clinical utility was evaluated at baseline using criteria of appropriate, accessible, practicable 
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and acceptable. Interface pressure was measured at first pressure garment fitting, one and 
three months post fitting and analysed using Linear Mixed Models.  
 
Randomised controlled trial:  
An RCT was completed with participants (0-18 years) referred for scar management after a 
new burn or following burn scar reconstruction surgery. Participants were randomised to: (1) 
topical silicone gel only, (2) pressure garment therapy only, or (3) topical silicone gel plus 
pressure garment therapy. Primary outcomes included scar thickness and scar itch intensity. 
Secondary outcomes included health-related quality of life (HRQoL), scar severity, 
adherence, adverse effects and treatment satisfaction. Outcomes were measured on up to 
two scar sites per person at baseline, one week post scar management commencement, 
three and six months post-burn or reconstruction surgery. Data were analysed using 
descriptive statistics and mixed effects regression.  
 
Results 
Systematic review 
Sixteen papers were included. Unclear to high risk of bias was identified for all risk of bias 
categories except random sequence generation. There was insufficient data to enable meta-
analysis of primary outcomes for silicone product or combined intervention investigations. 
Meta-analysis for pressure garment therapy (high vs low interface pressure) identified a 
reduction in scar thickness at one and two months post-intervention commencement, SMD 
(95% CI)=-0.54 (-0.89, -0.18) and -0.62 (-1.12, -0.12) respectively.  
 
Pilot longitudinal cohort study 
Thirty-four children were recruited. Participants had a median (IQR) age of three (1.5, 7.5) 
years and 61% were male. Stationary test-retest reliability of the Pliance X was acceptable 
for research use (ICC=0.87, n=27). Pliance X was appropriate and acceptable for children 
who were not distressed. At first garment fitting, 32% of stationary and 25% of dynamic 
measurements were within 15 to 25mmHg. Pressure variations were recorded at one and 
three months with scar location (MD (95%CI)=8.06 (0.99, 15.13), p=0.03) and %TBSA (MD 
(95%CI)=12.46 (3.85, 21.06), p=0.01) identified as predictors of stationary interface 
pressure.  
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Randomised controlled trial 
Participants (n=153) had a median (IQR) age of 4.86 (1.62, 10.17) years, a median (IQR) 
%TBSA of 1% (0.5, 3) and 64.7% of participants were male. At six months post-burn injury, 
the topical silicone gel alone group had thinner scars when compared to the combined 
intervention group, MD (95%CI)=-0.04 (-0.07, -0.00) (p=0.05). There were less adverse 
effects in the topical silicone gel alone group than the pressure garment therapy alone group 
(MD (95% CI)=-1.36 (-2.66, -0.06), p=0.04). No statistically significant differences were 
identified between the intervention groups for scar itch intensity, scar severity, or HRQoL 
(p>0.05). Treatment satisfaction and adherence were greater when interventions were used 
alone. 
 
Discussion and clinical implications 
A clinically useful and reliable interface pressure measuring device has been identified and 
recommended for use in paediatric post-burn pressure garment therapy fit and review. A 
combined intervention approach (topical silicone gel plus pressure garment therapy) was no 
more effective than individual interventions for preventing and managing paediatric post-
burn scarring. If further research supports these findings, topical silicone gel or pressure 
garment therapy alone can be recommended considering health professional experience 
and family preference.  
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CHAPTER 1  Introduction 
 
The prevention and management of abnormal burn scarring poses a burden to patients and 
to health care services around the globe [1-3]. Physical and cosmetic changes to the skin 
have functional and psychosocial implications for the person impacting on their emotional, 
physical, cognitive and social functioning and thus their engagement in valued occupations 
[4,5]. Non-invasive burn scar prevention and management has involved silicone and 
pressure garment therapy for approximately forty years [6-8]. The goal of these interventions 
is to minimise the development and impact of abnormal burn scarring on the person’s health-
related quality of life [6,9-13]. Despite the wide spread use of silicone and pressure garment 
therapy and anecdotal reports of their success, evidence of the effectiveness of these 
interventions in preventing and managing the physical and sensory symptoms of post-burn 
scarring remains unclear. The impact of the intervention on the health-related quality of life 
of children over the course of scar management, the percentage of children adhering to their 
prescribed scar management intervention, the burden of these interventions on paediatric 
patients and their families, and health professionals and caregivers’ satisfaction with 
prescribed scar interventions has rarely been measured.  
 
The overarching aim of this research was therefore to use a broad evaluative framework to 
determine the effectiveness of silicone and pressure garment therapy for the prevention and 
management of physical and sensory symptoms of post-burn scarring in children. The aim 
was achieved through the completion of three studies. Firstly, a systematic review was 
completed to evaluate the current evidence regarding silicone and pressure garment 
therapy. Secondly, a pilot longitudinal cohort study investigating (a) the reliability and clinical 
utility of the Pliance X® device and (b) the pressure (mmHg) supplied by the pressure 
garment at the interface of the pressure garment and burn scar was conducted. Thirdly, a 
randomised controlled trial comparing the effectiveness of topical silicone gel and pressure 
garment therapy in preventing and managing the primary outcomes of scar thickness and 
itch intensity was conducted with children with burns.  
 
The above aim is addressed in this thesis over seven chapters. Chapter Two provides an 
overview of the current state of the literature in regards to abnormal burn scar 
pathophysiology and the trajectory of abnormal burn scarring. The types of assessment of 
abnormal burn scarring and background information for silicone and pressure garment 
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therapy interventions are also described. Chapter Three provides greater insight into the 
interventions assessed during this thesis. The chapter includes an in depth analysis of the 
effectiveness of silicone and pressure garment therapy post-burn in the form of a systematic 
review. To allow a comprehensive assessment of intervention effectiveness, studies 
involving adults and children were included in the systematic review despite the paediatric 
focus of this thesis. The implications of using adult data for paediatric clinical care will be 
discussed in later chapters. Chapter Four is divided into two sections to address both aims 
of the pilot longitudinal cohort study. In Part A, the psychometric properties of the Pliance 
X® were investigated and reported on to support the device’s use as an outcome measure 
in the randomised controlled trial presented in the following chapters. Part B of the chapter 
presents the results of the interface pressure assessment. As such, Chapter Four comprises 
two publications: the reliability and clinical utility of the Pliance X® and the variability of 
pressure at the interface of pressure garments and burn scars in children. Chapter Five is 
also derived from a publication. The publication is the study protocol describing in depth 
methodology for the randomised controlled trial, the results of which are presented in 
Chapter Six (submitted manuscript). Finally, Chapter Seven is a detailed review of the work 
completed during this candidature including a discussion of what the results mean for 
children living with, or at risk of, post-burn scarring.  
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CHAPTER 2  Literature Review 
2.1 Chapter foreword 
The literature review presented in this chapter provides an overview of burn injuries, the 
healing process and considerations for scar management interventions to provide context 
for the burn recovery journey. A brief review of burn epidemiology and burn wound healing 
processes provides background to the complex, and not well understood, pathophysiology 
of abnormal burn scar development. The burn scar trajectory and impact on the health-
related quality of life of the person with a burn injury and methods for assessing post-burn 
scarring is then reviewed. The burn scar trajectory and assessment process provides 
context for the current theories regarding the mechanism of action of silicone products and 
pressure garment therapy for the prevention and management of abnormal post-burn 
scarring. A brief presentation of the effectiveness of pressure garment therapy and silicone 
products then follows.  
 
  
4 
 
2.2 Epidemiology of burn injuries 
Burn injuries are an international healthcare concern ranking as one of the top fifteen leading 
causes of disease burden across the world and are the fifth most common cause of non-
fatal paediatric injury [14-16]. Paediatric burn injuries are typically scald, contact or flame 
injuries with 153 per 100 000 children under 15 years of age experiencing a total body 
surface area (%TBSA) burn of less than 20% [15,17]. A global reduction in burn incidence, 
severity, mortality and length of hospital stay has been reported since the 1980’s [18]. 
However, the burden of post-burn scarring remains and is considered to be the greatest 
challenge of today’s burn care [19].  
 
2.3 Burn wound healing  
A burn is an injury to the skin and other tissues typically due to scald, contact, flame, friction, 
chemical or electrical injuries [16]. Burn injuries are traditionally classified according to the 
depth and the percentage of the total body surface area burned (% TBSA) [20]. After 
damage to the skin, the wound undergoes four stages of healing: haemostasis, 
inflammation, proliferation and maturation [19,21].  
 
Haemostasis involves the initiation of the coagulation and complement cascade to form a 
haemostatic fibrin clot [21-23], thus creating a scaffold for wound repair [19]. The 
inflammatory stage is then enabled through the cytokine recruitment of neutrophils, 
macrophages, epithelial cells, mast cells, endothelial cells and fibroblasts into the affected 
area to restore the skin barrier [21-23]. Proliferation involves the formation of granulation 
tissue (a mix of collagen and extracellular matrix) and requires a delicate balance of extra-
cellular matrix biosynthesis and degradation [21-23]. Breakdown of the extra-cellular matrix 
is performed by collagenase, proteoglycans and other proteases released by the cells of the 
inflammation stage [21-23]. The tensile strength of the scar is increased during the 
maturation stage when immature type III collagen fibres are remodelled into mature type I 
fibres [19]. The process of successful wound healing leads to a normotrophic scar because 
the skin rapidly acts to close the wound rather than regenerate new skin [21,23-25]. A 
normotrophic scar is similar to normal skin (i.e. thin and pliable, with a comparable colour) 
[25,26]. In comparison, abnormal scarring occurs when there is a breakdown in one or more 
of the wound healing stages [21-23].  
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2.4 Abnormal burn scar development and risk factors 
Abnormal burn scarring can be hypertrophic, atrophic, contracted [25] or pigmented. 
Approximately 30 to 75% of people experience hypertrophic scarring after a burn [6,27], with 
this range likely due to differences in characterising hypertrophic scar in research 
investigations. Hypertrophic scarring has recently been characterised as a scar with a height 
score greater than or equal to one on the Vancouver Scar Scale (VSS) using visual 
inspection of the scar [28], where a score of one indicates a scar height of 0 to 2mm above 
the skin surface [29]. Additional features of hypertrophic scarring commonly include 
increased itch and changes in texture, pliability, vascularity and pigmentation [12,22,23]. 
The term ‘abnormal scarring’ is used in this thesis as a broad term that includes physical 
and sensory scar characteristics impacting the emotional, physical, cognitive and social 
functioning of the person [4].  
 
It is hypothesised that a person will develop abnormal scarring if there is increased tension 
within the wound and if inflammatory cells (primarily fibroblasts) are maintained in a 
hyperactive state [19,21-23,30,31]. When increased tension is experienced within a wound, 
such as at wound edges and across joints, the mechanotransduction pathway is initiated, 
sustaining the activation of fibroblasts, keratinocytes and T-cell cytokines [30,31]. As a 
result, the inflammatory stage of wound healing is prolonged [32]. Hyperactive inflammatory 
cells, activation of the deep dermal fibroblasts and an increase in the level of T-helper 2 cells 
(compared to T-helper 1), increases the volume of profibrotic cytokines and collagen whilst 
synthesising low levels of collagenase, which in turn increases fibrotic gene expression 
[19,21-23,32]. Consequently, an imbalance occurs during the proliferation stage with 
increased synthesis, and reduced breakdown and remodelling of the extra-cellular matrix 
[21-23]. Dysregulation of the extra-cellular matrix impairs the maturation stage due to the 
resulting overproduction of immature type III collagen fibres that orient in bundles parallel to 
the epidermis [19,24].  
 
A number of potential risk factors that interrupt the normal wound healing process and 
contribute to subsequent abnormal scar development have been investigated. In a 
longitudinal study in the Netherlands (n=474, 61% male, mean age=1.8 to 45.6 years) 
%TBSA and wound depth were identified as significant predictors of scarring [33]. Higher 
%TBSA burns and deeper burns resulted in worse scarring measured using a mean score 
on a measure of scar severity (patient and observer versions of the Patient and Observer 
Scar Assessment Scale (POSAS)) [33]. There were no differences between children (less 
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than 18 years) and adults and age was not a significant predictor of scarring [33]. Contrary 
to this, a 2016 review of the literature (n=11 studies) identified younger age (between 11 
and 30 years) as having a negative association with scarring (i.e. those of younger age were 
more likely to develop hypertrophic scarring compared to the elderly) [24]. Age was 
supported as a risk factor in a 2012 systematic review [27] (n=48 articles) that found female 
gender, young age (unspecified), time to wound healing, multiple surgical procedures 
(unspecified number), grafting, burn severity and burn mechanism were predictors of burn 
scar severity. However, a lack of methodological rigour in included studies was reported 
[27].  
 
According to a retrospective chart review (n=703) additional risk factors include time to 
wound healing greater than six weeks, full thickness burn injuries greater than 56% TBSA 
and more than four surgical procedures [34]. Surgical procedures was supported as a risk 
factor in a 2008 retrospective study where an increased risk of scarring was reported with 
an odds ratio of 2.2 (95% CI 1.73-2.56) for every surgical procedure completed [25]. In 
comparison, a prospective case control study completed with adults (n=616, male=65%) 
[35] identified age (less than 30 years), Fitzpatrick skin type (types IV-VI), body location 
(head/ neck), mechanism of burn (flame), length of hospital stay (beyond 14 days), and 
surgery (as an indicator of wound depth) as risk factors for developing raised scarring. An 
additional retrospective analysis of prospectively collected data (n=295, age=34 years, 
male=70%) identified an increased rate of scarring of 0.11 on the modified Vancouver Scar 
Scale (mVSS) for every additional day the burn wound took to heal within the first 21 days 
[36]. The trend continued after day 21 though the rate of scarring slowed (0.02 points on the 
mVSS/day) [36]. In a paediatric cohort (n=186, age=5.3 years, male=58.1%) %TBSA, re-
epithelialisation time longer than 14 days, and multiple surgical procedures increased the 
risk of a raised scar [37]. In summary, younger age, location of the scar, skin type/ethnicity, 
larger %TBSA, deeper burn wounds, increased time to wound healing, and an increased 
number of surgical procedures are likely to increase the risk of abnormal scarring. 
 
2.5 Scar trajectory 
Results from three longitudinal studies have been able to determine the typical trajectory of 
abnormal burn scarring [33,38,39]. The first study used POSAS assessment (patient and 
observer) of grafted full thickness wounds treated with silicones or pressure garment therapy 
(n=474, male=61%, mean (SD) age=21.5 (12.0) years) [33]. The second study completed 
objective assessment of skin grafted sites treated with pressure garment therapy and 
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moisturiser (n=46, male=87%, mean (SD) age=41.2 (13.5) years, Fitzpatrick skin type II-
IV=83%) [38]. The third study assessed the burn scars of people (n=34, predominantly male) 
living in China receiving early (≤ 60 days post-burn, mean age (SE)=34.88 (2.82) years) or 
late (˃61 days post-burn, mean age (SE)=42.18 (3.32) years) pressure garment therapy 
using a modified VSS and objective devices [39]. 
 
It has been well documented that abnormal burn scars will experience a period of increased 
scar activity before beginning to resolve due to natural remodelling of the extracellular matrix 
[21,33,38,40]. Scar thickness is the primary characteristic used to differentiate between 
normal scar and skin from abnormal scars [40]. Scar thickness appears to increase in the 
first three months post-burn, despite scar management interventions [33,38]. One study 
reported a significant reduction in the objective assessment of thickness between three and 
six (p<0.0001) and six and twelve months post burn (p<0.0001) [38]. However, scar 
thickness did not return to the thickness of normal skin within that period [38]. A study using 
the POSAS [33] reported a statistically significant increase in thickness between three and 
twelve months and six and twelve months post burn (p≤0.001). A significant reduction was 
not seen until 12 months post-burn (p≤0.001) [33]. The third study highlighted the 
importance of early intervention (≤ 60 days post-burn vs. ˃61 days post-burn) for the 
management of scar thickness [39]. When pressure garment therapy was initiated within 
two months of the burn injury a reduction in thickness (p<0.05) was observed after six 
months of intervention (approximately 8 months post burn injury) [39]. 
 
Itch is also a common and prolonged symptom in abnormal post-burn scarring. Up to 80% 
of people living with burn scarring have reported persistent itch for at least three months 
post-burn and 67% of people have reported itch up to twenty-four months post-burn [40-43]. 
One study [33] reported a significant reduction in itch between three and twelve months 
post-burn injury (p≤0.001). In the Asian sample [39], itch in the early and late intervention 
groups significantly reduced after the completion of pressure garment therapy (p<0.01). Itch 
scores were significantly less in the early intervention groups compared to the late 
intervention group at all-time points (p<0.05) [39]. 
 
An increase in erythema and vascularity outcomes up until three months post-burn has been 
observed. At three to six months post-burn one sample reported stable results [38] and 
another reported signs of reducing erythema [33]. Both studies indicated a reduction in 
erythema/vascularity between six and twelve months post burn [33,38]. This differed to the 
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Asian sample [39]. The authors noted an improvement in erythema one month after scar 
management commencement (approximately two months post-burn) with continued 
improvement until six months post-intervention commencement (approximately eight 
months post-burn) [39]. Pigmentation, vascularity and pliability as measured by the VSS 
also significantly improved (p<0.01) after six months of intervention [39]. In comparison, 
improvements in all scar characteristics excluding pigmentation and relief have been 
reported between six and twelve months post-burn in a predominantly Caucasian sample 
[33,38].  
 
2.6 Impact of abnormal post-burn scarring 
Abnormal burn scarring can effect the physical, emotional, cognitive and social functioning 
of the person [44]. It is theorised that abnormal burn scarring can impact a person’s health-
related quality of life due to physical and sensory symptoms of the burn scar as well as the 
burden of burn scar interventions. Physical and sensory symptoms of the burn scar include 
itch, pain, sensitivity, raising of the scar, stretchability, contracture formation, hydration, 
fragility, and textural and colour differences [4,6,7,21,23,44-46]. Physical symptoms such as 
contracture can reduce the functional ability of the person. Sensory symptoms can include 
altered sensations, pain and itch [4,44,45]. Sensory symptoms (including the scratching that 
defines itch) can lead to additional medical needs if the skin is damaged, as well as affecting 
the person’s sleep, psychosocial functioning, and ability to participate in activities of daily 
living [41-43,47,48]. Disruptions to emotional, cognitive and social functioning due to post-
traumatic stress, feelings of anxiety [49], depression and dissatisfaction with scar 
appearance [50] further hamper engagement in previously valued occupational roles 
[50,51]. A unique consideration for paediatric post-burn scarring is the changing impact of 
the burn scar on the child’s life as they grow. For example, physical functioning may decline 
in response to physical growth of the child and consequent development of scar contracture.  
 
2.7 Assessment of abnormal post-burn scarring 
Accurate, valid and reproducible scar assessments can determine the effectiveness of burn 
scar interventions [3,52]. Subjective and objective measurements assess physical scar 
characteristics (such as thickness) whereas patient reported outcome measurements 
(PROMs) ensure the person’s lived experiences are included in the assessment process [5]. 
Due to changes in each scar characteristic at different times throughout the maturation 
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process (and consequent impact on the person), it has been recommended that a 
combination of assessment types be used to evaluate burn scarring [3].  
 
When selecting a scar assessment for an evaluative purpose, consideration should be given 
to the test-retest reliability of the assessment, reproducibility and responsiveness of the 
assessment as well as methods of scar selection and relocation [3,52]. The assessments 
used in the studies of this thesis have acceptable reliability and assess the area of scarring 
deemed the worst by the family. Efforts were made to promote accurate scar relocation 
including body location measurements, and identifying and recording anatomical landmarks. 
Details of the subjective, objective and PROMs used in this project and the processes 
followed for scar relocation are discussed in the respective methodology sections of 
Chapters Four, Five and Six. 
 
2.7.1 Additional considerations for assessing intervention effectiveness 
In the context of scar assessment for intervention effectiveness, there are additional 
considerations in the assessment process. Before an intervention can be deemed effective 
or ineffective it is necessary to determine: what intervention was delivered (materials and 
procedure); the dose of the intervention; who delivered the intervention; if the intervention is 
being used; and if it is being used as recommended [53]. Thus, participant adherence and 
health professional fidelity can influence the effectiveness of an intervention. 
 
Adherence is the concept that defines how closely a person’s behaviours correspond to the 
recommendation of their healthcare provider and can be viewed on a continuum [54]. The 
complexity and frequency of treatment, the convenience of the treatment and its ability to fit 
in with the daily routine of the person can contribute to adherence [55,56]. In addition, the 
person’s belief of treatment efficacy and satisfaction with the intervention can further 
influence adherence [54-56]. One study of parent’s experiences of burn scar interventions 
for their children (18 mothers, seven fathers, children aged one to nine years) identified that 
a balance between clinical care requirements and what fits best with the daily routines of 
the family is required [56]. Increased knowledge of the intervention and confidence in 
completing the intervention was also found to maintain adherence to scar management 
interventions such as pressure garment therapy, silicone, massage and splinting [56].  
 
In conjunction with patient adherence, therapist fidelity is an important component of 
standardising an intervention across all groups in a randomised controlled trial. Intervention 
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fidelity considers whether an intervention is provided or implemented as it was intended [57]. 
It includes fidelity to the interventions structure and processes [58]. Fidelity enables changes 
observed between the groups to be attributed to the intervention and not changes in the 
method or type of education provided to participants [57-59].  
  
2.8 Non-invasive scar intervention  
Prevention of abnormal scarring after a burn injury is the first priority of scar management 
[60]. Hydration and sun protection should be considered for all burn wounds to prevent 
hyperpigmentation secondary to ultraviolet exposure [60]. Non-invasive scar prevention and 
management interventions include silicone products, pressure garment therapy, massage 
therapy, exercise, and ultrasound [12]. The effectiveness of these interventions and their 
mechanisms of action remain unclear. However, there is increasing evidence to suggest 
that current non-invasive scar management interventions utilise the mechanotransduction 
process (influencing biochemical signals through mechanical forces) occurring within the 
scar cells [30-32]. This thesis focuses on silicone and pressure garment therapy as they are 
commonly used in burn centres worldwide [12]. 
 
2.8.1 Silicone products 
Silicone was first initiated as a scar management therapy by Perkins in the 1980s [61] and 
can take many forms: gel sheeting, ointments, topical gels or sprays. These silicone 
products have a similar chemical basis with a silica backbone and SiOC organic chains 
attached to a silicon atom via silicon carbon bonds [62]. The mechanism of action of silicone 
products to prevent and manage post-burn scarring has not been confirmed [11,63-65]. 
Hypotheses have included static electricity, application of pressure to the scar, increased 
perfusion to the scar and increased temperature [11,64,65]. However, these hypotheses 
have mostly been discarded. Persisting as a possible mechanism of action is the hypothesis 
that silicone molecules leach into the surrounding skin and scar tissue, directly exposing 
fibroblasts to silicone molecules [66,67]. However, there have been studies both supporting 
and refuting this hypothesis [66,68,69]. 
 
It is currently hypothesised that the silicone product forms a semi-occlusive barrier on the 
skin preventing the increased trans-epidermal water loss that occurs in post-burn scarring 
[61,62,70,71]. Hydration of the stratum corneum then increases, mimicking that of a mature 
scar and restoring homeostasis. Once homeostasis is achieved (or mimicked), epidermal 
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proliferation, activation of keratinocytes and collagen synthesis can be limited, allowing 
cellular processes to return to normal [61,70,71]. It is also postulated that silicone products 
work by reducing tension at the border of the scar and normal skin thus reducing mechanical 
input and neurogenic inflammation [32]. 
 
Over-hydration to the scar area and surrounding healthy tissue (i.e. more fluid retention than 
trans-epidermal water loss) is believed to lead to the adverse effects often reported during 
silicone use [9,61,63,70,72]. Skin maceration, odour, rash and pruritus have been reported 
as complications of silicone product use. Greater rates of adverse effects have been 
recorded in the paediatric cohort [62]. Topical silicone gels, in comparison to silicone gel 
sheeting, have been reported to result in reduced frequency and severity of adverse effects 
[63,72]. It can be postulated that topical silicone gels have lower levels of occlusion and 
increased permeability compared to silicone gel sheeting thus reducing the risk of over-
hydration. It is believed that adverse effects can be managed with graded wearing times and 
strict hygiene protocols [62]. 
 
In 2015 despite acknowledgement that the current evidence in this field is inconclusive and 
methodologically flawed, practice guidelines were developed for the use of silicone with 
people after a burn [72]. Broader literature outside of the burns population was used to assist 
with development of the guidelines. Recommendations included: (1) silicone products 
should be used with patients at a high risk of developing hypertrophic scarring, (2) silicone 
products should be used as a preventative measure and with immature scars, and (3) topical 
silicone gels are the preferred silicone product as they are less likely to result in adverse 
effects [72].   
 
Studies over the past two decades [10,65,73-81] have shown silicone products to have 
predominantly positive effects on post-burn scar characteristics such as overall scar 
severity, vascularity, pliability, pigmentation, pain, itch and thickness. Overall scar severity 
has been assessed using the POSAS (Patient and Observer versions) and various versions 
of the Vancouver Scar Scale (VSS) [10,79-81]. The effect sizes for scar severity could only 
be calculated by this author for one trial comparing topical silicone gel (Scarfade®), silicone 
gel sheeting (Epi-Derm®) and an onion extract (Contractubex®) [79]. Effect sizes have been 
found to be small to large in favour of the topical silicone gel. Similarly for vascularity, despite 
being measured in three studies [65,80,81] effect sizes were only able to be calculated for 
one study [65]. The study demonstrated a small to medium effect in favour of a silicone gel 
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sheet (CicaCare®) when compared to a propylene glycol and hydroxyethyl cellulose placebo 
sheeting at four months post intervention commencement. Pliability, pigmentation, pain and 
itch outcomes have all been in favour (small to large effect sizes) of silicone gel sheeting 
(CicaCare®) compared to a control (placebo and lanolin massage) at four and six months 
post-intervention commencement [65,78]. Large effect sizes have also been observed for 
scar thickness (strongest at six months) when silicone gel sheeting (CicaCare®) is compared 
to lanolin massage [78].  
 
None of the aforementioned trials reported on fidelity to intervention regimes. The majority 
either did not report adherence or did not report sufficient information regarding how 
adherence was assessed and the outcomes of these assessments. One study has 
investigated an adherence intervention as the primary focus with adults (primarily male) 
aged 19 to 61 years [77]. The impact of an extended education program (consisting of a 
video and five page instruction sheet) on adult patient adherence to silicone gel sheeting 
wearing regimes was assessed [77]. Using a self-report personal diary and record sheet, 
the authors identified a significant increase in hours of daily wear in the extended education 
group compared to the control group (mean (SD) 21.8 (3.0) hours and 10.1 (7.5) hours 
respectively, p<0.001) [77]. At six months post intervention commencement, participants in 
the extended education group also had significantly better pigmentation and pliability scores 
on the VSS (p=0.02) [77]. The significantly reduced scar thickness originally observed in the 
extended education group was not maintained at six months post intervention 
commencement [77]. The authors concluded that these results support the need to monitor 
adherence rates to determine if this is a confounding factor in studies of intervention 
effectiveness [77]. 
 
Unfortunately, in the 11 previously discussed studies investigating silicone products (two or 
three comparison groups), six different silicone products and six different control products 
were used. In addition, insufficient intervention details have been provided when compared 
to the Template for Intervention Description and Replication (TiDIER) guidelines [53]. There 
have also been numerous gaps in the reporting of factors such as depth of the burn wound, 
time to wound healing, and number of surgical procedures which are known to influence 
scar severity (as discussed previously). A wide variety of outcome measures were used 
across the studies and few studies reported evidence of responsiveness or reproducibility 
for included measures. Thus, the results of previous studies cannot be combined, limiting 
the ability to draw a conclusive statement regarding the effectiveness of silicone products. 
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In addition, children have rarely been included in previous samples, further limiting the 
evidence that pertains to a paediatric post-burn cohort.  
 
The question has also been raised as to whether the silicone chemical compound is 
necessary to provide therapeutic benefits to the patient or if it is solely the occlusive and 
hydrating nature of the gel that is the mechanism of action [61]. In one study [82], 26 patients 
were treated with silicone gel sheeting, a non-silicone gel sheeting, and a no treatment 
control (if three scar sites were available). Participants were eligible if they were aged 
between 15 and 53 years. Three scars were due to trauma and details of the intervention 
products were not provided. After 4.5 months of intervention a significant difference was 
shown between the gel sheeting groups and the control groups for linear measurements 
(length, p=0.01; width, p=0.001) and colour (p<0.001), although there was no significant 
difference between the silicone gel sheeting and non-silicone gel sheeting groups (length, 
p=0.52; width, p=0.34). It must be noted though that none of the scars assessed in this study 
were due to burn injuries, which have been documented as having distinct differences to 
other scars such as contractures and subsequent range of motion restrictions [12].  
 
A second study was completed assessing the effectiveness of silicone versus non-silicone 
products. The study [83] compared the effects of several different silicone products versus 
a hydrating gel cream on 40 healthy adult volunteers. Topical silicone gels included Kelo-
Cote® (InTe Medical, Belgium), Dermatix® (Meda Pharmaceuticals, Belgium), and BAP Scar 
Care® (silicone gel plus vitamin E, BAP Medical, Belgium). Silicone gel sheeting products 
included BAP Scar Care S® and BAP Scar Care T® (BAP Medical, Belgium), Scarban® 
Elastic (Tricolast, Belgium) and Mepiform® (Molnlycke Health Care, Belgium). The non-
silicone hydrating gel was Alhydran® (BAP Medical, Belgium) which has aloe vera as its 
main ingredient [83]. Volunteers underwent skin ‘stripping’ to mimic the trans-epidermal 
water loss environment of a burn scar. Each of the different interventions were then applied 
and trans-epidermal water loss and hydration of the stratum corneum were tested. Three 
hours after skin stripping occurred, a non-silicone hydrating gel cream (Alyhdran®) and a 
topical silicone gel (BAP Scar Care®) were both found to significantly reduce the trans-
epidermal water loss when compared to the alternative topical silicone gels Dermatix® and 
Kelo-Cote® (p<0.05). All topical silicone gels and the non-silicone gel reportedly increased 
the hydration levels of the stratum corneum. However, water content was significantly higher 
in the Alhydran® (non-silicone gel) and BAP Scar Care® (topical silicone gel) treated sites 
(p<0.05). When the silicone gel sheeting products were assessed, hydration levels were 
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reportedly highest in the areas treated with thick silicone gel sheeting (i.e. Scarban® Elastic 
and BAP Scar Care S®). These results support the contention that adverse events from 
silicone gel sheeting may be due to over-hydration of the area and that silicone molecules 
may not be central for the occlusion and hydration of scar sites. However, additional 
research is required to explore this further.  
 
Additional information regarding the effectiveness of silicone products is provided in a 
systematic review in Chapter Three. The systematic review provides additional information 
regarding risk of bias within and across studies and detailed information regarding effect 
size calculations. 
 
2.8.2 Pressure garments 
Pressure therapy for scar management has been well documented throughout history. 
However, the implementation of pressure garment therapy in its modern form was initiated 
in the late 1960’s and early 1970’s [84]. Modern pressure garment therapy involves fitting 
an elasticised piece of material to the area at risk of scarring for 23 hours per day until scar 
maturation [1,85,86]. Pressure garments can be in the form of off-the-shelf ready to wear 
pressure garments or can be customised to the body proportions of the person.  
 
Whilst there are many hypotheses regarding the mechanism of action of pressure garment 
therapy, there is no definitive conclusion as to how this intervention modality affects burn 
scarring. One hypothesis is that the pressure from the garment reduces blood flow to the 
area and causes hypoxia in the cells. In turn, collagenase activity increases and collagen 
breaks down [8,13,87,88]. In addition, hypoxia of the microvasculature may reduce 
fibroblast, mast cell and histamine production [62]. However, there is growing support for 
the theory of mechanotransduction. It is postulated that the integrity of the extra cellular 
matrix is improved during pressure garment therapy by increasing its rigidity [32]. Thus, 
mechanoreceptor activity is increased, resulting in subsequent apoptosis of cells [32] and 
remodelling of collagen fibres into a structured linear pattern [8,13,62,87]. However, these 
theories are yet to be confirmed [86].  
 
Studies investigating the effectiveness of pressure garment therapy are limited in number 
and there are conflicting conclusions regarding effectiveness. One study found pressure 
garment therapy to have no impact on time to scar maturation when compared to a no 
pressure garment control in patients (predominantly male) with superficial partial burn 
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injuries taking longer than fourteen days to heal or requiring skin grafting (p=0.51) [89]. 
However, when effect sizes were calculated there was a small effect in favour of pressure 
garment therapy. Another study compared pressure garment therapy to a control group 
receiving 15 minutes of massage per day (within a four-arm RCT) [11]. Participants were 
predominantly male with a mean age of 21 years and scars were mainly located on the limbs 
[11]. The investigators identified no statistically significant differences between the four 
groups for itch on the visual analogue scale at six months (p=0.09) [11]. Significantly less 
pain was identified in all of the groups after six months of intervention (p=0.05), although no 
statistically significant difference between the control group and pressure garment group 
was reported [11]. Similarly, a significant improvement in pliability was reported in all groups 
(p<0.001), although no significant difference between the control group and the pressure 
garment group was reported at six months post-intervention commencement [11]. When the 
effectiveness of pressure garment therapy was assessed in a meta-analysis [1], no 
significant results were identified for the scar characteristics of colour (p=0.27), vascularity 
(p=0.48), pliability (p=0.20), and pigmentation (p=0.14). 
 
Scar thickness is the one scar characteristic that has consistently been found to improve 
after pressure garment therapy using objective outcome measures [8,13,90]. A systematic 
review was completed of patients (both adults and children post-burn) receiving pressure 
garment therapy of 15 to 25mmHg compared to 10mmHg up to four weeks post burn re-
epithelialisation [1]. The review found a significant difference for scar height only  in a meta-
analysis (d (95% CI)=-0.31 (-0.63,0.00), p=0.05) [1]. Pigmentation, vascularity, pliability, 
colour and overall scar severity were not significant [1]. However, the clinical importance of 
an improvement in just one scar characteristic is yet to be determined [1]. Higher levels of 
interface pressure (15 to 25mmHg) and early initiation of pressure garment therapy are 
reported to result in improved scar outcomes [8,13,39,90]. Interface pressure above 
40mmHg is reported to result in adverse effects such as skin breakdown and paraesthesia 
[13,87]. Additional information regarding previous studies into pressure garment therapy 
effectiveness is provided in Chapter Three and will include meta-analysis, effect size 
calculations and risk of bias assessments. 
 
No study of pressure garment therapy effectiveness has reported methods of ensuring 
fidelity to the intervention protocol and few have reported adherence outcomes [8,90]. 
Investigations into pressure garment therapy adherence (separate to effectiveness studies) 
have reported a variable adherence rate of 15.3% to 81.3% [54,91]. Reasons for low 
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adherence include physical impairments such as pain, perspiration, itch, increased effort 
required to apply the garment and immobility whilst wearing the garment [54,91]. 
Psychological impairments such as fear and anxiety regarding wearing and maintaining the 
garment, embarrassment, and inadequate education regarding pressure garment use, 
maintenance, expected results and timeframe for wear have also been reported [54,91]. 
Additionally, pressure garments have been reported to impact on bony growth and 
exacerbate skin breakdowns [1,7,87,91].  
 
Further complicating a summary of existing evidence and designing future pressure garment 
therapy studies is that the ideal level of pressure at the interface of the pressure garment 
and burn scar is unknown. Theoretically, a consistent pressure of 24 to 25mmHg would be 
required to overcome local capillary pressure [13,86,87]. However, some reports have 
documented improvements in scar characteristics using 10 to 15mmHg of pressure [92]. 
The low levels of pressure from interim pressure garment therapy (3 to 5.8mmHg) [93] were 
also originally considered adequate for improving scar outcomes [85]. Additionally, the 
method of measuring interface pressure has widely varied. Chapter Four evaluates the 
reliability and clinical utility of interface pressure measuring devices including an assessment 
of the Pliance X®. Chapter Four also investigates the level of pressure at the interface of the 
pressure garment and burn scar in children receiving usual care pressure garment therapy 
within the setting that the research in this thesis has been completed. 
 
2.8.3 Combined silicone and pressure garment therapy  
Silicone and pressure garment therapy are often used in combination for the prevention and 
management of post-burn scarring. The preferred silicone product is placed directly onto 
clean, dry, healed skin, and when dry (topical silicone gel), or secure (silicone gel sheeting) 
the pressure garment can be donned over the silicone product. It has been hypothesised 
that the differing mechanisms of action will combine and thus be more effective for the 
prevention and management of burn scarring [62]. However, it can also be postulated that 
a combined approach is no more effective than a single intervention as each intervention 
works to return cellular processes to normal.  
 
Overall scar severity when assessed with the VSS found no statistically significant difference 
between a combined (pressure garment therapy plus silicone gel sheeting) intervention and 
a pressure garment only intervention (p=0.65 and p=0.40 at three and six months 
respectively) [94]. However, a small to medium effect size in favour of the combined 
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intervention group was observed and was strongest at six months post intervention 
commencement. Participants in this study ranged from 16 to 64 years, were Caucasian and 
the majority had received skin grafting [94]. A second study was completed with adults who 
received split skin grafting for their burn injuries and were randomly allocated to: (1) 
combined silicone gel sheeting and pressure garment therapy; or (2) combined silicone 
spray and pressure garment therapy with a within person comparison of pressure garment 
therapy alone [9]. Statistically significant results were recorded for both the combined and 
pressure garment therapy alone groups 18 months after intervention commencement for 
overall scar severity (VSS) (p<0.001), chromometry (combined p<0.001, pressure garment 
only p=0.003), itch (combined p=0.005, pressure garment only p=0.003) and pain scales 
(p=0.005 for both) [9]. Profilometry (a measure of scar surface topography) results indicated 
a significant improvement in the combined intervention group compared to the pressure 
garment therapy alone group (p=0.047 and p=0.570 respectively) [9]. Effect sizes calculated 
by our research team (presented in detail in Chapter Three), supported the superiority of the 
combined interventions for scar severity and colour with small to medium effect sizes in 
favour of the combined intervention at 18 months post intervention commencement 
regardless of silicone type. This evidence would suggest that a combined silicone and 
pressure garment intervention provided a small benefit for scar severity and colour but there 
was no benefit for other scar characteristics. 
 
A four group randomised controlled trial (combined therapies vs pressure garment alone vs 
silicone gel sheeting vs massage) was completed with a cohort of Asian participants (mean 
age=21 years) with developed scars predominantly located on the limbs. Scar colour 
(lightness, redness and yellowness) was measured with a spectrocolorimeter. A statistically 
significant improvement in lightness colour scores for all intervention groups (p<0.001) at 
six months post intervention commencement was reported [11]. Significantly more yellow 
scars were reported in the combined therapies group compared to the control group at four 
months post intervention commencement (p=0.01) [11]. In a previous study [78] the authors 
had reported that Chinese skin is more yellow pre-injury, thus an improvement in 
‘yellowness’ reflects a return to normal skin colouring. Effect sizes (calculated and presented 
in the systematic review presented in Chapter Three) fluctuated between being in favour of 
each of the four intervention types at various points across the intervention continuum for 
scar colour. All groups had a statistically significant improvement in itch at six months post-
intervention commencement (p<0.001) [11]. Calculations of effect size demonstrated a 
greater effect for combined interventions when compared to pressure garment therapy 
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alone. However, when compared to silicone gel sheeting, the silicone product had a greater 
effect than pressure garment therapy on itch. Scar thickness results indicated no statistically 
significant differences for participants in the silicone gel sheeting group [11]. However, there 
was a significant improvement at six months post-intervention commencement for the 
pressure garment therapy alone group (p<0.001) [11]. A significant improvement for the 
combined group (p<0.001) from two to six months post-intervention commencement when 
compared to the massage control group was also observed [11]. When considering effect 
sizes, the combined intervention group had a greater effect than silicone gel sheeting and 
pressure garment therapy alone at all-time points except six months post-intervention 
commencement. At six months post-intervention commencement, silicone gel sheeting had 
a greater effect than the combined intervention. 
 
Conflicting results has meant no consensus regarding the effectiveness of a combined 
pressure garment therapy and silicone intervention approach has been reached. Potentially 
influencing the variability of results is the large range in intervention commencement 
timeframes (between approximately 60 days and 14 months post-burn), a lack of 
measurement and reporting of interface pressure, a lack of reporting of whether there were 
baseline differences in the severity of scarring, and the different skin types of participants 
[53]. Fidelity to intervention regimes has also not been addressed and there was only one 
report of an attempt at measuring participant adherence to interventions in a study 
comparing a combined intervention to pressure garment therapy in adults [94]. Unfortunately 
due to the small completion rate in that study (n=4/22, 18%) analyses were unable to be 
completed [94]. 
 
Additional information regarding the effectiveness of a combined intervention approach is 
provided in the systematic review in Chapter Three. 
 
2.9 Summary 
Abnormal burn scarring impacts the physical, cognitive, emotional and social health of the 
person and their family after a burn and can limit engagement in previously valued 
occupational roles. Current non-invasive interventions for the prevention and management 
of abnormal scarring after a burn have many proposed mechanisms of action and 
inconsistencies in evidence of effectiveness. There is also inadequate information regarding 
treatment satisfaction and adherence to the interventions. In addition, interventions can elicit 
a number of potential adverse effects and costs for the person and the health care provider. 
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Previous investigation in the paediatric population is limited. It is therefore imperative that 
these interventions undergo a rigorous investigation that includes outcomes that are 
important to patients with burn scars and with a paediatric post-burn cohort to determine 
which, if any, intervention is the most effective in managing post-burn abnormal scarring.  
 
2.10  Chapter conclusion 
Chapter Two has discussed background information to provide context to the scar 
development process and introduced the two scar management interventions that will be 
discussed in this thesis. The following chapter is a systematic review that will provide 
additional information regarding the effectiveness of pressure garment therapy and silicone 
products, both alone and in combination, for the prevention and management of post-burn 
scarring. 
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CHAPTER 3 Systematic review and meta-analysis of the 
effectiveness of silicone and pressure garment therapy 
 
It is anticipated that this Chapter will be updated and submitted for publication. Updates will 
include an updated search period to identify recently published studies, searches of grey 
literature including Open Grey and clinical trial registers, and the inclusion of the results of 
the randomised controlled trial presented in Chapter Six. 
 
As an author on the potential publication I made a major contribution to the conception and 
design of the project (60%), analysis (85%) and interpretation of the research data (80%) 
and drafted the potential publication (85%) with input and feedback from the supervisory 
team and co-authors as appropriate. 
  
21 
 
3.1 Chapter foreword 
The Australian National Health and Medical Research Council hierarchy of evidence states 
systematic reviews and randomised controlled trials provide the highest order of evidence 
for intervention effectiveness. Thus, a systematic review of randomised controlled trials was 
completed for this thesis to determine the effectiveness of silicone and pressure garment 
therapy for the prevention and management of abnormal post-burn scarring. Preliminary 
searches across six databases using variations of the terms burns, scars, silicone, pressure, 
did not identify any randomised controlled trials published in English assessing the 
effectiveness of silicone and pressure garment therapy solely in a paediatric population. 
Therefore, this systematic review incorporates randomised controlled trials assessing the 
effectiveness of the targeted interventions in both adult and child participants. Chapter Three 
extends on the information discussed in the literature review regarding the effectiveness of 
silicone and pressure garment therapy by presenting results of risk of bias assessments 
within and across studies, standardised mean difference (effect size) calculations, and meta-
analysis. 
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3.2 Introduction 
Mortality rates attributed to burn injury have been declining whilst the burden of post-burn 
scarring remains [1-3]. Reports indicate that between 30 and 75% of people are impacted 
by hypertrophic scarring (one form of abnormal scarring) after a burn [25,27,95] although 
the definition of hypertrophic scarring has not always been well defined by authors. 
Hypertrophic scarring has recently been defined by a scar height score of greater than or 
equal to one on the Vancouver Scar Scale (VSS) (0 to 2mm above the skin surface) [28] 
and is characterised by raised, rigid and red skin [38]. Additional symptoms of abnormal 
burn scarring include altered sensations, tightness, hardness, roughness, and colour 
changes due to vascularity and pigmentation changes [7,21,23,44-46,95]. Physical 
symptoms and changes to the appearance of the scar compared to normal skin can result 
in reduced engagement with daily activities [5]. Scar interventions such as silicone and 
pressure garment therapy are used to prevent or manage physical, cosmetic and sensory 
differences of the burn scar compared to pre-burned skin. However, scar interventions can 
be costly and time consuming for the person, their family and the health service. Thus, it is 
important to determine which physical scar interventions are most effective to prevent and 
manage abnormal post-burn scarring.  
 
To date, assessment of the effectiveness of burn scar interventions in clinical trials has been 
hampered by poor methodology, choice of measurement tools, variations in the time interval 
post-burn or post-wound re-epithelialisation and poor reporting of intervention details [96]. 
This has been reflected in previous systematic reviews with conclusions regarding the 
effectiveness of silicone and pressure garment therapy on physical scar outcomes differing 
across the reviews. Previous authors have discussed potential explanations for conflicting 
results such as small sample sizes and differences in patient populations, interventions used 
including different silicone products and pressure dosages, time of treatment 
implementation and outcome measures used [1,7,12]. These differences have prevented or 
reduced the amount of data available for meta-analyses [12,97]. In addition, in previous 
systematic reviews of clinical trials there has been a lack of consideration of factors that 
might independently contribute to changes in scar outcomes, such as attrition, adherence 
and intervention fidelity. Previous authors have also differed in their assessment of the 
quality of studies (including the type of risk of bias assessment used).  
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3.2.1 Rationale 
Previous systematic reviews have assessed the effectiveness of silicone or pressure 
garment therapy as individual interventions or have included these treatments in broader 
assessments of non-invasive interventions. The effectiveness of silicone products and 
pressure garment therapy alone compared to when used in combination has not been 
systematically reviewed despite being used in this manner in clinical practice. The current 
systematic review also extends the evidence available from previous systematic reviews by 
including additional studies in this field and using rigorous methodology that has not typically 
been applied previously. Assessment of the risk of bias across outcomes using Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) [98] and 
considering factors such as attrition in risk of bias assessments adds to the rigour of this 
review. Further increasing the rigour of this systematic review is the consolidation of in depth 
intervention data using the Better reporting of interventions Template for Intervention 
Description and Replication (TIDiER) guidelines [53], including an evaluation of planned and 
actual intervention fidelity. Also increasing the rigour of this review is the calculation of effect 
estimates (standardised mean differences) of outcomes in individual studies, and identifying 
at which time point interventions have the greatest effect on specific outcomes. Additionally, 
the outcomes that are included in this systematic review extend beyond the physical scar 
characteristics that have been the focus of prior systematic reviews and includes patient 
focused outcomes of health-related quality of life and adherence.   
 
3.2.2 Objectives 
The aim of this systematic review is to determine:  
(1) The effectiveness of silicone and pressure garment therapy alone or in combination for 
the prevention and management of health-related quality of life; scar sensitivity; adverse 
effects; physical scar characteristics; surgical and cosmetic outcomes for people with, or at 
risk of, abnormal burn scarring. The results of these outcomes will also be interpreted in light 
of the outcomes of adherence, fidelity, and attrition in included studies.  
(2) The time-points at which the interventions are most effective. 
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3.3 Method 
3.3.1 Protocol and registration 
The systematic review was conducted according to the protocol registered in PROSPERO 
(ID: CRD42019121786) and is reported according to the PRISMA guidelines [99]. Ethical 
approval was not required.   
 
3.3.2 Eligibility criteria 
Inclusion criteria were summarised using a PICO-ST approach (Population, Intervention, 
Comparison, Outcome, Setting and Study design, Time). 
(1) Population: human participants of any age with, or at risk of, post-burn scarring to 
any body location excluding eye burns alone and respiratory burns. 
(2) Intervention: pressure garment therapy (high and low dosage as determined by 
authors) and silicone products (topical silicone gel, silicone gel sheeting, silicone 
sprays, silicone-based pressure garment inserts or silicone-based pressure garment 
lining). Education programs were included if they assessed the effectiveness of 
silicone products and/ or pressure garment therapy on burn scar outcomes as 
described in the remaining eligibility criteria. 
(3) Comparison: no treatment, placebo, standard care, or a different dose of the same 
intervention (e.g. high vs low interface pressure) 
(4) Outcome: primary outcomes included health-related quality of life, scar sensitivity 
(including scar pain, itch intensity, uncomfortable sensations), scar thickness, and 
adverse effects. Secondary outcomes included additional physical scar 
characteristics (colour, texture, pigmentation, pliability, elasticity, movement 
restrictions, trans-epidermal water loss, dryness, hardness); cosmetic outcomes 
(overall scar severity as measured by total scores of scar scales); psychosocial 
outcomes; interface pressure; surgical outcomes; and cost outcomes. In addition, 
adherence, intervention fidelity and rates and reasons for participant drop-out in 
studies were reviewed. 
(5) Setting: no restrictions were placed on the intervention setting (e.g. hospital inpatient 
and outpatient environments, burns camps, community and home settings were 
included). 
(6) Study design: no restrictions regarding study design were applied during the literature 
search to enable identification of all relevant studies. However, during full text review, 
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all study designs other than randomised controlled trials (RCT) were excluded 
(including exclusion of cross-over randomised controlled trials). 
(7) Time: interventions were to be applied after burn wound re-epithelialisation as 
determined by authors of the included studies (e.g. at 85%, 95% or 100% re-
epithelialisation). Outcome assessment time points were considered short-term 
outcomes if assessed at less than six months-post burn injury, intermediate outcomes 
if assessed at six months up until 12 months post-burn injury or as long-term 
outcomes if assessed at or beyond 12 months post-burn injury. No date restriction 
was implemented during the literature search to ensure all relevant RCTs were 
identified.  However, during title and abstract screening studies published earlier than 
1990 were excluded as no known RCTs were published prior to 1990. 
(8) Language: no language restrictions were applied during the literature search however 
only randomised controlled trials published in English were included as the authors 
did not have the resources to translate journal articles. 
 
3.3.3 Search strategy and information sources 
A literature search was performed in the databases of PubMed (including Medline), 
Cumulative Index of Nursing and Allied Health Literature (CINAHL), EMBASE, OT Seeker, 
Physiotherapy Evidence Database (PEDro) and the Cochrane database (date last searched 
April 2018). Hand searching of papers from the journals of Burns, Burn Care and Research, 
Burns and Trauma, and Scars, and Wounds and Healing was also conducted. Search terms 
included variations of terms such as keloid, cicatrix, hypertrophic, scar, burns, thermal injury, 
pressure garment and silicone (refer to Appendix 2 for full search strategy for one database). 
 
3.3.4 Study selection and data extraction 
Two reviewers (JLW, MS) independently screened the titles and abstracts of identified 
studies according to the inclusion criteria previously listed. The same two reviewers 
independently screened the full texts of potentially eligible articles as per the inclusion 
criteria. Data extraction for eligible included studies was completed by one reviewer (JLW). 
A second reviewer (AT) independently extracted data for 20% of eligible included studies 
and peer checked data extraction of the remaining data by the first reviewer. Agreement of 
at least 80% between the two reviewers was reached as per A MeaSurement Tool to Assess 
systematic Reviews (AMSTAR2) guidelines [100]. Discussion was continued until 100% 
consensus was reached. A data extraction template was developed and piloted by the 
authors and included: (1) results (including scar-related outcomes, raw data, p value and 
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systematic review author calculated standardised response means, Appendix 3); (2) 
participant characteristics of included studies (Appendix 4) and; (3) interventions of included 
studies (Appendix 5). After piloting, the results table was modified to include the addition of 
the time point at which the largest effect of the intervention was seen in line with aim two. 
The participant characteristics table was modified to include risk factors of post-burn scarring 
such as number of surgical interventions. The intervention characteristics table was updated 
to include all components specified in the TiDIER guidelines [53].  
 
3.3.5 Data items extracted 
Extracted sociodemographic and clinical characteristics of participants included age, 
gender, location of scar site, skin type or ethnicity, % total body surface area (%TBSA) 
burned, maximum depth of injury, type of wound healing (i.e. spontaneous or grafting), time 
to wound healing, number of surgical procedures, comorbidities, and study inclusion and 
exclusion criteria. Intervention characteristics of interest included a description of the 
intervention; frequency, intensity and duration of the intervention; when the intervention 
commenced; the length of the intervention; the setting and mode of intervention delivery as 
well as who delivered the intervention; any modifications to the intervention; planned or 
reported adherence and fidelity to the intervention; and attrition as per the TiDIER guidelines 
[53]. Collated study results included the outcome (as determined in the eligibility criteria), 
the outcome measure and time point of the measurement; the result and number of 
participants the result pertained to; reported significance level; and if available, the reported 
standardised mean difference (effect size). If effect sizes were not reported by the study 
authors, these were calculated. Also recorded was the intervention that the standardised 
mean difference favoured and the time point at which the largest effect was observed.  
 
3.3.6 Risk of Bias 
The risk of bias for individual studies was rated using the Cochrane tool for randomised 
trials. Risk of bias was independently assessed by two assessors (MS, ZT). Where there 
was disagreement, discussion was continued until there was agreement or disagreements 
were resolved by a third party (SM). Cochrane risk of bias items include selection bias, 
performance bias, detection bias, attrition bias, reporting bias and other bias [101]. Other 
bias included funding and conflicts of interest declarations, choice of outcome 
measurements, sample size, appropriateness of data analysis and balance differences 
between the groups. The Cochrane Risk of Bias summary and graph was developed using 
Review Manager (Revman) 5.3 (Copenhagen: The Nordic Cochrane Centre, Cochrane 
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Collaboration, 2014). Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) was used to determine the quality of evidence at the outcome level 
across the categories of risk of bias, inconsistency, indirectness, imprecision and publication 
bias for all critical outcomes [102]. Critical outcomes were determined by consensus 
amongst the authors based on outcome measures that are the most valid, reproducible and 
responsive to change. Additionally, outcomes were considered critical if they were generally 
the focus of rehabilitation efforts by health professionals treating scarring, and outcomes 
that capture the sensory and functional outcomes that have been identified as most 
important to patients [5,44,103]. For this review critical outcomes were selected to be the 
primary outcomes of health-related quality of life, scar sensitivity, scar thickness and 
adverse effects. The quality of evidence for critical outcomes was downgraded if there was: 
a high risk of bias (according to Cochrane risk of bias results); inconsistency (low 
heterogeneity as determined by I2 in meta-analyses or differences in direction of effect) 
[104]; imprecision of results (sample size <100, number of studies <5) [105]; or there was 
evidence of indirectness (heterogeneous population, interventions, follow up time frames) 
[106]. 
 
3.3.7 Analyses 
3.3.7.1 Summary measures 
A narrative synthesis was used to describe the study selection, study characteristics, and 
risk of bias of included studies. Descriptive statistics, such as numbers and percentages, 
were used to summarise patient characteristics and outcomes data.  
 
3.3.7.2 Synthesis of results 
3.3.7.2.1 Standardised mean differences (SMD) 
Standardised mean differences and 95% confidence intervals were calculated at the study 
level for between group mean differences at end points or for changes over time for 
continuous outcomes (where available) using Revman 5.3. Both between group means and 
change scores and other estimates in published studies were reported. Standardised mean 
differences were interpreted as 0.2 representing a small effect, 0.5 a moderate effect, and 
0.8 a large effect [107]. Odds ratios and 95% confidence intervals were reported or 
calculated for non-continuous outcomes. 
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3.3.7.2.2 Meta-analyses 
The completion of meta-analyses was determined based on the clinical heterogeneity of 
participants, interventions, outcome and time post-burn [108]. For example, scar height 
above the skin surface measured using subjective assessment by an observer was not 
regarded as able to be pooled with objective data using ultrasound measurement of scar 
thickness above and below the skin surface. Where data were considered too clinically 
heterogeneous for meta-analysis a narrative synthesis was used to summarise the results. 
Meta-analyses were conducted using RevMan 5.3 where there were two or more 
homogenous trials. The I2 statistic was used to measure heterogeneity after studies were 
deemed sufficiently clinically homogenous to conduct a meta-analysis. An I2 value of 25% 
was considered low, 50% moderate and 75% high [109]. Data were pooled using the random 
effects model. Publication bias at the outcome level was investigated by examining 
relationships between study sizes and effect sizes in funnel plots using RevMan 5.3. 
 
3.4 Results 
3.4.1 Study selection 
Sixteen papers were included after screening potential articles (n=4266) removing 
duplicates (n=1322), screening title and abstracts (n=2944) and the full texts of relevant 
papers (n=59). Figure 3.1 illustrates the flow diagram of the study screening and selection 
process as well as papers excluded and reasons for exclusion. Silicone products were the 
intervention most often investigated in clinical trials. Of the included studies, seven 
investigated silicone products (n=265) [10,65,77-81]. Five studies (n=377 participants) 
investigated pressure garment therapy alone [8,13,89,90,110] and four (n=180 participants) 
investigated combined silicone and pressure garment therapy [9,11,62,94]. Of the included 
studies, no studies were considered overlapping. 
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Figure 3-1 PRISMA Flowchart 
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3.4.2 Study characteristics 
3.4.2.1 Silicone products 
Two of the studies investigating silicone products were conducted in Thailand [80,81], one 
in Turkey [79], one in Hong Kong/ China [78], one in Iran [65], one in Canada [77] and one 
in the Netherlands [10]. The ages of participants included in silicone intervention 
effectiveness studies were variable and only three studies included child participants 
[65,78,79]. Other participant and clinical characteristics such as skin type and %TBSA were 
rarely reported (n=1/7, 14.29% and 2/7, 28.57% of studies respectively). Six different 
silicone products and five different control products were assessed across the seven 
studies. At least two different measures were used to assess each of the eight outcomes in 
two or more studies. Additional details can be viewed in Appendix 4 and 5 (participant 
characteristics and interventions). 
 
Topical silicone gels were the silicone product most commonly investigated (n=4). Dermatix® 
(Meda Pharma, Amstelveen, The Netherlands) was compared to a placebo control cream 
in one study [10]. A silicone gel combined with an herbal extract was investigated in two 
studies [80,81]. One study compared the herbal extract and silicone combination (Cybele 
Scagel®, Bangkok Botanica, Thailand) to aloe vera gel [80] and one study compared the 
same herbal extract and silicone combination gel (Cybele Scagel®, Bangkok Botanica, 
Thailand) to a silicone only gel (Dermatix®, Invida Pharmaceuticals Ltd) and a placebo gel 
[81]. One study compared the effectiveness of a topical silicone gel (Scarface®, Hanson 
Medical Inc. Kingston, WA, USA), silicone gel sheeting (Epi-DermTM, Biodermis, Las Vegas, 
NV, USA) and a topical onion extract gel (Contractubex®, Merz Pharma, Frankfurt, 
Germany) [79]. Adherence was not reported in any study of topical silicone gels. Silicone 
gel sheeting was compared to a placebo control in one study [65] and to a lanolin massage 
control in another study [78]. Both studies required participants to aim for 24 hours of silicone 
gel sheeting wear, although actual adherence was not reported.  
 
A further study investigated the effects of an enhanced education program on the adherence 
and therefore effectiveness of silicone gel sheeting [77]. Participants were required to use 
Cica-Care® (Smith & Nephew, Memphis, TN) silicone gel sheeting with a graded approach, 
beginning at 12 hours per day and aiming for 24 hours per day. Participants were asked to 
record their daily hours of wear and were either given the standard level of education (verbal 
instructions and one page handout) or the extended level of education (video and five page 
handout). Additional details are provided in Appendix 5 (Intervention table). 
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Intervention commencement varied from full wound re-epithelialisation to four years post-
burn injury and the intervention length ranged from two to twelve months post-intervention 
commencement. Modifications to the intervention were predominantly altered wearing 
regimes due to reported adverse effects and no study reported intervention fidelity. Details 
regarding who delivered the intervention were not always provided but included physicians 
and therapists together [77] or individually [10,78] or burns nursing staff [81]. 
 
3.4.2.2 Pressure garment therapy 
In the five studies investigating pressure garment therapy, two were conducted in the United 
States of America [8,89], one in the United Kingdom [110], one in Belgium [13] and one in 
Hong Kong/ China [90]. Limbs were the most common body location assessed and 
participants were predominantly male, with an average age of 30 years. Two studies 
included both child and adult participants [8,110]. One study [90] included participants 
experiencing scarring due to causes other than burn injury (trauma and surgery, though 
greater than 50% were due to burn injuries). The most common intervention comparison in 
studies investigating pressure garment therapy (three of the four studies, n=167), was high 
or normal levels of interface pressure versus low levels of interface pressure [8,13,90]. The 
definition of ‘high/normal’ pressure was similar across the studies (approx. 20 to 25mmHg) 
whereas ‘low’ pressure varied from less than 5mmHg to 15mmHg. All three studies 
measured the interface pressure at each review point although various interface pressure-
measuring devices were used. Devices included Pliance X® [90], I-Scan® [8] and an 
evaluation of the force required to stretch the pressure garment [13]. One study compared 
the effectiveness of pressure garment therapy in increasing rates of scar maturation 
compared to a no treatment control [89].  
 
Three studies [8,13,90] recommended pressure garment wear for 23 hours per day although 
only two reported actual hours of daily wear of pressure garments [8,110]. In one of these 
studies [8] only 50% of participants reportedly completed self-report adherence 
questionnaires with a mean hours of daily wear equaling mean (SD) 20.4 (3.9) hours per 
day. A second study [110] reported a similar mean hours of daily wear at 21 hours per day. 
The earliest reported pressure garment therapy commencement was two weeks post wound 
re-epithelialisation with the latest time point mean (SD) 5.21 (1.94) months post-injury. There 
was some discrepancy in the recommended length of time in months for pressure garment 
therapy use. Recommendations varied between five and twelve months or until scar maturity 
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and no measure of intervention fidelity was reported. Appendix 4 and 5 provide further 
information. 
 
3.4.2.3 Combined silicone and pressure garment interventions 
Participants involved in combined intervention studies were recruited in Belgium [111], 
Ireland [94], China [11], and Germany [9]. Participants were predominantly male, and 
included child and adult participants in one study [11]. Scars were predominantly located on 
the limbs. Two studies investigated the effectiveness of pressure garment therapy in 
conjunction with silicone gel sheeting (Mepiform® strip, Molnlycke Health Care Ltd, 
Bedfordshire, England) [94], Cica-Care®, Smith and Nephew Company Ltd HK [11]) with a 
comparison group of pressure alone [94] or lanolin massage [11]. One study investigated 
silicone gel sheeting (Mepiform®, Molnlycke Health Care Goteborg, Sweden) and silicone 
spray (Dermatix®, Valeant Pharmaceuticals International, Aliso Viejo, California) [9] in 
conjunction with pressure garment therapy compared to a pressure garment only within-
person control. The two scars were required to be at least two centimetres away from each 
other [9]. The final study investigated the within-person effectiveness of various occlusive 
plates (silicone plates (Otto Bock Orthopaedic Industries, Son, The Netherlands); elastomer; 
gel; plastic plate) in combination with pressure garment therapy. The four plates were 
secured to the skin beneath a pressure garment [111].  
 
In three of the studies [11,94,111], the interventions were to be worn for 23 hours per day 
where possible, and one study [9] did not provide details regarding wearing regime. No 
details of pressure at the interface of the pressure garment and burn scar were provided in 
any study. Only one study planned to assess adherence [94], however there was a poor 
completion rate for the self-report adherence diaries. Four of the 30 recruited participants 
(13%) completed the diaries which was inadequate for statistical analysis [94]. Intervention 
lengths ranged from three to twelve months and commencement post-burn ranged from 
immediately after wound re-epithelialisation to mean (SD) 14.9 (30.8) months post-injury. 
Refer to Appendix 4 and 5 for additional details (participant characteristics and intervention 
tables). 
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3.4.3 Risk of bias within and across studies 
3.4.3.1 Risk of bias within studies (Cochrane risk of bias tool) 
3.4.3.1.1 Silicone products 
Randomised controlled trials assessing the effectiveness of silicone had unclear to high risk 
of bias in all categories except random sequence generation (low risk) for two studies [65,80] 
and incomplete outcome data (low risk) for one study [79].  
 
3.4.3.1.2 Pressure garment therapy 
The studies assessing the effectiveness of pressure garment therapy had unclear to high 
risk of bias across all categories except for a low risk of bias in random sequence generation 
for three studies [8,90,110].  
 
3.4.3.1.3 Combined silicone and pressure garment interventions 
The studies assessing the effectiveness of combined interventions had unclear to high risk 
of bias across all categories except for a low risk of bias in random sequence generation for 
three studies [9,11,94]. 
 
3.4.3.1.4 Summary of risk of bias within studies 
As illustrated in Figure 3.2 (risk of bias graph) there was evidence of low and unclear risk of 
bias for random sequence generation across all randomised controlled trials. The majority 
of studies had an unclear risk for allocation concealment, blinding of participants and 
outcome assessment. There was a predominantly unclear and high risk of bias for the 
categories of incomplete outcome data and selective reporting. There was a high risk of bias 
for the category ‘other biases’ including funding and conflicts of interest declarations and 
sample size calculations.   
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Figure 3-2 Risk of bias graph 
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3.4.3.2 Risk of bias across studies (GRADE tool) 
3.4.3.2.1 Silicone products 
There was no evidence for health-related quality of life outcomes for silicone products. The quality of evidence was low for scar thickness 
and very low for scar sensitivity. 
Table 3-1 GRADE Assessment: Silicone products 
 
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of bias Inconsistency Indirectness Imprecision Other considerations 
Silicone 
products 
control 
Relative 
(95% CI) 
Absolute 
(95% CI) 
Scar thickness (assessed with: TUPS) 
1  randomised 
trials  
serious a not serious  serious b,c serious d,e,f publication bias 
strongly suspected 
very strong 
association g 
22  23  -  SMD 9.11 
SD lower 
(11.16 
lower to 
7.05 lower)  
⨁⨁◯◯ 
LOW  
CRITICAL  
Scar itch intensity (assessed with: Various) 
3  randomised 
trials  
serious h serious i,j,k,l not serious  not serious  publication bias 
strongly suspected m 
115  115  -  - ⨁◯◯◯ 
VERY LOW  
CRITICAL  
Scar pain (assessed with: VSS) 
1  randomised 
trials  
serious h not serious  serious b,n,o serious d,e,f none  34  34  -  SMD 0.14 
SD lower 
(0.62 lower 
to 0.33 
higher)  
⨁◯◯◯ 
VERY LOW  
CRITICAL  
 
Abbreviations: 
CI: Confidence interval; SMD: Standardised mean difference 
 
a. Areas of unclear and high risk of bias on 
Cochrane Risk of bias tool.  
b. Represented a narrow range of the 
population of interest  
c. Developed scars (average 14.9 months 
post-injury)  
d. Small sample size  
e. Small magnitude of included studies (< 5 
studies)  
f. Minimal data regarding adverse events  
g. Inconsistencies in reporting of results  
h. Areas of unclear and high risk of bias on 
Cochrane Risk of Bias tool. Low risk of bias 
for random sequence generation category 
only.  
i. Different outcome measures  
j. Different intervention types  
k. Different control products  
l. Difference in populations  
m. Industry funding reported for one trial  
n. Intervention uncommon  
o. Time frame of outcome measurement 
could have missed peak scar period  
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3.4.3.2.2 Pressure garment therapy 
No pressure garment therapy study assessed health-related quality of life outcomes. The quality of evidence was moderate for scar 
thickness and very low for scar sensitivity. 
Table 3-2  GRADE Assessment: Pressure garment therapy 
 
Abbreviations: 
CI: Confidence interval; SMD: Standardised mean difference 
 
a. Areas of unclear and high risk of bias on 
Cochrane Risk of bias tool  
b. Represented a narrow range of population 
of interest  
c. Scars were developed by the time 
interventions were implemented  
d. Small sample size  
e. Small magnitude of included studies (<5 
studies)  
f. Minimal/no data regarding adverse effects  
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
Pressure 
garment 
therapy 
Control (low 
dose or no 
pressure) 
Relative 
(95% CI) 
Absolute 
(95% CI) 
Thickness (assessed with: Various) 
3  randomised 
trials  
serious a not serious  not serious  not serious  none  97  87  -  SMD 0.38 
SD lower 
(0.99 
lower to 
0.23 
higher)  
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Itch (assessed with: VAS) 
1  randomised 
trials  
serious a not serious  serious b,c serious d,e,f none  28  25  -  SMD 0.17 
SD higher 
(0.37 
lower to 
0.71 
higher)  
⨁◯◯◯ 
VERY LOW  
CRITICAL  
Pain (assessed with: VAS) 
1  randomised 
trials  
serious a not serious  serious b,c serious d,e,f none  28  25  -  SMD 0.31 
SD higher 
(0.24 
lower to 
0.85 
higher)  
⨁◯◯◯ 
VERY LOW  
CRITICAL  
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3.4.3.2.3 Combined silicone and pressure garment interventions 
No study assessed health-related quality of life in the combined interventions studies. Similar to the silicone studies, the quality of evidence 
for scar thickness was low and very low for scar sensitivity when assessing risk of bias across outcomes for combined interventions.  
 
Table 3-3  GRADE Assessment: Combined interventions 
 
Certainty assessment № of patients Effect 
Certainty Importance № of 
studies 
Study 
design 
Risk of bias Inconsistency Indirectness Imprecision 
Other 
considerations 
Combined 
interventions 
(silicone 
products + 
pressure 
garment 
therapy) 
Single 
interventions 
(silicone or 
pressure 
garment 
therapy) 
Relative 
(95% CI) 
Absolute 
(95% CI) 
Thickness (assessed with: TUPS) 
1  randomised 
trials  
serious a not serious  not serious  serious b,c,d none  24  48  -  - ⨁⨁◯◯ 
LOW  
CRITICAL  
Itch (assessed with: VAS) 
2  randomised 
trials  
serious a not serious  not serious  serious b,c,d publication bias 
strongly suspected e 
48  73  -  - ⨁◯◯◯ 
VERY LOW 
CRITICAL  
Pain (assessed with: VAS) 
2  randomised 
trials  
serious a serious f not serious  serious b,c,d publication bias 
strongly suspected e 
48  73  -  - ⨁◯◯◯ 
VERY LOW 
CRITICAL  
 
Abbreviations:  
CI: Confidence interval 
 
a. Areas of unclear and high risk of bias on Cochrane Risk of bias tool  
b. Small sample size  
c. Small magnitude of included studies (< 5 studies)  
d. Minimal data regarding adverse effects 
e. Industry funding reported 
f. Inconsistency in size and direction of effect  
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3.4.3.2.4 Summary of risk of bias across studies 
In summary thickness outcomes were determined to be of low (silicone alone and combined 
interventions) or moderate (pressure garment therapy alone) quality evidence. A very low 
quality of evidence was observed for itch and pain sensory outcomes for silicone and 
pressure garment therapy alone and in combination. 
 
3.4.4 Synthesis of results 
3.4.4.1 Standardised mean differences (effect sizes) of individual studies 
Standardised mean differences of individual studies are presented in Appendix 3 (Results 
of included studies). 
 
3.4.4.1.1 Silicone products 
Primary outcomes 
Small and small to medium standardised mean differences were observed for the outcomes 
of pain (SMD (95% CI)=-0.24 (-0.72, 0.24)) and itch (SMD (95% CI)=-0.34 (-0.82, 0.14)) in 
favour of silicone gel sheeting when compared with a placebo group after one month of 
intervention [65]. The greatest influence on pain was observed at one month post-
intervention commencement [65]. The effect size for itch increased to a medium to large 
standardised mean difference at four months post-intervention commencement (SMD (95% 
CI)=-0.71 (-1.21, -0.22)), which was the largest observed effect size for itch [65]. The 
standardised mean difference for thickness outcomes was large at all-time points in one 
study (SMD (95% CI)=-6.92 (-8.53, -5.31); -6.07 (-7.50, -4.63); -9.11 (-11.16, -7.05) at two, 
four and six months post-intervention commencement respectively) [78]. The effect size was 
also large at six months post-intervention commencement when comparing the 
effectiveness of an enhanced education program compared to a conventional education 
program (SMD (95% CI)=-1.16 (-2.02, -0.30))  [77]. 
 
Five studies documented information on adverse effects. One study reported no adverse 
effects from silicone gel sheeting [65]. Another study [78] reported less adverse effects for 
silicone gel sheeting than other interventions but no detail was provided regarding the type 
or rate of adverse effects or which intervention this was compared to. In contrast, one study 
reported skin maceration and pruritus in two participants (32 participants total sample, 15 
scars in the silicone gel sheeting group) receiving silicone gel sheeting but no adverse 
effects were reported for participants receiving topical silicone gel or the topical onion extract 
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[79]. An additional study reported no side effects for the topical silicone gel or the placebo 
gel [10] and no side effects were reported when using the topical silicone gel combined with 
the herbal extract [80]. 
 
Secondary outcomes 
After one month of silicone gel sheeting use compared with a placebo, small standardised 
mean differences in favour of the intervention were observed for vascularity (SMD (95% 
CI)=-0.19 (-0.66, 0.29)) and pliability (SMD (95% CI)= -0.25 (-0.73, 0.22)) outcomes in one 
study [65]. The greatest influence on vascularity (SMD (95% CI)=-0.46 (-0.94, 0.02)) and 
pigmentation (SMD (95% CI)=-0.60 (-1.08, -0.11)) was observed at four months post-
intervention commencement for one study [65]. The largest effect on pliability in favour of 
silicone gel sheeting was at four and six months post-intervention commencement in two 
studies (SMD (95% CI)=-0.75 (-1.24, -0.26); SMD (95% CI)=-5.43 (-6.75, -4.12)) [65,78] 
respectively. 
 
3.4.4.1.2 Pressure garment therapy 
Primary outcomes 
No study reported health-related quality of life outcomes. One study reported sensory 
outcomes of itch and pain [90]. For itch (up to one month post intervention ceasing with an 
intervention period of five months) standardised mean differences were in favour of low 
pressure dosages. The greatest effect was observed at four months post-intervention 
commencement; SMD (95% CI=0.37 (-0.17, 0.92); 0.41 (-0.14, 0.95); 0.17 (-0.37, 0.71) at 
three, four and five months post-intervention commencement respectively [90]. Pain was 
also reduced in the low pressure group, with the greatest intervention effect observed at one 
month post-intervention commencement (SMD (95% CI=0.48 (-0.06, 1.03)) [90].  
 
All three studies identified greater standardised mean differences for scar thickness in the 
normal or high compression group. The effect of normal pressure on scar thickness (small 
to medium standardised mean difference, SMD (95% CI)=-0.45 (-0.91, 0.01); -0.39 (-0.85, 
0.07); -0.33 (-0.79, 0.13) at one, two and three months respectively) remained reasonably 
consistent across a three month period in one study comparing normal to low pressure [13]. 
An additional study also found a small effect on thickness in favour of normal versus low 
pressure (SMD (95% CI)=-0.19 (-0.72, 0.33)) though the time period post-burn for this 
finding was unclear [8]. The greatest effect on scar thickness was seen at one month post-
intervention commencement for one study, SMD (95% CI)=-0.45 (-0.91, 0.01) [13] and four 
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months post-intervention commencement in another, SMD (95% CI)=-1.06 [-1.64, -0.48] 
[90]. The delayed effect of the intervention in the second study could be due to the age of 
the scar when interventions were implemented (mean (SD) 4.96 (1.80) months). 
 
Only one study investigating pressure garment therapy reported the presence of adverse 
effects [110]. The mean (95% CI) number of adverse effects throughout the study period 
(assumed to be 12 months) was slightly higher in the pressure garment versus no pressure 
garment group (0.98 (0.43, 1.52) vs 0.91 (0.38, 1.43) respectively). The type of adverse 
effects recorded across both groups included wound breakdown, blisters, rash, itch, 
infection, paraesthesia, allergies, contractures, steroid injection, and surgical scar revision 
[110].  
  
Secondary outcomes 
All studies reported difficulty maintaining a consistent level of pressure over the study period 
potentially due to difficulties ensuring an adequate fit of the pressure garment, fabric 
degradation, variable adherence, and accuracy of the interface pressure assessment device 
[8,13,90]. Two studies noted pressure garments in the normal/high compression group 
experienced greater levels of pressure loss over time compared to the low compression 
group [13,90]. Pressure loss ranged from approximately 11% to 20% of the original interface 
pressure [13,90].  
 
Negligible standardised mean differences were observed for erythema across a three month 
period in one study comparing normal to low pressure (SMD (95%CI)=-0.10 (-0.55, 0.36);  
-0.10 (-0.55, 0.36); -0.09 (-0.55, 0.36) at one, two and three months respectively) [13]. The 
largest effect on erythema in favour of normal interface pressure was observed at four 
months post-intervention commencement in another study (SMD (95% CI)=-0.76 (-1.32,  
-0.20)) [90]. In comparison, the effect on hardness was observed to have a small to medium 
effect in favour of higher compression levels in one study period, (SMD (95%CI)=-0.56  
(-1.12, -0.01), study period five) [8]. Small standardised mean differences were observed for 
months one, two and three post-intervention commencement in favour of low pressure for 
pliability scores (SMD (95% CI)=0.29 (-0.26, 0.83); 0.20 (-0.34, 0.74) at one and two months 
respectively) [90]. The effect switched to a small to medium standardised mean difference 
in favour of high pressure dosage at four months post-burn, when the greatest pliability 
intervention effect was seen (SMD (95% CI)=-0.52 (-1.07, 0.03)) [90]. The same pattern was 
observed for pigmentation [90] with effect sizes in favour of the low pressure dosage at one, 
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two and three months post-burn, before switching at four months post-burn when the effect 
sizes were in favour of high pressure dosages. The greatest effect for pigmentation was 
observed at two months post-intervention commencement (SMD (95% CI)=0.38 (-0.16, 
0.93)).  
 
3.4.4.1.3 Combined silicone and pressure garment interventions 
Primary outcomes 
In one study involving adults from China, thickness, pain and itch outcomes for silicone gel 
sheeting versus combined interventions had a medium to large effect from four months and 
a large effect at one month after the intervention ceased [11]. Standardised response means 
were in favour of the combined intervention group when compared to pressure garment 
therapy alone for itch. However, silicone gel sheeting alone was more effective than the 
combined group for itch outcomes at all time points measured [11]. The largest effect was 
seen at six months post-intervention commencement in favour of silicone gel sheeting when 
compared to pressure garment therapy (SMD (95% CI)=1.74 (1.10, 2.37)). During the six 
month intervention period, standardised response means were in favour of the combined 
intervention group when compared to pressure garment therapy and silicone gel sheeting 
alone for the pain outcome. When comparing active interventions (i.e. pressure and silicone 
therapy alone or combined), the largest effect for pain was observed at six months post-
intervention commencement in favour of the combined interventions when compared to 
pressure garment therapy (SMD (95% CI)=0.92 (0.38, 1.46)). When interventions were 
compared to the control (massage) the largest effect was seen at one month post the 
intervention ceasing in favour of the silicone gel sheeting (SMD (95% CI)=-1.01 (-1.63,  
-0.38)). Pressure garment therapy was less effective than any other intervention (combined 
intervention, silicone gel sheeting alone and massage) for managing itch and pain [11]. 
 
Combined interventions were more effective for reducing thickness when compared to 
silicone gel sheeting at two months post-intervention commencement and one month post-
intervention ceasing. Pressure garment therapy was more effective than the control in 
improving thickness at all-time points, however was less effective than silicone gel sheeting 
or combined interventions [11]. The largest effect sizes were seen at one month post-
intervention ceasing when comparing any intervention to the control group for thickness 
(SMD (95% CI)=-1.01 (-1.61, -0.42); -1.20 (-1.84, -0.56); -1.37 (-1.99, -0.74) for pressure 
garment therapy; silicone gel sheeting and combined respectively). When comparing active 
interventions to each other, the greatest effect size (medium effect) for scar thickness was 
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seen at two months post-intervention commencement when comparing combined 
interventions to pressure garment therapy  (in favour of the combined group, SMD (95% CI) 
=0.42 (-0.10, 0.93)) [11]. 
 
One study reported drop out (27.3%); sample size n=6/22, due to adverse effects [111]. 
Adverse effects included skin irritation from the edges of the occlusive plates or the tape 
securing the occlusive plates [111]. Another study [94] reported skin breakdown from the 
silicone gel sheeting component of the intervention between weeks 12 and 24 for one 
participant (0.03%; sample size, n=30). Dermatitis and skin maceration were reported for 
31.5% for participants using a combination of silicone gel sheeting and pressure garment 
therapy in another study [9]. Comparatively, no adverse effects were reported for those 
participants using the combined silicone spray and pressure garment therapy intervention 
[9]. 
 
Secondary outcomes 
When assessing scar severity on the Vancouver Scar Scale (VSS), small and small to 
medium standardised mean differences were found in favour of combined interventions at 
three, six [94] and eighteen months [9]. Standardised mean differences were also found in 
favour of combined interventions regardless of the silicone product at seven days, and one, 
two, three [111] and eighteen months [9] for erythema (a* values, Minolta Chromameter 
device). The largest effect was seen at one month post-intervention commencement (SMD 
(95% CI=-0.96 (-1.65, -0.26)) in favour of the elastomer occlusive plate plus pressure 
garment therapy [111]. There were mixed effects for colour (L*, a*, b* values, 
Spectrocolorimeter device) at two, four and six months post-intervention commencement 
and one month post the intervention ceasing in a four-arm study comparing pressure 
garment therapy, silicone gel sheeting, combined interventions and a fifteen minute lanolin 
massage control [11]. The largest standardised mean difference for a* was at four months 
post-intervention commencement in favour of the control group versus silicone gel sheeting 
(SMD (95% CI)=1.20 (0.56, 1.84)). Further results are reported in detail in Appendix 3. The 
greatest effect for pliability was identified at six months post-intervention commencement in 
favour of silicone gel sheeting compared to pressure garment therapy (SMD (95% CI)=0.45 
(-0.09, 1.00)) and in favour of silicone gel sheeting when compared to the control (SMD 
(95% CI)=-0.45 (-1.04, 0.14)).  
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3.4.4.2 Meta-analysis 
3.4.4.2.1 Silicone products 
Primary outcomes 
Data were insufficient to enable meta-analysis of primary outcomes for silicone 
interventions.  
 
Secondary outcomes 
Two studies [65,78] were able to be combined for meta-analysis for one secondary outcome 
(pliability). These studies were combined as they investigated the same intervention 
(silicone gel sheeting), at the same time point (four months post-intervention 
commencement) using the same outcome measure (VSS). Meta-analysis found silicone gel 
sheeting improved pliability at four months post-burn in comparison to a control group who 
received a placebo gel or lanolin massage. A large standardised mean difference was 
identified, SMD (95% CI)=-1.89 (-4.19, 0.41). Heterogeneity was high (I2=95%) for this 
comparison although the direction of the results were similar, being in favour of silicone gel 
sheeting. Subgroup analyses were not possible to further investigate heterogeneity as only 
two studies were available for inclusion in the meta-analysis. Pliability was not considered a 
critical outcome. Thus, a GRADE quality of evidence was not completed. The forest plot is 
illustrated in Figure 3.3. 
 
 
Figure 3-3 Silicone intervention: Pliability 4 months post-intervention commencement 
 
3.4.4.2.2 Pressure garment therapy 
Primary outcomes 
Meta-analysis for one primary outcome (scar thickness) was able to be completed at one 
(Figure 3.4), two (Figure 3.5) and three (Figure 3.6) months post-intervention 
commencement for two studies. Studies were combined due to a similar intervention (high 
vs low interface pressure garment therapy), measured at the same time using objective 
thickness measurement devices (TUPS and Dermascan C). High pressure dosage 
significantly reduced scar thickness at one and two month time points (SMD (95% CI)= 
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-0.54 (-0.89, -0.18) and -0.62 (-1.12, -0.12), I2=0% and 48% respectively). A medium 
standardised mean difference, was also recorded at three months post-intervention 
commencement (SMD (95% CI)=-0.65 (-1.33, 0.02)) though heterogeneity had increased 
I2=71%. The difference in time of intervention commencement (two weeks post re-
epithelialisation versus mean (SD) 5.21 (1.94) months post-burn injury) could potentially 
influence the size of the effect at three months post-intervention commencement thus 
increasing heterogeneity. Despite increasing heterogeneity, the direction of the effect was 
the same (in favour of high interface pressure) and the quality of evidence was ranked as 
moderate using GRADE. 
 
 
Figure 3-4 Pressure garment therapy intervention: Thickness 1 month post-intervention commencement 
 
 
Figure 3-5 Pressure garment therapy intervention: Thickness 2 months post-intervention commencement 
 
 
Figure 3-6 Pressure garment therapy intervention: Thickness 3 months post-intervention commencement 
 
Secondary outcomes 
One secondary outcome (erythema a* value) was able to be considered for meta-analysis 
at one, two and three months post-intervention commencement. A small standardised mean 
difference was observed at one month post-intervention commencement (SMD (95% CI) = 
-0.26 (-0.64, 0.12), Figure 3.7). The effect size increased to a small to moderate 
standardised mean difference (SMD (95% CI)=-0.34 (-0.87, 0.19) and -0.38 (-0.99, 0.23) at 
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two (Figure 3.8) and three (Figure 3.9) months post-intervention commencement 
respectively). Standardised mean differences were in favour of a high pressure dosage for 
the reduction of erythema at all time points. Heterogeneity of the included studies increased 
from 14% at one month post-intervention commencement to 65% at three months post-
intervention commencement. Similarly to the thickness outcome, the time of intervention 
commencement could have influenced the size of the effect seen with more potential for 
improvement in the study participants who received the delayed intervention [90]. The 
quality of the evidence was not ranked using GRADE as erythema was not considered a 
critical outcome. 
 
 
Figure 3-7 Pressure garment therapy intervention: Erythema 1 month post-intervention commencement 
 
 
Figure 3-8 Pressure garment therapy intervention: Erythema 2 months post-intervention commencement 
 
 
Figure 3-9  Pressure garment therapy intervention: Erythema 3 months post-intervention commencement 
 
3.4.4.2.3 Combined silicone and pressure garment interventions 
Meta-analysis of studies investigating combined interventions was unable to be completed 
due to differences in intervention, follow up time points and outcome measures used. 
 
3.5 Discussion 
The aim of this systematic review was to determine: (1) the effectiveness of silicone and 
pressure garment therapy (alone or in combination) for the prevention and management of 
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post-burn scarring and; (2) the time-points at which the interventions were most effective. 
The search yield of this systematic review identified one new trial (in English) assessing the 
effectiveness of pressure garment therapy and two new trials assessing the effectiveness 
of silicone products with the addition of an herbal extract since the completion of earlier 
systematic reviews. The results of this review highlighted that investigation of health-related 
quality of life in randomised controlled trials assessing silicone and pressure garment 
therapy has not been completed. This is despite the clinical significance of findings related 
to individual scar characteristics being questioned in previous systematic reviews [1] and 
increasing awareness in the literature of the importance of using patient-reported outcome 
measures [5,44] assessing constructs such as health-related quality of life. Knowledge of 
adherence to interventions, and the implications of interventions on different sub-
populations such as wound healing type (i.e. grafting versus spontaneous healing) and body 
locations is limited. Additionally, this review highlighted a lack of evaluation of intervention 
fidelity in randomised controlled trials of silicone and pressure garment therapy to date.  
 
Interestingly, calculated effect sizes for two studies investigating the effectiveness of silicone 
[65] or pressure garment therapy alone [90], demonstrated one month post-intervention 
commencement to have the greatest effect on burn scar pain and four months-post 
intervention commencement to have the greatest effect on itch. However, the interventions 
from these two studies were initiated between two and five months post-burn injury. 
Therefore, the greatest effect on burn scar itch was slightly delayed compared to previous 
longitudinal work where a reduction in sensory symptoms was reported from three months 
post-burn injury [33]. In comparison, a study assessing the effectiveness of combined 
pressure garment therapy and silicone gel sheeting versus each of these interventions alone 
and a control group, identified six months post-intervention commencement as the period of 
greatest intervention effect for sensory symptoms [11]. Silicone gel sheeting was the most 
effective for itch management and combined interventions were most effective for pain. The 
different findings could potentially have been due to population differences (Caucasian 
versus Asian skin types), time of intervention commencement (wound re-epithelialisation 
versus mean (SD) 14.9 (30.8) months post-burn) or pressure dosage. In contrast to previous 
studies conclusions that pressure garment therapy is most effective at higher pressure 
dosages, the standardised mean difference calculations for itch and pain identified lower 
pressure to have the greatest effect on these sensory symptoms. However, the authors of 
that study [112] noted that different amounts of padding were inserted beneath the pressure 
garment to ensure the correct pressure was applied to the burn scar. The high pressure 
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group had more padding than participants in the low pressure group and the authors 
postulated that reduced itch in the low pressure group was due to less layers of padding and 
thus increased thermoregulation.  
 
Results of this review have implications for pressure garment therapy dosage prescription. 
If further research identifies greater effect sizes at lower interface pressures for management 
of sensory symptoms then it may be that pressure garment therapy should be prescribed at 
lower dosages (15mmHg and under), particularly in the early stages of scar management. 
The effectiveness of low interface pressure for sensory symptom management is worth 
investigating further in future pressure garment therapy studies. 
 
For scar thickness outcomes, two studies [13,90] investigating the effectiveness of pressure 
garment therapy identified a small to medium effect on scar thickness when interface 
pressure levels were in the normal to high range (20mmHg) at one month post-intervention 
commencement. A large effect was identified at four months post-intervention 
commencement. Meta-analysis identified improvements in scar thickness in favour of a 
normal to high interface pressure level at one, two and three months post-intervention 
commencement. When silicone gel sheeting was directly compared to pressure garment 
therapy, pressure garment therapy was less effective in reducing scar thickness when 
considering effect size calculations. However, when the combined silicone gel sheeting and 
pressure garment therapy group was compared to the interventions alone, the standardised 
mean differences favoured the combined intervention group. This finding is similar to the 
results reported in a previous systematic review [12]. When assessing scar thickness in 
silicone only investigations (versus control), silicone was reported to reduce scar thickness 
across the study period [78]. The greatest effect on thickness was calculated to be at six 
months post-burn injury in the silicone study assessing the effectiveness of an adherence 
intervention [77]. 
 
The reporting of adverse effects was more common in studies of silicone products compared 
to pressure garments. However, only one pressure garment study [110] pre-specified 
adverse effects as an outcome measure and three silicone studies [9,65,94] pre-specified 
procedures regarding the identification of adverse effects such as withdrawal from the study, 
discontinuation of treatment or exclusion from analyses. Greater rates of adverse effects 
were reported for silicone gel sheeting products compared to other silicone products. It is 
hypothesised that silicone gel sheeting results in greater rates of adverse effects compared 
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to other silicone products due to hydration of the scar and surrounding skin beyond the 
amount required to resume homeostasis in trans-epidermal water loss [9,61,63,70,72]. The 
presence of adverse effects in one combined intervention group [94] were attributed to the 
silicone gel sheeting component though further investigation is needed to confirm whether 
adverse effects can be attributed to the pressure or silicone component.  
 
The greatest effect for secondary outcomes such as pigmentation, colour, vascularity and 
pliability was commonly observed at four months post-intervention commencement for 
studies investigating silicone or pressure garment therapy interventions alone. A peak in 
intervention effect at four months post-intervention commencement could indicate that a 
minimum of four months of intervention is necessary for improvements to be seen in these 
physical scar characteristics. However, differences in intervention commencement need to 
be taken into consideration. Further research is required close to this time point to determine 
if it could be critical for evaluating the peak effect of interventions. The large standardised 
mean difference identified in the meta-analysis of pliability adds support to the conclusion 
[12] that silicone is beneficial for pliability of the scar.  
 
Three previous systematic reviews have assessed the effectiveness of pressure garment 
therapy alone [1,97] and silicone gel sheeting [63] for the prevention and management of 
abnormal scarring. The pressure garment reviews focused on post-burn scarring [1,97] 
whereas the silicone gel sheeting review incorporated all scarring resulting from a full 
thickness wound [63]. The studies included in the earlier pressure garment therapy 
systematic review were reported by the authors to be of a high quality using the Jadad and 
Schultz scales [1]. The Jadad and Schultz scale only considers randomisation, blinding and 
attrition and it has been suggested that the responsiveness of the scale may be too low for 
rehabilitation research [113]. Outcomes were limited to overall scar appearance, height, 
vascularity, pliability and colour or pigmentation [1]. Meta-analysis was completed for overall 
scar appearance on an unidentified scale. The results of this review reported a potential 
impact on burn scar thickness but did not identify conclusive support for the use of pressure 
garment therapy in the management of burn scarring and recommended future research in 
the field [1]. The clinical significance of improvements in a single scar characteristic such as 
thickness was questioned [1]. The most recent pressure garment therapy review completed 
in 2017 [97] included 12 studies which were judged by the authors to be a moderate quality 
overall using the Cochrane risk of bias tool. However, studies evaluating physical scar 
characteristics such as scar thickness using scar scales and objective measures were 
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pooled and no assessment of the risk of bias across outcomes using GRADE was used. In 
addition, only studies examining pressure of 15 to 25mmHg (the minimally effective pressure 
range) and physical outcomes on the Vancouver Scar Scale (VSS) thickness, colour, 
pigmentation, hardness and vascularity were examined. Yet, as found in our review lower 
level pressures (<15mmHg) were identified as being more effective than higher level 
pressures for some outcomes at some time points. Thus, by focusing on pressure levels of 
15 to 25mmHg, the effect of lower level pressures was not determined. The effect of higher 
pressures dropping to lower pressures in the same participants (mirroring clinical practice) 
[90,114,115] was also not determined. Further, effect sizes of individual studies were not 
calculated to interpret the results. The authors concluded there was evidence to support the 
use of pressure garment therapy for reducing the overall VSS score, pigmentation and 
redness as well as increasing scar brightness [97].  
 
Two systematic reviews have evaluated the effectiveness of a combined silicone and 
pressure garment therapy approach, though this has been as part of reviews with a broader 
focus. In 2014, a systematic review [7] examined the effectiveness of conservative (silicone 
products, pressure garment therapy, combined silicone and pressure garment therapy, 
topical emollients, systemic therapies) and select surgical interventions (intralesional 
therapy, laser, non-specified surgical interventions) for managing hypertrophic burn 
scarring. In relation to silicone and pressure garment therapy, the authors concluded that 
conflicting information was available for pressure garment therapy though results were 
positive for silicone products [7]. When the interventions were used in combination, the 
evidence was inconclusive. A lack of statistical power in completed studies and issues of 
bias were noted [7]. In 2016, an additional systematic review was completed assessing the 
effectiveness of conservative interventions only (i.e. silicone products, pressure garments, 
combined silicone and pressure garment therapy, massage, hydration and ultrasound) [12]. 
The authors of this review concluded that pressure therapy was most effective for reducing 
scar thickness with a greater reduction in scar thickness observed in higher pressure groups 
[12]. However, the authors’ noted that a minimally effective dosage of pressure has not been 
identified [12]. Silicone products were concluded to be effective for pliability and potentially 
erythema outcomes. When used in combination however, inconclusive results were 
reported, as in the 2014 review.  
 
One of the difficulties in interpreting the effectiveness of burn scar interventions in the past 
has been a lack of knowledge regarding the natural progression of burn scarring. However, 
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recent longitudinal studies [33,38] have mapped scar progression in adults and children. It 
is not clear whether these studies included people at risk of scarring or those who presented 
with abnormal scarring. Longitudinal work has indicated that in the presence of standard 
treatment (silicones, pressure, moisturiser), most scar characteristics (itch, pain, thickness, 
vascularity, colour, pliability) improve between six and 12 months post-burn. Some 
characteristics significantly improve between three and six months post-burn (pigmentation 
and vascularization) but other characteristics significantly decline (pliability, relief and 
thickness; indicating scar worsening) [33]. These findings are supported by the results in 
this review whereby greatest intervention effects for vascularity, colour and pliability were 
observed at four months post-intervention commencement (likely to coincide with 
approximately six months post-burn injury for most studies). Pain and itch progressively 
decreased between three and six months post-burn but the greatest decrease occurred 
between six and 12 months [33]. Effect sizes calculated from this review indicate that the 
greatest reduction in pain and itch symptoms is at one and four months post-intervention 
commencement. Thus, it is expected that on average within the first six months post-burn, 
scar progression in the presence of intervention may improve, be stable or worsen whilst 
serial measurement from six to 12 months post-burn should show improvements. The one 
study that assessed long term effectiveness of interventions (combined vs. pressure 
garment therapy alone) [9] had small to medium standardised mean differences at 18 
months post-burn for overall scar score, itch and scar texture. These results potentially 
indicate that scar characteristics continue to improve beyond the 12 month point. 
 
The clinical importance of an improvement in one physical scar characteristic has been 
questioned in recent reports. It has been acknowledged that the person’s experience of the 
scar is complex and thus scar assessment requires a broad evaluative framework [5,45]. A 
recent study in adults found that for every one point increase in the total score on the 
modified Vancouver Scar Scale the person’s quality of life (as assessed by the Burn Specific 
Health Scale-Brief) reduced by 1.09 points [36]. However, there were no associations 
between individual scar characteristics on the mVSS and quality of life [36]. In addition, it 
was reported that a five point increase on the mVSS total score was required before a 
clinically important reduction in quality of life was described by the person [36]. Further work 
is required to identify clinically meaningful minimally important differences in scar 
assessments. Therefore, findings of statistically significant results or large standardised 
mean differences for one scar characteristic may not lead to clinically significant changes. 
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Person-centred care including patient driven goal setting and personalised scar assessment 
may assist in identifying clinically significant changes for the individual.  
 
It must be noted that recording of important intervention components and assessment and 
reporting of treatment adherence and clinician’s fidelity to interventions was poorly reported 
in the included studies. In addition, whilst interface pressure was measured and reported in 
assessment of high pressure versus low pressure garment therapy, this was not often 
reported in studies assessing the effectiveness of interventions combining silicone and 
pressure garment therapy. Thus, the dose of the intervention provided within and across 
studies was not clear. Therefore, it is difficult to determine if the limited number of clinically 
significant standardised mean differences between groups are due to a lack of effectiveness, 
poor adherence and intervention fidelity, adverse effects or a lack of consistent interface 
pressure application. There has also been insufficient investigation regarding the 
implications of scar site clustering on effect sizes and power in past studies. The risk of bias 
for all intervention types across studies was unclear or high for all risk of bias domains 
(excluding random sequence generation). Thus, the results across studies should be 
interpreted cautiously until further high quality research is conducted. It must also be noted 
that only one study completed follow up assessments at 18 months post-burn [9] and no 
study examined length of time to scar maturation as a variable limiting knowledge of long-
term outcomes. 
 
3.5.1 Future investigations 
In this review, standardised mean differences could only be calculated in single scar 
characteristics. In light of recent findings [36] that a five point reduction in the overall score 
on a measure of scar severity (calculated by adding all items on the mVSS) is needed to 
improve quality of life, future investigations need to extend beyond the traditional physical 
scar outcomes. Assessment needs to consider a comprehensive range of evaluative 
outcomes including health-related quality of life and cosmetic outcomes. The investigation 
and the reporting of adherence to scar interventions and the presence and type of adverse 
effects is also important as these outcomes may influence the interpretation of the results of 
effectiveness studies. Further investigation regarding the minimally effective pressure range 
is also required including assessment of the effectiveness of high versus low interface 
pressure on different scar characteristics and patient reported outcomes. 
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3.5.2 Limitations 
Meta-analysis or other assessment of results across studies was limited in this systematic 
review due to differences in participant groups, intervention products, time frames, outcome 
measures, and reports of adherence, fidelity and adverse effects. Heterogeneity as 
determined by the I2 statistic also increased over time. Increasing heterogeneity could be 
due to differences in time of intervention commencement, or differences in the control group 
and skin type and warrants further investigation. The author’s note that a core set of 
outcomes for future randomised controlled trials in the burns field is currently under 
development [116] and which may assist in directing the outcomes that should be 
considered in systematic reviews and future studies. The number of participants included in 
studies remains small, impacting study power. Multi-site studies may be required to 
accumulate evidence based on reasonable sample sizes but such studies come with their 
own challenges such as organisational differences, intervention and assessment 
implementation differences and difficulty maintaining clinical equipoise across sites.  
 
It is acknowledged that factors other than those presented in this study may be important 
for measuring the effectiveness of scar management interventions (i.e. sensation, skin 
dryness, daily activities, social functioning, mental health functioning). These outcomes 
have been assessed where applicable in included studies but the search strategy did not 
specifically include activities of daily living, social functioning, psychosocial health or mental 
health search terms for this review. It is possible that some studies were missed although 
this field is well known to the investigators. The authors acknowledge that there may be 
additional valuable studies available in languages other than English (n=4 non-English 
articles were excluded). The lack of reporting of adverse effects, adherence and fidelity in 
studies is also of note and needs to be considered in future studies in this field to allow an 
analysis of benefits versus harms and ensure interventions are being used and being used 
as recommended.  
 
3.6 Conclusions 
This systematic review adds new knowledge regarding intervention effectiveness for post-
burn scarring by using rigorous methodology and including studies that have not previously 
been included in systematic reviews. Risk of bias assessments both within and across trials 
and analyses of standardised mean differences contributed to the rigour of the review. 
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Analysis of standardised mean differences provided novel information regarding at which 
time point the intervention was most effective. 
 
The results of this systematic review suggest that the greatest effect of interventions is one-
month post intervention commencement for pain and four months post-intervention 
commencement for itch. The greatest effect for scar thickness is also early in the intervention 
period and silicone or pressure garment therapy can be used for the management of burn 
scar thickness. If pressure garment therapy is used, a higher level of pressure (20mmHg as 
opposed to <15mmHg) may be necessary for managing scar thickness. Additional physical 
scar characteristics require at least four months of scar management for the greatest effects 
to be observed. No comment can be made on the impact of silicone or pressure garment 
therapy for health-related quality of life outcomes, which is an important consideration for 
future studies. Results should be considered in light of the unclear or high risk of bias for 
allocation concealment, blinding of participants, outcome assessment, incomplete outcome 
data, selective reporting and other biases observed in the randomised controlled trials. 
Differences in outcome measures, interventions and assessment time points limit the ability 
to pool data of individual studies.  
 
The use of objective, reliable and valid outcome measures including interface pressure in 
adequately powered studies has been recommended in all systematic reviews to date and 
is a recommendation from this study. It is also recommended that future studies in this field 
have longer follow up time points and follow the TiDIER guidelines [53] when reporting trials 
to enable the replication of the study interventions and interpretation of the dose of 
intervention that is effective.  
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3.7 Chapter conclusion 
Chapter Three has investigated the effectiveness of silicone and pressure garment therapy 
for managing post-burn scarring in adults and children. Meta-analysis and synthesis of the 
results was restricted due to differences in participants, interventions, outcome measures, 
time periods post-burn and intervention commencement and duration. Recommendations 
from this systematic review were considered in the design and reporting of the randomised 
controlled trial discussed in Chapters Five and Six.  
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CHAPTER 4 Pressure at the interface of pressure garments 
and burn scars in children 
 
This chapter is based on two published papers in the journal Burns.  
Citations: 
1. Wiseman J, Simons M, Kimble R, Tyack Z. Reliability and clinical utility of the Pliance 
X for measuring pressure at the interface of pressure garments and burn scars in 
children. Burns 2018; 44(7):1820 
2. Wiseman J, Simons M, Kimble R, Tyack Z. Variability of pressure at the pressure 
garment-scar interface in children post-burn: a pilot longitudinal cohort study. Burns 
2019; 45(1):103 
 
 
As an author on both publications I made a major contribution to the conception and design 
of the project (50%), analysis (100%) and interpretation of the research data (80%) and 
drafted the publications (85%) with input and feedback from the supervisory team and 
statistician as appropriate. 
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4.1 Chapter foreword 
Pressure garment therapy is one of the most common prophylactic burn scar interventions 
in high-income countries. They can be in the form of ready to wear or custom-made 
garments and are recommended to be worn for 23 hours per day until scar maturation. 
Despite their long history of use, the mechanism of action and the effectiveness of pressure 
garment therapy has not been confirmed. The ideal pressure supplied by the pressure 
garment at the pressure garment-scar interface has also not been confirmed though is 
generally recommended to be in the range of 15 to 25 mmHg. It has not been common 
practice in clinical or research settings to measure the interface pressure of pressure 
garments. Interface pressure monitoring is limited by the availability of a valid, reliable, cost 
effective interface pressure measurement device. Therefore, the actual pressure applied to 
the area of interest is an unknown. As such, the effectiveness of pressure garment therapy 
in preventing and managing post-burn scarring is impacted by an inability to assess and 
recommend a therapeutic pressure ‘dosage’. 
 
The aim of the pilot longitudinal cohort study presented in this chapter was two-fold. Firstly, 
to identify the reliability and clinical utility of the Pliance X® interface pressure measurement 
device in children wearing their first pressure garment post-burn. Secondly, to determine the 
interface pressure over the first three months of wear of children’s first pressure garment 
post-burn and identify factors influencing interface pressure fluctuations. This chapter is 
divided into two sections to address both aims of the pilot longitudinal cohort study. Part A 
is based on the publication published in Burns in 2018, titled ‘Reliability and clinical utility of 
the Pliance X for measuring pressure at the interface of pressure garments and burn scars 
in children’. A detailed methodology, results and discussion will be presented.  
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PART A 
4.2 Introduction 
4.2.1 Background 
Pressure garment therapy has been a commonly used burn scar intervention for 
approximately 40 years [7,8,95]. It has been assumed that the pressure garment’s ability to 
supply a consistent level of pressure to the burn scar is an important component of the 
mechanism of action, although the exact mechanism remains unclear [8,13,86,87]. The 
therapeutic dose of pressure is also unclear. Theoretically, a consistent pressure of 24 to 
25mmHg would be required to overcome local capillary pressure [13,86,87]. However, some 
reports have documented improvements in scar characteristics using 10 to 15mmHg of 
pressure [92] and low levels of pressure from interim pressure garment therapy (3 to 
5.8mmHg) [93] have been considered an adequate method of supplying pressure garment 
therapy in the past [85]. Sustained pressure of above 40mmHg is reported to lead to 
detrimental outcomes including skin maceration and paraesthesia [11,13,87]. In the current 
literature it is accepted that pressures between 15 to 25mmHg have the greatest benefit, 
particularly for reducing scar thickness [8,13,90]. 
 
Few studies have evaluated and stated the level of pressure at the pressure garment-scar 
interface. This is despite several reports indicating that a consistent level of pressure should 
be applied to the burn scar until scar maturation [1,85,86]. In children, awareness of the level 
of pressure applied by pressure garments over time is particularly important as pressure is 
anticipated to fluctuate as children grow and their body shape changes. Further, knowledge 
of the interface pressure is required to determine the effectiveness of pressure garment 
therapy and to allow replication of effective therapeutic doses in future studies [53].  
 
The main difficulty in implementing interface pressure measurements in research and 
clinical practice has been a lack of a valid, reliable device that provides an accurate 
representation of the pressure at the pressure garment-scar interface [117]. The ideal 
pressure device should have a small, thin flexible sensor that is not impacted by temperature 
or curved surfaces and does not distort the garment (or the skin surface) when in situ 
[117,118].  
 
The Pliance X® (Novel Electronics, Munich, Germany) is a pressure measuring device that 
uses capacitive transducers in a thin flexible probe to measure pressure at the interface of 
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the pressure garment and burn scar [117,119]. The capacitive transducer technology uses 
electrical elements that change in response to pressure [117,119]. This form of sensor 
provides the Pliance X® system with increased flexibility, sensitivity and decreased 
temperature sensitivity and the sensors can be used individually or in a matrix format 
[117,119]. Interface pressures are relayed to a windows operating system either via fibra-
optic cable or via blue tooth where data can be stored and viewed within the Novel database 
[16]. 
 
Reliability testing of the Pliance X® has previously been completed on a hard surface during 
laboratory tests where the sensor was placed over a hard plastic disc and a standardised 
weight loaded on top. A Pearson’s Moment Correlation Coefficient of 0.998 and Inter-class 
Correlation Coefficient of 0.998 were obtained for test-retest reliability during lab testing 
[117]. Inter-rater reliability was 95% (confidence interval, 0.995-1.000) [117]. However, 
these results may not generalise to a soft surface. Accuracy of the Pliance X® was tested 
on a soft surface, by positioning the sensor beneath a sphygmomanometer on eight 
anatomical positions in five healthy volunteers. A maximum mean percentage difference of 
6.42% was recorded between the pressure reading of the Pliance X® and the 
sphygmomanometer cuff [117]. The investigators found the device to be easy to use with 
adults with mature scarring, requiring one to two training sessions [117]. The reliability and 
clinical utility of the Pliance X® has not been reported with children post-burn.  
 
4.2.2  Objectives 
The objectives of this paper were to determine: (1) the test-retest reliability of the Pliance X® 
using stationary measurements in children receiving pressure garment therapy for the 
prevention or treatment of burn scars; and (2) the clinical utility of the Pliance X® using 
stationary and dynamic measurements in this population.  
 
4.3 Methods 
4.3.1 Study Design 
Test-retest reliability and clinical utility of the Pliance X® were examined as part of a 
longitudinal cohort study investigating the pressure at the pressure garment-scar interface 
in children post-burn, with children consecutively sampled. Recruitment was completed 
between January and June 2016 and in August 2016. Recruitment was not conducted in 
July as the outcome assessor was unavailable.  
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A sample size of 19 participants were estimated to be required for an ICC of 0.9 and a 
minimally acceptable ICC of 0.7, using an alpha of 0.05 and 80 percent power [120]. An ICC 
of greater than 0.9 was expected based on ICCs that might reasonably be expected for 
immediate test-retest of an objective device and a previous reliability testing of the Pliance 
X® that obtained an ICC of greater than 0.9 [117], albeit in laboratory testing. Assessment 
of test-retest reliability requires data to meet the assumption of a stable response variable 
[121]. During dynamic measurements, the response variable was not expected to be stable 
due to potential inconsistencies when completing dynamic movements. Therefore, test-
retest reliability was completed for stationary measurements only. Reliability and clinical 
utility data was required as a precursor to use of the Pliance X® in a large randomised 
controlled trial investigating the effectiveness of topical silicone gel, pressure garment 
therapy and combined topical silicone gel and pressure garment therapy for the prevention 
and management of post-burn scarring in children [122].  
 
Ethical clearance was received from the Children’s Health Queensland Human Research 
Ethics Committee, Brisbane (HREC/15/QRCH/240). This study is reported according to 
STROBE guidelines [123]. 
 
4.3.2 Setting 
Data were collected at a metropolitan outpatient burns centre within a large tertiary children’s 
hospital. The most common burn injuries treated at this facility were scald and contact burns 
in the under two age group [17]. Patients were predominantly male [17]. In the study setting 
children with burn scars, or at risk of burn scars, were treated using a multi-modal approach 
to scar management including pressure garment therapy, inserts beneath pressure 
garments (where indicated), silicone products, moisturisers, and education regarding skin 
and sun protection.   
 
4.3.3 Participants 
4.3.3.1 Inclusion Criteria 
Participants eligible for inclusion in this study were children aged less than 18 years, at risk 
of burn scarring; children fitted with their first pressure garment within the first three months 
post-burn and likely to return to the participating burns outpatient clinic for follow up; and 
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children presenting to the burns clinic with a guardian able to provide informed consent. 
Children with scars or at risk of scars in any body location(s) were included. 
 
4.3.3.2 Exclusion Criteria  
Children not receiving pressure garment therapy for burn scar management; presence of a 
comorbidity (e.g. amputation) with the potential to effect the interface pressure; children 
involved with the Department of Child Safety where participation was considered to be 
contrary to the best interests of the child and family as determined by the burns 
multidisciplinary team were excluded. 
 
4.3.4 Procedure and study equipment 
Families meeting the inclusion criteria were approached after pressure garment therapy was 
recommended at the participating children’s hospital outpatient service. All measurements 
were completed face-to-face at the same hospital. The Pliance X® was used to measure 
pressure at the interface of the pressure garment and burn scar, recorded in millimetres of 
mercury (mmHg) [119]. A single long, thin sensor was used for all measurements to maintain 
consistency.  
 
The device was set up as illustrated in Figure 4.1 (dynamic measurements), or if working 
with a young child, the device was worn by the user in the novel belt to prevent dropping/ 
moving of the device by the child. Prior to measurement the sensor was positioned on a flat 
surface and was ‘unloaded’ (i.e. ‘zeroed’) to ensure there was no load on the sensor surface 
as per the device’s instructions. 
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Figure 4-1 Pliance X set up dynamic measurements 
 
To ensure the sensor was in the correct position the pressure garment was first donned over 
anchor points or areas typically difficult to don a pressure garment (e.g. heel of foot, fingers 
of gloves), whilst keeping the selected scar site visible. The sensor was then placed over 
the scar and the researcher held the sensor in place whilst the child or therapist donned the 
remainder of the pressure garment (e.g. pulled up the limb), as per Figure 4.2. Alternatively, 
the end of the pressure garment nearest the selected scar site was lifted up, allowing the 
sensor to slide over the skin and rest over the scar. The child was asked if the sensor was 
in the correct position if they were able to verbalise a response. The sensor was applied 
directly onto the skin without any substance applied to the skin in the 15 minutes prior to 
measurement. Skin products the participant was using (e.g. moisturiser, sunscreen, silicone) 
were not recorded. 
 
 
Figure 4-2 Inserting Pliance X sensor 
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A 10 second stationary measurement, followed by a 10 second dynamic measurement was 
then completed. Activities to promote movement for the dynamic measurement included ring 
stacking for children having pressure recorded on their upper body and walking for children 
completing lower body pressure measurements. On completion of the dynamic 
measurement, the sensor was removed by sliding the sensor out of the pressure garment 
(see Figure 4.3), or if this was difficult, the pressure garment was doffed, sensor removed, 
and the pressure garment re-donned. The sensor was then re-positioned at the pressure 
garment-scar interface, as previously described, and an immediate 10 second stationary 
retest measurement was completed. Relocation of the selected scar site was conducted 
using body measurements.   
 
 
Figure 4-3 Removing Pliance X sensor 
 
A 10 second period was used for stationary and dynamic measurements as this provided 
500 interface pressure data points which was anticipated to be sufficient for pressure 
analysis as well as being a tolerable period for young participants. Age appropriate 
distractions were used for stationary measurements as required (e.g. bubbles, toys, music, 
iPad) and ring stacking was selected for upper body dynamic measurements as it was 
considered an engaging activity for young children and tolerated by older children.  
 
Pliance X data was then converted to an ACSII format which allows the 500 pressure 
readings per measurement to be viewed outside of the Novel database and a mean pressure 
to be calculated for both stationary measurements and the one dynamic measurement. 
Calibration of the device was completed by the Australian Novel representative using the tru 
blu® calibration device as per manufacturers’ guidelines throughout the study period (every 
3 to 6months). The tru blue® device uses increasing air pressure to develop a unique 
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calibration curve for the sensor of choice [119]. The calibration curve provides a reference 
for pressure calculated during data collection [119].  
 
Clinical utility was assessed using four criteria to determine the effectiveness and relevance 
of a device (appropriate); funding and resource implications (accessible); functionality, 
suitability and training requirements (practicable); and acceptability to users including 
clinicians and families (acceptable) [124,125]. 
 
4.3.5 Data analysis 
Descriptive statistics (i.e. counts and percentages or medians and interquartile ranges for 
non-continuous data and means and standard deviations for continuous data) were used to 
analyse the sociodemographic and clinical characteristics of participants. Data were 
screened for normality and outliers. Extreme outlier values were removed prior to ICC 
analysis as recommended [126]. Statistical analyses were completed using SPSS24 
software (SPSS Inc., Chicago, IL, USA). A two way random effects model ICC with 95% 
confidence intervals was used to determine test-retest reliability. An ICC of greater than 0.7 
for research purposes and an ICC of greater than 0.9 for clinical (individual) purposes were 
deemed acceptable [126]. However, an ICC of greater than 0.9 was expected based on the 
use of an immediate test-retest interval of an objective device, and a reliability coefficient of 
0.998 in previous testing using a hard surface [117].  
 
4.4 Results 
4.4.1 Participants 
Baseline data was obtained from 31 participants. At baseline, participants of the longitudinal 
cohort study had a median age of three years, were predominantly male (61%), had a 
median percentage total body surface area burned (TBSA) of 3% and had a median of 42 
days post-burn. Baseline stationary interface pressure (Shapiro-Wilk p=0.07) and retest 
stationary interface pressure (Shapiro-Wilk p=0.07) were normally distributed. Additional 
details of the sociodemographic and clinical characteristics of the sample are reported in 
Table 4.1. 
 
4.4.2 Reliability  
Baseline data was collected on a single scar site for 31 participants, however the second 
stationary measure for examining test-retest reliability could only be completed for 28 
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participants due to patient distress (n=3). Agreement of the test and retest stationary 
interface pressure measurements were determined by a Bland Altman plot. Figure 4.4 
illustrates the mean of the baseline stationary interface pressure measurements versus the 
average difference between baseline stationary test and retest measurements,  
Mean (SD)=-1.63 (8.53). Extreme outlier data for one participant was removed prior to ICC 
analysis, therefore n=27. The sensor was observed to have moved beneath the seam of the 
pressure garment when the pressure garment was re-donned during the retest 
measurement for that participant. Test-retest reliability of the Pliance X was found to be 
acceptable for research purposes (ICC=0.87) however the coefficient was slightly lower than 
the expected ICC of 0.9 or higher for an objective device.   
 
 
Figure 4-4 Bland Altman plot of the test-retest reliability of the Pliance X (n=28) 
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Table 4-1 Sociodemographic and clinical characteristics of participants 
 
Participant characteristics Baseline  
Number of participants  (% of sample)a 
Number of participants  31 
Male gender 19 (61%) 
Age in years  
Median (IQR), range 
 
 
 3 (1.5, 7.5), 1-14 
%TBSA burned  
Median (IQR), range 
  3 (1, 6), 0.5-36 
Caregiver education  
Completed post school qualification 18 (58%) 
  Completed senior high school 11 (36%) 
   Missing 2 (6%)  
Grafted  14 (45%) 
Scar location  
 Torso 6 (19%) 
  Upper limb 9 (29%) 
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  Lower limb 16 (52%) 
Fitzpatrick skin type   
Type I – Always burn 3 (10%) 
 Type II – Tan with difficulty 2 (6%) 
    Type III – Tan about average 11 (35%) 
    Type IV – Tan more than 
    average 
5 (16%) 
    Type V – Brown skin 7 (23%) 
   Type VI – Black skin 0 (0%) 
       Missing 3 (10%) 
No. of days post-burn  
Median (IQR), range 
 
42 (31, 56), 20-103 
 
Abbreviations: IQR = interquartile range 
a Number (percentage) except where indicated 
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4.4.3 Clinical utility of the Pliance X®  
Clinical utility of the Pliance X® in the paediatric burn scar population is reported in detail in 
Table 4.2. Clinical utility for stationary and dynamic measurements was established using 
the baseline sample (n=31). Appropriateness and acceptability was supported for children 
of all ages who were not distressed, children who could follow instructions or children who 
could be distracted whilst measurements were being completed. Practicality and 
accessibility of the device was limited by costs, available technical support, the size of the 
sensors available for use in this study and the need for calculations of a mean interface 
pressure score.  
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Table 4-2 Clinical utility of the Pliance X® 
Dimensions of 
Clinical Utility 
Comments on Clinical Utility 
Appropriate Existence of formal evidence: Using the results of the current 
study, the reliability of the Pliance X® has been supported in both 
adult and paediatric patients for the purpose of measuring 
pressure at the pressure garment-scar interface. One study 
testing the device on a hard surface reported an ICC of 0.998 with 
clinical utility being supported in an adult group with mature 
hypertrophic scars [14]. This current study of children with burn 
scars in the post-acute period demonstrated a slightly lower 
reliability with an ICC of 0.87.  
Importance for clinical decision-making: The Pliance X® has a 
slim line, flexible sensor that can be positioned over curved 
surfaces without distorting the pressure garment or scar surface. 
The capacitive transducer technology reduces temperature 
sensitivity in comparison to other devices. The Pliance X® also 
objectively measured the pressure at the garment-scar interface 
for every 0.02 seconds of measuring time during this study.  
Impact on existing treatment process, current work or care: The 
Pliance X® can record interface pressure rapidly (less than 2 
minutes). However setting up the device (taking approximately 5 
minutes) and calculating the mean pressure (taking 
approximately 5 minutes per measurement) can be time intensive 
in a busy outpatient setting.  
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Accessible Cost: The cost of the device was approximately $48,000 AUD 
(approx. 32,270 Euros), with a very rapid delivery time frame (less 
than one week) between order approval and receipt of device. 
There was an additional cost to send the device to the Australian 
agent for calibration every three months in this study. However, a 
calibration device can be purchased to enable self-calibration as 
an alternative.   
 
Training: At the commencement of this study two face-to-face 
training sessions were completed for members of the author team 
by the agent for the company. Phone and email support was also 
accessed as required throughout the course of the study. There 
is only one Australian agent available to provide technical 
assistance. Although the European head office for the company 
can also provide support, the Australian/European time difference 
made same day technical support direct from the company 
difficult to obtain and needed to be negotiated in advance. A 
technical manual is available, however the authors found this 
manual difficult to navigate in order to problem solve error 
messages. 
Practicable Functional and suitable: The instrument can be strapped to a belt 
and worn by the user allowing the operator to use both hands. In 
this study, a long small sensor and a long wide sensor was 
available. However, a single long sensor was used for all 
measurements to provide consistency amongst the varying 
pressure garment styles and sizes. Despite using the small, 
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flexible sensor, it was not small enough to be used on small 
fingers and toes. A variety of currently available sensor types from 
Novel may increase the practicality of the device though they 
require testing. In addition, an immediate mean pressure reading 
was not available making real time pressure knowledge 
unobtainable in the clinical setting.  
 
Existence of complete methods, materials and instructions: Face-
to-face training was required to understand the procedure for 
measuring pressure using the device and converting the raw 
scores to a file format that would enable calculation of mean 
pressure results. Processes for measuring the pressure in 
children wearing pressure garments post-burn are documented in 
the methods section.  
Acceptable To the clinician and client: Pressure measurements can be taken 
quickly and the procedure is tolerated by most paediatric patients. 
It was found that young children would often tug at the sensor, 
attempting to remove it from beneath the pressure garment. It can 
also be difficult for young children to remain stationary for the 
required duration of the measurement procedure and/ or to 
complete standardised movements on demand. Whilst the hands 
free set up of the device was practical, the authors noted that 
families could be concerned by the unconventional appearance 
of the device when worn by the researcher. 
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4.5 Discussion 
This is the first known study to assess the test-retest reliability and clinical utility of the 
Pliance X® in children who were receiving initial pressure garment therapy post-burn. The 
Pliance X® was found to have acceptable test-retest reliability for research purposes, 
although was only close to acceptable based on expected values for an objective 
measurement device and clinical use. Appropriateness and acceptability of the Pliance X® 
was supported for use with children of all ages who were not distressed, children who could 
follow instructions, or children who could be distracted whilst measures were being 
completed. Testing of the Pliance X® in children is important as children can have difficulty 
remaining still and following instructions due to varying pre-morbid levels of comprehension 
and distractibility. Reminders of the burn injury and treatment can also result in increased 
child apprehension and distress during medical procedures [51,127]. These characteristics 
have the potential to impact on reliability and clinical utility assessments of pressure 
measuring devices.   
 
The Oxford Pressure Monitor®, PicoPress® (Medigroup, Melbourne, Australia), and 
Kikuhime® (Medigroup, Melbourne, Australia)  are other pressure monitoring devices that 
can be used however these have been reported to distort the pressure garment or skin/scar 
surface, thus affecting the accuracy of the pressure reading [90,118,128,129]. A mathematic 
model has been proposed for correction of Pico Press® pressure measurements, thus 
allowing a correction factor to be applied to the pressure measurements, increasing the 
devices accuracy [129]. However, the clinical utility of this mathematical model requires 
further investigation [129]. The Kikuhime® device has been reported as valid when 
compared with a water column in laboratory testing. One study reported an ICC of 0.996 
[130] and a second study identified a linear relationship between the Kikuhime® and water 
column [115]. To assess the Kikuhime’s® reliability for use with sporting compression 
garments, the Kikuhime® was tested on a single athlete beneath sporting compression 
leggings [130]. Acceptable reliability and reproducibility results were reported for the 
Kikuhime® with a typical error of measurement of 1.3±0.9mmHg for intra-rater and 
1.8±0.9mmHg for inter-rater reliability [130]. When the Kikuhime® was assessed beneath 
pressure garments in adults post-burn (n=55 scar sites) an intra-rater ICC of 0.90 was 
recorded [115].  
 
In comparison, the I-scan® (Tekscan, South Boston, United States of America) and 
Flexiforce® (Tekscan, South Boston, United States of America) devices have received 
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favour for their thin and flexible sensors. However, these sensor types are reportedly 
temperature sensitive, have reduced accuracy at lower levels of pressure (less than 
10mmHg), and benefit from extensive calibration prior to use [117,118]. Subdermal 
measurements using a needle attached to a low flow pressure transducer have also been 
previously tested to limit the influence of temperature, non-conforming surfaces and 
distortion of the scar surface or pressure garment [131]. However, this is not a clinically 
viable option, particularly in a paediatric cohort. In addition, the above devices only provide 
a ‘snapshot’ of the interface pressure, have not been tested in children or have not been 
tested during dynamic movements.  
 
Advantages of the Pliance X® over other pressure measuring devices include: (1) the slim 
line sensor that creates minimal distortion of the scar or pressure garment; (2) the flexible 
sensor conforms to curved surfaces and; (3) the ability to measure and record the pressure 
every 0.02 seconds, creating a large dataset from which to determine a mean pressure for 
stationary and dynamic measurements over time. Considerations from this study include: 
(1) the need for an immediate mean pressure reading to facilitate the routine use of the 
Pliance X in research and clinical practice (as during the study, time consuming calculations 
needed to be obtained after the clinical appointment); (2) additional technical support (e.g., 
an easy-to-read manual, more than one Australian agent); (3) a sensor that fits beneath the 
whole pressure garment; (4) cost of the device; and (5) the need to transport the device to 
the single agent in Australia for calibration. For regular ongoing use of the device it may be 
more cost effective to purchase and receive training to conduct the calibration on-site. 
 
4.5.1 Limitations  
A limitation of this study was that the ICC obtained (0.87) was slightly lower than the ICC on 
which the sample size estimate was based (0.90). However, the number of subjects tested 
for reliability was above the sample size estimate thus the study likely remained adequately 
powered.  As higher sample sizes of around 50 subjects has been discussed as ideal for 
reliability studies [132] these results should be confirmed in further testing. There were a 
number of participants who were too distressed to tolerate the completion of a second static 
pressure reading (n=3) and were therefore not included in the test-retest reliability 
component. Thus, the reliability results apply to children who are not distressed. 
Furthermore, validity of the device on soft surfaces has not been established though 
accuracy of the device has been supported when compared to a sphygmomanometer [117]. 
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Additional limitations of this study include potential inconsistencies in relocating the exact 
position of the scar beneath the pressure garment with the Pliance X® sensor, despite the 
use of body measurements for relocation. Difficulty in ensuring young children remain 
stationary and/ or complete standardised dynamic measures in the manner required is also 
a potential limitation. An inability to measure interface pressure on small digits or across the 
entire garment at a single time point impacted clinical utility as the size of the Pliance X® 
pressure-measuring sensor used in this study was limited to 10mm.  
 
4.5.2 Future directions 
It is recommended that further reliability testing be completed including additional test-retest 
data (n=50) for stationary measurements and inter-rater reliability of the device in children 
post-burn. Taping of the sensor to the skin beneath the pressure garment may assist with 
maintaining accuracy during reliability testing. The testing of additional sensor types to allow 
measurements of gloves in children and whole body pressure garments in children and 
adults post-burn would also be beneficial for future clinical and research investigations 
examining interface pressure for burn scar management. 
 
4.6 Conclusion 
To assist investigations of pressure garment therapy effectiveness, reliable assessment of 
the pressure garment-scar interface pressure is crucial. Devices used in the clinical settings 
must be reliable as well as clinically appropriate, accessible, practicable and acceptable. 
Previously available technologies have not provided a consistent and accurate 
representation of the interface pressure in a clinically viable manner. The Pliance X® was 
found to have close to acceptable test-retest reliability in a sample of non-distressed children 
using an immediate test-retest interval. The Pliance X® was found to be appropriate and 
mostly acceptable to families when used in a paediatric burn scar outpatient environment 
with children who are not distressed. Alterations to the sensor types, increased technical 
support and availability of an immediate mean pressure reading would enhance the 
practicality and accessibility of the Pliance X®.  
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Part B of this chapter is based on the 2019 publication in Burns, titled ‘Variability of pressure 
at the pressure garment-scar interface in children post-burn: a pilot longitudinal cohort 
study’. As the methodology of this study is a replica of part A of this chapter, a detailed 
background, results and discussion will be presented along with a brief methodology section. 
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PART B 
4.7 Background 
The application of pressure to the burn scar via pressure garment therapy is a common burn 
scar management intervention in high income countries [7,8,95]. However, pressure 
garment therapy has an unknown mechanism of action, an unconfirmed ideal pressure 
‘dosage’ at the interface of the pressure garment and burn scar and minimal high quality 
evidence supporting its use [12,90]. It has been postulated that an interface pressure at or 
above capillary pressure is required to occlude local capillaries, thus creating hypoxia in the 
cells leading to cellular changes including collagen breakdown [8,13,87]. Though it has also 
been suggested that a consistent level of pressure (unknown level) is required to improve 
the rigidity of the extra-cellular matrix, thus increasing mechanoreceptor activity and 
consequent apoptosis of cells, and reducing production of scar fibroblasts [32]. The exact 
mechanism of action however is still to be confirmed and thus impacts knowledge regarding 
the ideal ‘dosage’ of pressure garment therapy. 
 
A minimally effective interface pressure of 15mmHg has been previously recommended 
[1,117]. However it has also been suggested that a pressure at or above capillary pressure 
(24 to 25mmHg) is required. As a result, common consensus has been that pressure 
garment therapy must provide 15 to 25mmHg for 23 hours per day for improved scar 
outcomes [8,13,86,87,90]. Additionally, higher levels of interface pressure (e.g. 20-25mmHg 
vs 10-15mmHg [90]) have been reported to have greater effects on scar outcomes 
particularly scar thickness [1,12]. As a result it has been suggested that the ‘dose’ of 
pressure garment therapy may need to be increased to 20 to 25mmHg [90]. Though it must 
be noted this recommendation of higher pressure may be more suited to the developed adult 
hypertrophic scars included in that study. Pressure above 40mmHg is reported to result in 
adverse events such as skin breakdown [13,87]. The definitive level of pressure at the 
pressure garment-scar interface over time has not been ascertained in a paediatric 
population. 
 
Previous investigations into the level of pressure at the interface of the pressure garment 
and burn scar over time has been completed in adult populations in stationary postures. 
Adult studies have reported pressure reductions of up to 25% of the original interface 
pressure over the first one month of pressure garment wear [13,115]. Participants receiving 
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higher levels of compression (20mmHg) at baseline have been reported to experience 
greater reductions in the interface pressure than those receiving low level pressure garment 
therapy (10mmHg) [13]. Difficulty maintaining a consistent level of pressure over the study 
period has been identified in adults [8,90,115]. In addition, a wide variety of interface 
pressures at new pressure garment fitting has been reported in a paediatric investigation 
[133].  
 
Multiple factors have been postulated to influence interface pressure variations related to 
the person, wound, or environment. Person-related factors include body composition, body 
location of the scar, and the size of the limb [115,134]. These factors influence the hardness 
or softness of the area of interest and the diameter of the area being measured. Larger 
diameters are expected to result in reduced pressure due to the Law of Laplace (fabric 
tension is inversely proportional to circumference) [134], though a smaller radius of 
curvature has been found to contribute to a greater pressure loss over time [115]. It has 
been acknowledged that mobilisation may impact interface pressure readings and 
continuous pressure monitoring may provide greater insight into interface pressure levels, 
though continuous monitoring is not yet possible with current sensor types [90]. Burn wound-
related factors such as the type of wound (graft or healed wound) and the maturity of the 
scar when pressure garments are applied influence pressure fluctuations due to resulting 
changes in the rigidity of the scar [8,117]. When pressure has been measured sub-dermally, 
greater pressures have been identified over bony prominences compared to those 
measured over ‘soft’ sites such as musculature [131]. Environmental-related factors include 
moisturisers, silicone products, pressure garment design variables (e.g. fabric type, tension 
and colour) and fabric stress relaxation have also been acknowledged as potential factors 
influencing pressure variations due to stretch and breakdown of the pressure garment fabric 
[86,90,134-136].  
 
It must be noted that different pressure measuring devices have been used in previous 
investigations into interface pressure levels with a burns population including the Kikuhime® 
(Medigroup, Melbourne, Australia) [115], Pliance X® (Novel, Munich, Germany) [117] and I-
scan® (Tekscan, South Boston, United States of America) [118,133]. The 3mm thickness of 
the Kikuhime® sensor [130] has the potential to distort the pressure garment and the scar 
surface and thus may impact the accuracy of the results [118], though it has a reported 
acceptable reliability (ICC = 0.90) in the adult post-burn population [115]. The Pliance X® 
and I-scan have low profile sensors (<1mm [117,137], Pliance X®=10mm wide). The I-scan 
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is reported to experience reduced accuracy when measuring low interface pressures, such 
as those beneath a pressure garment, and additional calibration procedures prior to use are 
reported to increase its accuracy [118]. The Pliance X® has acceptable reliability for research 
use (ICC=0.87) in a paediatric post-burn population [138] and excellent test-retest reliability 
(ICC=0.998) when assessed on a hard surface and acceptable accuracy on a soft surface 
when compared to a sphygmomenometer cuff [117].  
 
4.7.1 Objectives 
The primary objectives of this pilot study were to determine: (1) the pressure at the pressure 
garment-scar interface, and (2) the percentage of participants who were receiving pressures 
of 15 to 25mmHg at first pressure garment fitting and subsequent follow ups over the first 
three months of scar management for children and adolescents with, or at risk of, scarring 
after a burn. The secondary objective was to identify whether select factors (namely 
participant age, percent total body surface area burned (%TBSA), scar location, scar 
thickness, wound healing type, pressure garment manufacturer, and pressure garment 
colour) influenced interface pressure.  
 
It was hypothesised that: (1) the mean interface pressure at baseline would not be outside 
of the recommended range of 15 to 25mmHg and would reduce by 25 percent over the first 
one month of wear; and (2) the location of the scar would influence the interface pressure.  
 
4.8 Methods 
4.8.1 Study Design 
This study was a pilot longitudinal cohort study with consecutively sampled participants. 
Recruitment was completed from January to June 2016 as well as during the month of 
August 2016. Recruitment was not conducted in July as the outcome assessor was 
unavailable. Follow up data was collected by November 2016.  
 
Ethical clearance was received from the Children’s Health Queensland Human Research 
Ethics Committee, Brisbane (HREC/15/QRCH/240). This study is reported according to 
STROBE guidelines [123]. 
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4.8.2 Setting 
Data were collected in the burns outpatient unit of a large quaternary metropolitan children’s 
hospital in Australia. Patients attending the unit with acute burn injuries were predominantly 
male, treated for scald and contact burn injuries and had a median age of two years [17].  
 
4.8.3 Participants 
4.8.3.1 Inclusion Criteria 
Inclusion criteria for this study included children and adolescents aged less than 18 years 
with, or at risk of, post-burn scarring; children and adolescents fitted with their first custom 
made pressure garment within the first three months post-burn; children and adolescents 
likely to return to the participating burns outpatient centre for fitting and ongoing review of 
their pressure garment; and children and adolescents accompanied by a parent or guardian 
who was able to provide informed consent.  
 
4.8.3.2 Exclusion Criteria  
Children and adolescents who had not been prescribed a pressure garment for burn scar 
management; children and adolescents with comorbidities that might influence the interface 
pressure such as an amputation, and children and adolescents involved with the Department 
of Communities (Child Safety) were excluded, which was standard practice at the study site 
at the time of recruitment. Children receiving pressure garment therapy for the prevention 
or management of burn scarring on fingers and/ or toes only were also excluded if the sensor 
was too large to fit beneath the pressure garment at the extremities. 
 
4.8.4 Sample Size 
A sample size of 33 participants were estimated to be required to test the primary objective. 
This estimate was based on an anticipated mean pressure of 20.0mmHg at baseline, a 
correlation of 0.7 between pressure measurements at baseline and one month follow-up, 
clustering of scar sites within participants, a standard deviation of the mean pressure over 
the study period of 5mmHg, a 1% significance level, a power of 90%, and the inclusion of 
body location of the garment as a covariate.   
  
Expected mean pressure losses were based on a pressure loss of 4.82 (2.99) mmHg (20%) 
over a one month period in a normal compression group for thigh and forearm garments in 
adults [13]. Correlations between pressure readings over time were based on the lowest 
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correlation reported for intra-observer reliability (0.83 over a one month period using a 
Kikuhime® pressure sensor to the forearm and calf) [115] as no values were available for 
the Pliance X® using scar sites. A lower correlation of 0.7 was anticipated based on expected 
greater variability in body locations than the forearm and calf [13].     
 
4.8.5 Outcomes 
Participant sociodemographic and clinical characteristics: were recorded from the caregiver 
and medical records. Characteristics included gender, age, percentage total body surface 
area burned (%TBSA), caregiver education, wound healing type, scar location (torso, upper 
limb, lower limb), Fitzpatrick skin type and number of days post-burn. Pressure garment 
characteristics collected from the medical record included pressure garment manufacturer, 
fabric and colour. 
 
Interface pressure: was measured using the Pliance X device® (Novel, Munich, Germany) 
[119]. Test-retest reliability has been supported [117,138] as discussed.  
 
Scar severity: was measured using the Patient and Observer Scar Assessment Scale 
(POSAS). Items of the POSAS including observer reported thickness, vascularity, pliability, 
pigmentation, relief and overall opinion and patient report items of itch, pain, colour, 
stiffness, thickness, irregularity and overall opinion were collected. Caregiver proxy report 
was collected for participants of all ages. The POSAS has been reported to have adequate 
test-retest reliability for observer reported thickness in adults [103] and children of all ages 
(unpublished data). 
 
A limited number of predictor variables were selected due to the pilot design of the study. 
Variables were selected due to their clinical relevance and potential impact on interface 
pressure based on previous research [8,115,131,134]. Predictor variables included 
participant age, %TBSA, scar location, scar thickness, wound healing type, pressure 
garment manufacturer, and pressure garment colour.  
 
4.8.6 Procedures 
The lead author recruited potential participants when they attended the outpatient 
department of the participating burns centre for scar management. Verbal and written 
information regarding the study process was provided. Data collection was commenced at 
the scar management appointment once written consent was received. 
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4.8.6.1 Intervention 
Participants in this study received pressure garment therapy as part of a multi-modal 
approach to burn scar management. All therapists had received training in measurement 
practices for custom-made pressure garments as part of their orientation to clinical service 
provision. Standard clinical practice at the participating burns centre was to fit pressure 
garments that extend 5cm beyond the scar border where able, to avoid the lower pressure 
that is known to exist around the pressure garment opening [139,140]. 
 
Participants were provided with two custom-made pressure garments fabricated by the 
pressure garment manufacturer of the therapist’s choice approximately every three months 
until scar maturation, as per standard practice at the participating burns centre. Participants 
(and their families) were instructed in how to don the pressure garment and ensure it is worn 
for 23 out of 24 hours every day; follow washing instructions as per the manufacturer’s 
directions; moisturise up to five times per day and use sunscreen when out in the sun for 
longer than 15 minutes. Pressure garment design, use of zips and inserts in pressure 
garments as well as silicone products were chosen at the treating occupational therapist’s 
discretion. Exercises and splints were also prescribed by the treating occupational therapist 
or physiotherapist where deemed appropriate. Occupational therapists were blinded to the 
results of the interface pressure at each review point. 
 
Families were requested to attend appointments at the participating burns centre at one and 
three months post pressure garment fitting. Ongoing scar management appointments were 
then scheduled approximately every three months (after the study period) until pressure 
garment cessation/ scar maturation or as required by the family. These timeframes were 
considered feasible for families and the health service to enable assessment of the scar and 
pressure garment fit. 
 
4.8.6.2 Interface pressure measurement procedure 
One long, thin sensor of the Pliance X® was used for all interface pressure measurements 
to maintain consistency. The Pliance X® was set up as illustrated in Figure 4.5 and 4.6 or if 
working with a young child, the device was set up and worn by the user in the Novel belt to 
prevent dropping/ moving of the device by the child. Prior to measurement, the sensor was 
positioned on a flat surface and ‘zeroed’ to ensure there was no load on the sensor surface 
as per the device’s instructions. The sensor was then positioned beneath the pressure 
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garment and over the scar, at the pressure garment-scar interface. To do this, the pressure 
garment was donned over anchor points, the sensor was placed over the scar and held in 
place by the researcher whilst the remainder of the pressure garment was donned. 
Alternatively, the edge of the pressure garment nearest the selected scar site was raised, 
allowing the sensor to slide over the skin, beneath the pressure garment and rest over the 
scar. The sensor was not taped in place during the study.  
 
 
Figure 4-5 Pliance X set up for upper limb stationary measurements 
 
 
Figure 4-6 Pliance X set up for upper limb dynamic measurements 
 
One 10 second stationary measurement, followed by one 10 second dynamic measurement 
was completed. A 10 second period was used for stationary and dynamic measurements as 
this provided 500 interface pressure data points which was anticipated to be sufficient for 
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pressure analysis as well as being tolerable for young participants. Age appropriate 
distractions were used for stationary measurements as required. Activities performed during 
dynamic measurements included walking during lower limb measurements and ring stacking 
during upper limb measurements. On completion of the dynamic measurement, the sensor 
was removed and the pressure garment re-donned. A second stationary measurement was 
then completed for test-retest reliability testing of the Pliance X® [138]. Calibration of the 
device was completed as per manufacturers’ guidelines throughout the study period (every 
three to six months) by the Australian agent of Novel using the tru blu® (Novel, Munich, 
Germany) calibration device. Relocation of the selected scar site at the one and three month 
follow up time points was conducted using body measurements and photographs.  
 
4.8.7 Data Analysis 
Descriptive statistics were calculated for all outcomes including means and standard 
deviations for normally distributed continuous variables and median and inter-quartile range 
(IQR) for non-normally distributed data. Categorical variables were reported using 
frequencies and percentages. Normality of the data was assessed using the Shapiro-Wilk 
test. Correlations between continuous variables and interface pressure were assessed 
using Pearson Product-Moment Correlation or Spearman’s rank correlation (when normality 
was not demonstrated). Due to sparse distribution of age, %TBSA and colour these 
variables were categorised. The Wilcoxon Signed Rank Test for ordinal data and McNemar 
Test for nominal data for related-sample data were used to examine differences in 
sociodemographic and clinical variables of participants.   
 
Univariate Linear Mixed Model (LMM) analyses with patient as random intercept were 
performed to assess the influence of time, age (less than or equal to 5 years vs. greater than 
5 years), %TBSA (%TBSA less than 10% vs. greater than or equal to 10%), scar location 
(upper limb vs. other), scar thickness (POSAS observer thickness score), wound healing 
type (grafted vs. spontaneous), pressure garment manufacturer (Jobskin® (Smith and 
Nephew, Nunawading, Victoria, Australia), Therapeutic Support Laboratory® (Abbortsford, 
Victoria, Australia) and Second Skin® (Osborne Park, Western Australia, Australia)), and 
pressure garment colour (black, dark colours (e.g. blue, purple), light colours (e.g. green, 
pink)) on stationary and dynamic interface pressure. Statistical analyses were completed 
using SPSS24 software (SPSS Inc., Chicago, IL, USA) and significance was set at p < 0.05.  
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4.9 Results 
Thirty-four children consented to participate in the study. Baseline data was obtained from 
31 participants, one-month follow-up data was obtained from 19 participants and three-
month follow-up data was obtained from 17 participants with reasons for non-participation 
shown in Figure 4.7. Participants who did not attend the follow up appointment with the 
original pressure garment that had undergone interface pressure measurement were 
considered lost to follow up as interface pressure could not be measured on the same 
pressure garment. There was no significant differences between baseline and one month 
and baseline and three months for sociodemographic and clinical variables (p>0.05, as per 
Table 4.3), except for scar thickness (baseline to three months, p=0.05). However, it was 
expected that scar thickness would increase at the three month follow up due to the peak in 
burn scarring that occurs at this time [33]. Stationary pressure was normally distributed at 
baseline but not at one month post pressure garment fitting (Shapiro Wilk p=0.07 and 0.005 
respectively). Spearman’s rank order correlation of stationary interface pressure at first 
pressure garment fitting and one month post pressure garment fitting demonstrated a strong, 
positive correlation (rs=0.70, p=0.002) fitting with the assumptions for sample size. 
 
Figure 4-7 Flowchart of study participants 
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4.9.1 Participants 
At baseline, participants had a median age of three years (IQR: 6), were predominantly male 
(61%), had a median %TBSA of 3% (IQR: 5), median POSAS observer thickness score of 
2 (IQR: 2) and a median of 42 days post burn (IQR: 25). Additional details of the 
sociodemographic and clinical characteristics of the sample are reported in Table 4.3. 
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Table 4-3 Participant sociodemographic and clinical characteristics 
 
Participant characteristics Number of participants  (% of sample)ab 
 Baseline 1 month follow-upc 3 month follow-upc 
Number of participants  31 19 17 
Male gender 19 (61%) 11 (58%)c 8 (47%)c 
Age in years  
Median (IQR), range 
3 (6), 1-14 4 (7.4), 1-13c 3 (5.5), 1-13c 
%TBSA burned  
Median (IQR), range 
3 (5), 0.5-36 4 (5.5), 0.5-36c 3 (5.75), 0.5-17 
(p=0.32)c 
Caregiver education  c c 
  Completed post school  
  qualification 
18 (58%) 14 (74%) 14 (82%) 
  Completed senior high school 11 (36%)  4 (21%) 3 (18%) 
   Missing   2 (6%)   1 (5%)   
Grafted  14 (45%) 10 (53%)c 9 (53%)c 
Scar location  c c 
 Upper limb 9 (29%) 8 (42%) 8 (47%) 
  Other 22 (71%) 11 (58%) 9 (53%) 
Fitzpatrick skin type   c c 
Type I – Always burn 3 (10%) 3 (16%) 4 (23%) 
  Type II – Tan with difficulty 2 (6%) 1 (5%) 1 (6%) 
    Type III – Tan about average 11 (35%) 11 (58%) 8 (47%) 
    Type IV – Tan more than average 5 (16%) 0 (0%) 1 (6%) 
    Type V – Brown skin 7 (23%) 3 (16%) 3 (18%) 
   Type VI – Black skin 0 (0%) 0 (0%) 0 (0%) 
       Missing   3 (10%)   1 (5%)   0 (0%) 
No. of days post-burn  
Median (IQR), range 
42 (25),  
20-103 
71 (28),  
53-103 
126 (35),  
96-163 
Scar thickness - POSAS Observer 
numeric rating scale 
Median (IQR), range 
2 (2), 1-4 2 (1), 1-4 
(p=0.16) 
3 (3), 1-6 
(p=0.05) 
       Missing      1 
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Pressure garment manufacturer c c 
   Jobskin 13 (42%) 8 (42%) 8 (47%) 
   Therapeutic Support Laboratory  16 (52%) 9 (47%) 8 (47%) 
   Second Skin 2 (6%) 2 (11%) 1 (6%) 
Pressure garment fabric  c c 
   Powernet 27 (87%) 16 (84%) 15 (88%) 
   Primatech 3 (10%) 3 (16%) 2 (12%) 
       Missing   1 (3%)   
 
Abbreviation: IQR = interquartile range 
a Number (percentage) except where indicated 
b Missing data where stated, otherwise there was no missing data 
c p values for participants at 1 or 3 month follow up compared to baseline, p = 1.00 except 
where specified 
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4.9.2 Interface pressure 
The mean stationary and dynamic interface pressure for each time point are illustrated in 
Table 4.4. Univariate linear mixed model analyses of stationary and dynamic interface 
pressure changes were not statistically significant over time (p=0.23 and p=0.06 
respectively). At baseline, the mean (SD) stationary interface pressure was 15.54mmHg 
(11.33) and approximately one third (32%) of participants recorded pressures within the 15 
to 25mmHg range. At one month post pressure garment fitting, the mean (SD) stationary 
interface pressure was 11.50mmHg (9.9) and 11% of participants had pressures within 15 
to 25mmHg. At three months post pressure garment fitting approximately 24% of 
participants had an interface pressure within the 15 to 25mmHg range with a mean (SD) 
stationary interface pressure of 12.92mmHg (9.36).  
 
Table 4-4 Mean (SD) interface pressure over time 
 Time n Mean 
pressure  
mmHg  
SD Minimum 
pressure 
mmHg 
Maximum 
pressure 
mmHg 
Coefficienta Significancea Overall 
significance
a 
Stationary         0.27 
 Baseline 31 15.54 11.33 0.00 49.32 0.62 0.78  
1 month  19 11.50 9.90 0.00 39.12 -2.35 0.26  
3 months  17 12.92  9.36 0.35 30.92 reference   
Dynamic         0.06 
 Baseline  28 20.04  15.85 3.43 63.52 7.15 0.07  
1 month  19 22.53  30.21 1.95 119.13 10.66 0.03  
3 months  17 12.41  8.27 0.00 25.26 reference   
 
a Coefficient, significance and overall significance from linear mixed model using time as 
fixed effect and patient as random intercept
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In comparison, mean (SD) dynamic interface pressures were 20.04mmHg (15.85) at 
baseline, 22.53mmHg (30.21) at one month and 12.41mmHg (8.27) at three months post 
pressure garment fitting. One quarter (25%) of participants were within 15 to 25mmHg at 
baseline, reducing to 11% at one month and increasing to 29% of participants within the 15 
to 25mmHg range at three months post pressure garment fitting. Figure 4.8 illustrates the 
percentage of participants within 15 to 25mmHg in further detail.  
 
Figure 4-8 Percentage of participants receiving <15mmHg, 15-25mmHg, >25mmHg pressure 
 
In contrast to the hypothesis, both increases and decreases of the mean interface pressure 
were observed during stationary and dynamic measurements when comparing baseline to 
one and three months post pressure garment fitting (Table 4.5).  
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Table 4-5 Mean (SE) interface pressure changes over time 
 
↑ indicates pressure increases  
↓ indicates pressure decreases 
 
  
 Time n Mean pressure 
change, mmHg  
SE n Mean 
increase and 
decrease, 
mmHg 
Stationary Baseline to 1 month 17 2.65 1.80 9 
8 
↑ 3.49  
↓ 9.45 
1 month to 3 months 12 -3.13 2.45 10 
2 
↑ 6.27  
↓ 9.69 
 Baseline to 3 months 14 -0.38 2.67 6 
8 
↑8.65  
↓ 5.82 
Dynamic Baseline to 1 month 17 -5.59 4.57 8 
9 
↑17.47  
↓ 4.96 
1 month to 3 months 12 7.08 6.86 6 
6 
↑ 5.23  
↓19.38 
 Baseline to 3 months 13 8.29 3.78 4 
9 
↑ 4.19  
↓13.84 
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4.9.3  Factors influencing changes in stationary interface pressure 
Univariate Linear Mixed Model analyses with patient as random intercept (Table 4.6) 
identified scar location and %TBSA as significant predictors of stationary interface pressure. 
Upper limb scar sites recorded significantly lower stationary interface pressures than other 
body locations (p=0.03) and participants with greater than or equal to 10% TBSA recorded 
significantly lower stationary interface pressures than participants with less than 10% TBSA 
(p=0.006). Pressure garment manufacturer, pressure garment colour, scar thickness, wound 
healing type, and participant age were found to be non-significant predictors.  
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Table 4-6 Univariate linear mixed model analysis: select factors on stationary pressure 
Variable Parameter Coefficient SE  Significance 95% CI Overall 
significance 
Pressure location   
Intercept 
Lower limb and 
torso 
Upper limb  
 
8.77 
8.06 
 
reference 
 
2.90 
3.47 
 
 0.005 
0.03                 
 
2.85, 14.68 
0.99, 15.13 
0.03 
%TBSA    
Intercept 
<10% 
≥10%  
 
 3.89 
12.46 
reference 
 
3.88 
4.22 
 
 
0.323 
0.006 
 
-4.02, 11.81 
 3.85, 21.06 
0.006 
POSAS Observer 
thickness score 
Intercept 
POSAS Score 
14.46 
0.80 
6.64 
2.98 
0.034 
0.790 
1.14, 27.78 
-5.08, 6.78 
0.76 
Manufacturer  
  
 
Intercept 
Jobskin 
TSL 
Second skin  
 
12.90 
 2.33 
 1.15 
reference 
 
6.04 
6.62 
6.57 
 
 
 
 
     0.6, 
25.20 
-11.17, 
15.83 
-12.24, 
14.53 
0.92 
Wound healing  
Intercept 
Spontaneous  
Grafted 
 
15.36 
 -1.76 
reference 
 
2.47 
3.42 
  
10.32, 
20.41 
-8.72, 5.20 
0.61 
Pressure garment 
colour  
 
Intercept 
Black 
Dark  
Light  
 
11.39 
  2.82 
  5.02 
reference 
 
3.27 
4.60 
4.13 
 
 
 
 
 4.70, 18.08 
-6.54, 12.18 
-3.42, 13.46 
0.48 
Age   
Intercept 
≤ 5 years 
> 5 years  
 
15.19 
 -1.11 
reference 
 
3.04 
3.68 
 
 
 
 
   9.01, 
21.37 
  -8.60, 6.37 
0.76 
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4.9.4 Factors influencing changes in dynamic interface pressure 
Univariate Linear Mixed Model analyses did not identify any statistically significant predictors 
of dynamic pressure (Table 4.7).  
 
Table 4-7 Univariate linear mixed model analysis: select factors on dynamic pressure  
Variable Parameter Coefficient SE  95% CI Overall 
significance 
Pressure 
location  
 
Intercept 
Lower limb 
and torso 
Upper limb  
 
18.95 
-0.06 
 
(reference) 
 
5.29 
6.42 
 
 
 
    8.41, 29.50 
-12.86, 12.73 
0.99 
%TBSA  
Intercept 
<10% 
≥10%  
 
 7.36 
14.11 
(reference) 
 
7.88 
8.61 
 
 
-8.74, 23.46 
-3.47, 31.69 
0.11 
POSAS 
Observer 
thickness score 
Intercept 
POSAS Score 
17.32 
-2.51 
12.79 
5.69 
-8.41, 43.06 
-13.97, 8.95 
0.24 
Manufacturer  
Intercept 
Jobskin 
TSL 
Second skin  
 
13.27 
10.95 
 1.68 
(reference) 
 
12.71 
13.64 
13.59 
 
 
-12.84, 39.38 
-17.07, 38.96 
-26.24, 29.59 
0.38 
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Wound healing  
Intercept 
Spontaneous  
Grafted  
 
14.52 
  8.62 
(reference) 
 
4.74 
6.42 
 
 
  4.82, 24.22 
-4.50, 21.74 
0.19 
Pressure 
garment colour 
 
Intercept 
Black 
Dark 
Light  
 
12.47 
  2.38 
11.89 
 (reference) 
 
5.47 
8.10 
6.83 
 
 
   1.55, 23.40 
-13.78, 18.54 
-1.73, 25.52 
 
0.17 
Age   
Intercept 
≤ 5 years 
> 5 years  
 
16.37 
 4.28 
(reference) 
 
5.65 
6.94 
 
 
 4.86, 27.89 
-9.87, 18.42 
0.54 
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4.10  Discussion 
To the knowledge of the authors, this is the first study to investigate the level of pressure 
(mmHg) at the pressure garment-burn scar interface over time in a post-burn paediatric only 
cohort. Previous stationary interface pressure measurements have provided a snapshot of 
interface pressure. It has been discussed that continuous pressure monitoring may provide 
a more cohesive understanding of interface pressure over time [90]. Given that accurate, 
reliable continuous pressure measuring technology is not currently available, this study 
assessed interface pressure during 10 second movement periods that simulate children’s 
normal play activities.  
 
In line with the primary objective of the study, results suggest that the majority of children 
receiving pressure garment therapy after a burn at the participating centre were not receiving 
the recommended pressure to the burn scar from the first wear of the pressure garment. 
Less than 35% of participants demonstrated an interface pressure between 15 and 25mmHg 
at any time point during stationary or dynamic measurements, though the change in 
interface pressure over time was not statistically significant. Unexpectedly, interface 
pressure increases were recorded as well as the expected decreases over the course of the 
three month follow-up period. This is in contrast to the findings in adult studies where only 
pressure reductions were reported [8,13,115].  
 
Pressure increases may be unique to children in that their rate of growth and changes to 
body composition may be faster than pressure garment fabric stress and/ or breakdown, 
particularly given the median age of participants of three years. Whilst an observer 
assessment of scar thickness was not a significant predictor of interface pressure, an 
objective assessment of scar parameters such as thickness and pliability may shed more 
light on the increases in pressure observed in future studies due to changes in scar thickness 
and hardness. Substantial pressure increases, particularly when moving, have the potential 
to reduce the comfort of the pressure garment and therefore reduce adherence to the 
intervention. In addition, pressures were recorded at or above 40mmHg, the level reported 
to result in adverse events such as skin breakdown and paraesthesia [11,13,87]. Therefore, 
paediatric pressure garments may need to be reviewed with increased frequency compared 
to current clinical practice (every three months at the participating burns centre) to monitor 
interface pressures both above and below the currently believed therapeutic range of 15 to 
25mmHg.  
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The hypothesis that scar location would influence the interface pressure was confirmed 
during this study, though only for stationary interface pressure measurements. This is in line 
with previous work identifying scar location as a factor influencing interface pressure [115]. 
It has previously been hypothesised that a smaller radius of curvature would result in larger 
pressure losses [115]. The current study identified lower stationary interface pressures in 
the upper limb when compared to the torso and lower limb, potentially due to the smaller 
radius of curvature. In addition, this study identified %TBSA burn as a factor influencing 
stationary interface pressure with children with greater than or equal to 10% TBSA burns 
experiencing significantly lower interface pressures than participants with burns less than 
10% TBSA. This may be due to children with larger %TBSA burns requiring a pressure 
garment that covers a larger surface area, requiring more stretch from the child when 
donning the pressure garment and/ or slower weight gain during the immediate post-burn 
period.  
 
4.10.1 Limitations 
This pilot study is limited by a small sample size and higher than expected numbers lost to 
follow up at one and three month follow up time points (as per Figure 4.7). However, there 
were no significant differences between the participants and non-participants at one and 
three months compared to baseline suggesting that the drop out did not influence the results. 
A lack of power for some analyses may have resulted in non-significant findings for changes 
in interface pressure and additional predictors. Interface pressure results are not applicable 
to children’s fingers or toes that were too small to fit the sensor and are not representative 
of the pressure garment’s circumferential interface pressure due to the single 10mm sensor 
used in this study. In addition, there are potential inconsistencies in relocating the exact 
position of the scar beneath the pressure garment, and in ensuring young children remain 
stationary and/ or complete standardised dynamic measures in the manner required. 
Photographs and body measurements to assist with relocation and age appropriate 
distractions were used to reduce the impact of these limitations.  
 
Detailed information regarding pressure garment properties such as elasticity, shrinkage, 
and yield points were not available for assessment during this pilot study. Pressure garment 
washing techniques and skin products used beneath the pressure garments (i.e. 
moisturisers, silicones) were also not assessed during this pilot study. Additionally, objective 
assessment of scar parameters such as thickness was not completed in this pilot study. As 
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these factors have the potential to influence changes in pressure they should be included in 
future investigations. 
 
4.10.2 Future Directions 
Further investigation is required to determine the clinical outcomes of paediatric burn scars 
consistently treated with pressure garment therapy that applies less than 15mmHg, 15 to 
25mmHg and greater than or equal to 25mmHg of pressure. This work has commenced in 
an adult population [8,13,90] though the results need to be confirmed. In addition, the best 
method for incorporating pressure monitoring, and the cost-benefits/consequences of 
pressure monitoring in clinical practice needs to be established. The use of multiple sensors 
within the Pliance X® matrix or trialling additional sensor styles may allow for the assessment 
of circumferential interface pressure in future research investigations and assessment of the 
reliability of the Pliance X® during movement and on hard vs soft surfaces needs to be 
completed. Exploring the use of inserts to adjust interface pressure and the impact of 
interface pressure on children’s adherence to pressure garment therapy would also provide 
important information for clinical decision-making. For example, pressure alterations could 
be made that enable pressure garment therapy that is considered effective for scar 
management, as well as maintaining user comfort. Investigation of all potential predictors of 
stationary interface pressure is also required. Stratifying results in future intervention studies 
by the predictors of pressure change identified in this study would assist in better 
understanding changes in pressure. Application of a consistent level of interface pressure 
and a pressure garment that is worn for the recommended 23 hours per day would 
standardise the clinical use and future research into the effectiveness of pressure garment 
therapy in preventing and managing scarring post-burn.  
 
4.11 Conclusion 
This pilot study identified deviations from the recommended 15 to 25mmHg interface 
pressure range during first fitting of a pressure garment in a small sample of children post-
burn. Fluctuations in the interface pressure were observed over the three month period 
during stationary and dynamic measurements. Percentage total body surface area burned 
and scar location were identified as predictive factors of stationary interface pressure. 
Further evidence regarding the most effective interface pressures as well as routine 
monitoring of interface pressure is required to enable accurate decision-making regarding 
if/when pressure garment alterations or re-supply is required. This may need to occur more 
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frequently than is currently completed in clinical practice, which is approximately every three 
months at the participating burns centre. Measurement of interface pressure during studies 
of pressure garment effectiveness would determine the dose of pressure that results pertain 
to and enable replication of effective interface pressure for research and clinical applications. 
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4.12  Chapter conclusion 
The pilot longitudinal cohort study presented in this chapter demonstrated that the Pliance 
X® had close to acceptable test-retest reliability (ICC = 0.87) for clinical use with children 
who are not distressed, are able to follow instructions or able to be distracted whilst 
stationary measurements are completed. With additional reliability testing to confirm the 
results of this study and to identify the inter-rater reliability of the device, there is the potential 
for the Pliance X® to be transitioned to clinical use. Regular clinical use of the device will be 
beneficial for children receiving pressure garment therapy as results of this study also 
identified substantial fluctuations in interface pressure over the first three months of wear of 
the pressure garment. Less than 35% of participants were receiving the recommended 
interface pressure (15 to 25mmHg) at first pressure garment fitting and ongoing pressure 
increases and decreases were observed over the study period. Participant’s %TBSA and 
the body location of the burn scar were identified as factors influencing stationary interface 
pressure changes. Thus, there is a need for regular interface pressure monitoring and 
subsequent alterations to the pressure garment on a more regular basis to ensure adequate 
and consistent pressure is being provided to the burn scar across all body locations and for 
all burns sizes.  
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CHAPTER 5 Randomised controlled trial methodology 
 
This chapter is based on a published paper in the journal TRIALS.  
Citation:  
Wiseman J, Simons M, Kimble R, Ware R, McPhail S, Tyack Z. Effectiveness of topical 
silicone gel and pressure garment therapy for burn scar prevention and management in 
children: study protocol for a randomised controlled trial. Trials 2017;18(1):72 
 
As an author on the publication I made a major contribution to the conception of the project 
(60%), and drafted the publication (80%) with input and feedback from the supervisory team 
and statistician as appropriate. 
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5.1 Chapter foreword 
The functional and cosmetic sequalae of abnormal burn scarring in children have long-term 
repercussions for the child and their family. The interventions of pressure garments and 
silicone products prescribed to prevent and manage abnormal scarring also have broader 
impacts on the child and their family than just the physical scar. Despite being used across 
the world for over forty years, the effectiveness of these treatments particularly in children, 
remain unclear. 
 
As the literature review and systematic review highlighted, research studies investigating 
the effectiveness of scar interventions in children are limited. Current studies have not 
considered the broader implications of intervention effectiveness regarding outcomes such 
as health-related quality of life, treatment satisfaction, adherence and intervention fidelity. 
Pressure beneath pressure garments has not typically been evaluated. In addition, one 
previous sample size estimate identified a sample of 384 participants would be necessary 
to achieve adequate power for assessing the effectiveness of silicone products and pressure 
garment therapy on the Vancouver Scar Scale (VSS) [94].  No previous randomised 
controlled trial has reached a sample size this large with most studies reporting less than 
100 participants at the final follow up. These reviews highlighted the need for a randomised 
controlled trial to assess the effectiveness of topical silicone gel, pressure garment therapy 
and combined topical silicone gel and pressure garment therapy in the paediatric post-burn 
population.  
 
Chapter Five is based on the publication titled ‘Effectiveness of topical silicone gel and 
pressure garment therapy for burn scar prevention and management in children: a study 
protocol for a randomised controlled trial’. It details the methodology for the randomised 
controlled trial of topical silicone gel, pressure garment therapy and combined treatment in 
the prevention and management of abnormal burn scars in children. Results of this study 
will be discussed in Chapter Six.  
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5.2 Introduction 
The protocol for this study has been reported as per the SPIRIT guidelines [141]. 
 
5.2.1 Background 
With mortality rates post-burn declining, the greatest burden to burn centres is scarring [1-
3]. In children, scarring has substantial ramifications for the child’s physical and 
psychological functioning, as well as health-related costs for the family and the health care 
service [7]. Characteristics associated with risk of scarring in children include percentage 
total body surface area burned (%TBSA), delayed wound healing, deep burn injuries, skin 
type, anatomical burn site and skin grafting [1,27,33,34,87]. 
 
 Abnormal scars have a documented prevalence rate of 30 to 75 percent post burn [27,95] 
and are defined as scars with physical and sensory symptoms that impact on health-related 
quality of life due to itch, raising, pain, tightness and contracture formation [7,95]. Qualitative 
research has also shown that the appearance and the impact of scars must be considered 
from the patient’s perspective, not just the perspective of the treating clinical team [44,45]. 
Scar prevention and management interventions are initiated with the goal of preventing or 
reducing scar itch, thickness, erythema and pliability with the ultimate goal of maintaining or 
improving overall appearance of the scar and quality of life [8-13].  
 
Scar thickness has traditionally been one of several characteristics used to define the 
severity of scarring and is included in most scar rating scales.  A meta-analysis of studies of 
pressure garment therapy effectiveness, a recent systematic review of non-invasive scar 
interventions including silicone products and pressure garments and a longitudinal study of 
scarring in people with burns receiving standard scar management have supported the 
importance of measuring scar thickness [1,12,40]. Scar thickness has been found to be the 
characteristic that most clearly distinguishes normal scar and normal skin from hypertrophic 
scars up to twelve months post-burn [40].   
 
Itch has been found post-discharge in approximately 80 percent of patients after burn injury 
and has been reported to persist for a prolonged period post-burn [41,42]. This symptom 
has a sustained debilitating impact on patients, influencing wound healing, psychological 
wellbeing, and engagement in activities of daily living [41,42]. It is therefore important that 
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the prevention and management of burn scars is optimum to reduce the impact of scar 
sequelae such as itch on psychosocial development, and health-related quality of life 
including the child’s ability to independently complete daily activities; and to prevent future 
invasive scar interventions.  
 
Burn scar prevention and management after skin healing in high income countries currently 
includes the use of silicone products or pressure garment therapy or pressure garment 
therapy combined with silicone products [7]. These treatments have been routine practice 
for burn scar prevention and management in high income countries for over forty years 
though their effectiveness remains unclear, particularly in children [7,8,95]. 
 
Silicone products can include topical silicone gels, silicone gel sheets, silicone sprays, and 
silicone oils [83]. A film forming topical silicone gel was selected for inclusion in this study 
as topical silicone gels have been recently recommended over other silicone products in 
clinical practice guidelines as they are thought to result in fewer adverse effects [72]. 
Strataderm® topical silicone gel (Stratpharma, Basel, Switzerland), a product used in the 
participating burns department prior to the trial commencing, has the advantage of a reduced 
frequency of application (once per day as opposed to twice per day) compared to other 
topical silicone gel products. It therefore has the potential to reduce the treatment burden to 
patients, improve adherence and reduce the cost of scar prevention and management 
compared to other scar therapies. Whilst the exact mechanism of action of topical silicone 
gels has not been confirmed [65,72,83], it is hypothesised that the occlusive nature of the 
gel reduces trans-epidermal water loss thus increasing the hydration of the stratum corneum 
[61,70]. This results in a ‘normalising’ of the cellular processes of the skin, consequently 
reducing collagen production [61,70]. Topical silicone gel may also provide a protective 
barrier against environmental contaminants [61,70]. It is important to note that whilst there 
is a reduced risk of adverse effects with the use of topical silicone gels there is still a risk of 
local dermatological reactions [70].  
 
Pressure garment therapy also works to normalize cellular processes however it does this 
through mechanical pressure. Pressures of 15 to 25mmHg are hypothesised to reduce 
capillary flow [8,13], thus limiting oxygen and nutrients in the affected area and preventing 
collagen production [142]. The burden of pressure garment therapy to patients and their 
families however can be high, if recommended wearing times of 23 hours per day for up to 
18 months or until scar maturation, are followed [1,86]. Adverse effects from pressure 
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garment therapy can include skin breakdown, altered bony growth and psychological 
distress from cosmetic differences [1,7,87,91]. The burden of treatment and presence of 
adverse effects can impact patient adherence to recommended prevention strategies and 
requires careful consideration when evaluating the effectiveness of these interventions.  
 
Previous studies have focused solely on the effectiveness of scar management interventions 
in relation to physical scar characteristics such as itch, height, pain, erythema, and range of 
motion [12]. They have not considered the broader evaluation of treatment burden (including 
adverse events), health-related quality of life or cost-effectiveness [143]. Also, past studies 
evaluating the effectiveness of topical silicone gels and pressure garments either have not 
included children, or where children have been included, the numbers have been small or 
have been case study reports [11,65,144]. To overcome the limitations of the evidence in 
paediatrics, adequately powered, randomised controlled studies that use a broad evaluation 
framework are required. Thus, a randomised controlled trial (RCT) of the effectiveness of 
topical silicone gel and pressure garment therapy in children will be conducted using such 
a framework.   
 
5.2.2 Objectives 
This study aims to determine the effectiveness of topical silicone gel versus pressure 
garment therapy versus combined topical silicone gel and pressure garment therapy, in the 
prevention and management of burn scars, in children aged zero to sixteen years post-burn 
or zero to eighteen years post burn scar reconstruction. This will be investigated using the 
primary outcomes of scar itch and thickness, six months post-burn or burn scar 
reconstruction. Current literature has been unable to demonstrate one treatment group as 
being superior to the others, however we hypothesise that there will be at least one pairwise 
difference between the group means for scar thickness at the six month end point.  
 
5.3 Methods 
5.3.1 Study Design 
A randomised controlled trial with three parallel arms will be conducted to examine the 
effectiveness of Strataderm topical silicone gel®, pressure garment therapy, and combined 
topical silicone gel and pressure garment therapy for the prevention and management of 
burn scars in children. Individual randomisation by patient will be undertaken using computer 
generated random numbers. Randomisation will occur using a 1:1:1 ratio between groups 
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in blocks of twelve and will be stratified by surgical intervention received (i.e. skin grafting in 
the acute phase, spontaneous skin healing in the acute phase, post-acute reconstructive 
surgery). Concealment of treatment allocation will be completed by the use of sealed, 
opaque, identical and serially numbered envelopes prepared in advance by an independent 
party. All outcomes will be measured at baseline (scar intervention commencement), three 
months and six months post-burn or reconstruction. The primary outcome measures and 
the level of pressure beneath pressure garments will also be measured at one week post-
baseline. The project has ethics approval from the Child Health Queensland Human 
Research Ethics Committee (HREC). A flow diagram of the data collection process is 
displayed in Figure 5.1. 
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Figure 5-1 Flow Diagram of Data Collection 
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A measure of fidelity will assist in determining whether the outcomes are a result of the 
intervention or the processes involved in delivering the intervention (e.g., the education of 
participants and caregivers by therapists) [145]. Checklists will be used to record whether 
the critical elements of the intervention have been delivered as a measure of fidelity. The 
fidelity checklist includes items regarding mechanism of action of allocated treatment, skin 
care, sun care, wear and care instructions of allocated treatment and potential adverse 
effects. 
 
5.3.2 Setting 
The primary setting for data collection will be a burns unit at a large tertiary metropolitan 
children’s hospital in Australia. Children who access this unit are predominantly male (60%), 
under the age of two years and most frequently present with a scald or contact burn injury. 
The incidence of flame and friction burns increases with age [17]. The primary setting 
provides outreach services via telehealth and receives patients from the Pacific Islands and 
interstate if required. If necessary, measurements may be taken at a co-located research 
centre, or the hospital in the patient’s local health district, and/ or at the client’s home to 
reduce potential burden for participants (and their families) and minimise participant dropout. 
 
5.3.3 Participants 
5.3.3.1 Inclusion Criteria 
The inclusion criteria are children with a burn injury who are managed in the acute phase 
post-burn (up to 16 years of age, as per current practice) or who receive burn scar 
reconstructive surgery (up to 18 years of age, as per current practice) at the participating 
Burns Centre and who require attendance at a scar management clinic after skin healing. 
Children who receive skin grafting, children with wounds that have not healed by day 17 
post-burn and children receiving surgery for burn scar reconstruction in all body locations 
with a %TBSA of less than or equal to 40 percent who are accompanied by a parent or 
guardian, who is able to provide informed consent, will be eligible for inclusion. Up to two 
scar sites per person will be recruited where possible with both sites receiving the same 
intervention. Children with a cognitive impairment that impedes the ability to communicate 
will be enrolled in the study, however, will not be required to complete self-report measures. 
Children and their families who do not speak English will be approached to participate in the 
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study with the use of an interpreter but will only have objective scar measures and itch 
Numeric Rating Scale (NRS) administered. 
 
5.3.3.2 Exclusion Criteria  
Exclusion criteria include children whose burns wounds have healed spontaneously within 
16 days and who have not been referred for scar management; children with isolated facial 
or ear burns; children with isolated genital burns; children with comorbidities that might 
influence the primary outcomes (such as a dermatological disorder), children who are 
referred to their local health service before scar management is commenced and children 
involved with the Department of Child Safety where the burns consultant and/or burn team 
members consider study involvement to be contraindicated.   
 
5.3.4 Procedures 
It is anticipated that data collection will take approximately 20 minutes at baseline, three and 
six month post burn or burn scar reconstruction appointments. It is expected that data 
collection will not exceed 10 minutes at the one week follow up point. 
 
5.3.5 Intervention 
Participants will receive standard care for the acute burn injury as determined by the burns 
multidisciplinary team. If a participant is recommended for scar management and their 
caregiver provides consent to participate, baseline assessment will be completed. 
Participants will then be randomly allocated into one of three scar management intervention 
groups according to the contents of the sealed envelope opened by an independent party. 
Group one will receive medical use topical silicone gel (Strataderm®). Group two will receive 
pressure garment therapy (Therapeutic Support Laboratory (TSL®), Abbortsford, Victoria, 
Australia) only. Group three will receive a combination of topical silicone gel and pressure 
garment therapy. The intervention products will be provided to the patient as per standard 
practice once the skin is healed (e.g. sufficient topical silicone gel will be provided to allow 
coverage of the scar area until the next appointment and two sets of pressure garments will 
be provided to each child participant at a new fitting).   
 
The study follow-up time periods will match standard occupational therapy review times (e.g. 
three months, and six months post-burn).  
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5.3.6 Outcomes 
5.3.6.1 Primary Outcomes 
Scar itch intensity and scar thickness will be measured as primary outcomes. Itch intensity 
will be self-reported for children aged five years and older using an 11-point numeric rating 
scale (NRS) (0 to 10). The Toronto Pediatric Itch Scale is an observation based scale rating 
itch behaviours on a scale of 0 (absence of itch) to 4 (severe itch with significant disruption) 
and will be completed by caregivers for children aged less than five years [41]. Caregivers 
for children of all ages will also complete the itch item of the Patient and Observer Scar 
Assessment Scale (POSAS, 0 to 10 NRS). Numeric rating scales have been recommended 
over visual analogue scales due to improved adherence, increased responsiveness and 
fewer missing values in adult pain and chronic itch populations [146,147]. Numerical testing 
will be conducted with all children aged less than eight years and any children known to 
have learning difficulties to ensure they have the capacity to use the NRS [148].  
 
Scar thickness will be measured using the GE Healthcare ultrasound. The GE healthcare 
ultrasound system has been found to have an Intra class Correlation Coefficient (ICC) of  
greater than 0.90 for test-retest reliability when used with children with burn scars [149]. 
When measuring scar thickness with the GE healthcare ultrasound, an image will be taken 
centrally from the site of interest (as opposed to peripherally on the scar border). An average 
of three measurements will be recorded and used in the analysis. 
 
5.3.6.2 Secondary Outcomes 
5.3.6.2.1 Scar Severity 
Scar severity will be measured using items of the Patient and Observer Scar Assessment 
Scale (POSAS) including observer scale items of thickness, vascularity, pliability, 
pigmentation and relief and patient scale items of itch, pain, colour, stiffness, thickness and 
irregularity. The POSAS has been found to be a reliable scar assessment and has the 
advantage of including a patient-report scale [33]. The POSAS observer scale has been 
found to have adequate test-retest reliability for pigmentation, pliability and overall opinion 
of the scar appearance in children [149]. Participants over the age of eight years, caregivers 
and therapists will also complete a questionnaire regarding their overall opinion of the scar. 
The DSMII ColorMeter® (Cortex Technology, Hadsund, Denmark) is an objective device that 
uses tristimulus reflectance colorimetry and narrow band photometry to measure the 
lightness, redness or erythema, and pigmentation of a scar [3,150]. The DSMII ColorMeter® 
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has been found to have an inter-observer reliability ICC of 0.94 for lightness, 0.94 for 
erythema and 0.83 for pigmentation when used on scars [150]. At the participating burns 
centre, the DSMII ColorMeter® was found to have an ICC greater than 0.75 for immediate 
test retest reliability on all scales when used with children with burn scars [149].  
 
5.3.6.2.2 Health-Related Quality of Life 
The Child Health Utility 9D (CHU9D) (a preference-based utility measure) will be used to 
measure health-related quality of life and economic evaluation of the interventions. Items 
covered by the CHU 9D include worried, sad, pain, tired, annoyed, school work/homework, 
sleep, daily routine, and able to join in activities. Preference weights from these are then 
converted to quality adjusted life years for economic evaluation [151]. The CHU 9D has been 
developed with and validated for use with children aged 7 to 17 years including validation 
with an Australian adolescent population [151]. The CHU9D and the EQ5D-Y have been 
found to have good levels of agreement (ICC=0.80) in an Australian adolescent population 
[152]. Children will self-complete this assessment (from 5 years) as able and caregiver proxy 
report will be completed for children of all ages.  
 
The Brisbane Burn Scar Impact Profile (BBSIP) will be used to measure the intensity and 
frequency of sensations such as pain, tightness and discomfort, as well as health-related 
quality of life specific to people with burn scars. This measure was developed and tested for 
preliminary validity in children with burn scars and is undergoing further testing with children 
and caregivers [45]. In adults with burn scars the Brisbane Burn Scar Impact Profile has 
been found to have acceptable reproducibility, responsiveness and longitudinal validity [45]. 
 
5.3.6.2.3 Resource Use and Costs 
Resource use and costs will be recorded for each participant from the perspective of the 
health service provider and costed at market rates. It will include trial interventions costs 
(e.g. the number and volume of topical silicone gel and pressure garment therapy products), 
as well as other burn-related resource use (and costs) that may be important to a health 
service deciding which of the interventions to implement in their model of care for patients 
with burns (e.g. moulds and splinting, overheads and labour time). Labour time (e.g. 
occupational therapists, physiotherapist, nurses, and surgeons) will be quantified for each 
patient (on the basis of time duration utilised and number of appointments required) and 
costed at the relevant state award rates for each respective discipline.   
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5.3.6.2.4 Patient adherence 
Patient adherence to wear and care regimes will be defined as “the extent to which a 
person’s behaviour coincides with medical or health advice” [153]. Adherence will be 
measured using self-report questionnaires to child and caregiver participants, which will 
include questions about the number of hours per day of topical silicone gel and pressure 
garment therapy wear and reasons for non-adherence to interventions. The percentage of 
patient-reported non-adherence (using the actual hours of wear and recommended hours of 
wear) will be measured for each intervention group at the three and six month follow-up 
[154]. In addition, adherence will be measured and reported by the numbers of patients 
randomly assigned to each intervention, receiving the intended treatment, time to cessation 
of the intended intervention, completing the intended intervention as per the protocol, and 
analysed for the primary outcomes [154].   
 
5.3.6.2.5 Treatment Satisfaction 
Treatment satisfaction has been reported to influence adherence to prescribed medical 
interventions [55,155] and so is important to monitor over time. Treatment satisfaction will 
be measured using a caregiver and treating therapist self-report 0 to 10 NRS. 
 
5.3.6.2.6 Discontinuation/ Adverse Events 
The proposed interventions are considered part of standard care at the participating burns 
centre, therefore minimal adverse events are expected. Known potential adverse events 
(e.g. a skin rash from topical silicone gel or skin damage from friction caused by pressure 
garments) have a standardised management protocol at the participating health service. 
Adverse effects of scar interventions will be monitored by reviewing patient medical records 
and by the self-report of caregivers, child participants (where appropriate) and treating 
therapists. All adverse effects will be reported to the clinical health service and overseeing 
human research ethics committee. Discontinuation or alteration of treatment will be at the 
discretion of the treating clinical team and will be monitored throughout the study. At the 
conclusion of the study participants will receive standard care.  
 
5.3.7 Confounding Factors 
There are a number of potential confounding factors in this study. These include surgical 
intervention received (i.e. skin grafting in the acute phase, spontaneous skin healing in the 
acute phase, post-acute reconstructive surgery), patient’s adherence to the treatment 
regime, whether all essential elements of the intervention were delivered by treating 
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therapists (therapist fidelity), the pressure beneath pressure garments, and/ or adverse 
events impacting on the allocated treatment.  
 
Patient adherence and therapist fidelity will be monitored via self-report checklists of salient 
elements of the intervention. Therapist fidelity will also be evaluated through the use of audio 
recordings of 20 percent of patient sessions [59]. Pressure beneath pressure garments will 
be measured in millimetres of mercury (mmHg) at the garment skin interface using the 
Pliance X® device [119]. An ICC of 0.998 has been reported for static measures of test-
retest reliability and an ICC of 0.995 to 1.00 has been reported for inter-rater reliability of the 
Pliance X® device [117].  
 
5.3.8 Blinding 
Baseline measures will be completed prior to randomisation. Due to the nature of the study 
double blinding will not be possible as treating therapists and patients and their families will 
be aware of the treatment modality. Investigator blinding will be difficult to maintain within 
this environment, therefore the primary investigator will complete all outcomes measures 
without blinding. Ultrasound images and the measurement of  burn scar thickness using the 
images taken by the primary investigator will be completed in real time at baseline, one week 
and three and six month follow up points. However, at the conclusion of data collection a 
second investigator (blinded to the results during data collection and to the patient’s identity 
i.e. non-identifiable to the second investigator) will measure burn scar thickness using the 
ultrasound images taken by the primary investigator. Only the results of the blinded assessor 
will be used in data analysis. The inter-rater variation between the investigators will be 
reported for the study.   
 
5.3.9 Statistics 
5.3.9.1 Sample Size 
The sample size estimate was calculated based on the primary outcome of scar thickness 
at six months post-burn for one scar site. We assumed a pooled standard deviation of 1.0mm 
based on a retrospective audit of data from our centre. To detect a statistically significant 
between-group difference of 0.76mm in scar thickness with 80 percent power and an alpha 
value of 0.017 (due to three pairwise comparisons), 36 participants are required in each of 
the three groups. Assuming a 20 percent drop out, the total number of participants who need 
to be recruited at baseline is 135 (45 participants per group).  
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5.3.9.2 Data Analysis 
Sociodemographic, clinical and intervention data will be summarised using descriptive 
statistics. For continuous outcomes either mean and standard deviation, or median and 
range will be used depending on the distribution of the variable. For categorical outcomes 
frequency and percentage will be reported. Data related to intervention benefits will be 
analysed on the “intention-to-treat” (ITT) principle, defined as participants analysed 
according to their randomly allocated study group regardless of treatment received who 
complete follow-up data collection and who receive the recommended length of intervention. 
Data related to intervention adverse effects will be analysed according to the ITT principle 
as well as per protocol defined as those who received and commenced the intervention. A 
sensitivity analysis will be conducted to compare the ITT and per-protocol approaches if 
appropriate. Baseline characteristics will be compared to assess the compatibility of groups. 
At baseline between group differences will be investigated using linear regression for 
continuous data and Fisher’s exact test for categorical data. Post-baseline, between group 
differences in adherence will also be investigated using linear regression at each time-point. 
Potential confounding variables for the primary outcomes are considered a-priori to be: age, 
days to re-epithelialisation, percent maximum burn depth, days post-burn when scar 
management commenced, Fitzpatrick skin type, percent TBSA, patient adherence, level of 
pressure beneath garment (for the groups treated with pressure garments), anatomical body 
site treated, surgical intervention received (skin grafting in the acute phase, spontaneous 
wound healing in the acute phase, post-acute reconstructive surgery), wound complications 
(e.g. infection), other interventions received (e.g. massage) including the use of itch 
medications [33,34,156].  
 
The primary outcomes will be analysed using mixed effects regression analyses to examine 
differences at six months post-burn, adjusting for the baseline value of the outcomes. Mixed 
effect regression analyses will be completed for each follow-up time point. Potential 
confounding variables that are identified as imbalanced between the groups will be entered 
into regression analyses. The time-varying covariates are patient adherence, level of 
pressure beneath garments, and other interventions received. All of the other potential 
confounding variables are non-time dependent co-variates. Sensitivity analyses will be 
completed for missing data using multiple imputation of missing observations by creating 
ten complete data sets [157] of missing dependent and independent data. For participants 
from whom data is collected from two scar sites, the multiple sites on these individuals will 
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be accounted for in analytic models by including the scar site as a random effect nested 
within participant. Initially all participants will be included in the analyses. The analyses will 
then be repeated after stratifying by surgical intervention (i.e. skin grafting in the acute 
phase, spontaneous skin healing in the acute phase, post-acute reconstructive surgery). 
Subsequently, the influence of sociodemographic, clinical and intervention factors, and 
primary and secondary outcomes not included as dependent variables, on primary and 
secondary outcomes will also be examined using regression models. Differences in health-
related quality of life between the intervention group and respective normative comparison 
groups will be analysed using t-tests, z-scores or equivalent non-parametric tests where 
appropriate. Differences in self-reported outcomes by children versus caregivers, between 
age-groups and in comparison to normative data will also be examined using univariate 
statistics such as t-tests, z-scores or non-parametric equivalents. Significance will be set at 
less than 0.05. Data will be analysed using SPSS (SPSS, Chicago) or Stata (StataCorp, 
College Station, TX, USA) where appropriate.  
 
5.3.10 Data Storage 
All information collected as part of this study will be stored safely in a locked filing cabinet in 
a locked office and in password protected computer files. Any information obtained in 
connection with this research project that has the potential to re-identify participants will 
remain confidential and securely stored. The data collected from this study will be kept for 
fifteen years, as per the recommendations of the National Health and Medical Research 
Council Guidelines (NHMRC).  
 
5.4 Discussion 
Silicone products and pressure garment therapy have been accepted treatments for burn 
scar management in high income countries for over forty years, though there is minimal 
evidence to support their use [7,8,87,95]. In addition, minimal research has been completed 
with a paediatric burns population or with any age group using a broad evaluation that 
investigates the effectiveness of scar prevention interventions, their impact on health-related 
quality of life, the burden of treatments on patients and their families, or the paediatric 
patient’s adherence to these interventions.  
 
Whilst little is known about adherence to recommended wear and care regimes for children 
using topical silicone gel and/ or pressure garments, adherence by children is likely less 
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than optimal. In adults, adherence to recommended pressure garment therapy has recently 
been recorded as 15 to 80 percent with reasons for non-adherence including the cosmetic 
appearance of garments, insufficient education regarding garment use as well as poor fit 
and discomfort [54]. Low rates of adherence to recommended silicone gel sheeting use (24 
hours per day) have also been reported in adults [77]. It is expected that adherence will be 
greater when using topical silicone gel (Strataderm®) compared to pressure garment therapy 
due to the reduced application time and no need for additional care/ maintenance of the 
product.  
 
The burden of topical silicone gel also appears lower than pressure garment therapy due to 
recommended application of the product one to two times daily (depending on scar location), 
fast drying time and durability. However, topical silicone gels may be time consuming to 
apply to an extensive body surface area and have been documented to cause local 
dermatological reactions [70]. Thus, further investigation of their effectiveness is required. 
 
The burden of pressure garment therapy can be high for patients and their families due to 
prolonged recommended wearing time, 23 hours per day until scar maturation [1,7], and the 
need for regular replacement of garments. Pressure garments can also cause discomfort 
when they are ill fitting, can instigate changes in bony growth, and can cause heat reactions 
and friction damage to new skin [1,87]. In addition to these physical symptoms, pressure 
garments may also result in emotional and psychological reactions in children with burn 
scars through visible cosmetic differences, separate from the visible difference that may 
result from scarring [45].  
 
5.4.1 Significance of the study 
This study will provide evidence of the effectiveness of three burn scar interventions for the 
prevention and management of burn scars in children. Specifically, evidence will be obtained 
regarding the effectiveness of topical silicone gel alone, pressure garment therapy alone, 
and a combination of topical silicone gel and pressure garment therapy. Future randomised 
control trials will be required to confirm these results, however if consistent results are 
achieved, changes in clinical practice may occur.   
 
By using a broad evaluation framework in combination with a design that carefully controls 
for confounding factors and investigates influencing factors, this study may determine which 
children benefit most from the scar management interventions of interest. Cost-effectiveness 
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of the RCT interventions, from a health service perspective, will also be examined as part of 
future work, which, to the knowledge of the authors, has not been examined in scar 
management intervention studies to date.  Examining and controlling for the influence of a 
range of potential confounders will maximise the rigour of the study and will inform future 
studies of the factors that influence scar outcomes. Whilst this study will follow participants 
up to six months post-burn, this study will pave the way for similar studies with follow-up to 
scar maturation (which can extend to eighteen months post-burn or longer) and multicentre 
trials.  
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5.5 Chapter conclusion 
Chapter Five was published as a study protocol and details the methodology for the 
randomised controlled trial aimed at assessing the effectiveness of topical silicone gel and 
pressure garment therapy for the prevention and management of post-burn scarring in 
children. The following chapter outlines the results of the randomised controlled trial and 
discusses the implications of those results.  
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CHAPTER 6 Effectiveness of topical silicone gel and 
pressure garment therapy for the prevention and 
management of abnormal burn scarring in children: results 
of a randomised controlled trial 
 
This Chapter is based on a submitted paper to the journal Archives of Physical Medicine 
and Rehabilitation.  
 
 
As an author on the potential publication I made a major contribution to the conception of 
the project (65%), analysis and interpretation of the research data (70%) and drafted the 
publication (85%) with input and feedback from the supervisory team and statistician as 
appropriate. 
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6.1 Chapter foreword 
Paediatric burn scar management poses a unique challenge to burn care professionals. The 
physical, cognitive, social and emotional consequences of abnormal burn scarring require 
management not just for the duration of scar maturation but also across the developmental 
stages of the child. Examples include the potential for contractures as the child grows and 
social and emotional transitional periods such as school commencement. Adherence, 
intervention burden and treatment satisfaction outcomes must also be considered from the 
caregiver perspective to ensure interventions can be completed within the context of the 
needs of the family unit. Previous assessment of the effectiveness of scar interventions have 
been based on studies involving adults or studies combining adult and child data. Thus, 
children as a population have not been the focus of prior work.  
 
The aim of the randomised controlled trial presented in this Chapter was to determine the 
effectiveness of topical silicone gel and pressure garment therapy both alone and in 
combination to prevent and manage abnormal post-burn scarring in children. The 
randomised controlled trial considered outcomes beyond the physical scar characteristics 
(i.e. scar severity, thickness, colour) reported on in previous randomised controlled trials 
and systematic reviews [8,11-13,65,78,97,111]. The current study included outcomes such 
as health-related quality of life (including intervention burden), adherence, and treatment 
satisfaction. In addition, this randomised controlled trial considered factors that had the 
potential to impact on the interpretation of the results such as adverse effects, intervention 
fidelity, and interface pressure or pressure ‘dosage’.  
 
The following chapter is based on the publication submitted to Archives of Physical Medicine 
and Rehabilitation in 2019, titled “Effectiveness of topical silicone gel and pressure garment 
therapy for the prevention and management of post-burn scarring in children: a randomised 
controlled trial”. It focuses on the results of the randomised controlled trial with data 
collection and analysis occurring as outlined in the protocol presented in Chapter Five. 
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6.2 Introduction 
6.2.1 Background 
There has been a global reduction in burn injury incidence, mortality, and severity over the 
last 30 years, however managing abnormal post-burn scarring remains challenging for 
rehabilitation teams [1-3]. Symptoms of abnormal burn scarring can impact a person’s daily 
activities through contracture, sensation changes, chronic itch, reduced body image and 
post-traumatic stress [4,27,41-45,47-49]. Characteristics associated with an increased risk 
of abnormal scarring post-burn have been postulated to include wound re-epithelialisation 
time, percentage total body surface area burned (%TBSA), burn depth, number of surgical 
procedures, skin type and anatomical burn site [1,27,33,34,87]. Scar interventions are 
initiated to prevent or reduce scar severity and improve overall scar appearance and health-
related quality of life [8-13]. Burn scar prevention and management typically includes the 
use of silicone products or pressure garment therapy, alone or in combination [7]. Whilst 
silicone and pressure garment therapy interventions have been used in routine practice for 
over forty years, their effectiveness remains unclear, particularly in children who have not 
been the focus of previous trials [7,8,95].  
 
Silicone products are postulated to reduce tension at the scar border (influencing the 
mechanotransduction pathway) and provide an occlusive barrier to the skin thus mimicking 
a mature stratum corneum and preventing trans-epidermal water loss [32,61,62,70,71]. In 
comparison, pressure garments are hypothesised to induce hypoxia in the microvasculature 
and impact the mechanotransduction pathway by providing support to the extra-cellular 
matrix thus stimulating apoptosis and remodelling of collagen fibres [8,13,32,62,87,88]. The 
combined application of these two interventions has been hypothesised to improve scar 
outcomes more than either intervention alone [11,62]. 
 
Systematic reviews [1,7,12,97] evaluating the effectiveness of silicone and pressure 
garment therapy have reported conflicting evidence for these interventions. Previous 
investigations are limited by a focus on physical and sensory scar characteristics rather than 
patient-centred outcomes such as treatment burden and health-related quality of life. 
Further, benefits have rarely been reported in light of harms as recommended [63,158] 
despite skin maceration and breakdown, rash, pruritus, and changes to bony growth being 
potential harms of silicone and pressure garment therapy [1,7,72,87,91]. 
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6.2.2 Objectives 
This study aimed to determine the effectiveness of topical silicone gel and pressure garment 
therapy alone and in combination for the prevention and management of abnormal burn 
scarring in children and young people.  
 
6.3 Methods 
6.3.1 Setting  
The primary setting for data collection was the participating burns centre at a large 
metropolitan children’s hospital in Australia. Children treated for an acute burn injury at the 
unit were typically male (60%), under the age of two years and most frequently presented 
with a scald or contact burn injury [17]. The participating burns centre receives patients from 
interstate and the Pacific Islands as required and provides outreach telehealth support to 
health services across the state of Queensland [17]. Secondary settings included a research 
centre co-located with the participating burns centre, four regional health district hospitals 
located between 120 and 620 kilometres from the participating burns centre, and 
participant’s homes located within an hour drive of the participating burns centre. Secondary 
settings were included in a bid to reduce burden for participants (and their families) travelling 
for appointments and to minimise participant dropout. 
 
6.3.2 Study Design 
A randomised controlled trial with three parallel arms was conducted to examine the 
effectiveness of topical silicone gel, pressure garment therapy, and combined topical 
silicone gel and pressure garment therapy for the prevention and management of burn 
scarring in children. Randomisation occurred using a 1:1:1 ratio between groups and was 
stratified by surgical intervention received (skin grafting in the acute phase, spontaneous 
skin healing in the acute phase, post-acute scar reconstructive surgery). All outcomes were 
measured at baseline (scar management commencement, approximately 95% wound re-
epithelialisation), three months, six months and twelve months post-burn injury or burn scar 
reconstruction surgery. Primary outcomes were also measured at one week post-scar 
management commencement. The primary focus of this report is the results at the primary 
endpoint of six months post-burn or burn scar reconstruction surgery.  
 
The study had ethics approval from the Children’s Health Queensland Human Research 
Ethics Committee: HREC/15/QRCH/249 (Lady Cilento Children’s Hospital: 
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SSA/16/QRCH/217, University of Queensland’s Human Research Ethics Committee: 
Approval number 2016000558). The study was also registered on the Australian New 
Zealand Clinical Trials Registry: ACTRN12616001100482. This study is reported according 
to the CONSORT guidelines [159].  
 
6.3.3 Participants 
6.3.3.1 Inclusion Criteria 
Children and young people managed in the acute phase post-burn (up to 16 years of age) 
or who received burn scar reconstructive surgery (up to 18 years of age) at the participating 
burns centre, and who required attendance at a scar management clinic after wound re-
epithelialisation were eligible for inclusion. Children included were those who received skin 
grafting, children with spontaneously healing wounds that did not heal by day 17 post-burn 
with a %TBSA of less than or equal to 40 percent, and children who received reconstruction 
surgery for a pre-existing burn scar.  
 
Age restrictions for acute (up to 16 years) and post-acute wounds (up to 18 years) were in 
line with current clinical practice at the participating burns centre. Day 17 post-burn injury 
for spontaneous wound healing was selected as the time point for referral to scar 
management as the aim of this trial was scar prevention. Day 17 is midway between the 14 
to 21 day wound healing range often referred to in the literature as increasing the risk of 
abnormal post-burn scarring. Additionally, day 17 post-burn injury for spontaneously healing 
wounds is a clinically meaningful time point for the participating burns centre. Children were 
likely to attend the participating burns centre for routine dressing changes on day three, day 
10 and day 17 following the application of a three-day dressing and two subsequent seven-
day dressings. The 40% TBSA criteria was implemented due to the increased medical care 
required for these children and as the burden of applying topical silicone gel to more than 
40% of the child’s body was considered too large by the clinical team. 
 
Children were eligible for inclusion if they were accompanied by a parent or guardian who 
was able to provide informed consent. Children with a cognitive impairment that impeded 
the ability to communicate were enrolled though not required to complete self-report 
measures. Children and their families from a non-English speaking background were 
approached for research, had objective scar measures and the itch Numeric Rating Scale 
(NRS) administered with the assistance of an interpreter. Additional outcome measures 
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were not validated in languages other than English and so were not completed. Up to two 
scar sites per person were included with both sites receiving the same intervention. 
 
6.3.3.2 Exclusion Criteria  
Exclusion criteria included children whose burn wounds healed spontaneously within 16 
days and were not referred for scar management; children with comorbidities that might 
influence the primary outcomes (such as a dermatological or neurological disorder), children 
with isolated facial, ear or genital burns; and children who were referred to their local health 
service before scar management was commenced. Additionally, children were considered 
ineligible where there was involvement with the Department of Child Safety and consent for 
research could not be achieved.   
 
The following exclusion criteria were added to the study protocol early after commencement 
of the trial (approximately five recruited participants): isolated facial, ear and genital burns 
and referral to local health service prior to scar management commencement. The criteria 
were added to the protocol due to the pragmatic nature of the intervention (i.e. difficulty 
applying compression to these locations and large outreach of the participating burns 
centre). Changes were made prior to publication of the protocol but after initial registration 
with the Australian and New Zealand Clinical Trial Registry (ANZCTR). 
 
6.3.4 Procedures 
All participants received standard care for the acute burn injury as determined by the burns 
multidisciplinary team. If the potential participant consented to the study, baseline 
assessment was completed prior to scar intervention randomisation at approximately 95% 
wound re-epithelialisation. If the potential participant did not consent to the study, consent 
was sought for the collection of sociodemographic and clinical characteristics to investigate 
differences between the sample of children who did and did not participate in the study. 
Thus, an assessment of the generalisability of the results could be made. 
 
Participants were randomised to: (1) medical use topical silicone gel (Strataderm® 
(Stratpharma, Basel, Switzerland)) only; (2) pressure garment therapy (Therapeutic Support 
Laboratory® (Abbortsford, Victoria, Australia)) only; or (3) combined topical silicone gel and 
pressure garment therapy. Objective outcome measures were completed on up to two scar 
sites during the clinical appointment, using distraction techniques as required to assist with 
keeping the child still. Paper based outcome measures were provided by the primary 
123 
 
investigator and were typically completed by families in the waiting room of the participating 
burns centre prior to the clinical appointment. If necessary, questionnaires were completed 
during or at the conclusion of the clinical appointment.  
 
Scar sites were selected in conjunction with the family and treating health professionals. The 
child and their family reported the worst scar site/s (e.g. thickest, itchiest, or of most 
concern). If families did not or could not report a worst site, the area most at risk of scarring 
or most tolerable for ultrasound imaging at 95% wound re-epithelialisation was selected for 
scar assessment according to the clinical assessment of treating health professionals. If a 
worst scar site or site most at risk of scarring was unable to be identified, the primary 
investigator selected the site that would assist in scar relocation. Body measurements, 
anatomical landmarks and descriptive summaries were used to assist with scar relocation. 
Photographs were inconsistently used due to camera availability. 
 
Due to the nature of the study, the primary investigator, treating therapists, participants and 
their families were aware of the treatment modality, thus double blinding was not possible. 
However, blinded assessment of scar thickness was completed to reduce the impact of 
potential bias and only the results of a blinded ultrasound assessor were used in data 
analysis. Measurement of burn scar thickness was completed in real time with the GE 
Healthcare Ultrasound by the primary investigator at baseline, one week, three, and six 
month follow up points. At the conclusion of the six months post-burn data collection, the 
blinded ultrasound assessor (a second investigator) measured participant’s burn scar 
thickness for all follow up time points using the ultrasound images taken by the primary 
investigator. The blinded ultrasound assessor was blinded to the participant’s identity, 
treatment group, and the primary investigator’s scar thickness measurement. Inter-rater 
variation between the two investigators was determined. 
 
The interventions investigated during this study were considered standard care at the 
participating burns centre, therefore known potential adverse effects (e.g. skin irritation from 
topical silicone gel or friction caused by pressure garments) had a standardised 
management protocol. Adverse effects were monitored through the self-report of caregivers, 
child participants (where appropriate) and treating health professionals. Caregivers were 
encouraged to contact the health service or the primary investigator immediately if adverse 
effects were identified. At each appointment, the treating occupational therapist reviewed 
the presence of adverse effects since the last appointment and documented reported 
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adverse effects on the fidelity checklist. All adverse effects were reported to the clinical 
health service and overseeing human research ethics committee. Discontinuation or 
alteration of treatment was at the discretion of the treating clinical team and was monitored 
throughout the study.  
 
Occupational therapists participating in the trial (at all participating health services, n=14) 
received training (verbal education, study information form and review of fidelity checklist) 
from the primary investigator regarding the study protocol, standardised intervention 
requirements and completion of the fidelity checklist. Occupational therapists completed the 
fidelity checklist during or at the cessation of scar management sessions, according to time 
constraints. In addition, occupational therapists received training in measurement for 
custom-made pressure garments as part of their orientation to the burns service.  
 
6.3.5 Intervention 
Participant’s initial intervention education was provided by treating occupational therapists 
at the participating burns centre. The treating occupational therapist could be different at 
each clinical appointment. Information was provided verbally accompanied by a 
standardised one page written hand out. Education components were listed on the 
intervention fidelity checklist and included the goals of scar management, the scar 
maturation process, proposed mechanisms of action of scar management interventions, and 
scar management product wear and care. Verbal instructions and practical demonstration 
was provided for topical silicone gel and pressure garment application.  
 
Intervention products were provided to the patient as per standard practice at the 
participating burns unit. Sufficient topical silicone gel for use until the child’s next clinical 
appointment was supplied. If necessary, families could contact the participating burns centre 
and have additional topical silicone gel tubes posted to their home. Treating occupational 
therapists advised participants that topical silicone gel should be applied at a minimum of 
once per day to clean, dry, healed skin. Families were advised to check the skin after eight 
hours of wear according to manufacturer’s directions to determine if a second application 
was required.  
 
Custom-made pressure garment measurements were taken by clinical occupational 
therapists at the participating burn centre according to manufacturer training. Custom-made 
pressure garments were fabricated by the manufacturer. Interface pressure over the scar 
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site of interest was assessed by the primary investigator at each research follow up time 
point, however treating occupational therapists were blinded to this information. Pressure 
garments were recommended to be worn for 23 hours per day and fit was reviewed at each 
clinical appointment by the occupational therapist. At the participating burns centre children 
were typically provided with two custom-made pressure garments that were replaced every 
three months depending on growth of the child and fabric degradation. Participants were 
advised that pressure garments should be washed according to the manufacturer’s 
instructions. The manufacturer provided donning and washing instructions in writing on the 
pressure garment packaging. Manufacturer washing instructions recommend: (1) hand 
wash in a mild detergent with cold water; (2) roll the pressure garment in a towel and wring 
out excess water; (3) dry in shade. 
 
All participants were advised to use moisturising cream and sunscreen as per usual care. 
Massage and ranging exercises were able to be recommended at the treating occupational 
therapist’s discretion and were considered in the analyses. Interventions could be ceased 
at any time during the study period if the treating occupational therapist deemed the scar to 
be mature. If participants required ongoing scar management at the conclusion of the study, 
participants received standard care at the discretion of the treating clinical team.  
 
6.3.6 Outcomes  
6.3.6.1 Primary Outcomes  
Primary outcomes were measured on two scar sites at baseline, 1-week post-scar 
management commencement, 3 and 6-months post-burn or burn scar reconstruction 
surgery. 
 
6.3.6.1.1 Scar thickness 
Scar thickness was measured using the GE Healthcare Ultrasound (paediatric intra-rater 
reliability ICC=0.95) [125]. Thickness was measured from the top of the epidermis to the 
bottom of the dermis. An average of three thickness measurements completed by the 
blinded investigator was used in data analysis. The smallest detectable change for the GE 
Healthcare Ultrasound has been reported as 0.06cm for the same rater with a standard error 
of measurement of 0.02cm [125]. The standard error of measurement (0.05cm) and thus the 
smallest detectable change (0.14cm) was greater when inter-rater variability was assessed 
[125]. Scar thickness assessed with the GE Healthcare Ultrasound has a strong correlation 
with the thickness (ρ=0.61) and pliability (ρ=0.62) items on the observer version of the 
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Patient and Observer Scar Assessment Scale (POSAS) [125]. Reliability of the ultrasound 
device for the assessment of normal skin thickness was not acceptable (ICC=0.61 and 0.33 
for intra-rater and inter-rater reliability) [125]. Therefore, normal skin thickness was not 
assessed in this study. 
 
6.3.6.1.2 Scar itch intensity 
Scar itch intensity was measured using caregiver proxy report on the Patient and Observer 
Scar Assessment Scale (POSAS) 1 to 10 numeric rating scale (NRS) for children of all ages. 
A score of one reflects no, not all and ten is described as yes, very much. Secondary 
measures of interest for scar itch intensity included self-report on an 11 point NRS (0=‘no 
itch’, 10=‘itch as bad as it could possibly be’) by children five years and older, and via 
caregiver observation on the Toronto Pediatric Itch Scale as per the study protocol [122]. 
Test-retest reliability for an itch NRS has been reported as acceptable (ICC=0.83) in an adult 
population [160]. The inter-observer agreement on the Toronto Pediatric Itch Scale has been 
reported as fair, kappa=0.52 [41]. 
 
6.3.6.2 Secondary Outcomes 
Secondary outcomes were measured on one scar site at baseline (excluding adherence, 
treatment satisfaction and adverse effects), 3 and 6-months post-burn or burn scar 
reconstruction surgery. 
 
6.3.6.2.1 Scar severity 
Scar severity was measured using individual items on the Patient and Observer Scar 
Assessment Scale (POSAS) [161] (excluding the surface area item) as there is conflicting 
evidence of structural validity of its total score [33,161-163]. The POSAS was completed by 
caregivers (patient version) and the primary investigator (observer version).  
 
Scar colour was measured using the DSMII ColorMeter® (Cortex Technology, Hadsund, 
Denmark). An average of three consecutive colorimeter measurements (for scar and normal 
skin) were taken immediately following each other for L* (lightness) and a* (erythema) 
measurements included in the analysis. Colorimeter L* measurements are reported as the 
difference between the scar site and contralateral normal skin (scar - normal skin) to account 
for seasonal changes in skin pigmentation. Where a contralateral site was not available (i.e. 
in the case of bilateral burn injuries), scar colour was compared to the nearest site of 
unaffected skin.  
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6.3.6.2.2 Health-related quality of life 
Caregiver report on health-related quality of measures was used as the primary approach. 
However, child self-report data was also collected where possible for triangulation of the 
results, comparing caregiver and child report.  
 
Generic health-related quality of life was assessed using the Child Health Utility 9D (CHU-
9D) [164]. The CHU-9D has one proxy report version for children aged five years and older 
and one version for children aged three to five years which was used for all children aged 
under five years in this study. Children from five years of age self-reported quality of life on 
the CHU-9D with assistance with reading questions as necessary. A result of less than one 
indicates a reduction in general health-related quality of life. Analysis was completed on all 
three versions of the CHU-9D. 
 
Burn specific health-related quality of life was measured using the Brisbane Burn Scar 
Impact Profile (BBSIP) version 1.0. The BBSIP has three paediatric versions that were 
completed for this study: caregivers of children aged less than eight years (ca0-8) [165], 
caregivers of children aged greater than eight years (ca8-18) [166] and children aged eight to 
eighteen years (ca8-18) [167]. Low scores indicate no or minimal influence on health-related 
quality of life. Analysis was completed on all three paediatric versions of the BBSIP. 
 
6.3.6.2.3 Adherence 
Patient adherence was measured using caregiver proxy report for children of all ages and 
child self-report for children aged eight years and older using an adherence questionnaire 
designed for this study. Assessment of adherence was based on responses to the following 
questions (completed according to the relevant intervention):  
 In the last month, on average how many times per day did you/your child apply topical 
silicone gel?  
 In the last month, on average how many hours per day/night did you/your child wear 
your/their pressure garment?  
Analysis was completed on caregiver proxy report as this was available for all age groups. 
Psychometric properties of the questionnaire have not been assessed. Pressure garment 
therapy adherence is reported as percentage adherence ((number of hours daily 
wear/recommended 23 hours of daily wear) x 100). 
 
128 
 
6.3.6.2.4 Treatment satisfaction 
Treatment satisfaction was assessed from a caregiver and treating occupational therapist 
perspective using an 11 point NRS for the following question (according to intervention 
allocation):   
 How satisfied are you with the ability of the silicone gel to prevent or treat scarring of 
the child’s skin?  
 How satisfied are you with the ability of the pressure garment to prevent or treat 
scarring of the child’s skin?  
A score of 0=very dissatisfied and 10=very satisfied. 
 
6.3.6.3 Other outcomes 
6.3.6.3.1 Adverse Effects 
The number and type of adverse effects was collected [158]. Adverse effects were classified 
as skin irritation, sensory symptoms (i.e. itch, pain, pins and needles), wound breakdown, 
swelling, bony changes, lost/misplaced interventions and problems with interventions (i.e. 
running out of topical silicone gel, ill-fitting pressure garment). The CONSORT extension for 
better reporting of harms in randomised trials was implemented [158]. 
 
6.3.6.3.2 Intervention fidelity 
Intervention fidelity [145] was monitored through the completion of a paper-based checklist 
completed by treating occupational therapists (see Appendix 6). The checklist was 
specifically designed for this study in liaison with the occupational therapy consultant of the 
participating burns centre (who was a member of the investigating team). When necessary, 
verbal feedback regarding missed education components was provided at the end of the 
scar management session to treating occupational therapists by the primary investigator. 
Occupational therapists could report an item as ‘not applicable’. At the conclusion of the six 
month data collection, fidelity checklists were scored. Scoring was completed as a 
percentage of items completed, compared to the number of items applicable at each follow-
up. The principal investigator also completed audio recordings of sessions for 20% of 
participants. 
 
6.3.6.3.3 Intervention burden 
The single items of the caregiver report BBSIP0-8  and BBSIP8-18 and child report BBSIP8-18 
addressing intervention burden were used to assess burden at three and six months post-
burn or burn scar reconstruction surgery. A lower score indicated less burden. 
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6.3.6.3.4 Interface pressure 
Interface pressure of one scar site (the scar site reported to be the most severe at baseline 
by the caregiver) was measured using the Pliance X® (Novel Electronics, Munich, Germany) 
at each follow up time point, except when the machine was undergoing calibration. The 
Pliance X has appropriate test-retest reliability and clinical utility for evaluative measurement 
in a paediatric burn scar population (ICC=0.87) [138]. 
 
6.3.7 Sample Size 
The sample size estimate was based on the primary outcome of scar thickness for one scar 
site at six months post-burn. A pooled standard deviation of 1.0mm was assumed based on 
a retrospective audit of data from our centre. To detect a statistically significant between-
group difference of 0.76mm [11] in scar thickness with 80 percent power and an alpha value 
of 0.017 (due to three pairwise comparisons), 36 participants were required in each of the 
three groups. A 20 percent drop out was assumed, therefore the total number of participants 
needed to be recruited at baseline was 135 (45 participants per group).  
 
6.3.8 Randomisation 
6.3.8.1 Sequence generation 
Individual patient randomisation was undertaken using computer generated random 
numbers using nested permuted blocks of twelve.  
 
6.3.8.2 Allocation concealment 
Concealment of treatment allocation was completed via sealed, opaque, identical and 
serially numbered envelopes prepared in advance by an independent party who was not 
involved in the trial. The allocation list was stored securely in a research facility separate to 
the recruitment location. 
 
6.3.8.3 Implementation 
Sequence generation and allocation concealment was completed in advance of the study 
commencing by two separate parties who had no involvement with potential or actual study 
participants including group allocation. Participants were enrolled in the study at the 
participating burns centre by the primary investigator when the wound was at or near 95% 
re-epithelialisation according to the clinical judgement of the treating multidisciplinary team. 
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Allocation concealment envelopes were opened by an independent party not involved in the 
trial after baseline measurements were completed.  
 
6.3.9 Statistical analyses 
Sociodemographic and clinical characteristics and intervention data were summarised using 
descriptive statistics (e.g. mean and standard deviation, median and interquartile range, 
frequency and percentage) and were compared at baseline to assess the compatibility of 
groups. It was planned that the pre-specified variables that were identified as imbalanced 
between the groups would be entered into regression analyses. Select sociodemographic 
and clinical characteristics of participants who declined to participate in the study or withdrew 
immediately after randomisation and consented to the collection of sociodemographic and 
clinical characteristics were assessed and compared to those who participated in the study 
to examine differences between the groups. 
 
Data were analysed using an “intention-to-treat” (ITT) approach. ITT was defined as an 
analysis of participants (who completed follow-up data collection) according to their 
randomly allocated intervention group regardless of the actual treatment received. Between-
group differences in the primary and secondary outcomes were investigated using the time 
by group interaction term from mixed effects regression at each time-point. Participants were 
treated as a random effect in the regression models and for those participants with data 
collected from two scar sites, scar site was accounted for as a random effect nested within 
participant. Effectiveness was determined using the results of the ITT regression analyses 
at six months post-burn injury or burn scar reconstruction. As pre-specified, sensitivity 
analyses were conducted to compare the ITT to a per-protocol approach.  
 
Complete data was compared to missing data using multiple imputation of missing 
observations using ten created data sets [157]. Stratification of results by surgical group 
(spontaneous wound healing, skin grafting, scar reconstruction surgery) was also completed 
as per the protocol. To examine the influence of scar location on the effectiveness of the 
intervention a post-hoc analysis was conducted stratifying the results of the primary 
outcomes by scar location (upper limb, lower limb, torso). Standardised mean differences 
(SMD) were calculated for primary outcomes. Normality of the residuals was assessed by 
visual inspection for blinded scar thickness measurements. Significance was set at less than 
0.05.  
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Descriptive data was analysed using SPSS (SPSS, Chicago, USA) and mixed effects 
models using Stata (StataCorp, College Station, Texas, USA) where appropriate. 
Standardised mean differences were calculated using Review Manager (RevMan) 5.3 
(Copenhagen: The Nordic Cochrane Centre, Cochrane Collaboration, 2014). 
 
6.4 Results 
Participants were recruited from the participating burns centre between August 2016 and 
November 2017. Outcome data collection for the six month follow up time point ceased in 
May 2018. One hundred and fifty-nine participants were recruited to the trial. Recruitment 
was ceased once the estimated sample size was reached and attrition had been accounted 
for. Six participants withdrew from the trial immediately after randomisation due to 
intervention preferences of the child or their family (topical silicone gel n=1, pressure 
garment therapy n=5, combined intervention n=0). Figure 6.1 illustrates the number of 
participants recruited per group, as well as the number of participants data was collected for 
at each time point (including reasons for missing data). 
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Topical silicone gel 
6 month follow up completed n = 44 
Lost to follow up n = 7 
  Failed to attend n = 6 
  Returned to local health service n = 0 
  Withdrew from trial n = 1 
Discontinued intervention post-6mth f/up n = 1 
  Family requested addition of pressure garment n= 1 
Pressure garment therapy 
6 month follow up completed n = 39 
Lost to follow up n = 10 
  Failed to attend n = 10 
  Returned to local health service n = 0 
Discontinued intervention post-6mth f/up n = 0 
 
Combined interventions 
6 month follow up completed n = 40 
Lost to follow up n = 13 
  Failed to attend n = 11 
  Returned to local health service n = 2 
Discontinued intervention post-6mth f/up n = 1 
  Not tolerating pressure garment n = 1 
 
Topical silicone gel 
Participants, n = 44 
Scar sites analysed, scar thickness n = 51 
Pressure garment therapy 
Participants, n = 39 
Scar sites analysed, scar thickness n = 43 
 
Combined interventions 
Participants, n = 40 
Scar sites analysed, scar thickness n = 48 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-1 CONSORT Flowchart   
Assessed for eligibility n = 293 Excluded n = 134 
  Not meeting inclusion criteria n = 54 
  Declined to participate n = 80 
Randomised n = 159 
 
Topical silicone gel 
Baseline measurements n = 52 
  Randomised to and received intervention n = 51 
  Randomised to and withdrew from trial n = 1 
 
Pressure garment therapy 
Baseline measurements n = 54 
  Randomised to and received intervention n = 49 
  Randomised to and withdrew from trial n = 5 
 
 
Combined interventions  
Baseline measurements n = 53 
  Randomised to and received intervention n = 53 
  Randomised to and withdrew from trial n = 0 
 
 
Topical silicone gel 
1 week follow up completed n = 50 
Lost to follow up n = 2 
  Failed to attend n = 1 
  Returned to local health service n = 1 
  Discontinued intervention n = 0  
 
Pressure garment therapy 
1 week follow up completed n = 49 
Lost to follow up n = 0 
  Failed to attend n = 0 
  Returned to local health service n = 0 
  Discontinued intervention n = 0 
 
Combined interventions 
1 week follow up completed n = 51 
Lost to follow up n = 2 
  Failed to attend n = 1 
  Returned to local health service n = 1 
  Discontinued intervention n = 0 
 
Topical silicone gel 
3 month follow up completed n = 48 
Lost to follow up n = 3 
  Failed to attend n = 3 
  Returned to local health service n = 0 
Discontinued intervention post-3mth f/up n = 1 
  Wound breakdown n = 1 
 
Pressure garment therapy 
3 month follow up completed n = 46 
Lost to follow up n = 3 
  Failed to attend n = 3 
  Returned to local health service n = 0 
Discontinued intervention post-3mth f/up n = 2 
  Not tolerating pressure garment n = 1 
  Family requested addition of silicone n = 1 
 
Combined interventions 
3 month follow up completed n = 42 
Lost to follow up n = 11  
  Failed to attend n = 9 
  Returned to local health service n = 2 
Discontinued intervention post-3mth f/up n = 7 
  Not tolerating pressure garment n = 6 
  Wound breakdown n = 1 
 
Analysis 
Follow-Up 
Allocation 
Enrolment 
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6.4.1 Sociodemographic and clinical characteristics of participants 
The 153 participants who were allocated an intervention had a median (IQR) age of 4.9 (1.6, 
10.2) years, a median (IQR) %TBSA burned of 1.0% (0.5, 3.0) and 64.7% of participants 
were male. The majority of burn injuries were located on the limbs (87.0%) and were due to 
contact burn injuries (41.8%). Table 6.1 demonstrates the sociodemographic and clinical 
characteristics of participants in each intervention group at baseline. None of the 
characteristics pre-specified as potentially associated with the outcomes were different 
between the groups at baseline. Data were missing for the original %TBSA and depth of 
burn of 11 participants who had received reconstruction surgery on a pre-existing burn scar 
as there was not a data registry at the time of their injury. Data were not missing for other 
sociodemographic or clinical characteristics for these participants. Table 6.2 reports the 
baseline scores of select outcome measures. 
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Table 6-1 Social and clinical demographics of included participants 
 
 Topical silicone 
gel onlyab 
Pressure garment 
onlyab 
Combinedabc 
 
No. of participants 51 49 53 
Age, median (IQR) 3.54 (1.52, 8.78) 8.86 (1.82, 10.87) 4.86 (1.75, 10.05) 
Male Gender  31 (61%) 26 (53%) 42 (79%) 
Skin type    
  Type I – Always burn  4 (8%)  6 (12%)  6 (11%) 
  Type II – Tan with difficulty  8 (16%)  9 (18%)  7 (13%) 
  Type III – Tan about     
average 
22 (43%) 16 (33%) 17 (32%) 
  Type IV – Tan more than   
average 
 7 (14%) 12 (25%) 13 (25%) 
  Type V – Brown skin  9 (17%)  5 (10%)  7 (13%) 
  Type VI – Black skin  1 (2 %)  0 (0%)  1 (2%) 
    Missing   0 (0%)  1 (2%)  2 (4%) 
%TBSA of burn, median (IQR)  1.25 (0.5, 3.0) 1.00 (0.5, 2.0) 1.50 (0.5, 3.0) 
  Missing  3  6  3 
Burn depth    
  Full thickness  8 (16%)  9 (18%)  8 (15%) 
  Deep Partial 30 (59%) 24 (49%) 28 (53%) 
  Superficial partial 10 (19%) 11 (23%) 14 (26%) 
    Missing  3 (6%)  5 (10%)  3 (6%) 
Mechanism of injury    
  Scald 16 (31%) 12 (25%) 18 (34%) 
  Contact 19 (37%) 24 (49%) 21 (40%) 
  Flame  1 (2%)  3 (6%)  3 (6%) 
  Friction  9 (18%)  5 (10%)  6 (11%) 
  Electrical  0 (0%)  1 (2%)  2 (3%) 
  Chemical  3 (6%)  1 (2%)  0 (0%) 
  Other  1 (2%)  0 (0%)  0 (0%) 
    Missing  2 (4%)  3 (6%)  3 (6%) 
Scar location    
  Torso 10 (20%)  6 (12%)  4 (8%) 
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  Upper limb 23 (45%) 20 (41%) 27 (51%) 
  Lower Limb 18 (35%) 23 (47%) 22 (41%) 
Surgical group    
  Spontaneous 34 (67%) 31 (63%) 33 (63%) 
  Grafted 14 (27%) 13 (27%) 15 (28%) 
  Reconstruction   3 (6%)   5 (10%)   5 (9%) 
Days to re-epithelialisation, 
median (IQR) 
 
26 (21, 34) 
 
24 (20, 29) 
 
25 (21.5, 31.5) 
Wound infection  8 (16%)  8 (16%) 12 (23%) 
    Missing  0 (0%)  0 (0%)  1 (2%) 
Additional interventions    
  Ranging exercises  2 (4%)  2 (4%)  6 (11%) 
  Massage   4 (8%)  1 (2%)  2 (4%) 
Number of itch medications    
  0 33 (65%) 34 (69%) 37 (70%) 
  1 15 (29%) 13 (27%) 10 (19%) 
  2  3 (6%)  1 (2%)  6 (11%) 
  3  0 (0%)  1 (2%)  0 (0%) 
Type of itch medication    
  Gabapentin  4 (8%)  5 (10%)  6 (11%) 
  Cetirizine 14 (28%) 11 (22%) 14 (26%) 
  Promethazine  2 (4%)  1 (2%)  2 (4%) 
  Loratadine  1 (2%)  1 (2%)  0 (0%) 
Interface pressure (mmHg)    
  Stationary N/A 35.10 (32.49) 25.22 (23.04) 
  Dynamic N/A 33.67 (31.15) 32.02 (26.45) 
Caregiver education    
  Completed post school 
qualifications 
33 (64%) 22 (45%) 27 (51%) 
  Completed senior high school  8 (16%) 15 (31%) 16 (30%) 
  Completed junior high school  8 (16%) 10 (20%)  6 (11%) 
  Did not go to school  1 (2%)  0 (0%)  1 (2%) 
    Missing  1 (2%)  2 (4%)  3 (6%) 
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Abbreviations: 
N/A = not applicable 
IQR = interquartile range 
 
a Number (percentage) except where indicated 
b Missing data where stated, otherwise there was no missing data 
c Combined = topical silicone gel + pressure garment therapy 
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Sociodemographic and clinical characteristics for participants who declined or withdrew from 
the trial at baseline and consented to collection of demographic data is illustrated in 
Appendix 7. Mann Whitney U Legacy test identified that children who did not participate in 
the study had darker skin types (skin type p=0.01), a younger median age (age p=0.02) and 
a greater frequency of caregiver post school qualifications (caregiver education p<0.001). 
Burn depth, %TBSA, burn mechanism, wound healing type and gender were not significantly 
different between the two groups (p>0.05). However, there is missing sociodemographic 
and clinical characteristic data for this cohort as not all caregivers consented to data 
collection. Reasons for non-participation included wanting the occupational therapist’s 
opinion on the best intervention (34.9%), having a preferred intervention option based on 
the caregiver’s own knowledge, research or experience (16.3%), not wishing to return to the 
participating metropolitan or regional burns centre (16.3%) and miscellaneous (e.g. 
unknown, no reason provided, 32.6%). 
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Table 6-2 Baseline scores of select outcomes 
 
a Combined = topical silicone gel + pressure garment therapy 
 
 
 
 Topical silicone 
gel 
Pressure garment 
therapy 
Combineda 
 Mean (SD),  
n 
Mean (SD), 
n 
Mean (SD), 
n 
Scar thickness (cm) 0.17 (0.08), 
60 
0.16 (0.08), 
50 
0.16 (0.08), 
60 
Scar itch intensity (NRS) 
 
   
  Caregiver report 4.51 (2.62), 
59 
4.94 (2.68), 
54 
4.16 (2.83), 
63 
  Child self-report 3.10 (3.16), 
21 
3.59 (2.86), 
27 
3.25 (2.52), 
24 
Scar severity (POSAS) 
 
   
  Caregiver overall 7.25 (2.39), 
48 
6.90 (2.43), 
49 
6.61 (2.32), 
51 
  Observer overall 4.17 (1.12), 
60 
4.15 (1.18), 
53 
4.02 (1.17), 
62 
Scar colour (Colorimeter) 
 
   
  Erythema a* parameter 34.83 (6.64), 
58 
33.23 (8.97), 
52 
31.42 (8.69), 
61 
  Pigmentation L* parameter -15.40 (10.22), 
51 
-15.90 (8.74), 
47 
-12.84 (12.73), 
58 
Impact of burn scar (BBSIP) 
 
   
  Caregivers < 8 years 2.43 (0.83), 
36 
2.02 (0.53), 
23 
2.16 (0.89), 
32 
  Caregivers > 8 years 2.00 (0.61), 
14 
2.34 (0.82), 
26 
2.15 (0.94), 
20 
  Child self-report 8-18years 1.90 (0.91), 
12 
2.02 (0.84), 
25 
1.95 (0.92), 
19 
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6.4.2 Primary outcomes 
6.4.2.1 Burn scar thickness 
Pre-specified analysis 
The combined intervention did not perform as well as either of the interventions alone (Table 
6.3), and when compared to topical silicone gel at six months post-burn injury the difference 
was statistically significant (MD=-0.04cm (95%CI: -0.08, -0.00), p=0.05). There were no 
significant differences when comparing the topical silicone gel and pressure garment 
therapy alone groups (MD (95%CI)=0.00cm (-0.04, 0.04), p=0.93) or the pressure garment 
therapy and combined intervention groups (MD (95%CI)=0.04cm (-0.00, 0.07), p=0.07). Per 
protocol analysis (Appendix 8) identified no significant difference between the groups at any 
time point (p>0.05). Intention to treat (ITT) analysis with imputations for missing data also 
identified no significant differences between the groups at any time point (p>0.05) (Table 
6.3).  
 
ITT analysis when stratified according to surgical group indicated no significant differences 
between the groups at any time point for the spontaneously healed or reconstruction cohorts 
(p>0.05). For participants who received skin grafting, the combined intervention did not 
perform as well as either of the interventions alone. The difference was significant when 
comparing the topical silicone gel to the combined intervention group, MD (95% CI)=-0.09cm 
(-0.16, -0.01) (p=0.03). Appendix 9 provides additional information.  
 
Additional analysis 
Post-hoc analysis stratification by scar location (ITT) (Appendix 10) identified a significant 
difference in scar thickness at six months post-burn injury; topical silicone gel vs combined 
intervention MD (95%CI)=-0.07cm (-0.12, -0.02); combined intervention vs pressure 
garment therapy: MD (95%CI)=0.06cm (0.01, 0.11). Standardised mean differences (effect 
sizes) are reported in Appendix 11.  
 
The mean (SD) of all burn scar thickness results for the primary investigator and blinded 
sonographer were within 0.05cm of each other. This was considered acceptable, based on 
an inter-rater SEM=0.05cm using the GE Healthcare Ultrasound device in this population 
[125]. 
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6.4.2.2 Burn scar itch intensity 
6.4.2.2.1 Caregiver proxy report NRS, all ages 
Pre-specified analysis 
No significant differences (p>0.05) were identified for caregiver reported burn scar itch 
intensity at any time point using ITT (Table 6.3: six months post-burn regression results and 
Appendix 12: three months post-burn regression results) or per protocol analyses (Appendix 
8). Stratification according to surgical group (Appendix 9) identified no significant difference 
between the groups (p>0.05).  
 
Additional analysis 
Stratification according to scar location identified no significant difference (p>0.05) between 
the groups for caregiver reported itch intensity (Appendix 10). Standardised mean 
differences (effect sizes) are reported in Appendix 11. 
 
6.4.2.2.2 Child self-report, five years and older 
No significant differences between the groups were identified at six months post-burn injury 
(p>0.05, Table 6.3).
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Table 6-3 Six months post-burn injury mixed effects regression results 
 
 Topical 
silicone gel 
Pressure 
garment therapy 
Combineda Topical silicone gel vs 
pressure garment 
Topical silicone gel vs 
combined 
Combined vs pressure 
garment therapy 
 Mean (SD), 
n 
Mean (SD), 
n 
Mean (SD), 
n 
Mean difference (CI) p Mean difference (CI) p Mean difference (CI) p 
Scar thickness (cm)  
  Complete case    
 
0.18 (0.10), 
51 
 
0.18 (0.09), 
43 
 
0.22 (0.14), 
48 
 
-0.00 (-0.04, 0.04) 
 
0.93 
 
-0.04 (-0.07, -0.00) 
 
0.05 
 
0.04 (-0.00, 0.07) 
 
0.07 
  Multiple imputation 
 
- - - -0.00 (-0.04, 0.04) 0.92 -0.03 (-0.07, 0.01) 0.11 0.03 (-0.01, 0.07) 0.18 
Scar itch intensity (NRS)          
  Caregiver report 1.90 (1.72), 
50 
1.83 (1.69), 
41 
1.65 (1.45), 
48 
0.03 (-0.91, 0.98) 0.94 -0.20 (-0.71, 1.12) 0.67 -0.17 (-1.12, 0.79) 0.73 
  Child self-report 
 
1.71 (2.59), 
17 
1.04 (1.61), 
23 
0.83 (1.29), 
18 
0.69 (-0.76, 2.15) 0.35 0.80 (-0.74, 2.35) 0.31 -0.11 (-1.54, 1.32) 0.88 
 
a Combined = topical silicone gel + pressure garment therapy 
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6.4.2.2.3 Toronto Pediatric Itch Scale: caregiver proxy report for children less than 
five years 
No significant differences were identified between the groups at three or six months post-
burn injury (p>0.05). Refer to Appendix 13 for additional information. 
 
6.4.3 Secondary outcomes 
6.4.3.1 Scar severity 
Patient and Observer Scar Assessment Scale (POSAS) 
No significant differences were identified between the groups for patient reported POSAS 
outcomes (itch, thickness, stiffness, overall opinion of the scar) (p>0.05) or observer 
reported POSAS outcomes (vascularity, pliability, thickness, pigmentation, relief, overall 
opinion of the burn scar) (p>0.05) (Appendix 14). 
 
Colour 
No significant differences were identified between the intervention groups for erythema or 
pigmentation (p>0.05) (Appendix 14). 
 
6.4.3.2 Health-related quality of life 
Children’s Health Utility 9D (CHU-9D) 
No significant differences were identified between the groups for caregiver report for children 
less than five years, caregiver report for children five years and older or child self-report from 
five years of age (p>0.05). Exact values are reported in Appendix 15. 
 
Brisbane Burn Scar Impact Profile (BBSIP) 
No significant differences were identified for any items on the BBSIP for caregivers of 
children aged less than eight years, caregivers of children eight years and older or children 
between eight and 18 years of age (p>0.05) at six months post-burn or burn scar 
reconstruction surgery. Additional detail is provided in Appendix 16. 
 
6.4.3.3 Treatment satisfaction 
Caregiver satisfaction (measured using NRS) 
At six months post-burn or burn scar reconstruction surgery, caregiver satisfaction with 
topical silicone gel was very similar when used alone compared to when used in combination 
with pressure garment therapy (mean (SD)=6.87 (2.33) and 6.35 (2.97) respectively). 
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Comparatively, caregiver satisfaction for pressure garment therapy at six months post-burn 
or burn scar reconstruction surgery reduced from mean (SD) 7.53 (1.92) to 6.03 (2.81) when 
used alone compared to when used in combination with topical silicone gel.  
 
Occupational therapist satisfaction (measured using NRS) 
Occupational therapist satisfaction with topical silicone gel and pressure garment therapy 
reduced when used in combination with each other compared to alone at six months post-
burn injury or burn scar reconstruction surgery. The mean (SD) of therapist satisfaction with 
topical silicone gel reduced from 7.03 (2.10) when used alone to 5.86 (2.56) when used in 
combination. The pressure garment therapy satisfaction mean (SD) reduced from 6.40 
(2.14) to 5.11 (3.35) when used alone compared to in combination at six months post-burn 
or burn scar reconstruction surgery.  
 
6.4.3.4 Adherence 
Topical silicone gel 
At six months post-burn or burn scar reconstruction surgery ITT analysis identified that the 
percentage of people that reported using the topical silicone gel at least once per day 
reduced from 91.43% to 82.76% when used alone, compared to when it was used in 
combination with pressure garment therapy. Similarly in the per protocol analysis, the 
percentage of people that reported using the topical silicone gel at least once per day 
reduced from 91.43% to 83.33% at six months post-burn injury or burn scar reconstruction 
surgery. 
 
Pressure garment therapy 
Mean (SD) adherence to pressure garment therapy reduced from 77.51% (31.99) when 
used alone to 58.48% (42.89) when used in combination at six months post-burn injury or 
burn scar reconstruction surgery. Per protocol analysis identified a similar trend for reduced 
adherence to pressure garment therapy when used in combination with topical silicone gel. 
Mean (SD) percentage hours of wear reduced from 77.08% (32.68) to 61.56% (41.73). 
 
6.4.3.5 Adverse effects 
Types of adverse effects are listed in detail in Appendix 17 and included wound breakdown, 
skin irritation, sensory symptoms, swelling, intervention problems (e.g. holes in pressure 
garment), and lost intervention. Three participants (7.0%) in the topical silicone gel alone 
group and four participants (10.3%) in the combined intervention group reported one 
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adverse event at six months post-burn injury or burn scar reconstruction surgery. In 
comparison, eight participants (21.6%) in the pressure garment therapy alone group 
reported one adverse effect and one participant (2.7%) reported two adverse effects at six 
months post-burn injury. At six months post-burn or burn scar reconstruction surgery, ITT 
mixed effects regression identified more adverse effects in the pressure garment therapy 
alone group compared to the topical silicone gel alone group (p=0.04), see Appendix 17. 
Per protocol analysis identified a significant difference at six months post-burn injury, with 
participants who used topical silicone gel alone experiencing less adverse effects than those 
who used pressure garment therapy alone (p=0.03). Refer to Appendix 17 for additional 
information.  
 
6.4.3.6 Intervention fidelity 
No statistically significant differences in occupational therapists fidelity to the intervention 
were identified using the fidelity checklist (p>0.05). Results are reported in Appendix 18. 
Audio data was of insufficient quality to allow analysis. 
 
6.4.3.7 Intervention burden 
No statistically significant differences in treatment burden were identified at six months post-
burn injury (p>0.05) (see Appendix 19). 
 
6.4.3.8 Interface pressure 
No significant differences between the pressure garment alone and combined interventions 
group in the level of stationary or dynamic pressure at the interface of the pressure garment 
and burn scar were identified (p>0.05) (see Appendix 20). 
 
6.5 Discussion 
A greater scar thickness was observed in the combined intervention group when compared 
to the topical silicone gel group. Additionally, superior caregiver reported treatment 
satisfaction and adherence was reported when the interventions were used individually 
rather than in combination. More adverse effects occurred in the pressure garment alone 
group compared to the topical silicone gel alone group. No difference was observed between 
the topical silicone gel and pressure garment alone groups for any outcome. Together these 
findings indicate there was no benefit to using a combination of topical silicone gel and 
145 
 
pressure garment therapy compared to the interventions alone at six months post-burn, 
which is typically the peak of abnormal burn scar characteristics [33,38].  
 
Despite potential differences in mechanism of action for silicone products and pressure 
garments [8,13,32,61,62,70,71,87,88], the goal of both interventions, alone and in 
combination, remains the same. The goal of interventions is to reduce keratinocyte, 
fibroblast, mast cell, and histamine production, thus increasing collagenase activity and the 
subsequent collagen breakdown [32,61,70,71]. The results of this study suggest that it is 
plausible that both interventions may be equally effective at achieving this goal on their own, 
particularly in the thinner skin of the paediatric population.  
 
The finding of a greater scar thickness in the combined group compared to the silicone group 
and no between group differences for scar severity is in contrast to previous findings in 
adults [9,11,94]. Reduced thickness and increased pliability in paediatric pre-injury skin 
compared to adults [168,169] and a lower mean %TBSA in the study sample than typically 
reported in adult studies may partly explain these findings. In addition, the use of a 
preventative approach mirroring clinical practice may have meant the severity of scarring 
and impact on health-related quality of life of the children in this trial was lower than in adults. 
It should also be noted that the minimally clinically important difference for scar thickness 
has not been determined. The extent of the difference in this study was not considered 
clinically important as it was below the smallest detectable change of the GE Healthcare 
Ultrasound device [125]. 
 
Assessment of potential influencing factors identified no differences between the groups in 
fidelity or interface pressure. Thus, it is reasonable to conclude that the results of the 
randomised controlled trial were due to the intervention and not a result of variation in the 
amount or type of intervention received [170,171]. Interestingly, the reported rates of 
adherence to the interventions and the caregivers and occupational therapists satisfaction 
with the interventions both reduced when interventions were used in combination.  
 
Adherence can be hampered by increasing intervention complexity and frequency, and 
reduced convenience [5,54,55]. Therefore, the increased requirements of the combined 
intervention group may have increased the complexity and frequency of the intervention 
such that adherence was negatively influenced. There was an increased intervention burden 
reported by caregivers of children aged less than eight years using pressure garment 
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therapy compared to topical silicone gel; however, results were not statistically significant. 
If parents and caregivers continue to report a higher burden for pressure garment therapy 
in young children (less than eight years), alternative treatment options may need to be 
explored. 
 
Also of interest was the finding of a greater number of adverse effects in the pressure alone 
group compared to the silicone alone group but not in the combined group (with an 
equivalent pressure dosage) compared to silicone alone. This may suggest that silicone 
provides a layer of protection to the skin for adverse effects such as skin irritation or wound 
breakdown. Alternatively, the reduced adherence to pressure in the combined group may 
have reduced the likelihood of participants experiencing these effects.  
 
6.5.1 Limitations 
Attrition is a well documented concern in burn scar research with up to 80% attrition reported 
in paediatric studies over an undisclosed timeframe [172]. In a bid to prevent attrition, 
additional processes were initiated prior to recruitment such as research appointments after 
business hours to reduce the burden on families traveling during school and work times. A 
greater rate of attrition was identified in the combined intervention group compared to the 
pressure garment and silicone alone groups at six months post-burn injury or burn scar 
reconstruction surgery indicating a potential intervention effect on attendance at 
appointments. To determine the influence of attrition, an analysis of burn scar thickness at 
6-months post-burn using multiple imputations for missing data was completed. As this 
analysis did not identify a between group difference in scar thickness there is further support 
for the conclusion that there was no benefit to a combined intervention approach for the 
children involved in this study. 
 
The study results may not generalize to the limited number of participants included with 
Fitzpatrick Skin Type VI (black skinned persons), and facial scar sites which were not 
included. The fewer number of participants receiving scar reconstruction surgery for a pre-
existing burn scar compared to those with acute burn injuries also suggests the findings 
require replication for this group in particular. The scar sites assessed in this study may not 
be representative of the entire scar. Assessment of the audio recordings for intervention 
fidelity was unable to be completed due to technical reasons. 
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6.5.2 Future Directions 
Further investigation is required to confirm the results of this study. The minimally clinically 
important difference for outcomes such as scar thickness needs to be determined. The 
effectiveness of topical silicone gel and pressure garment therapy for the prevention and 
management of post-burn scarring on specific body locations at higher risk of scarring than 
other locations would also benefit from further investigation. The effectiveness of the study 
interventions to prevent long-term surgical procedures and improve outcomes at twelve 
months or longer post-burn is also yet to be determined. An assessment of long-term 
outcomes would provide new knowledge to the burn scar field regarding the longitudinal 
progression of paediatric burn scarring in the presence of standard interventions and the 
long-term impact of the burn scar on the child’s life. 
 
Assessment of the effectiveness of lower interface pressure for prevention and management 
of sensations in the short term and the effectiveness of alternative interventions such as 
silicone gel sheeting, taping and pressure garment therapy inserts for the prevention and 
management of physical and sensory scar characteristics, health-related quality of life, and 
intervention burden is also required. 
 
6.6 Conclusion 
No benefit to a combined topical silicone gel and pressure garment therapy intervention was 
identified for the prevention and management of abnormal scarring in children at 6-months 
post-burn injury. Topical silicone gel alone reduced scar thickness more than the combined 
intervention and had a similar rate of adverse effects. Pressure garment therapy alone had 
a higher rate of adverse effects at 6-months post-burn or burn scar reconstruction surgery 
compared to topical silicone gel, though the effects were non-serious. A combined 
intervention approach resulted in lower adherence and caregiver and occupational therapist 
treatment satisfaction than individual scar interventions. Future studies are required to 
confirm the results.   
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6.7 Chapter conclusion 
The randomised controlled trial presented in this Chapter is the first known study of its kind 
to assess the effectiveness of these interventions in a paediatric cohort exclusively and to 
document adverse effects in order to report the benefits versus harm. The results 
demonstrated that there was no benefit to using a combination of topical silicone gel and 
pressure garment therapy for the prevention and management of post-burn scarring in 
children with burns less than 40% TBSA to all areas (excluding head and neck) at six months 
post-burn injury. There was also no difference in effectiveness in physical scar 
characteristics and health-related quality of life outcomes between topical silicone gel alone 
and pressure garment therapy alone for the children involved in this study. Treatment 
adherence and satisfaction was greater when interventions were used individually. 
Therefore, family centred care and health professional clinical reasoning may be paramount 
in prescribing either topical silicone gel or pressure garment therapy for this population group 
in the future. 
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CHAPTER 7 Discussion 
7.1 Overview 
Burn injuries are a healthcare concern around the world with 153 per 100 000 children under 
15 years of age experiencing a burn of less than 20% TBSA, predominantly due to a scald, 
contact or flame injury [14,15,17]. Medical advancements in the field have seen a reduction 
in burn mortality and severity [18], thus bringing burn scar prevention and management to 
the fore as patients and health services respond to the burden of abnormal post-burn 
scarring.  
 
The prevalence of abnormal scarring post-burn injury has not been accurately recorded. It 
ranges in the literature from 30 to 75% though the definition of scarring has not been well 
defined [6,27] and Australian prevalence rates are not available. Abnormal post-burn 
scarring can be red, raised, rigid (hypertrophic) [25,38], thinner or more fragile than normal 
skin (atrophic) or contracted [25]. Physical and sensory characteristics of abnormal burn 
scarring can impact the emotional, physical, cognitive and social functioning of the person 
[4]. A person’s ability to engage in previously valued occupations such as work, school and 
social outings can be reduced [5]. Children can also experience reduced mood, post-
traumatic stress symptoms and an altered body perception [173,174]. 
 
Non-invasive scar interventions such as silicone products, pressure garments, massage and 
taping are used prophylactically to attempt to prevent and manage the development of 
abnormal scarring. Silicone and pressure garment therapy were selected for investigation 
during this thesis. The current hypothesis is that these interventions work by influencing 
biochemical signals and fibrotic gene expression through the input or alteration of inbound 
mechanical forces [32]. Despite being used in their current forms for at least forty years, the 
evidence for these interventions, particularly in the paediatric post-burn cohort, is limited. 
 
Systematic reviews and randomised controlled trials in this field have found conflicting 
results for the effectiveness of silicone and pressure garment therapy. To the knowledge of 
this author there has not been a randomised controlled trial completed solely with children. 
Studies have predominantly assessed the effectiveness of interventions on physical scar 
characteristics without considering health-related quality of life, intervention fidelity and 
adverse effects. Comparison of results across studies have been impacted by differences 
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in intervention types, patient populations, outcome measures used, and time frames of 
intervention implementation.  
 
7.2 Main findings including recommendations for future research 
The overarching aim of this thesis was to determine the effectiveness of silicone and 
pressure garment therapy for the prevention and management of post-burn scarring in 
children. This comprised of two sub-aims: (1) an investigation of interface pressure for 
paediatric pressure garment therapy and (2) an assessment of the effectiveness of silicone 
versus pressure garment therapy for the prevention and management of post-burn scarring. 
Aim one was achieved through the completion of a pilot longitudinal cohort study assessing: 
(a) the test-retest reliability and clinical utility of the Pliance X® (Novel Electronics, Munich, 
Germany) (an interface pressure measuring device) in children receiving pressure garment 
therapy post-burn; and, (b) the level of pressure supplied by the pressure garment at the 
interface of the pressure garment and burn scar. Aim two was achieved through the 
completion of a systematic review and randomised controlled trial assessing the 
effectiveness of silicone versus pressure garment therapy for burn scar management.  
 
7.2.1 Evidence of interface pressure 
Traditionally in clinical practice there has been an assumption that a standard 10 or 20 
percent reduction factor applied to circumferential body measurements results in a pressure 
garment fit of the ideal pressure range [175]. However, questions have arisen in the literature 
regarding what is the ideal pressure range and which scar characteristics benefit the most 
from this pressure range. The range considered ‘ideal’ in this thesis was 15 to 25mmHg, 
which includes the lowest and highest acceptable pressures reported by most authors [1,97]. 
Reliable and reproducible research investigating the effectiveness of interface pressures of 
less than 10mmHg for reducing scar severity has not been completed on burn scars. There 
has been one pilot study (n=8) investigating the effect of interim pressure garment therapy 
on donor sites which found a trend of reduced thickness in donor sites treated with pressure 
of 3 to 5.8 mmHg [93]. In contrast, a study completed with adult Asian participants with 
scarring 5.21 (1.91) months post-burn [90] identified pressure garments with higher (20 to 
25mmHg) interface pressures as more effective than lower (10mmHg) interface pressures 
in managing burn scar thickness. However, lower pressures (10mmHg) were found to have 
the greatest effect on the outcomes of itch and pain compared to higher pressure (20 to 
25mmHg). This raises the question regarding which pressure magnitude would best meet 
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therapy goals. Previous randomised controlled trials have focused on physical scar 
characteristics such as scar thickness, however qualitative research has indicated that 
sensory components of scarring are of great importance to the person and their family 
[44,103]. Therefore, pressure garment therapy may need to be adapted across the scar 
continuum rather than the current practice of one pressure dose for the duration of the scar 
management phase. Results of the systematic review completed for this research project 
showed that the greatest effect for pain management was within the first month of 
intervention implementation and within the first four months for itch management. Thus, 
initiating low dose pressure garment therapy in the short term after the burn injury (one 
month of pressure garment use, up to three months post-burn injury) may prove most 
beneficial for managing sensory symptoms. It is also feasible that the comfort of pressure 
garment therapy may be related to the level of interface pressure [175], thus low dose 
pressure garment in the short term may increase comfort and subsequent rates of  
adherence. The pressure dosage could then be increased to 15 to 25mmHg to manage 
thickness during its peak period three to six months post-burn injury [33,38]. However, an 
investigation into the effect of low interface pressure on a paediatric cohort is required. 
 
The implementation of different pressure magnitudes at different time points in the scar 
management journey highlights the importance of accurate, reliable and clinically 
appropriate interface pressure measuring devices to monitor the pressure applied. Interface 
pressure assessment has evolved from estimating the force required to lift the pressure 
garment fabric to the use of specifically designed objective devices [115,117,118,133]. 
However, as discussed in Chapter Four, the clinical utility, accuracy, reliability, validity and 
reproducibility of these devices is not always adequate. The Kikuhime® (Medigroup, 
Melbourne, Australia) reportedly has appropriate reliability and validity [115,130] and the 
PicoPress® (Medigroup, Melbourne, Australia) can be used for dynamic pressure 
assessment. However, the accuracy of the devices has been questioned as the sensors 
reportedly distort the scar surface and pressure garment [90,118,128,129]. The thin and 
flexible sensors of the Tekscan devices (I-scan® and Flexiforce®, South Boston, United 
States of America) overcome the difficulty of distorting the scar surface but reportedly have 
difficulties with accuracy at low interface pressure levels (less than 10mmHg) and 
temperature sensitivity [117,118]. 
 
This thesis proposes Pliance X® (Novel, Electronics, Munich, Germany) as a reliable, 
clinically appropriate and acceptable device. Since the completion of the project discussed 
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in Chapter Four, a new model of the Pliance X® has become available. The new software 
interface potentially reduces the set up time, increases the readability of the immediate 
pressure results and may improve acceptability to families. Therefore, the device’s new 
software may increase the practicability, accessibility and acceptability of the device. The 
sensors are the same as those investigated, therefore it can reasonably be assumed that 
the reliability of the device remains the same but this should be confirmed. The Pliance X® 
had a test-retest reliability intra-class correlation coefficient (ICC) of 0.87 in a paediatric post-
burn population. An ICC of 0.87 makes it appropriate for research use though it falls short 
of the 0.90 ICC recommended for clinical use [121]. However, in this clinical context it could 
be argued that 0.87 is acceptable for clinical use given that a single fixed interface pressure 
is not the aim of the intervention at present, rather an interface pressure within an acceptable 
pressure range is sought. Additional test-retest reliability testing with a larger sample size is 
required as well as inter-rater reliability testing to determine reliability in a clinical setting 
where patients are likely to be reviewed by different health professionals.  
 
The question has also been raised as to whether an assessment of stationary or dynamic 
interface pressure is the most acceptable in the paediatric population. Traditionally, interface 
pressure results have been reported as stationary pressures. However, given that children 
spend a large portion of their time engaging in active occupations it is argued that the 
assessment of dynamic pressure may be more applicable. The research presented in this 
thesis was the first to investigate and publish dynamic interface pressures in children 
wearing pressure garments post-burn. Pressure dosages over the assumed clinically 
acceptable level (40mmHg) were observed during dynamic assessment. Sustained 
pressures at or above this level have been reported to result in adverse effects such as skin 
maceration and paraesthesia [11,13,87]. High interface pressures may be occurring with 
greater frequency than previously suspected potentially contributing to reduced comfort and 
subsequent non-adherence. It would be beneficial to develop and implement a formula 
where the stationary interface pressure predicts the dynamic interface pressure that will 
occur once the person returns to their usual occupations. Researchers in Hong Kong [112] 
have developed a model that enables this prediction to be completed, however this has not 
been tested in a paediatric population. 
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7.2.2 Evidence of the effectiveness of silicone and pressure garment therapy 
in children post-burn 
7.2.2.1 Implications of the systematic review 
A systematic review was completed to assess the state of the evidence for silicone and 
pressure garment therapy. Other systematic reviews in this field exist [1,7,12,97], however 
it was determined that an updated review was necessary to determine the effectiveness of 
silicone and pressure garment therapy specifically in the broader context of health-related 
quality of life and adverse effects. The physical and sensory scar characteristics that have 
been the focus of prior systematic reviews were also included. The systematic review 
presented in this thesis also examined the quality of the evidence at the outcome level using 
Grading of Recommendations Assessment, Development and Evaluation (GRADE), which 
has not been considered in prior systematic reviews. GRADE provides a structure for 
summarising and rating the quality of evidence at the outcome level [176]. 
 
Whilst this thesis has a paediatric focus, studies included adults and children were included 
in the systematic review as there had not been any randomised controlled trials published 
in English completed exclusively with children at the time of the review. Six of the sixteen 
included studies [8,11,65,78,79,110] involved child participants alongside adults in their 
investigations though the exact number of children that results pertained to was rarely 
documented. Children and adults have differences in skin and scar thickness and pliability 
[168,169]. Additionally, characteristics of paediatric scars such as the size of the scar, 
location and impact on function and health-related quality of life may change as the child 
grows. Hence, the results of the review may not translate directly to children with post-burn 
scarring, but it was a starting point for paediatric enquiry. It is anticipated that as evidence 
accumulates in children, the direction of intervention effects on physical scar characteristics 
will be the same as that recorded in adult studies (i.e. pressure garment therapy reducing 
scar thickness). However, the size of the effect may differ due to the differences in paediatric 
and adult skin and scar.  
 
Results of the systematic review demonstrated a high risk of bias in included randomised 
controlled trials. At the outcomes level, a low to moderate quality of evidence was found for 
thickness outcomes, but a very low quality of evidence was found for itch and pain outcomes. 
The systematic review also highlighted a lack of previous investigation into outcomes other 
than physical scar characteristics. No studies investigated participant’s health-related quality 
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of life or the burden of scar interventions. Studies most often reported on adverse effects 
when they included a silicone intervention and adherence was more often reported when a 
pressure garment intervention was being evaluated. Fidelity to intervention components by 
treating clinicians in randomised controlled trials was not discussed in any included study.  
 
Standardised mean differences (effect sizes) calculated for the systematic review identified 
single interventions (i.e. silicone or pressure garment therapy alone vs control or different 
dose) to have the greatest effect on pain outcomes at one month post-intervention 
commencement (approximately three months post-burn, small to moderate SMD=0.24 to 
0.48). The greatest effect on itch was observed at four months post-intervention 
commencement (medium to large SMD=0.41 to 0.71) though the quality of evidence was 
very low for sensory outcomes. Effect size calculations (SMD between 0.33 and 1.06 
between one and six months post-intervention commencement) identified a greater effect 
on scar thickness for higher interface pressure levels (20mmHg) compared to lower interface 
pressure levels (10mmHg). Meta-analysis was limited due to disparities in interventions, 
populations and outcomes. There was meta-analysis evidence to support the effect of 
silicone gel sheeting on pliability though the quality of evidence for this outcome was not 
assessed (pliability was not considered a critical outcome) and the control groups for the 
interventions differed (placebo gel and massage). There was moderate quality meta-
analysis evidence to support the effectiveness of pressure garment therapy for managing 
scar thickness. However, these findings must be considered in light of the limitations 
previously discussed (i.e. high risk of bias).  
 
7.2.2.2 Implications of the randomised controlled trial 
The randomised controlled trial was completed in an attempt to determine the effectiveness 
of topical silicone gel and pressure garment therapy for the prevention and management of 
abnormal burn scarring specifically in children. It has been hypothesised that improved scar 
outcomes will be observed when using a combination of silicone and pressure garment 
therapy. Theoretically, the different mechanisms of action will provide a synergistic effect 
thus increasing the intervention effectiveness and speeding up the scar maturation process 
[11,62]. This theory has been supported in previous studies in adults where greater 
effectiveness was found for physical scar outcomes in the combined intervention groups 
[9,11,94]. However, results of the randomised controlled trial presented in this thesis suggest 
that there is no benefit to using a combined intervention approach over a single modality of 
pressure garment therapy or topical silicone gel for paediatric scar management up to six 
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months post-burn injury. As knowledge surrounding mechanotransduction increases and 
theories regarding mechanism of action develop, it seems increasingly plausible that the two 
interventions are as beneficial alone as they are in combination. Both interventions 
potentially reduce keratinocyte, fibroblast, mast cell, and histamine production, increasing 
collagenase activity and subsequent collagen breakdown. Changes to cellular processes is 
potentially achieved either through mimicking homeostasis (silicone), by reducing tension at 
the scar border (silicone gel sheeting and pressure garment therapy) [32,61,70,71] or by 
applying supportive mechanical forces to the extra-cellular matrix (pressure garments) [32]. 
To the knowledge of this researcher, at the time of this thesis submission there has not been 
a consensus regarding the level of interface pressure required to support the extra-cellular 
matrix for a therapeutic effect. Therefore, both interventions may be equally effective at 
preventing fibrotic gene expression and reducing collagen output, particularly in the thinner 
skin of the paediatric population.  
 
Findings from the systematic review completed in this thesis were able to inform the 
development of the randomised controlled trial protocol. The randomised controlled trial 
design also considered the recommendations of the most recent Cochrane systematic 
review in this field [63]. The recommendations included blinded assessment of the benefits 
and harms of interventions using valid, repeatable, standardised and objective outcome 
measures over at least 12 months [63]. Recommendations also included the collection and 
reporting of scar type and recurrence [63]. The randomised controlled trial addressed all 
criteria except the collection of recurrence data and distinction between scar types as 
recurrence was deemed unlikely in the study period. The study collected data up to 12 
months post-burn though this has not been reported in this thesis due to time constraints. It 
is anticipated that the results of the 12 month follow up time point will be submitted for 
publication at a later date. 
 
7.2.2.2.1 Physical and sensory scar characteristics 
Scar thickness and scar itch intensity were the primary outcomes of the randomised 
controlled trial. The clinical importance of a single physical scar characteristic such as 
thickness alone has been questioned [1,5]. However, burn scar thickness is often used as 
a clinical indicator of the success of an intervention and scar itch intensity has been reported 
as clinically important by people (adults and children) living with a burn injury [44]. Further, 
a moderate correlation between burn scar pliability and burn scar thickness has been 
identified (r=-0.38) in participants with post-burn scarring (social and clinical characteristics 
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unknown) [177]. Increased scar thickness and reduced pliability may impact range of motion 
and function, both of which are known to be important to people living with post-burn scarring 
[5]. Normative data for skin thickness, elasticity, erythema and melanin has been collated in 
an adult population (20 to 85 years) [178]. A data bank of the same information for children 
would allow results of studies such as those presented in this thesis to be compared to 
healthy non-burned individuals to better postulate the impact of post-burn scarring. 
 
7.2.2.2.2 Health-related quality of life 
For the first time, health-related quality of life was assessed in the randomised controlled 
trial using patient-reported outcome measures. Generic and injury specific patient-reported 
outcome measures have been recommended in burn care to collect information from the 
injured person’s perspective about general health outcomes as well as outcomes specific to 
the condition or injury of interest [179]. Research has shown that adolescents aged 11 to 18 
years and their parents had high agreement for physical functioning domains on the Burns 
Outcomes Questionnaire at six months post-burn injury [180]. However, agreement reduced 
when considering sensory and psychosocial domains such as itch, appearance, emotional 
health and family disruption [180]. Thus, it is important to collect data from the child’s 
perspective as well as the caregiver. However, in paediatric burn injury the majority of burn 
injuries are experienced by children too young to reliably self-report on complex sensory 
and health-related quality of life measures. As a result, caregiver proxy report is often the 
only consistent means of evaluation across all age groups. The studies completed in this 
thesis collected data from the perspective of the child where possible, but have often used 
caregiver proxy report as the primary approach in data analyses to enable data across the 
ages to be collated. In the randomised controlled trial, most of the results for child self-
reported generic and burn specific health-related quality of life were not dissimilar to the 
results reported by their caregivers up to six months post-burn injury. If this remains the 
same during long-term follow up it may be possible for caregiver-proxy report to remain as 
the primary analysis approach for select items of these outcome measures. Further 
assessment of triangulation of results at longer time periods is required. 
 
7.2.2.2.3 Intervention adherence and burden 
Adherence plays an important role in determining intervention effectiveness. One commonly 
accepted method of adherence data collection is the use of calendars and diaries as it allows 
direct reporting of adherence without relying on memory of past behaviours, and multiple 
time points are clearly documented [181]. However the burden of this is high for participants 
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and raters and completion rates are low [181] as evidenced by the response rate of 18% in 
one study assessing the effectiveness of a combined silicone and pressure garment therapy 
intervention versus pressure garment therapy alone [94]. Self-report frequency 
questionnaires are often used due to ease of completion for participants. They are also 
inexpensive, fast, and have face validity [181]. However, they may not be suitable for young 
children, and can be impacted by response biases [181]. Thus, a standard measure of 
adherence has not been developed in the burns population.  
 
Intervention complexity, frequency, and convenience can enhance or hinder adherence 
[5,54,55]. In the combined intervention group of the randomised controlled trial the 
complexity and frequency of the intervention was increased, likely reducing its convenience 
and ability to fit in with the family’s daily routine. Therefore, the lack of difference in scar 
outcomes between the combined and single intervention groups could be a reflection of 
reduced adherence and the intervention not being used as recommended rather than a lack 
of effectiveness of the combined intervention.  
 
An additional consideration for the paediatric post-burn population is the burden of the 
intervention, not just to the child, but also to their families. By using a combined topical 
silicone gel and pressure garment intervention over a single therapy modality, the 
intervention burden may increase, consequently reducing intervention adherence and 
satisfaction. Whilst no differences between the groups were identified for intervention burden 
at six months post-burn injury, the study was not powered for this outcome. It would therefore 
be worth investigating intervention burden further in the future. Qualitative interviews could 
provide rich data on a family’s perspective of scar management interventions and assist with 
identifying specific components of the intervention that increase or reduce intervention 
burden and adherence.  
 
7.2.2.2.4 Adverse effects 
The total number and type of adverse effects were collated for this study and the CONSORT 
extension for better reporting of harms in randomised trials was implemented [158]. 
Categories of adverse effects included wound breakdown, skin irritation, sensory symptoms, 
swelling, intervention problems (i.e. holes in pressure garment, depleted supply of topical 
silicone gel), and lost interventions. Significantly more adverse effects were identified in the 
pressure garment therapy alone group compared to the topical silicone gel alone group. 
There was no significant difference when comparing the interventions alone to the combined 
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intervention group. One hypothesis included a potential for the topical silicone gel to provide 
a protective layer against skin irritation and wound breakdown by the pressure garment. It 
was also postulated that the reduced adherence in the combined intervention group reduced 
the likelihood of experiencing adverse effects in the combined intervention group. There is 
also the potential for artificial inflation of the total number of pressure garment therapy 
adverse effects (when pressure garment therapy is adhered to) due to the increased 
potential for problems with the pressure garment compared to the topical silicone gel such 
as fraying, holes and fit issues. However, it was considered important to document these 
intervention problems as they contribute to the experience of using pressure garment 
therapy and may contribute to intervention burden. The presence of bony deformations 
following pressure garment use was also considered and reported by treating health 
professionals. Whilst there was no report of this effect in the six month period analysed for 
this thesis, it will need to be considered in the long-term data analysis. Objective assessment 
of bony deformations may be beneficial in future investigations. It may be beneficial for future 
studies to focus on more serious (e.g. infection, changes in muscle and bone structure, 
fever, allergic reaction) versus less serious adverse effects to better determine the benefits 
versus harms of these interventions. 
 
7.2.2.2.5 Intervention fidelity 
Finally, the work discussed in this thesis is the first in the burns field to implement and record 
intervention fidelity. Fidelity to an intervention protocol supports the internal validity of the 
trial being conducted [170,171]. It reduces the influence of multiple intervention providers 
and ensures the intervention is delivered as intended [170,171]. Without a pre-determined 
fidelity checklist being implemented and monitored, it is difficult to draw conclusions 
regarding whether any observed effectiveness changes were due to the intervention itself 
or differences in how the intervention was delivered [170,171]. Results of the fidelity 
checklist identified a fidelity score of 90 to 97% across the intervention groups with no 
significant differences between groups. Therefore, it can be assumed that the results of the 
randomised controlled trial are a representation of differences in the effect of the intervention 
(considering adherence) and not differences in the implementation of the intervention 
protocol by the various treating occupational therapists. 
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7.3 Clinical implications, recommendations and translation 
The results of this thesis have highlighted new knowledge regarding prescribing and fitting 
pressure garments post-burn. Applying a 20 percent reduction factor to circumferential body 
measurements does not ensure a pressure garment will apply an interface pressure of 
between 15 and 25mmHg at the first fitting of the pressure garment, as found in Chapter 
Four. Substantial variations in interface pressure level (both pressure increases and 
decreases) can occur over time and when the child is moving. Therefore, it is necessary to 
measure the level of pressure at the interface of the pressure garment and burn scar over 
time to ensure the pressure garment is providing the desired level of pressure. The dosage 
of pressure garment therapy may need to change over time to suit the changing needs of 
the person and their goals for scar management. Regular review of pressure garments using 
typical clinical indicators (i.e. appearance of fit, patient report of comfort) plus interface 
pressure assessment will enable health professionals to objectively review the fit of the 
pressure garment. The Pliance X® is a reliable interface pressure measuring device with 
adequate clinical utility to enable ongoing investigation within the clinical environment. 
 
Systematic review of the literature has highlighted many variations in intervention type, 
outcome measurements, and time points in previous investigations into silicone and 
pressure garment therapy effectiveness for burn scar management. As a result, a conclusive 
statement regarding the effectiveness of these interventions has not been possible to date. 
A move towards a common set of outcome measures in the burn field may help to reduce 
these disparities in the future [116]. The results of the randomised controlled trial did not 
identify any benefit to using a combination of topical silicone gel and pressure garment 
therapy for the prevention and management of abnormal scarring up to six months post-
burn injury in children. Results of this study also suggest that the use of a single intervention 
is likely to increase the family’s adherence to that intervention. Therefore, health 
professional clinical reasoning regarding the recommended intervention and the risk and 
benefits of each intervention on their own can be presented to families to enable an informed 
decision regarding intervention implementation. Customisation of the intervention to the 
family’s values, preferences, and daily routines as well as reducing the complexity and 
frequency of the intervention may increase family motivation and adherence to the scar 
intervention [5,54,55,173].  
 
Stratification by wound healing type (spontaneous healing, grafting, and reconstruction 
surgery of a pre-existing burn scar) and post-hoc stratification by body location (upper limb, 
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lower limb, and torso) was completed to assess effectiveness of interventions in more detail. 
Participants who received skin grafting had significantly thicker scars in the combined 
intervention group compared to the topical silicone gel alone group at six months post-burn. 
Post-hoc analysis also identified greater scar thickness on upper limb scars for participants 
receiving a combined intervention compared to topical silicone gel and pressure garment 
therapy alone at six months post-burn. As no participants had scars measured on the face 
during the study period, results cannot be generalised to facial scarring. Stratification 
analyses strengthen the argument that there is no benefit to using a combined intervention 
approach for the prevention and management of abnormal scarring at six months post-burn 
injury in children. However, analyses completed by stratification of the groups reduces the 
available sample size and the subsequent power of the analysis. Therefore, targeted 
investigation of the effectiveness of interventions by wound healing type or specific body 
locations requires further investigation. 
 
Despite the data presented in the randomised controlled trial being limited to six months-
post burn injury, this time frame likely includes the peak period of scar severity for most 
physical scar characteristics [33,38]. Longer-term data for this study was collected (up to 12 
months post-burn injury), however time constraints have meant this data cannot be 
presented in this thesis. Analysis of the long-term outcome data will provide novel and 
valuable information regarding the longer-term effectiveness of topical silicone gel and 
pressure garment therapy in children. It will also provide insight into the longitudinal 
progression of paediatric burn scars when using topical silicone gel and pressure garment 
therapy. It is anticipated that these results will be published outside of this thesis. The body 
of work presented in this thesis has contributed to the development of course material for 
the Australian and New Zealand Burns Association rehabilitation training course [182]. The 
course provides new and experienced therapists with information and resources to provide 
up to date evidence based practice for their patients. 
 
7.3.1 Highlights: clinical findings and recommendations 
1. The Pliance X® is a reliable, clinically appropriate and acceptable device for 
measuring paediatric interface pressure. 
2. Interface pressure fluctuates in paediatric pressure garments used for burn scar 
management. Thus, interface pressure assessment needs to be completed at each 
pressure garment review. 
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3. Interface pressure may need to be altered over the scar continuum if a lower (less 
than 15mmHg) interface pressure is confirmed to be more beneficial for sensory 
symptoms in the immediate post-acute period (approximately one month post-
intervention commencement, up to three months post-burn). Interface pressure may 
then need to be increased to approximately 20mmHg for management of burn scar 
thickness from three months post-burn injury. 
4. Larger (greater than 10%) %TBSA burns and upper limb body locations have 
significantly lower stationary interface pressure in children compared to less than or 
equal to 10% TBSA burns and other body locations. Therefore, burn injuries of 
greater than 10% TBSA and upper limb scar locations may require pressure garment 
inserts to ensure the pressure garment is providing an adequate level of pressure. 
5. There was no benefit to using a combination of topical silicone gel and pressure 
garment therapy for the prevention and management of physical and sensory 
characteristics of abnormal burn scarring or health-related quality of life at six months 
post-burn injury in children in the study sample. These findings need to be confirmed 
in further studies but this study provides preliminary evidence of no difference in the 
effectiveness of topical silicone gel and pressure garment therapy.  
6. A greater rate of adverse effects was observed in the pressure garment therapy alone 
group compared to the topical silicone gel alone group at six months post-burn injury 
or burn scar reconstruction surgery. At six months post-burn injury adverse effects 
with the greatest frequency included skin irritation and problems with the intervention 
such as an ill-fitting garment or misplaced intervention.  
7. A combined intervention approach may reduce adherence and intervention 
satisfaction at six months post-burn injury in a paediatric population. 
 
7.4 Research Limitations  
Despite taking a broad evaluative approach to this research and drawing on 
recommendations from previous work in this field there are a number of limitations to this 
research project.  
 
7.4.1 Assessment of paediatric interface pressure  
The pilot nature (and consequent small sample size, n=34) of the longitudinal cohort study 
meant only a small number of interface pressure predictor variables that were considered to 
be clinically important (based on prior research) could be explored. Follow up appointments 
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were restricted to the participating burns centre, therefore, participants included those 
children likely to attend the burns centre for follow up. Thus, results regarding interface 
pressure may only pertain to children living in metropolitan areas. Additionally, whilst every 
effort was made to maintain engagement in research at follow-up time points, the 45% 
attrition rate was larger than the anticipated 20% attrition rate. However this attrition was 
less than the 56.4% reported in longitudinal paediatric burns research [172] and was 
considered to be representative of those children attending the burns clinic for follow up. 
Attrition for the pilot longitudinal cohort study was due to non-attendance at scheduled 
appointments or attending the appointment without the pressure garment, thus preventing 
interface pressure assessment.  
 
7.4.2 Assessment of the effectiveness of topical silicone gel and pressure 
garment therapy in children post-burn 
The results of this randomised controlled trial pertain to Therapeutic Support Laboratory® 
(Abbortsford, Victoria, Australia) pressure garment therapy and Strataderm® (Stratpharma, 
Basel, Switzerland) topical silicone gel only. Alternative scar interventions such as massage, 
scar taping, various interface pressures (and insert types) and silicone gel sheeting were 
not the focus of this research and require further investigation. Co-interventions of massage, 
range of motion and itch medications were captured and did not differ between the groups. 
Additionally, whilst a broad array of outcomes were considered in the randomised controlled 
trial, a measure of function was not included. Previous research has identified a reduced 
range of motion, dexterity and function in activities of daily living in adults wearing hand 
pressure garments [175]. The impact of silicone and pressure garment therapy on children’s 
engagement in childhood occupations and activities of daily living would benefit from further 
investigation. It must also be acknowledged that the sample size of the randomised 
controlled trial was powered on the outcome of scar thickness. As a result, the likelihood of 
type I and II errors in the results for secondary outcomes and stratification samples must be 
acknowledged.  
 
Rates of attrition can also impact the final power of the analysis. Measures were 
implemented in an attempt to reduce attrition for the randomised controlled trial including 
research appointments outside of business hours and at regional health services by the 
primary investigator. As a result, attrition in the randomised controlled trial was contained to 
20% (compared to 45% in the longitudinal cohort study) which is within the acceptable rate 
for longitudinal research [172]. Rates and reasons for attrition were reasonably well 
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balanced between the topical silicone gel and pressure garment therapy alone groups 
however, there was a higher rate of attrition in the combined intervention group. Higher 
attrition in the combined intervention group potentially demonstrates an intervention effect 
on drop out, possibly indicating a greater treatment burden or reflecting the reduced 
treatment satisfaction recorded in the combined intervention group.  
 
In an attempt to increase the generalisability of study results, the eligibility criteria of the 
randomised controlled trial was kept as broad as possible. Therefore patient groups not 
usually approached for research at the participating burns centre, such as those families 
who do not speak English and those involved with Child Safety, were included. However, 
results of this research are limited to children under the age of sixteen years (for acute burn 
injuries), burn injuries less than or equal to 40% TBSA, and Fitzpatrick skin types I to V, thus 
this is the group to whom the results can be generalised.  
 
It has been acknowledged in the literature that there is no common process for identifying 
essential intervention components [183], thus the adherence and intervention fidelity 
checklists were developed specifically for the work completed in this thesis. These checklists 
have not undergone psychometric testing to assess reliability, reproducibility or validity. 
Completion of psychometric testing on these assessments would enable these checklists to 
be used with confidence in future investigations and provide a common platform for 
comparing adherence and fidelity across paediatric burn scar studies. 
 
7.5 Concluding statement 
Abnormal scarring after a burn poses a considerable burden to the child, their family and 
the health service. There has been conflicting support for the effectiveness of silicone and 
pressure garment therapy for the prevention and management of physical and sensory scar 
characteristics. Research involving children post-burn has been limited in quantitative 
investigations of these interventions to date. This thesis aimed to determine the 
effectiveness of silicone and pressure garment therapy for the prevention and management 
of abnormal post-burn scarring in children.  
 
A clinically useful and reliable interface pressure measuring device (Pliance X®) has been 
identified and recommended for use in fitting paediatric pressure garments and monitoring 
interface pressure over time. A low to moderate quality of evidence was identified in existing 
studies of silicone and pressure garment therapy. A lack of previous investigation into the 
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effect of these interventions on paediatric health-related quality of life, intervention burden, 
treatment satisfaction, and adverse effects was observed. No difference in the effectiveness 
of topical silicone gel and pressure garment therapy for the prevention and management of 
physical and sensory scar characteristics in children post-burn has been identified in the 
work completed in this thesis. No difference in the effectiveness of these two interventions 
on the health-related quality of life of children was observed. Enhanced intervention 
satisfaction and adherence to interventions was recorded in participants receiving individual 
topical silicone gel or pressure garment interventions. Thus, it can be concluded that there 
was no benefit to using a combined topical silicone gel and pressure garment therapy 
intervention approach for paediatric abnormal burn scar prevention and management. 
 
The work presented in this thesis has contributed new knowledge to the field of paediatric 
burn scar management. It has provided the first known evidence of pressure garment 
interface pressure and topical silicone gel and pressure garment therapy effectiveness 
exclusively in children from a randomised controlled trial. Replication of this work in both 
children and adults will contribute to a stronger evidence base regarding the effectiveness 
of the interventions investigated in this thesis. Analysis of the 12 month follow up data for 
the randomised controlled trial will also provide new knowledge regarding the longer term 
effectiveness of topical silicone gel and pressure garment therapy for the prevention and 
management of paediatric post-burn scarring. The work completed in this thesis will pave 
the way for future research in this field. 
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Appendix 2: EMBASE Search Strategy 
 
 Search term Last Update Results 
#1 ‘keloid’/exp OR keloid OR keloid* OR hypertrophic 
OR ‘cicatrix’/exp OR cicatrix OR ‘scar’/exp OR scar 
OR scars OR scarred OR ‘scarring’/exp OR 
scarring OR ‘skin’/exp OR skin 
11-04-2018 1 243 918 
#2 ‘scar’/exp OR ‘hypertrophic scar’/exp 11-04-2018 66 034 
#3 #1 OR #2 11-04-2018 1 243 918 
#4 burns:ti,ab OR burn:ti,ab OR burned OR scald* OR 
‘thermal injury’/exp OR ‘thermal injury’ OR ‘thermal 
injuries’ 
11-04-2018 129 179 
#5 ‘burn’/exp 11-04-2018 70 291 
#6 #4 OR #5 11-04-2018 150 845 
#7 ‘silicone’/exp OR silicone OR ‘pressure’/exp OR 
pressure 
11-04-2018 1 288 871 
#8 #3 AND #6 AND #7 11-04-2018 2117 
#9 #8 AND (‘Article’/lt OR ‘Article in Press’/lt OR 
‘Review’/lt) 
11-04-2018 1592 
#10 #8 AND (‘Conference Abstract’/lt OR ‘Conference 
Paper’/lt OR ‘Conference Review’/lt OR ‘Editorial’/lt 
OR ‘Letter’/lt OR ‘Note”/lt OR ‘Short Survey’/lt 
11-04-2018 453 
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Appendix 3: Results of included studies 
3.1 Silicone therapy 
 
OUTCOME 
Measure 
Time period  
(measure unit) 
FIRST AUTHOR 
YEAR 
RESULTS (n) 
(intervention vs control) 
 
SIGNIFICANCE STANDARDISED 
MEAN 
DIFFERENCE 
FAVOURSa 
Thickness outcomes 
 
   
 
 
Border height 
Digital Photography 
Assessment 
Baseline  
(mean (SD)) 
So 2003 
1.15 (0.56) vs 1.08  (0.52) 
(n=13 vs n=12) 
(enhanced education vs 
conventional education) 
p=0.73 - - 
Border height 
Digital Photography 
Assessment 
6 months  
(mean (SD)) 
So 2003 
0.46  (0.66) vs 1.42 (0.67) 
(n=13 vs n=12) 
(enhanced education vs 
conventional education) 
p=0.81 
-1.40 [-2.29, -0.51] 
 Favours 
enhanced 
education 
Thickness 
Digital Photography 
Assessment 
Baseline  
(mean (SD)) 
So 2003 
1.31 (0.63) vs 1.58 (0.52) 
(n=13 vs n=12) 
(enhanced education vs 
conventional education) 
p=0.268 - - 
Thickness 
Digital Photography 
Assessment 
6 months  
(mean (SD)) 
So 2003 
0.54 (0.52) vs 1.33 (0.78) 
(n=13 vs n=12) 
(enhanced education vs 
conventional education) 
p=0.008 
-1.16 [-2.02, -0.30] 
 Favours 
enhanced 
education 
Thickness  
TUPS 
Baseline  
(marginal mean (SD)) 
Li Tsang 2006 
5.77 (0.16) vs 6.12 (0.17)  
(n=22 vs n=23) 
(SGS vs CG) 
N/A - - 
Thickness  
TUPS 
2 months  
(marginal mean (SD)) 
Li Tsang 2006 
4.76 (0.17) vs 6.17 (0.20)  
(n=22 vs n=23) 
(SGS vs CG) 
N/A 
-6.92 [-8.53, -5.31] 
 
 
 
Favours SGS 
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Thickness  
TUPS 
4 months  
(marginal mean (SD)) 
Li Tsang 2006 
4.47 (0.18) vs 5.82 (0.25) 
(n=22 vs n=23) 
(SGS vs CG) 
N/A 
-6.07 [-7.50, -4.63] 
 
Favours SGS 
Thickness  
TUPS 
6 months  
(marginal mean (SD)) 
Li Tsang 2006 
4.17 (0.17) vs 6.16 (0.25)  
(n=22 vs n=23) 
(SGS vs CG) 
N/A 
-9.11 [-11.16, -7.05] 
 
Favours SGS: 
strongest effect 
at 6 months 
Itch outcomes 
 
   
 
 
Itch 
VSS 
Baseline (mean ± SE) 
Momeni 2009 
1.56 ± 0.11 
vs 1.50 ± 0.12 
(n=38 vs n=38) 
(SGS vs placebo) 
N/A - - 
Itch 
VSS 
1 month (mean ± SE) 
Momeni 2009 
0.94 ± 0.15 
vs 1.24 ± 0.15  
(n=34 vs n=34) 
(SGS vs placebo) 
N/A 
-0.34 [-0.82, 0.14] 
 
Favours SGS 
Itch 
VSS 
4 months (mean ± SE) 
Momeni 2009 
0.41 ± 0.10 
vs 0.97 ± 0.16 
(n=34 vs n=34) 
(SGS vs placebo) 
N/A 
-0.71 [-1.21, -0.22] 
 
 
Favours SGS: 
strongest effect 
at 4 months 
Itch 
mVSS 
Week 12 
Keorochana 2015 
No details provided  
 (n=35 vs n=35) 
(topical silicone gel+herbal extract 
vs aloe vera) 
p=0.025 - 
Favours topical 
silicone gela 
Itch 
mVSS 
Week 20 
Keorochana 2015 
No details provided  
 (n=35 vs n=35) 
(topical silicone gel+herbal extract 
vs aloe vera) 
p=0.047 - 
Favours topical 
silicone gela 
Itch 
mVSS 
Week 24 
Keorochana 2015 
No details provided  
 (n=35 vs n=35) 
(topical silicone gel+herbal extract 
vs aloe vera) 
p=0.026 - 
Favours topical 
silicone gela 
Itch 
POSAS 
3 months 
Van der Wal 2010 
No details provided  
(n=46 vs n=46) 
(Dermatix vs placebo) 
p=0.018 - 
Favours topical 
silicone gel 
(Dermatix)a 
Itch 
POSAS 
6 months 
Van der Wal 2010 
No details provided  
(n=46 vs n=46) 
(Dermatix vs placebo) 
p=0.013 - 
Favours topical 
silicone gel 
(Dermatix)a 
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Pain outcomes 
 
   
 
 
Pain 
VSS 
Baseline (mean ± SE) 
Momeni 2009 
1.24 ± 0.15 
vs 1.29 ± 0.13 
(n=38 vs n=38) 
(SGS vs placebo) 
N/A - - 
Pain 
VSS 
1 month (mean ± SE) 
Momeni 2009 
1.0 ± 0.15 
vs 1.15 ± 0.14 
(n=34 vs n=34) 
(SGS vs placebo) 
N/A 
-0.24 [-0.72, 0.24] 
 
Favours SGS: 
strongest effect 
at 1 month 
Pain 
VSS 
4 months (mean ± SE) 
Momeni 2009 
0.76 ± 0.14 
vs 0.88 ± 0.14 
(n=34 vs n=34) 
(SGS vs placebo) 
N/A 
-0.14 [-0.62, 0.33] 
 
- 
Scar severity outcomes 
 
   
 
 
Scar severity 
POSAS (Observer) 
 
Van der Wal 2010 
No details provided 
 (n=46 vs n=46) 
(Dermatix vs placebo) 
p=0.154 
 
- - 
Scar severity 
mVSS 
Week 12 
Keorochana 2015 
No details provided 
 (n=35 vs n=35) 
(topical silicone gel+herbal extract 
vs aloe vera) 
P=0.044 - 
Favours topical 
silicone gela 
Scar severity 
mVSS 
Week 16 
Keorochana 2015 
No details provided  
 (n=35 vs n=35) 
(topical silicone gel+herbal extract 
vs aloe vera) 
p=0.002 - 
Favours topical 
silicone gela 
Scar severity 
mVSS 
Week 20 
Keorochana 2015 
No details provided  
 (n=35 vs n=35) 
(topical silicone gel+herbal extract 
vs aloe vera) 
p=0.001 - 
Favours topical 
silicone gela 
Scar severity 
mVSS 
Week 24 
Keorochana 2015 
No details provided  
 (n=35 vs n=35) 
(topical silicone gel+herbal extract 
vs aloe vera) 
p<0.001 - 
Favours topical 
silicone gela 
Scar severity 
Overall VSS 
Baseline  
(mean (SD)) 
 
Karagoz 2009 
9.5 (0) vs 10.0 (2.1) vs 9.4 (1.4) 
 (n=15 vs n=15 vs n=15) 
(gel vs gel sheet vs onion extract) 
N/A - - 
201 
 
Scar severity 
Overall VSS 
After application 
(mean (SD)) 
Karagoz 2009 
4.4 (1.4) vs 4.8 (2.1) vs 6.1 (1.4) 
(n=15 vs n=15 vs n=15) 
(gel vs gel sheet vs onion extract) 
N/A 
Gel vs Gel sheet  
-0.22 [-0.94, 0.50] 
Gel vs Onion extract  
-1.18 [-1.97, -0.40] 
Gel sheet vs Onion 
extract  
-0.71 [-1.45, 0.03] 
Gel vs Gel sheet  
Favours gel 
Gel vs Onion 
extract  
Favours gel 
Gel sheet vs 
Onion extract  
Favours gel 
sheet 
Scar severity 
Overall mVSS 
8-24weeks 
Nimpoonyakampong 
2017 
No details provided 
(n=36 vs n=36) 
(silicone gel vs placebo) 
p<0.05 - 
Favours silicone 
gela 
Scar severity 
Overall mVSS 
8-24weeks 
Nimpoonyakampong 
2017 
No details provided 
(n=36 vs n=36) 
(silicone derivative gel vs placebo) 
p<0.05 - 
Favours silicone 
derivative gela 
Scar severity 
Overall mVSS 
8-24weeks 
Nimpoonyakampong 
2017 
No details provided 
(n=36 vs n=36) 
(silicone derivative gel vs silicone 
gel) 
p=0.61 - - 
Erythema outcomes 
 
   
 
 
Erythema 
DermaSpectrometer 
 
Van der Wal 2010 
No details provided 
 (n=46 vs n=46) 
(Dermatix vs placebo) 
p = 0.151 - - 
Colour outcomes 
 
   
 
 
Colour 
Digital Photography 
Assessment 
Baseline (mean (SD)) 
So 2003 
2.15 (0.80) vs 2.25 (0.62) 
(n=13 vs n=12) 
(enhanced education vs 
conventional education) 
p=0.81 - - 
Colour 
Digital Photography 
Assessment 
6 months (mean (SD)) 
So 2003 
1.31 (0.86) vs 2.00 (0.95) 
(n=13 vs n=12) 
(enhanced education vs 
conventional education) 
p=0.08 
-1.20 [-2.07, -0.34] 
 
Favours 
enhanced 
education group 
Vascularity outcomes 
 
   
 
 
Vascularity  
VSS   
Baseline  
(mean ± SE) 
Momeni 2009 
2.18 ± 0.15 
vs 2.12 ± 0.18 
(n=38 vs n=38) 
(SGS vs placebo) 
N/A 
 
- 
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Vascularity  
VSS   
1 month 
 (mean ± SE) 
Momeni 2009 
1.59 ± 0.16 
vs 1.79 ± 0.20 
(n=34 vs n=34) 
(SGS vs placebo) 
N/A 
-0.19 [-0.66, 0.29] 
 
Favours SGS 
Vascularity  
VSS   
4 months 
 (mean ± SE) 
Momeni 2009 
0.97 ± 0.18 vs 
1.50 ± 0.21 
(n=34 vs n=34) 
(SGS vs placebo) 
N/A 
-0.46 [-0.94, 0.02] 
 
Favours SGS: 
strongest effect 
at 4 months 
Vascularity 
mVSS 
Week 16 
Keorochana 2015 
No details provided  
 (n=35 vs n=35) 
(topical silicone gel+herbal extract 
vs aloe vera) 
p=0.005 - 
Favours topical 
silicone gela 
Vascularity 
mVSS 
Week 20 
Keorochana 2015 
No details provided 
(n=35 vs n=35) 
(topical silicone gel+herbal extract 
vs aloe vera) 
p=0.003 - 
Favours topical 
silicone gela 
Vascularity 
mVSS 
Week 24 
Keorochana 2015 
No details provided  
 (n=35 vs n=35) 
(topical silicone gel+herbal extract 
vs aloe vera) 
p=0.002 - 
Favours topical 
silicone gela 
Vascularity 
mVSS 
4 months 
Nimpoonyakampong 
2017 
No details provided 
(n=36 vs n=36) 
(silicone gel vs placebo) 
p=0.007 - 
Favours silicone 
gela 
Vascularity 
mVSS 
4 months 
Nimpoonyakampong 
2017 
No details provided 
(n=36 vs n=36) 
(silicone derivative gel vs placebo) 
p=0.014 - 
Favours silicone 
derivative gela 
Vascularity 
mVSS 
5 months 
Nimpoonyakampong 
2017 
No details provided 
(n=36 vs n=36) 
(silicone derivative gel vs placebo) 
p=0.314 - - 
Vascularity 
mVSS 
6 months 
Nimpoonyakampong 
2017 
No details provided 
(n=36 vs n=36) 
(silicone derivative gel vs placebo) 
p=0.004 - 
Favours silicone 
derivative gela 
Pliability outcomes 
 
   
 
 
Pliability 
VSS 
1 month (mean ± SE) 
Momeni 2009 
2.0 ± 0.22 
vs 2.32 ± 0.21 
(n=34 vs n=34) 
(SGS vs placebo) 
N/A 
-0.25 [-0.73, 0.22] 
 
Favours SGS 
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Pliability 
VSS 
4 months (mean ± SE) 
Momeni 2009 
0.97 ± 0.13 
vs 1.74 ± 0.21 
(n=34 vs n=34) 
(SGS vs placebo) 
N/A 
-0.75 [-1.24, -0.26] 
Favours SGS: 
strongest effect 
at 4 months 
Pliability 
mVSS 
Week 12 
Keorochana 2015 
No details provided  
(n=35 vs n=35) 
(topical silicone gel+herbal extract 
vs aloe vera) 
p>0.05 - 
Favours topical 
silicone gela 
Pliability  
VSS 
2 months  
(marginal mean (SD)) 
Li Tsang 2006 
2.62 (0.11) vs 2.94 (0.12) 
(n=22 vs n=23) 
(SGS vs CG) 
p=0.008 
 
-2.73 [-3.56, -1.90] 
 
 
Favours SGS 
Pliability  
VSS 
4 months  
(marginal mean (SD)) 
Li Tsang 2006 
2.37 (0.11) vs 2.78 (0.15) 
(n=22 vs n=23) 
(SGS vs CG) 
p=0.004 
 
-3.05 [-3.93, -2.17] 
 
Favours SGS 
Pliability  
VSS 
6 months  
(marginal mean (SD)) 
Li Tsang 2006 
1.99 (0.11) vs 2.72 (0.15) 
(n=22 vs n=23) 
(SGS vs CG) 
p<0.001 
 
-5.43 [-6.75, -4.12] 
 
Favours SGS: 
strongest effect 
at 6 months 
Pliability 
mVSS 
4 months 
Nimpoonyakampong 
2017 
No details provided 
(n=36 vs n=36) 
(silicone gel vs placebo) 
p=0.038 - 
Favours silicone 
gela 
Pliability 
mVSS 
5 months 
Nimpoonyakampong 
2017 
No details provided 
(n=36 vs n=36) 
(silicone gel vs placebo) 
p=0.003 - 
Favours silicone 
gela 
Pliability 
mVSS 
6 months 
Nimpoonyakampong 
2017 
No details provided 
(n=36 vs n=36) 
(silicone gel vs placebo) 
p=0.001 - 
Favours silicone 
gela 
Pigmentation outcomes 
 
   
 
 
Pigmentation  
VSS 
Baseline (mean ± SE) 
Momeni 2009 
1.24 ± 0.14 
vs 1.21 ± 0.11 
(n=38 vs n=38) 
(SGS vs placebo) 
N/A 
0.04 [-0.41, 0.49] 
 
- 
Pigmentation  
VSS 
1 month (mean ± SE) 
Momeni 2009 
0.79 ± 0.13 
vs 0.88 ± 0.09 
(n=34 vs n=34) 
(SGS vs placebo) 
N/A 
-0.14 [-0.61, 0.34] 
 
 
- 
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Abbreviations: 
Silicone gel sheeting 
Control group  
 
a Determined by standardised mean difference except where indicated 
  
Pigmentation  
VSS 
4 months (mean ± SE) 
Momeni 2009 
0.29 ± 0.08 
vs 0.59 ± 0.09 
(n=34 vs n=34) 
(SGS vs placebo) 
N/A 
-0.60 [-1.08, -0.11] 
 
Favours SGS: 
strongest effect 
at 4 months 
Pigmentation 
mVSS 
Week 16 
Keorochana 2015 
No details provided  
 (n=35 vs n=35) 
(topical silicone gel+herbal extract 
vs aloe vera) 
p=0.035 - 
Favours topical 
silicone gela 
Pigmentation 
mVSS 
Week 20 
Keorochana 2015 
No details provided  
 (n=35 vs n=35) 
(topical silicone gel+herbal extract 
vs aloe vera) 
p=0.002 - 
Favours topical 
silicone gela 
Pigmentation 
mVSS 
Week 24 
Keorochana 2015 
No details provided  
 (n=35 vs n=35) 
(topical silicone gel+herbal extract 
vs aloe vera) 
p=0.022 - 
Favours topical 
silicone gela 
Scar surface outcomes 
 
   
 
 
Scar surface 
Digital Photography 
Assessment 
Baseline  
(mean (SD)) 
So 2003 
1.92 (1.12) vs 2.17 (0.72) 
(n=13 vs n=12) 
(enhanced education vs 
conventional education) 
p=0.55 - - 
Scar surface 
Digital Photography 
Assessment 
6 months  
(mean (SD)) 
So 2003 
1.00 (0.82)  vs 1.67 (0.99) 
(n=13 vs n=12) 
(enhanced education vs 
conventional education) 
p=0.09 
-0.72 [-1.53, 0.10] 
 Favours 
enhanced 
education 
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3.2 Pressure garment therapy 
OUTCOME 
Measure 
Time period  
(measure unit) 
FIRST 
AUTHOR YEAR 
RESULTS (n) 
(intervention vs control) 
 
SIGNIFICANCE STANDARDISED 
MEAN DIFFERENCE 
FAVOURSa 
Thickness outcomes 
 
   
 
 
Thickness 
Dermascan C 
Baseline  
(mean (CI)) 
Van den 
Kerckhove 2005 
 
0.85 (0.74-0.96)  vs  
0.85 (0.74-0.96) 
(n=41 vs n=34) 
(normal compression vs low 
compression) 
N/A - - 
Thickness 
Dermascan C 
Month 1 
 (mean (CI)) 
Van den 
Kerckhove 2005 
 
0.57 (0.46-0.69)  vs  
0.74 (0.60-0.90) 
(n=41 vs  n=34) 
(normal compression vs low 
compression) 
N/A 
-0.45 [-0.91, 0.01] 
 Favours normal 
pressure: strongest 
effect at one month 
Thickness 
Dermascan C 
Month 2  
(mean (CI)) 
Van den 
Kerckhove 2005 
 
0.48 (0.36-0.62) vs  
0.64 (0.49-0.81) 
(n=41 vs  n=34) 
(normal compression vs low 
compression) 
N/A 
-0.39 [-0.85, 0.07] 
 
Favours normal pressure 
Thickness 
Dermascan C 
Month 3  
(mean (CI)) 
Van den 
Kerckhove 2005 
 
0.40 (0.27-0.54) vs  
0.54 (0.39-0.72) 
(n=41 vs  n=34) 
(normal compression vs low 
compression) 
N/A 
-0.33 [-0.79, 0.13] 
 
Favours normal pressure 
Thickness  
Ultrasonography 
Study period 5  
(mean (SD)) 
Engrav 2010 
2.8 (3.2) vs 3.4 (3.0) 
(n=28 vs  n=28) 
(normal compression vs  
low compression) 
N/A 
 
-0.19 [-0.72, 0.33] 
 
Favours normal pressure 
Thickness 
TUPS 
Baseline  
(mean (SD)) 
Lai 2010 
4.94 (0.90) vs 5.10 (1.07) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A - - 
Thickness 
TUPS 
1 month post-
intervention  
Lai 2010 
4.18 (0.95) vs 4.85 (1.04) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A 
-0.66 [-1.22, -0.11] 
Favours high pressure 
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(mean (SD)) 
Thickness 
TUPS 
2 months post-
intervention  
(mean (SD)) 
Lai 2010 
3.72 (0.98) vs 4.64 (1.02) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A 
-0.91 [-1.48, -0.34] 
Favours high pressure 
Thickness 
TUPS 
3 months post-
intervention  
(mean (SD)) 
Lai 2010 
3.39 (1.02) vs 4.44 (1.00) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A 
-1.02 [-1.60, -0.45] 
Favours high pressure 
Thickness 
TUPS 
4 months post-
intervention  
(mean (SD)) 
Lai 2010 
3.14 (1.07) vs 4.26 (1.00) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A 
-1.06 [-1.64, -0.48] 
Favours high pressure: 
strongest effect at 4 
months post-intervention 
commencement 
Thickness 
TUPS 
5 months post-
intervention  
(mean (SD)) 
Lai 2010 
2.96 (1.10) vs 4.09 (1.01) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
 
 
N/A 
-1.05 [-1.63, -0.47] 
Favours high pressure 
Thickness 
POSAS Observer 
Baseline  
Median (IQR) 
Moiemen 2018 
3 (2-5) vs 3 (2-4) 
(n=43 vs n=42) 
(PGT vs no PGT) 
N/A - - 
Height 
VSS 
Baseline  
Median (IQR) 
Moiemen 2018 
1 (1-1) vs 1 (0-1) 
(n=43 vs n=42) 
(PGT vs no PGT) 
N/A - - 
Itch outcomes 
 
   
 
 
Itch 
VAS 
1 month post 
intervention 
(mean (SD)) 
Lai 2010 
43.91 (22.84) vs 44.36 (20.84) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A 
-0.02 [-0.56, 0.52] 
- 
Itch 
VAS 
Lai 2010 
39.90 (22.02) 
vs 40.19 (20.42) 
(n=28 vs n=25) 
N/A 
-0.01 [-0.55, 0.53] 
- 
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2 months post-
intervention 
(mean (SD)) 
(high compression vs  
low compression) 
Itch 
VAS 
3 months post-
intervention 
 (mean (SD)) 
Lai 2010 
43.30 (19.85) vs 36.40 (16.00) 
(n=28 vs n=25) 
(high compression vs 
 low compression) 
N/A 
0.37 [-0.17, 0.92] 
Favours low pressure 
Itch 
VAS 
4 months post-
intervention 
 (mean (SD)) 
Lai 2010 
41.04 (18.51) vs 33.86 (15.88) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A 
0.41 [-0.14, 0.95] 
Favours low pressure: 
largest effect at 4 
months 
Itch 
VAS 
5 months post-
intervention 
(mean (SD)) 
Lai 2010 
34.57 (17.91) vs 31.70 (15.04) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A 
0.17 [-0.37, 0.71] 
- 
Pain outcomes 
 
   
 
 
Pain 
VAS 
1 month post 
intervention 
(mean (SD)) 
Lai 2010 
13.06 (10.25) vs 8.81 (6.39) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A 
0.48 [-0.06, 1.03] 
Favours low pressure: 
largest effect at 1 month 
Pain 
VAS 
2 months post-
intervention 
 (mean (SD)) 
Lai 2010 
11.64 (9.63) vs 8.16 (6.37) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A 
0.42 [-0.13, 0.96] 
Favours low pressure 
Pain 
VAS 
3 months post-
intervention 
 (mean (SD)) 
Lai 2010 
11.24 (9.99) vs 8.64 (6.27) 
(n=28 vs n=25) 
(high compression vs 
 low compression) 
N/A 
0.30 [-0.24, 0.85] 
Favours low pressure 
Pain 
VAS 
4 months post-
intervention 
(mean (SD)) 
Lai 2010 
10.24 (10.06) vs 8.26 (6.85) 
(n=28 vs n=25) 
(high compression vs 
 low compression) 
N/A 
0.22 [-0.32, 0.77] 
Favours low pressure 
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Pain 
VAS 
5 months post-
intervention 
(mean (SD)) 
Lai 2010 
10.00 (9.97) vs 7.41 (5.88) 
(n=28 vs n=25) 
(high compression vs 
 low compression) 
N/A 
0.31 [-0.24, 0.85] 
Favours low pressure 
Adverse effects 
 
 
  
 
 
Number of adverse 
effects 
Mean difference  
(95% CI) 
Moiemen 2018 
0.98 (0.43, 1.52) vs 
 0.91 (0.38, 1.43) 
(n=43 vs n=42) 
(PGT vs no PGT) 
N/A - - 
Overall scar quality 
outcomes 
   
 
 
Overall Scar Quality 
Vancouver Scar 
Scale 
1 month post-
intervention 
(mean (SD)) 
Lai 
2010 
10.86 (1.63) vs 11.04 (1.72) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A 
-0.11 [-0.65, 0.43] 
- 
Overall Scar Quality 
Vancouver Scar 
Scale 
2 month post-
intervention 
(mean (SD)) 
Lai 
2010 
10.43 (1.67) vs 10.44 (1.56) 
(n=28 vs n=25) 
(high compression vs 
 low compression) 
N/A 
-0.01 [-0.55, 0.53] 
- 
Overall Scar Quality 
Vancouver Scar 
Scale 
3 month post-
intervention 
(mean (SD)) 
Lai 
2010 
9.68 (1.79) vs 10.32 (1.63) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A 
-0.37 [-0.91, 0.18] 
Favours high pressure 
Overall Scar Quality 
Vancouver Scar 
Scale 
4 month post-
intervention 
(mean (SD)) 
Lai 
2010 
8.46 (1.58) vs 9.64 (1.89) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A 
-0.67 [-1.23, -0.12] 
Favours high pressure 
Overall Scar Quality 
Vancouver Scar 
Scale 
Lai 
2010 
7.82 (1.44) vs 9.00 (1.68) 
(n=28 vs n=25) 
(high compression vs  
N/A 
-0.75 [-1.31, -0.19] Favours high pressure: 
strongest effect at 5 
months 
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5 month post-
intervention 
(mean (SD)) 
low compression) 
Overall Scar Quality 
POSAS Observer 
Median (IQR) 
Baseline 
Moiemen 2018 
5 (4-6) vs 4 (3-5) 
(n=43 vs n=42) 
(PGT vs no PGT) 
N/A - - 
Overall Scar Quality 
Vancouver Scar 
Scale 
Median (IQR) 
Baseline 
Moiemen 2018 
7 (5-9) vs 6 (4-7) 
(n=43 vs n=42) 
(PGT vs no PGT) 
N/A - - 
Hardness outcomes 
 
   
 
 
Hardness 
RexDurometer 
Study period 1  
(mean (SD)) 
Engrav 2010 
 
47 (7) vs 46 (6) 
(n=51 vs 51) 
(normal compression vs  
low compression) 
N/A 
 
0.15 [-0.24, 0.54] 
 
- 
Hardness 
RexDurometer 
Study period 2  
(mean (SD)) 
Engrav 2010 
 
46 (8) vs 49 (7) 
(n=44 vs 44) 
(normal compression vs  
low compression) 
N/A 
-0.40 [-0.82, 0.03] 
 
Favours normal pressure 
Hardness 
RexDurometer 
Study period 3  
(mean (SD)) 
Engrav 2010 
 
47 (7) vs 48 (8) 
(n=37 vs 37) 
(normal compression vs  
low compression) 
N/A 
-0.13 [-0.59, 0.32] 
 
- 
Hardness 
RexDurometer 
Study period 4  
(mean (SD)) 
Engrav 2010 
 
45 (7) vs 48 (7) 
(n=33 vs 33) 
(normal compression vs  
low compression) 
N/A 
-0.42 [-0.91, 0.06] 
 
Favours normal pressure 
Hardness 
RexDurometer 
Study period 5  
(mean (SD)) 
Engrav 2010 
 
45 (7) vs 49 (7) 
(n=26 vs 26) 
(normal compression vs  
low compression) 
N/A 
-0.56 [-1.12, -0.01] 
 
Favours normal 
pressure: strongest 
during study period 5 
Erythema outcomes 
 
   
 
 
Erythema 
Minolta 
Chromameter 
Baseline 
Van den 
Kerckhove 2005 
 
9.29 (8.61-9.97) vs  
9.29 (8.61-9.97) 
(n=41 vs  n=34) 
(normal compression vs 
N/A - - 
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(mean (CI))  low compression) 
Erythema 
Minolta 
Chromameter 
Month 1 
(mean (CI)) 
Van den 
Kerckhove 2005 
 
6.95 (6.23-8.22) vs  
7.23 (6.02-7.87) 
(n=41 vs  n=34) 
(normal compression vs 
 low compression) 
N/A 
-0.10 [-0.55, 0.36] 
 
- 
Erythema 
Minolta 
Chromameter 
Month 2 
(mean (CI)) 
Van den 
Kerckhove 2005 
 
5.73 (5.00-7.00) vs  
6.01(4.80-6.65) 
(n=41 vs  n=34) 
(normal compression vs  
low compression) 
N/A 
-0.10 [-0.55, 0.36] 
 
- 
Erythema 
Minolta 
Chromameter 
Month 3 
(mean (CI)) 
Van den 
Kerckhove 2005 
 
5.08 (4.32-6.40) vs  
5.36 (4.11-6.05) 
(n=41 vs  n=34) 
(normal compression vs  
low compression) 
N/A 
-0.09 [-0.55, 0.36] 
 
- 
Colour outcomes 
 
   
 
 
Colour 
MinoltaChromometer 
L  
(mean (SD)) 
Engrav 2010 
56.3 (18.6) vs 55.2 (17.6) 
(n=unknown) 
(normal compression vs  
low compression) 
N/A - - 
Colour 
MinoltaChromometer 
A  
(mean (SD)) 
Engrav 2010 
9.0 (9.7) vs 9.5 (9.2) 
(n=unknown) 
(normal compression vs  
low compression) 
N/A - - 
Colour 
MinoltaChromometer  
B 
(mean (SD)) 
Engrav 2010 
8.2 (3.2) vs 8.5 (4.5) 
(n=unknown) 
(normal compression vs  
low compression) 
N/A - - 
Colour 
Spectrocolorimeter 
L 
 Baseline  
(mean (SD)) 
Lai 2010 
24.88 (9.89) vs 26.71 (7.55) 
(n=28 vs n=25) 
(high compression vs 
 low compression) 
N/A - - 
Colour 
Spectrocolorimeter 
A  
Baseline  
(mean (SD)) 
Lai 2010 
98.00 (49.38) vs 110.68 
(63.96) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A - - 
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Colour 
Spectrocolorimeter 
B  
Baseline  
(mean (SD)) 
Lai 2010 
11.24 (2.25) vs 10.91 (1.90) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A - - 
Colour 
Spectrocolorimeter 
L  
1 month post-
intervention 
 (mean (SD)) 
Lai 2010 
25.04 (13.40) vs 28.92 (11.98) 
(n=28 vs n=25) 
(high compression vs 
 low compression) 
N/A 
-0.30 [-0.84, 0.24] 
Favours high pressure: 
strongest effect at 1 
month 
Colour 
Spectrocolorimeter 
A  
1 month post-
intervention 
 (mean (SD)) 
Lai 2010 
76.72 (46.86) vs  
103.34 (60.77) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A 
-0.49 [-1.03, 0.06] 
Favours high pressure 
Colour 
Spectrocolorimeter 
B  
1 month post-
intervention   
(mean (SD)) 
Lai 2010 
11.31 (2.22) vs 11.07 (1.94) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A 
0.11 [-0.43, 0.65] 
- 
Colour 
Spectrocolorimeter 
L  
2 months post-
intervention 
 (mean (SD)) 
Lai 2010 
25.96 (11.98) vs 27.61 (10.69) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A 
-0.14 [-0.68, 0.40] 
- 
Colour 
Spectrocolorimeter 
A  
2 months post-
intervention 
 (mean (SD)) 
Lai 2010 
63.40 (46.07) vs 97.02 (58.21) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A 
-0.64 [-1.19, -0.08] 
Favours high pressure 
Colour 
Spectrocolorimeter 
B  
2 months post-
intervention 
 (mean (SD)) 
Lai 2010 
11.63 (2.31) vs 11.30 (1.80) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A 
0.16 [-0.38, 0.70] 
- 
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Colour 
Spectrocolorimeter 
L  
3 months post-
intervention 
(mean (SD)) 
Lai 2010 
28.35 (13.84) vs 30.34 (9.88) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A 
-0.16 [-0.70, 0.38] 
- 
Colour 
Spectrocolorimeter 
A  
3 months post-
intervention 
 (mean (SD)) 
Lai 2010 
54.35 (46.31) vs 91.46 (56.05) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A 
-0.72 [-1.27, -0.16] 
Favours high pressure 
Colour 
Spectrocolorimeter 
B  
3 months post-
intervention 
(mean (SD)) 
Lai 2010 
11.79 (2.20) vs 11.40 (1.87) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A 
0.19 [-0.35, 0.73] 
Favours low pressure 
Colour 
Spectrocolorimeter 
L  
4 months post-
intervention 
 (mean (SD)) 
Lai 2010 
29.55 (15.00) vs 32.05 (10.54) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A 
-0.19 [-0.73, 0.35] 
Favours high pressure 
Colour 
Spectrocolorimeter 
A   
4 months post-
intervention 
 (mean (SD)) 
Lai 2010 
47.32 (47.03) vs 86.27 (54.09) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A 
-0.76 [-1.32, -0.20] 
Favours high pressure: 
strongest effect at 4 
months 
Colour 
Spectrocolorimeter 
B   
4 months post-
intervention 
 (mean (SD)) 
Lai 2010 
11.86 (2.33) vs 11.49 (1.91) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A 
0.17 [-0.37, 0.71] 
- 
Colour 
Spectrocolorimeter 
L  
5 months post-
intervention 
Lai 2010 
29.50 (15.08) vs 32.11 (11.24) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A 
-0.19 [-0.73, 0.35] 
Favours high pressure 
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 (mean (SD)) 
Colour 
Spectrocolorimeter 
A 
5 months post-
intervention  
(mean (SD)) 
Lai 2010 
42.59 (47.74) vs 80.04 (54.15) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A 
-0.73 [-1.28, -0.17] 
Favours high pressure 
Colour 
Spectrocolorimeter 
B  
5 months post-
intervention 
 (mean (SD)) 
Lai 2010 
11.95 (2.29) vs 11.53 (1.91) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A 
0.20 [-0.35, 0.74] 
Favours low pressure: 
strongest effect at 5 
months 
Vascularity 
outcomes 
   
 
 
Vascularity 
VSS 
1 month post 
intervention 
(mean (SD)) 
Lai 2010 
2.54 (0.64) vs 2.52 (0.65) 
(n=28 vs n=25) 
(high compression vs 
 low compression) 
N/A 
0.03 [-0.51, 0.57] 
 
- 
Vascularity 
VSS 
2 months post-
intervention 
 (mean (SD)) 
Lai 2010 
2.36 (0.68) vs 2.36 (0.64) 
(n=28 vs n=25) 
(high compression vs 
 low compression) 
N/A 
0.00 [-0.54, 0.54] 
- 
Vascularity 
VSS 
3 months post-
intervention 
 (mean (SD)) 
Lai 2010 
1.93 (0.66) vs 2.36 (0.64) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A 
-0.65 [-1.21, -0.10] 
Favours high pressure 
Vascularity 
VSS 
4 months post-
intervention 
(mean (SD)) 
Lai 2010 
1.75 (0.52) vs 2.16 (0.69) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A 
-0.67 [-1.22, -0.11] 
Favours high pressure 
Vascularity 
VSS 
5 months post-
intervention 
 (mean (SD)) 
Lai 2010 
1.50 (0.51) vs 1.96 (0.61) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A 
-0.81 [-1.37, -0.25] 
Favours high pressure: 
greatest effect at 5 
months 
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Vascularity 
POSAS Observer 
Baseline  
Median (IQR) 
Moiemen 2018 
6 (4-7) vs 6 (4-7) 
(n=43 vs n=42) 
(PGT vs no PGT) 
N/A - - 
Vascularity 
VSS  
Baseline 
Median (IQR) 
Moiemen 2018 
2 (1-2) vs 2 (1-2) 
(n=43 vs n=42) 
(PGT vs no PGT) 
N/A - - 
Pliability outcomes 
 
   
 
 
Pliability 
VSS 
Baseline  
(mean (SD)) 
Lai 2010 
3.25 (0.75) vs 2.96 (0.74) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A - - 
Pliability 
VSS 
1 month post 
intervention 
(mean (SD)) 
Lai 2010 
3.18 (0.77) vs 2.96 (0.74) 
(n=28 vs n=25) 
(high compression vs 
 low compression) 
N/A 
0.29 [-0.26, 0.83] 
Favours low pressure 
Pliability 
VSS 
2 months post-
intervention 
 (mean (SD)) 
Lai 2010 
3.07 (0.77) vs 2.92 (0.70) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A 
0.20 [-0.34, 0.74] 
Favours low pressure 
Pliability 
VSS 
3 months post-
intervention 
 (mean (SD)) 
Lai 2010 
2.89 (0.74) vs 2.84 (0.69) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A 
0.07 [-0.47, 0.61] 
- 
Pliability 
VSS 
4 months post-
intervention 
(mean (SD)) 
Lai 2010 
2.36 (0.78) vs 2.76 (0.72) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A 
-0.52 [-1.07, 0.03] 
Favours high pressure: 
greatest effect at 4mths 
Pliability 
VSS 
5 months post-
intervention 
(mean (SD)) 
Lai 2010 
2.07 (0.86) vs 2.40 (0.71) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A 
 
-0.52 [-1.07, 0.03] 
Favours high pressure 
Pliability Moiemen 2018 4 (2-5) vs 3 (3-4) N/A - - 
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POSAS Observer 
Median (IQR) 
Baseline 
(n=43 vs n=42) 
(PGT vs no PGT) 
Pliability 
VSS 
Median (IQR) 
Baseline 
Moiemen 2018 
2 (1-2) vs 2 (1-2)  
(n=43 vs n=42) 
(PGT vs no PGT) 
 
N/A 
- - 
Pliability 
VSS 
Median (IQR) 
Week 1 
Moiemen 2018 
2 (2-3) vs 2 (2-3) 
(n=41 vs n=35) 
(PGT vs no PGT) 
N/A - - 
Pliability 
VSS 
Median (IQR) 
Month 1 
Moiemen 2018 
2 (2-3) vs 2 (2-2)  
(n=38 vs n=37) 
(PGT vs no PGT) 
N/A - - 
Pliability 
VSS 
Median (IQR) 
Month 3 
Moiemen 2018 
2 (1-2) vs 2 (1-3)  
(n=36 vs n=32) 
(PGT vs no PGT) 
N/A - - 
Pliability 
VSS 
Median (IQR) 
Month 6 
Moiemen 2018 
1 (1-2) vs 2 (1-2)  
(n=35 vs n=31) 
(PGT vs no PGT) 
N/A - - 
Pliability 
VSS 
Median (IQR) 
Month 12 
Moiemen 2018 
1 (1-2) vs 1 (1-1)  
(n=21 vs n=21) 
(PGT vs no PGT) 
N/A - - 
Elasticity outcomes 
 
   
 
 
Elasticity 
Cutometer 
Median (IQR) 
Baseline 
Moiemen 2018 
86.5 (80-93.5) vs 85 (82-90) 
(n=16 vs n=10) 
(PGT vs no PGT) 
N/A - - 
Elasticity 
Cutometer 
Median (IQR) 
Week 1 
Moiemen 2018 
86.5 (82.5-89.5) vs 90 (-) 
(n=4 vs n=1) 
(PGT vs no PGT) 
N/A - - 
Elasticity 
Cutometer 
Median (IQR) 
Moiemen 2018 
70 (63-82) vs 78 (-) 
(n=4 vs n=1) 
(PGT vs no PGT) 
N/A - - 
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1 Month 
Elasticity 
Cutometer 
Median (IQR) 
Month 3 
Moiemen 2018 
78 (70-84) vs 77.5 (69.5-86.5) 
(n=5 vs n=4) 
(PGT vs no PGT) 
N/A - - 
Elasticity 
Cutometer 
Median (IQR) 
Month 6 
Moiemen 2018 
81 (79-82) vs 90 (85-95) 
(n=7 vs n=5) 
(PGT vs no PGT) 
N/A - - 
Elasticity 
Cutometer 
Median (IQR) 
Month 12 
Moiemen 2018 
61.5 (57.5-68.5) vs 71 (70-91) 
(n=4 vs n=3) 
(PGT vs no PGT) 
N/A - - 
Pigmentation 
outcomes 
   
 
 
Pigmentation 
VSS 
Baseline 
(mean (SD)) 
Lai 2010 
2.68 (0.61) vs 2.36 (0.76) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A 
 
 
Pigmentation 
VSS 
1 month post 
intervention 
 (mean (SD)) 
Lai 2010 
2.61 (0.69) vs 2.40 (0.71) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A 
0.30 [-0.25, 0.84] 
Favours low pressure 
Pigmentation 
VSS 
2 months post-
intervention 
 (mean (SD)) 
Lai 2010 
2.61 (0.69) vs 2.32 (0.80) 
(n=28 vs n=25) 
(high compression vs 
 low compression) 
N/A 
0.38 [-0.16, 0.93] 
Favours low pressure: 
greatest effect at 2 
months 
Pigmentation 
VSS 
3 months post-
intervention 
(mean (SD)) 
Lai 2010 
2.57 (0.69) vs 2.40 (0.71) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A 
 
0.24 [-0.30, 0.78] 
Favours low pressure 
Pigmentation 
VSS 
4 months post-
intervention 
 (mean (SD)) 
Lai 2010 
2.25 (0.89) vs 2.32 (0.75) 
(n=28 vs n=25) 
(high compression vs 
 low compression) 
N/A 
-0.08 [-0.62, 0.46] 
- 
Pigmentation Lai 2010 2.14 (0.85) vs 2.36 (0.76) N/A -0.27 [-0.81, 0.27] Favours high pressure 
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VSS 
5 months post-
intervention 
(mean (SD)) 
(n=28 vs n=25) 
(high compression vs 
 low compression) 
Pigmentation 
POSAS Observer 
Baseline  
Median (IQR) 
Moiemen 2018 
4 (2-7) vs 3 (2-6) 
(n=43 vs n=42) 
(PGT vs no PGT) 
N/A - - 
Pigmentation 
VSS 
Baseline  
Median (IQR) 
Moiemen 2018 
2 (0-3) vs 2 (0-2) 
(n=43 vs n=42) 
(PGT vs no PGT) 
N/A - - 
Pigmentation 
VSS 
Week 1 
Median (IQR) 
Moiemen 2018 
2 (1-2) vs 2 (1-2) 
(n=41 vs n=35) 
(PGT vs no PGT) 
N/A - - 
Pigmentation 
VSS 
Month 1 
Median (IQR) 
Moiemen 2018 
2 (1-2) vs 2 (1-2) 
(n=38 vs n=37) 
(PGT vs no PGT) 
N/A - - 
Pigmentation 
VSS 
Month 3 
Median (IQR) 
Moiemen 2018 
2 (1-2) vs 2 (1-2) 
(n=36 vs n=32) 
(PGT vs no PGT) 
N/A - - 
Pigmentation 
VSS 
Month 6 
Median (IQR) 
Moiemen 2018 
2 (0-3) vs 2 (0-2) 
(n=35 vs n=31) 
(PGT vs no PGT) 
N/A - - 
Pigmentation 
VSS 
Month 12 
Median (IQR) 
Moiemen 2018 
2 (1-2) vs 1 (0-2) 
(n=21 vs n=21) 
(PGT vs no PGT) 
N/A - - 
Skin texture 
outcomes 
   
 
 
Relief 
POSAS Observer 
Baseline  
Median (IQR) 
Moiemen 2018 
4 (2-5) vs 3 (2-4) 
(n=43 vs n=41) 
(PGT vs no PGT) 
N/A - - 
Time to scar 
maturation 
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Mean time to scar 
maturation  
(mean ± SEM) 
Chang 1995 
242.5±17.5 days vs 
265.7±18.1 days 
(n=55 vs n=50) 
(PG vs no PG) 
 p>0.05 
-0.17 [-0.52,0.19] 
  Favours pressure 
garment therapy 
Interface pressure 
outcomes 
   
 
 
Interface pressure 
Strain-force curve 
Baseline 
(mean (SD)) 
Van den 
Kerckhove 2005 
19.75 (3.44) vs 11.85 (2.41) 
(n=41 vs n=34) 
(normal compression vs 
 low compression) 
N/A - N/A 
Interface pressure   
Strain-force curve 
One month 
(mean (SD)) 
Van den 
Kerckhove 2005 
14.93 (3.59) vs 9.28 (2.65) 
(n=41 vs n=34) 
(normal compression vs  
low compression) 
N/A - N/A 
Pressure loss 
baseline to one 
month 
Strain-force curve 
(mean (SD)) 
Van den 
Kerckhove 2005 
4.82 (2.99) vs 2.57 (1.54) 
(n=41 vs n=34) 
(normal compression vs  
low compression) 
N/A - N/A 
Interface pressure  
iScan 
Study period 1 
(mean (SD)) 
Engrav 2010 
26.3 (6.4) vs 3.5 (5.0) 
(n=41 vs n=41) 
(normal compression vs  
low compression) 
N/A - N/A 
Interface pressure  
iScan 
Study period 2 
(mean (SD)) 
Engrav 2010 
24.5 (4.1) vs 9.9 (3.7) 
(n=43 vs n=43) 
(normal compression vs  
low compression) 
N/A - N/A 
Interface pressure  
iScan 
Study period 3 
(mean (SD)) 
Engrav 2010 
24.2 (5.8) vs 10.3 (7.1) 
(n=36 vs n=36) 
(normal compression vs  
low compression) 
N/A - N/A 
Interface pressure  
iScan 
Study period 4 
(mean (SD)) 
Engrav 2010 
20.6 (6.0) vs 12.3 (4.1) 
(n=31 vs n=31) 
(normal compression vs  
low compression) 
N/A - N/A 
Interface pressure 
loss 
Pliance X 
1 month post-
intervention 
Lai 
2010 
-3.27 (0.36) vs -1.47 (0.25) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A - N/A 
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a Determined by standardised mean difference except where indicated 
  
(mean (SD)) 
Interface pressure 
loss 
Pliance X 
2 month post-
intervention 
(mean (SD)) 
Lai 
2010 
-3.64 (0.29) vs -1.77 (0.22) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A - N/A 
Interface pressure 
loss 
Pliance X 
3 month post-
intervention 
(mean (SD)) 
Lai 
2010 
-4.09 (0.35) vs -2.07 (0.28) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A - N/A 
Interface pressure 
loss 
Pliance X 
4 month post-
intervention 
(mean (SD)) 
Lai 
2010 
-3.09 (0.29) vs -1.41 (0.20) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A - N/A 
Interface pressure 
loss 
Pliance X 
5 month post-
intervention 
(mean (SD)) 
Lai 
2010 
-3.58 (0.20) vs -1.73 (0.15) 
(n=28 vs n=25) 
(high compression vs  
low compression) 
N/A - N/A 
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3.3 Combined interventions 
 
OUTCOME 
Measure 
Time period  
(measure unit) 
FIRST AUTHOR 
YEAR 
RESULTS (n) 
(intervention vs control) 
 
SIGNIFICANCE STANDARDISED 
MEAN 
DIFFERENCE 
FAVOURSa 
 
Thickness outcomes 
 
   
 
 
Thickness 
TUPS 
Baseline  
(mean (SD)) 
 
Li-Tsang 2010 
6.07 (2.70) vs 5.76 (1.68) vs 
6.39 (2.31) vs 6.20 (1.98) 
(n=30 vs n=24 vs  
n=29 vs n=21) 
(PG vs SGS vs PGSG vs CG) 
N/A - - 
Thickness 
TUPS 
2 months  
(mean (SD)) 
 
Li-Tsang 2010 
5.69 (2.27) vs 5.28 (1.56) vs 
4.91 (1.26) vs 5.39 (1.70) 
(n=30 vs n=24 vs  
n=29 vs n=21) 
(PG vs SGS vs PGSG vs CG) 
N/A 
PG vs SGS 
0.20 [-0.33, 0.74] 
PG  vs Combined 
0.42 [-0.10, 0.93] 
SGS vs Combined 
0.26 [-0.28, 0.80] 
PG  vs Control 
0.14 [-0.41, 0.70] 
SGS  vs Control 
-0.07 [-0.65, 0.52] 
Combined vs Control 
-0.32 [-0.89, 0.24] 
PG vs SGS 
Favours SGS 
PG vs  
Combined 
Favours 
Combined 
SGS vs  
Combined 
Favours  
Combined 
PG vs Control 
- 
SGS vs Control 
- 
Combined vs 
Control 
Favours 
Combined 
Thickness 
TUPS 
4 months  
(mean (SD)) 
 
Li-Tsang 2010 
5.48 (2.34) vs 4.90 (1.13) vs 
4.72 (1.38) vs 5.77 (1.44) 
(n=30 vs n=24 vs  
n=29 vs n=21) 
(PG vs SGS vs PGSG vs CG) 
N/A 
PG vs SGS 
0.30 [-0.24, 0.84] 
PG vs Combined 
0.39 [-0.13, 0.90] 
SGS vs Combined 
0.14 [-0.40, 0.68] 
PG vs Control 
PG vs SGS 
Favours SGS 
PG vs  
Combined 
Favours 
Combined 
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-0.14 [-0.70, 0.42] 
SGS vs Control 
-0.67 [-1.27, -0.06] 
Combined vs Control 
-0.74 [-1.32, -0.15] 
SGS vs  
Combined 
- 
PG vs Control 
- 
SGS vs Control 
Favours SGS 
Combined vs 
Control 
Favours 
Combined 
Thickness 
TUPS 
6 months 
(mean (SD)) 
 
Li-Tsang 2010 
5.15 (2.01) vs 4.61 (0.84) vs 
4.63 (1.20) vs 5.44 (1.21) 
(n=30 vs n=24 vs  
n=29 vs n=21) 
(PG vs SGS vs PGSG vs CG) 
N/A 
PG vs SGS 
0.33 [-0.21, 0.87] 
PG vs Combined 
0.31 [-0.20, 0.82] 
SGS vs Combined 
-0.02 [-0.56, 0.52] 
PG vs Control 
-0.17 [-0.72, 0.39] 
SGS vs Control 
-0.79 [-1.40, -0.18] 
Combined vs Control 
-0.66 [-1.24, -0.08] 
PG vs SGS 
Favours SGS 
PG vs  
Combined 
Favours 
Combined 
SGS vs  
Combined 
- 
PG vs Control 
- 
SGS vs Control 
Favours SGS 
Combined vs 
Control 
Favours 
Combined 
Thickness 
TUPS 
1 month post intervention 
(mean (SD)) 
 
Li-Tsang 2010 
4.49 (1.59) vs 4.25 (0.95) vs 
4.02 (0.98) vs 6.7 (2.76) 
(n=30 vs n=24 vs  
n=29 vs n=21) 
(PG vs SGS vs PGSG vs CG) 
N/A 
PG vs SGS 
0.18 [-0.36, 0.71] 
PG vs Combined 
0.35 [-0.16, 0.86] 
SGS vs Combined 
0.23 [-0.31, 0.78] 
PG vs Control 
-1.01 [-1.61, -0.42] 
SGS vs Control 
-1.20 [-1.84, -0.56] 
Combined vs Control 
-1.37 [-1.99, -0.74] 
PG vs SGS 
- 
PG vs 
Combined 
Favours 
Combined 
SGS vs  
Combined 
Favours 
Combined 
PG vs Control 
Favours PG 
SGS vs Control 
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Favours SGS 
Combined vs 
Control 
Favours 
Combined 
Itch outcomes 
 
   
 
 
Itch 
VAS 
Baseline  
(mean (SD)) 
 
Li-Tsang 2010 
4.78 (3.35) vs 3.61 (2.88) vs 
4.35 (3.01) vs 4.47 (2.45) 
(n=30 vs n=24 vs  
n=29 vs n=21) 
(PG vs SGS vs PGSG vs CG) 
N/A - - 
Itch 
VAS 
2 months  
(mean (SD)) 
 
Li-Tsang 2010 
5.5 (2.43) vs 2.19 (2.69) vs 
4.33 (2.38) vs 3.66 (2.80) 
(n=30 vs n=24 vs 
 n=29 vs n=21) 
(PG vs SGS vs PGSG vs CG) 
N/A 
PG vs SGS 
1.28 [0.69, 1.87] 
PG vs Combined 
0.48 [-0.04, 1.00] 
SGS vs Combined 
-0.84 [-1.40, -0.27] 
PG s Control 
0.70 [0.12, 1.28] 
SGS vs Control 
-0.53 [-1.12, 0.07] 
Combined vs Control 
0.26 [-0.31, 0.82] 
PG vs SGS 
Favours SGS 
PG vs  
Combined 
Favours 
Combined 
SGS vs  
Combined 
Favours SGS 
PG vs Control 
Favours Control 
SGS vs Control 
Favours SGS 
Combined vs 
Control 
Favours Control 
Itch 
VAS 
4 months  
(mean (SD)) 
 
Li-Tsang 2010 
5.18 (2.99) vs 2.0 (1.45) vs 
3.0 (3.32) vs 3.68 (2.79) 
(n=30 vs n=24 vs  
n=29 vs n=21) 
(PG vs SGS vs PGSG vs CG) 
N/A 
PG vs SGS 
1.29 [0.70, 1.88] 
PG VS Combined 
0.68 [0.16, 1.21] 
SGS vs Combined 
-0.37 [-0.92, 0.17] 
PG vs Control 
0.51 [-0.06, 1.07] 
SGS vs Control 
-0.76 [-1.37, -0.15] 
Combined vs Control 
-0.22 [-0.78, 0.35] 
PG vs SGS 
Favours SGS 
PG vs  
Combined 
Favours 
Combined 
SGS vs  
Combined 
Favours SGS 
PG vs Control 
Favours Control 
SGS vs Control 
Favours SGS 
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Combined vs 
Control 
Favours 
Combined 
Itch 
VAS 
6 months  
(mean (SD)) 
 
Li-Tsang 2010 
5.6 (2.71) vs 1.63 (1.49) vs 
3.23 (3.65) vs 2.09 (2.07) 
(n=30 vs n=24 vs 
 n=29 vs n=21) 
(PG vs SGS vs PGSG vs CG) 
N/A 
PG vs SGS 
1.74 [1.10, 2.37] 
PG vs Combined 
0.73 [0.20, 1.26] 
SGS vs Combined 
-0.55 [-1.10, 0.00] 
PG vs Control 
1.40 [0.77, 2.03] 
SGS vs Control 
-0.25 [-0.84, 0.33] 
Combined vs Control 
0.36 [-0.20, 0.93] 
PG vs SGS 
Favours SGS 
PG vs  
Combined 
Favours 
Combined 
SGS vs  
Combined 
Favours SGS 
PG vs Control 
Favours Control 
SGS vs Control 
Favours SGS 
Combined vs 
Control 
Favours Control 
Itch 
VAS 
1 month post intervention 
(mean (SD)) 
 
Li-Tsang 2010 
3.09 (2.34) vs 1.05 (1.31) vs 
1.86 (3.09) vs 2.63 (1.91) 
(n=30 vs n=24 vs  
n=29 vs n=21) 
(PG vs SGS vs PGSG vs CG) 
N/A 
PG vs SGS 
1.03 [0.46, 1.60] 
PG vs Combined 
0.44 [-0.07, 0.96] 
SGS vs Combined 
-0.33 [-0.87, 0.22] 
PG vs Control 
0.21 [-0.35, 0.77] 
SGS vs Control 
-0.96 [-1.58, -0.34] 
Combined vs Control 
-0.29 [-0.85, 0.28] 
PG vs SGS 
Favours SGS 
PG vs  
Combined 
Favours 
Combined 
SGS vs  
Combined 
Favours SGS 
PG vs Control 
Favours Control 
SGS vs Control 
Favours SGS 
Combined vs 
Control 
Favours 
Combined 
Itch 
VAS 
Baseline  
(mean (SD)) 
Steinstraesser 2011 
3.8 (3.1) vs 3.4 (2.7) vs  
3.8 (3.7) vs 4.4 (3.7) 
(n=19 vs n=19 vs 
 n=19 vs n=19) 
N/A - - 
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(silicone spray + PG vs PG 
alone vs silicone gel sheet + 
PG) 
Itch 
VAS 
18 months  
(mean (SD)) 
Steinstraesser 2011 
0.0 (0.0) vs 0.0 (0.0) vs  
0.3 (1.1) vs 0.7 (1.6) 
(n=19 vs n=19 vs  
n=19 vs n=19) 
(silicone spray + PG vs PG 
alone vs silicone gel sheet + 
PG vs PG alone) 
 
 
N/A 
Silicone spray + 
pressure vs pressure 
alone 
=  insufficient 
information for SMD 
Silicone gel sheet + 
pressure vs pressure 
alone 
-0.29 [-0.92, 0.35] 
Silicone spray + 
pressure vs silicone 
gel + pressure 
= insufficient 
information for SMD 
Favours silicone 
gel sheet+PG 
Pain outcomes 
 
   
 
 
Pain 
VAS 
Baseline  
(mean (SD)) 
Li-Tsang 2010 
2.28 (0.78) vs 1.61 (2.26) vs 
1.88 (2.34) vs 1.42 (2.47) 
(n=30 vs n=24 vs  
n=29 vs n=21) 
(PG vs SGS vs PGSG vs CG) 
N/A - - 
Pain 
VAS 
2 months  
(mean (SD)) 
Li-Tsang 2010 
2.0 (2.69) vs 1.19 (2.06) vs 
1.0 (1.69) vs 0.41 (0.90) 
(n=30 vs n=24 vs  
n=29 vs n=21) 
(PG vs SGS vs PGSG vs CG) 
N/A 
PG vs SGS 
0.33 [-0.21, 0.87] 
PG vs Combined 
0.44 [-0.08, 0.95] 
SGS vs Combined 
0.10 [-0.44, 0.64] 
PG vs Control 
0.73 [0.15, 1.31] 
SGS vs Control 
0.47 [-0.12, 1.07] 
Combined vs Control 
0.41 [-0.16, 0.98] 
PG vs SGS 
Favours SGS 
PG vs  
Combined 
Favours 
Combined 
SGS vs  
Combined 
- 
PG vs Control 
Favours Control 
SGS vs Control 
Favours Control 
Combined vs 
Control 
Favours Control 
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Pain 
VAS 
4 months  
(mean (SD)) 
 
Li-Tsang 2010 
2.09 (2.66) vs 0.78 (1.18) vs 
0.64 (1.44) vs 1.25 (1.77) 
(n=30 vs n=24 vs 
 n=29 vs n=21) 
(PG vs SGS vs PGSG vs CG) 
N/A 
PG vs SGS 
0.60 [0.05, 1.15] 
PG vs Combined 
0.67 [0.14, 1.19] 
SGS vs Combined 
0.10 [-0.44, 0.65] 
PG vs Control 
0.35 [-0.21, 0.92] 
SGS vs Control 
-0.31 [-0.90, 0.28] 
Combined vs Control 
-0.38 [-0.95, 0.19] 
PG vs SGS 
Favours SGS 
PG vs  
Combined 
Favours 
Combined 
SGS vs  
Combined 
- 
PG vs Control 
Favours Control 
SGS vs Control 
Favours SGS 
Combined vs 
Control 
Favours 
Combined 
Pain 
VAS 
6 months  
(mean (SD)) 
 
Li-Tsang 2010 
2.70 (3.16) vs 0.84 (1.64) vs 
0.46 (1.19) vs 1.54 (2.20) 
(n=30 vs n=24 vs  
n=29 vs n=21) 
(PG vs SGS vs PGSG vs CG) 
N/A 
PG VS SGS 
0.71 [0.15, 1.26] 
PG VS Combined 
0.92 [0.38, 1.46] 
SGS vs Combined 
0.27 [-0.28, 0.81] 
PG vs Control 
0.41 [-0.16, 0.97] 
SGS vs Control 
-0.36 [-0.95, 0.23] 
Combined vs Control 
-0.63 [-1.21, -0.05] 
PG VS SGS 
Favours SGS 
PG VS  
Combined 
Favours 
Combined 
SGS vs  
Combined 
Favours 
Combined 
PG vs Control 
Favours Control 
SGS vs Control 
Favours SGS 
Combined vs 
Control 
Favours 
Combined 
Pain 
VAS 
1 month post intervention 
(mean (SD)) 
 
Li-Tsang 2010 
2.0 (2.79) vs 0.10 (0.45) vs 
0.33 (1.04) vs 1.36 (1.74) 
(n=30 vs n=24 vs  
n=29 vs n=21) 
(PG vs SGS vs PGSG vs CG) 
N/A 
PG vs SGS 
0.89 [0.33, 1.45] 
PG vs Combined 
0.78 [0.25, 1.31] 
SGS vs Combined 
-0.27 [-0.82, 0.27] 
PG vs SGS 
Favours SGS 
PG vs  
Combined 
Favours 
Combined 
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PG vs Control 
0.26 [-0.30, 0.82] 
SGS vs Control 
-1.01 [-1.63, -0.38] 
Combined vs Control 
-0.74 [-1.32, -0.16] 
SGS vs  
Combined 
Favours SGS 
PG vs Control 
Favours Control 
SGS vs Control 
Favours SGS 
Combined vs 
Control 
Favours 
Combined 
Pain 
VAS 
Baseline  
(mean (SD)) 
 
Steinstraesser 2011 
1.6 (2.6) vs 1.4 (3.1) vs  
1.1 (2.1) vs 2.1 (3.2) 
(n=19 vs n=19 vs  
n=19 vs n=19) 
(silicone spray + PG vs PG 
alone vs silicone gel sheet + 
PG) 
N/A - - 
Pain 
VAS 
18 months  
(mean (SD)) 
 
Steinstraesser 2011 
0.1 (0.5) vs 0.0 (0.0) vs  
0.0 (0.0) vs 0.5 (1.9) 
(n=19 vs n=19 vs  
n=19 vs n=19) 
(silicone spray + PG vs PG 
alone vs silicone gel sheet + 
PG) 
N/A 
Silicone spray + 
pressure vs pressure 
alone 
NA 
Silicone gel sheet + 
pressure vs pressure 
alone 
NA 
Silicone spray + 
pressure vs silicone 
gel + pressure 
NA 
 
 
- 
 
 
Scar severity outcomes 
 
   
 
 
Scar severity 
Overall VSS 
Baseline  
(mean (SD)) 
Harte 2009 
7.27 (2.15) vs 7.18 (2.64) 
(n=11 vs n=11) 
(PG vs PGSG) 
p=0.943 - - 
Scar severity 
Overall VSS 
12 weeks  
(mean (SD)) 
Harte 2009 
5.89 (2.09) vs 5.40 (2.59) 
(n=11 vs n=11) 
(PG vs PGSG) 
p=0.659 
 
0.20 [-0.64, 1.04] 
 Favours 
combined 
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Scar severity 
Overall VSS 
24 weeks  
(mean (SD)) 
Harte 2009 
4.82 (2.14) vs 4.00 (2.32) 
(n=11 vs n=11) 
(PG vs PGSG) 
p=0.400 
 
0.35 [-0.49, 1.20] 
 
Favours 
combined: 
strongest effect 
at 6 months 
CHANGE OVER TIME 
Scar severity 
Overall VSS 
Baseline to 12 weeks 
Harte 2009 
1.44 (1.51) vs 1.80 (1.03) 
(n=11 vs n=11) 
(PG vs PGSG) 
p=0.505 
 
- - 
CHANGE OVER TIME 
Scar severity 
Overall VSS 
Baseline to 24 weeks 
Harte 2009 
2.45 (2.25) vs 3.18 (2.75) 
(n=11 vs n=11) 
(PG vs PGSG) 
p=0.505 
 
- - 
Scar severity 
Overall VSS 
Baseline  
(mean (SD)) 
Steinstraesser 2011 
6.1 (1.8) vs 5.9 (2.0) vs  
5.6 (1.2) vs 5.7 (2.0) 
(n=19 vs n=19 vs  
n=19 vs n=19) 
(silicone spray + PG vs PG 
alone1 vs silicone gel sheet + 
PG vs PG alone2) 
Silicone spray + PG 
Pliability: p<0.001 
Height: p = 0.041 
Vascularity: p = 
0.001 
 
PG alone 1 
Pliability: p<0.001 
Height: p = 0.001 
Vascularity: 
p<0.001 
 
Silicone gel+ PG 
Pliability: p = 0.002 
Height: p = 0.003 
Vascularity: p = 
0.001 
 
PG alone 2 
Pliability: p = 0.002 
Height: p = 0.01 
Vascularity: p = 
0.001 
 
 
- - 
Scar severity 
Overall VSS 
18 months  
(mean (SD)) 
Steinstraesser 2011 
2.3 (1.9) vs 1.7 (1.5) vs 
1.5 (1.6) vs 1.9 (1.1) 
(n=19 vs n=19 vs  
n=19 vs n=19) 
N/A 
Silicone spray + PG 
0.34 [-0.30, 0.98] 
 
Favours silicone 
spray+PG 
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(silicone spray + PG vs PG 
alone vs silicone gel sheet + 
PG) 
Silicone gel+ PG vs 
PG alone 
-0.29 [-0.92, 0.35] 
 
Silicone spray + 
pressure VS silicone 
gel + pressure 
0.45 [-0.20, 1.09] 
 
Favours silicone 
gel + PG 
 
 
Favours silicone 
gel + PG  
 
 
Erythema outcomes 
 
   
 
 
Erythema  
A value 
Minolta Chromameter 
Baseline  
(mean (SD)) 
 
Van den Kerckhove 
2001 
17.33 (2.82) vs 17.81 (2.35) 
vs 16.66 (3.43) vs 16.99 
(3.57) 
(n=18 vs n=18 vs  
n=18 vs n=18) 
(elastomer vs gel vs  
plastic vs control) 
N/A - - 
Erythema  
A value 
Minolta Chromameter 
7 days  
(mean (SD)) 
 
Van den Kerckhove 
2001 
14.94 (2.04) vs 14.96 (2.78) 
vs 14.70 (2.15) vs 15.68 (3.62) 
(n=18 vs n=18 vs  
n=18 vs n=18) 
(elastomer vs gel vs  
plastic vs control) 
N/A 
Elastomer vs Control 
-0.25 [-0.90, 0.41] 
Gel vs Control 
-0.22 [-0.87, 0.44] 
Plastic vs Control  
-0.32 [-0.98, 0.34] 
Elastomer vs Gel  
-0.01 [-0.66, 0.65] 
Elastomer vs Plastic 
0.11 [-0.54, 0.77] 
Gel vs Plastic  
0.10 [-0.55, 0.76] 
 
Elastomer vs 
Control  
Favours 
elastomer 
Gel vs Control  
Favours Gel 
Plastic vs 
Control  
Favours Plastic 
Elastomer vs 
Gel  
- 
Elastomer vs 
Plastic  
- 
Gel vs Plastic  
- 
 
Erythema  
A value 
Minolta Chromameter 
30 days 
(mean (SD)) 
Van den Kerckhove 
2001 
14.14 (1.78) vs 14.80 (2.15) 
vs 14.61 (3.13) vs  
16.36 (2.67) 
(n=18 vs n=18 vs  
n=18 vs n=18) 
N/A 
Elastomer vs Control 
-0.96 [-1.65, -0.26] 
Gel vs Control  
-0.63 [-1.30, 0.04] 
Plastic vs Control  
Elastomer vs 
Control  
Favours 
Elastomer 
Gel vs Control  
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 (elastomer vs gel vs 
 plastic vs control) 
-0.59 [-1.26, 0.08] 
Elastomer vs Gel  
-0.33 [-0.99, 0.33] 
Elastomer vs Plastic 
-0.18 [-0.84, 0.47] 
Gel vs Plastic 
0.07 [-0.58, 0.72] 
Favours Gel 
Plastic vs 
Control  
Favours Plastic 
Elastomer vs 
Gel  
Favours 
Elastomer 
Elastomer vs 
Plastic  
Favours 
Elastomer 
Gel vs Plastic  
- 
 
Strongest effect 
at 30 days 
Erythema  
A value 
Minolta Chromameter 
60 days  
(mean (SD)) 
 
Van den Kerckhove 
2001 
13.87 (2.18) vs 14.37 (2.29) 
vs 15.28 (3.00) vs  
15.19 (2.83) 
(n=18 vs n=18 vs  
n=18 vs n=18) 
(elastomer vs gel vs  
plastic vs control) 
N/A 
Elastomer vs Control  
-0.55 [-1.21, 0.12] 
Gel vs Control 
 -0.31 [-0.97, 0.35] 
Plastic vs Control  
0.03 [-0.62, 0.68] 
Elastomer vs Gel  
-0.26 [-0.91, 0.40] 
Elastomer vs Plastic 
-0.56 [-1.23, 0.11] 
Gel vs Plastic  
-0.33 [-0.99, 0.32] 
 
Elastomer vs 
Control  
Favours 
Elastomer 
Gel vs Control  
Favours Gel 
Plastic vs 
Control  
Favours Control 
Elastomer vs 
Gel  
Favours 
Elastomer 
Elastomer vs 
Plastic  
Favours 
Elastomer 
Gel vs Plastic  
Favours Gel 
Erythema  
A value 
Minolta Chromameter 
90 days  
(mean (SD)) 
Van den Kerckhove 
2001 
14.19 (2.42) vs 14.64 (2.29) 
vs 14.89 (2.76) vs  
15.24 (2.17) 
(n=18 vs n=18 vs  
n=18 vs n=18) 
Control vs 
elastomer p<0.001 
Control vs gel 
p=0.004 
Elastomer vs Control 
-0.45 [-1.11, 0.22] 
Gel vs Control  
-0.26 [-0.92, 0.39] 
Plastic vs Control  
Elastomer vs 
Control  
Favours 
Elastomer 
Gel vs Control  
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(elastomer vs gel vs  
plastic vs control) 
Control vs plastic 
p=0.37 
-0.14 [-0.79, 0.52] 
Elastomer vs Gel  
-0.19 [-0.84, 0.47] 
Elastomer vs Plastic 
-0.26 [-0.92, 0.39] 
Gel vs Plastic  
-0.10 [-0.75, 0.56] 
 
Favours Gel 
Plastic vs 
Control  
Favours Plastic 
Elastomer vs 
Gel  
Favours 
Elastomer 
Elastomer vs 
Plastic  
Favours 
Elastomer 
Gel vs Plastic  
- 
 
Colour outcomes 
 
   
 
 
Colour 
Spectrocolorimeter 
L (Lightness) 
Baseline  
(mean (SD)) 
Li-Tsang 2010 
46.5 (3.86) vs 45.6 (2.73) vs   
47.3 (4.91) vs 45.8 (4.27) 
(n=30 vs n=24 vs  
n=29 vs n=21) 
(PG vs SGS vs PGSG vs CG) 
N/A - - 
Colour 
Spectrocolorimeter  
A (Redness) 
Baseline  
(mean (SD)) 
Li-Tsang 2010 
8.56 (2.09) vs 9.33 (2.77) vs 
8.49 (2.30) vs 8.13 (1.49) 
(n=30 vs n=24 vs  
n=29 vs n=21) 
(PG vs SGS vs PGSG vs CG) 
N/A - - 
Colour 
Spectrocolorimeter  
B (Yellowness) 
Baseline 
 (mean (SD)) 
Li-Tsang 2010 
 
9.65 (2.78) vs 9.95 (2.67) vs 
10.2 (2.71) vs 8.59 (2.54) 
(n=30 vs n=24 vs  
n=29 vs n=21) 
(PG vs SGS vs PGSG vs CG) 
N/A - - 
Colour 
Spectrocolorimeter 
L  
2 months 
 (mean (SD)) 
 
Li-Tsang 2010 
47.4 (5.95) vs 45.9 (3.45) vs 
47.6 (5.44) vs 47.0 (5.73) 
(n=30 vs n=24 vs  
n=29 vs n=21) 
(PG vs SGS vs PGSG vs CG) 
N/A 
PG vs SGS 
0.30 [-0.24, 0.84] 
PG vs Combined 
-0.03 [-0.55, 0.48] 
SGS vs Combined 
-0.36 [-0.91, 0.19] 
PG vs Control 
0.30 [-0.27, 0.86] 
PG vs SGS 
Favours SGS 
PG vs  
Combined 
- 
SGS vs  
Combined 
Favours SGS 
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SGS vs Control 
0.03 [-0.56, 0.61] 
Combined vs Control 
0.36 [-0.21, 0.92] 
PG vs Control 
Favours Control 
SGS vs Control 
- 
Combined vs 
Control 
Favours Control 
Colour 
Spectrocolorimeter  
A 
2 months  
(mean (SD)) 
 
Li-Tsang 2010 
7.61 (2.05) vs 9.67 (1.31) vs 
8.18 (1.69) vs 7.12 (2.20) 
(n=30 vs n=24 vs  
n=29 vs n=21) 
(PG vs SGS vs PGSG vs CG) 
N/A 
PG vs SGS 
-1.15 [-1.73, -0.57] 
PG vs Combined 
-0.30 [-0.81, 0.21] 
SGS vs Combined 
0.96 [0.39, 1.53] 
PG vs Control 
0.23 [-0.33, 0.79] 
SGS vs Control 
1.41 [0.75, 2.07] 
Combined vs Control 
0.54 [-0.03, 1.12] 
PG vs SGS 
Favours PG 
PG vs  
Combined 
Favours PG 
SGS vs  
Combined 
Favours 
Combined 
PG vs Control 
Favours Control 
SGS vs Control 
Favours Control 
Combined vs 
Control 
Favours Control 
Colour 
Spectrocolorimeter  
B 
2 months  
(mean (SD)) 
 
Li-Tsang 2010 
9.65 (3.67) vs 10.70 (2.98) vs 
10.30 (2.23) vs 7.76 (3.63) 
(n=30 vs n=24 vs  
n=29 vs n=21) 
(PG vs SGS vs PGSG vs CG) 
N/A 
PG vs SGS 
-0.31 [-0.85, 0.23] 
PG vs Combined 
-0.21 [-0.72, 0.30] 
SGS vs Combined 
0.15 [-0.39, 0.69] 
PG vs Control 
0.51 [-0.06, 1.08] 
SGS vs Control 
0.88 [0.26, 1.49] 
Combined vs Control 
0.86 [0.27, 1.45] 
PG vs SGS 
Favours PG 
PG vs  
Combined 
Favours PG 
SGS vs  
Combined 
- 
PG vs Control 
Favours Control 
SGS vs Control 
Favours Control 
Combined vs 
Control 
Favours Control 
Colour 
Spectrocolorimeter  
L 
Li-Tsang 2010 
47.9 (5.47) vs 47.0 (4.17) vs 
49.2 (4.47) vs 47.0 (4.07) 
(n=30 vs n=24 vs  
N/A 
PG vs SGS 
0.18 [-0.36, 0.72] 
PG vs Combined 
PG vs SGS 
- 
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4 months  
(mean (SD)) 
 
n=29 vs n=21) 
(PG vs SGS vs PGSG vs CG) 
-0.26 [-0.77, 0.26] 
SGS vs Combined 
-0.55 [-1.10, 0.01] 
PG vs Control 
0.18 [-0.38, 0.74] 
SGS vs Control 
0.00 [-0.59, 0.59] 
Combined vs Control 
0.50 [-0.07, 1.07] 
PG vs  
Combined 
Favours PG 
SGS vs  
Combined 
Favours SGS 
PG vs Control 
- 
SGS vs Control 
- 
Combined vs 
Control 
Favours Control 
Colour 
Spectrocolorimeter  
A 
4 months 
(mean (SD)) 
 
Li-Tsang 2010 
7.76 (1.66) vs 8.94 (1.62) vs  
8.25 (2.23) vs 6.91 (1.71) 
(n=30 vs n=24 vs  
n=29 vs n=21) 
(PG vs SGS vs PGSG vs CG) 
N/A 
PG vs SGS 
-0.71 [-1.26, -0.15] 
PG vs Combined 
-0.25 [-0.76, 0.27] 
SGS vs Combined 
0.34 [-0.20, 0.89] 
PG vs Control 
0.50 [-0.06, 1.07] 
SGS vs Control 
1.20 [0.56, 1.84] 
Combined vs Control 
0.65 [0.07, 1.23] 
PG vs SGS 
Favours PG 
PG vs  
Combined 
Favours PG 
SGS vs  
Combined 
Favours 
Combined 
PG vs Control 
Favours Control 
SGS vs Control 
Favours Control 
Combined vs 
Control 
Favours Control 
Colour 
Spectrocolorimeter  
B 
4 months  
(mean (SD)) 
 
Li-Tsang 2010 
10.30 (2.88) vs 11.30 (3.17) 
vs 10.10 (3.18) vs 9.08 (3.14) 
(n=30 vs n=24 vs  
n=29 vs n=21) 
(PG vs SGS vs PGSG vs CG) 
N/A 
PG vs SGS 
-0.33 [-0.87, 0.21] 
PG vs Combined 
0.07 [-0.45, 0.58] 
SGS vs Combined 
0.37 [-0.17, 0.92] 
PG vs Control 
0.40 [-0.16, 0.97] 
SGS vs Control 
0.69 [0.09, 1.30] 
Combined vs Control 
0.32 [-0.25, 0.88] 
PG vs SGS 
Favours PG 
PG vs  
Combined  
- 
SGS vs  
Combined 
Favours 
Combined 
PG vs Control 
Favours Control 
SGS vs Control 
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Favours Control 
Combined vs 
Control 
Favours Control 
Colour 
Spectrocolorimeter  
L 
6 months  
(mean (SD)) 
 
Li-Tsang 2010 
49.7 (5.17) vs 48.8 (5.25) vs 
49.8 (4.94) vs 47.5 (4.71) 
(n=30 vs n=24 vs  
n=29 vs n=21) 
(PG vs SGS vs PGSG vs CG) 
N/A 
PG vs SGS 
0.17 [-0.37, 0.71] 
PG vs Combined 
-0.02 [-0.53, 0.49] 
SGS vs Combined 
-0.19 [-0.74, 0.35] 
PG vs Control 
0.43 [-0.13, 1.00] 
SGS vs Control 
0.26 [-0.33, 0.84] 
Combined vs Control 
0.47 [-0.10, 1.04] 
PG vs SGS 
Favours SGS 
PG vs  
Combined 
- 
SGS vs  
Combined 
Favours SGS 
PG vs Control 
Favours Control 
SGS vs Control 
Favours Control 
Combined vs 
Control 
Favours Control 
Colour 
Spectrocolorimeter  
A 
6 months  
(mean (SD)) 
 
Li-Tsang 2010 
7.94 (1.78) vs 8.49 (1.95) vs 
7.31 (2.21) vs 6.65 (2.05) 
(n=30 vs n=24 vs  
n=29 vs n=21) 
(PG vs SGS vs PGSG vs CG) 
N/A 
PG vs SGS 
-0.29 [-0.83, 0.25] 
PG vs Combined 
0.31 [-0.20, 0.82] 
SGS vs Combined 
0.55 [0.00, 1.11] 
PG vs Control 
0.67 [0.10, 1.24] 
SGS vs Control 
0.91 [0.29, 1.52] 
Combined vs Control 
0.30 [-0.26, 0.87] 
PG vs SGS 
Favours PG 
PG vs  
Combined 
Favours 
Combined 
SGS vs  
Combined 
Favours 
Combined 
PG vs Control 
Favours Control 
SGS vs Control 
Favours Control 
Combined vs 
Control 
Favours Control 
Colour 
Spectrocolorimeter  
B 
6 months  
(mean (SD)) 
Li-Tsang 2010 
11.10 (2.86) vs 10.60 (2.86) 
vs 11.10 (2.74) vs 7.86 (2.85) 
(n=30 vs n=24 vs  
n=29 vs n=21) 
(PG vs SGS vs PGSG vs CG) 
N/A 
PG vs SGS 
0.17 [-0.37, 0.71] 
PG vs Combined 
0.00 [-0.51, 0.51] 
SGS vs Combined 
PG vs SGS 
Favours SGS 
PG vs  
Combined  
- 
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 -0.18 [-0.72, 0.37] 
PG vs Control 
1.12 [0.52, 1.72] 
SGS vs Control 
0.94 [0.32, 1.56] 
Combined vs Control 
1.14 [0.54, 1.75] 
SGS vs  
Combined 
Favours SGS 
PG vs Control 
Favours Control 
SGS vs Control 
Favours Control 
Combined vs 
Control 
Favours Control 
Colour 
Spectrocolorimeter  
L 
1 month post intervention 
(mean (SD)) 
 
Li-Tsang 2010 
51.5 (5.33) vs 49.5 (4.30) vs 
51.6 (3.77) vs 48.0 (5.07) 
(n=30 vs n=24 vs  
n=29 vs n=21) 
(PG vs SGS vs PGSG vs CG) 
N/A 
PG vs SGS 
0.40 [-0.14, 0.94] 
PG vs Combined 
-0.02 [-0.53, 0.49] 
SGS vs Combined 
-0.51 [-1.07, 0.04] 
PG vs Control 
0.66 [0.09, 1.23] 
SGS vs Control 
0.31 [-0.37, 0.99] 
Combined vs Control 
0.81 [0.23, 1.40] 
PG vs SGS 
Favours SGS 
PG vs  
Combined 
- 
SGS vs  
Combined 
Favours SGS 
PG vs Control 
Favours Control 
SGS vs Control 
Favours Control 
Combined vs 
Control 
Favours Control 
Colour 
Spectrocolorimeter  
A 
1 month post intervention 
(mean (SD)) 
 
Li-Tsang 2010 
7.05 (1.65) vs 8.35 (1.99) vs 
7.07 (1.53) vs 7.96 (1.78) 
(n=30 vs n=24 vs  
n=29 vs n=21) 
(PG vs SGS vs PGSG vs CG) 
N/A 
PG vs SGS 
-0.71 [-1.26, -0.15] 
PG vs Combined 
-0.01 [-0.52, 0.50] 
SGS vs Combined 
0.72 [0.16, 1.28] 
PG vs Controlled 
-0.53 [-1.09, 0.04] 
SGS vs Control 
0.20 [-0.39, 0.79] 
Combined vs Control 
-0.53 [-1.11, 0.04] 
PG vs SGS 
Favours SGS 
PG vs  
Combined 
- 
SGS vs  
Combined 
Favours SGS 
PG vs Control 
Favours PG 
SGS vs Control 
Favours Control 
Combined vs 
Control 
Favours 
Combined 
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Colour 
Spectrocolorimeter  
B 
1 month post intervention 
(mean (SD)) 
 
Li-Tsang 2010 
11.80 (2.45) vs 11.80 (3.50) 
vs 12.40 (2.77) vs 9.63 (2.45) 
(n=30 vs n=24 vs  
n=29 vs n=21) 
(PG vs SGS vs PGSG vs CG) 
N/A 
PG vs SGS 
0.00 [-0.54, 0.54] 
PG vs Combined 
-0.23 [-0.74, 0.29] 
SGS vs Combined 
-0.19 [-0.73, 0.35] 
PG vs Controlled 
0.87 [0.29, 1.46] 
SGS vs Control 
0.70 [0.09, 1.30] 
Combined vs Control 
1.03 [0.43, 1.63] 
PG vs SGS 
- 
PG vs  
Combined 
Favours PG 
SGS vs  
Combined 
Favours SGS 
PG vs Control 
Favours Control 
SGS vs Control 
Favours Control 
Combined vs 
Control 
Favours Control 
Colour  
Minolta Chroma Meter  
A 
Baseline  
(mean (SD)) 
 
Steinstraesser 2011 
15.1 (2.3) vs 15.2 (2.3) vs 
15.7 (2.5) vs 16.6 (2.4) 
(n=19 vs n=19 vs  
n=19 vs n=19) 
(silicone spray + PG vs PG 
alone vs silicone gel sheet + 
PG vs PG alone 2) 
N/A - - 
Colour  
Minolta Chroma Meter  
A 
18 months  
(mean (SD)) 
 
Steinstraesser 2011 
10.9 (1.8) vs 10.9 (2.1)  vs 
11.1 (1.1) vs 11.8 (1.6) 
(n=19 vs n=19 vs  
n=19 vs n=19) 
(silicone spray + PG vs PG 
alone vs silicone gel sheet + 
PG vs PG alone 2) 
N/A 
Silicone spray + 
pressure vs pressure 
alone 
0.00 [-0.64, 0.64] 
Silicone gel sheet + 
pressure vs pressure 
alone 
-0.50 [-1.15, 0.15] 
Silicone spray + 
pressure vs silicone 
gel + pressure 
-0.13 [-0.77, 0.51] 
 
 
Silicone spray + 
PG 
 
Silicone gel 
sheet + PG 
 
Silicone spray + 
PG 
Pliability outcomes 
 
   
 
 
Pliability 
VSS 
Baseline  
Li-Tsang 2010 
3.26 (0.78) vs 3.16 (0.81) vs 
2.82 (0.80) vs 2.95 (0.80) 
(n=30 vs n=24 vs  
N/A - - 
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(mean (SD)) n=29 vs n=21) 
(PG vs SGS vs PGSG vs CG) 
Pliability 
VSS 
2 months  
(mean (SD)) 
 
Li-Tsang 2010 
2.92 (0.93) vs 2.87 (0.67) vs 
2.74 (0.85) vs 2.76 (0.72) 
(n=30 vs n=24 vs 
 n=29 vs n=21) 
(PG vs SGS vs PGSG vs CG) 
N/A 
PG vs SGS 
0.06 [-0.48, 0.60] 
PG vs Combined 
0.20 [-0.31, 0.71] 
SGS vs Combined 
0.17 [-0.38, 0.71] 
PG vs Control 
0.19 [-0.37, 0.74] 
SGS vs Control 
0.16 [-0.43, 0.74] 
Combined vs Control 
-0.02 [-0.59, 0.54] 
PG vs SGS 
- 
PG vs  
Combined 
Favours 
Combined 
SGS vs  
Combined 
Favours 
Combined 
PG vs Control 
Favours Control 
SGS vs Control 
Favours Control 
Combined vs 
Control 
- 
Pliability 
VSS 
4 months 
(mean (SD)) 
 
Li-Tsang 2010 
2.76 (0.95) vs 2.59 (0.85) vs 
2.62 (0.71) vs 2.88 (0.69) 
(n=30 vs n=24 vs  
n=29 vs n=21) 
(PG vs SGS vs PGSG vs CG) 
N/A 
PG vs SGS 
0.18 [-0.35, 0.72] 
PG vs Combined 
0.16 [-0.35, 0.68] 
SGS vs Combined 
-0.04 [-0.58, 0.50] 
PG vs Control 
-0.14 [-0.70, 0.42] 
SGS vs Control 
-0.37 [-0.96, 0.23] 
Combined vs Control 
-0.36 [-0.93, 0.20] 
PG vs SGS 
Favours SGS 
PG vs  
Combined 
- 
SGS vs  
Combined 
- 
PG vs Control 
- 
SGS vs Control 
Favours SGS 
Combined vs 
Control 
Favours 
Combined 
Pliability 
VSS 
6 months  
(mean (SD)) 
 
Li-Tsang 2010 
2.68 (0.94) vs 2.28 (0.78) vs 
2.52 (0.73) vs 2.66 (0.88) 
(n=30 vs n=24 vs  
n=29 vs n=21) 
(PG vs SGS vs PGSG vs CG) 
N/A 
PG vs SGS 
0.45 [-0.09, 1.00] 
PG vs Combined 
0.19 [-0.32, 0.70] 
SGS vs Combined 
-0.31 [-0.86, 0.23] 
PG vs SGS 
Favours SGS 
PG vs  
Combined 
Favours 
Combined 
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PG vs Control 
0.02 [-0.54, 0.58] 
SGS vs Control 
-0.45 [-1.04, 0.14] 
Combined vs Control 
-0.17 [-0.74, 0.39] 
SGS vs  
Combined 
Favours SGS 
PG vs Control 
- 
SGS vs Control 
Favours SGS 
Combined vs 
Control 
- 
Pliability 
VSS 
1 month post intervention 
(mean (SD)) 
 
Li-Tsang 2010 
2.30 (0.97) vs 1.95 (0.78) vs 
2.12 (0.74) vs 2.91 (0.79) 
(n=30 vs n=24 vs 
 n=29 vs n=21) 
(PG vs SGS vs PGSG vs CG) 
N/A 
PG vs SGS 
0.39 [-0.15, 0.93] 
PG vs Combined 
0.21 [-0.31, 0.72] 
SGS vs Combined 
-0.22 [-0.76, 0.32] 
PG vs Control 
-0.67 [-1.24, -0.09] 
SGS vs Control 
-1.20 [-1.84, -0.56] 
Combined vs Control 
-1.02 [-1.62, -0.42] 
PG vs SGS 
Favours SGS 
PG vs  
Combined 
Favours 
Combined 
SGS vs  
Combined 
Favours SGS 
PG vs Control 
Favours PG 
SGS vs Control 
Favours SGS 
Combined vs 
Control 
Favours 
Combined 
Profilometry outcomes 
 
   
 
 
Profilometry  
PRIMOS 
2 months  
(mean (SD)) 
 
Steinstraesser 2011 
323.1 (197.5) vs 278.7 
(212.1) vs 233.6 (197.5)  
vs 248.5 (62.1) 
(n=19 vs n=19 vs  
n=19 vs n=19) 
(silicone spray + PG vs PG 
alone vs silicone gel sheet + 
PG) 
N/A - - 
Profilometry  
PRIMOS 
18 months  
(mean (SD)) 
Steinstraesser 2011 
257.6 (178.3) vs 291.6 
(145.1) vs 270.5 (136.2) vs 
310.0 (174.2) 
(n=19 vs n=19 vs  
N/A 
Silicone spray + 
pressure vs pressure 
alone 
-0.20 [-0.84, 0.43] 
Favours silicone 
spray + PG 
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Abbreviations: 
PG = Pressure garment 
SGS = Silicone gel sheeting 
PGSG = Combined: pressure garment + silicone gel sheeting 
CG = Control group  
 
a Determined by standardised mean difference except where indicated 
 
  
n=19 vs n=19) 
(silicone spray + PG vs PG 
alone vs silicone gel sheet + 
PG vs PG alone) 
Silicone gel sheet + 
pressure vs pressure 
alone 
-0.25 [-0.89, 0.39] 
Silicone spray + 
pressure vs silicone 
gel + pressure 
-0.08 [-0.72, 0.56] 
 
Favours silicone 
gel sheet + PG 
 
Favours silicone 
spray+PG 
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Appendix 4: Participant characteristics of included studies 
 
4.1 Silicone therapy 
 
First 
author 
Year 
 
Intervention Age Gender Location 
of scar-
site 
Skin 
type/ 
ethnicity 
%TBSA Maximum 
depth of 
injury 
Type of 
wound 
healing 
Time to 
wound 
healing 
Number of 
surgical 
procedures 
Comorbidities Inclusion/ 
exclusion 
So 
2003 
 
Enhanced 
education 
intervention 
vs 
conventional 
education 
Treatment 
47 (10) 
years 
(31–61 
years) 
 
Control 
38 (10) 
years 
(19–57 
years) 
Treatment 
F:  3 
M: 10 
 
Control 
F: 4 
M: 8 
 
No details 
provided - 
no 
significant 
difference 
between 
groups 
No 
details 
provided 
Treatment 
26 (16)% 
Control 
16 (17)% 
No details 
provided 
Split 
thickness 
graft 
No details 
provided 
 
Age of 
scars 
Treatment 
14.9 
(11.7) 
weeks 
 
Control 
12.4 
(12.6) 
weeks 
No details 
provided 
No details 
provided 
Included: 
Pre-existing 
hypertrophic 
scar  
 
Excluded:  
Cognitive 
impairment 
Non-English 
speaking 
Open 
wounds 
Facial 
scarring 
Receiving 
surgical scar 
interventions 
Li-Tsang 
2006 
  
Silicone gel 
sheeting vs 
massage 
therapy 
Mean: 
29.65 
(17.60) 
years 
F: 16 
M: 29 
No details 
provided 
Chinese No TBSA 
details 
provided 
Scar size 
≤ 
20x20cm 
No details 
provided 
No details 
provided 
No details 
provided, 
scar to be 
˃ 3mm 
thick 
No details 
provided 
No details 
provided 
Included: 
< 50 years of 
age 
20x20cm 
hypertrophic 
burn, scald 
or trauma 
scar 3mm 
thick+ 
Momeni 
2009 
Cica care 
vs placebo 
Median: 
22 years 
F: 18 
M: 16 
Hand: 4 
Upper 
arm: 8 
Not 
reported 
TBSA not 
reported. 
No details 
provided 
No details 
provided 
No details 
provided 
No details 
provided 
No details 
provided 
Included: 
5x5cm 
homogenous 
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(1.5-60 
years) 
Forearm: 
2 
Thigh: 7 
Lower 
leg: 1 
Face: 9 
Trunk: 3 
5x5cm 
area 
hypertrophic 
burn scar 
 
Excluded: 
Family 
history of 
keloids 
Open wound 
Wound 
infection 
Silicone 
sensitivity 
Karagoz 
2009 
Silicone gel 
vs silicone 
gel 
sheeting vs 
topical 
onion 
extract 
Mean: 24 
years 
 
(Range:  
3 – 55 
years) 
 
 
F: 20 
M: 12 
Head and 
neck: 4 
(8.9%) 
Upper 
limb: 29 
(64.4%) 
Lower 
limb: 3 
(6.7%) 
Trunk: 9 
(20%) 
No 
details 
provided 
No details 
provided 
No details 
provided 
No details 
provided 
No details 
provided 
No details 
provided 
No details 
provided 
Included: 
Burn scars < 
6 months old 
with no prior 
interventions  
 
Excluded: 
Chemical 
burns, scars 
from 
incisions or 
other injuries 
Van der 
Wal 
2010 
 
Silicone gel 
vs placebo 
Mean: 38 
years 
 
(Range: 
18-69 
years) 
 
F: 10 
M: 13  
 
 
Group 1: 
TSG 
Trunk 
front: 3 
Upper 
limb: 13 
Lower 
limb: 7 
 
Group 2: 
Placebo 
Trunk 
front: 6 
Upper 
limb: 10 
Lower 
limb: 7 
No 
details 
provided 
 
 
No details 
provided 
 
 
No details 
provided – 
deep burns 
reported on 
in 
background 
No details 
provided 
No details 
provided 
No details 
provided 
No details 
provided 
Included: 
18+ years 
Two 
comparable 
burn scars  
 
Excluded: 
Language 
barrier 
Silicone/ 
occlusive 
dressing 
sensitivity 
Condition 
impacting 
adherence 
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Keorocha
na 
2015 
Silicone gel 
+ herbal 
extract vs 
aloe vera 
gel 
Study 
group 
Mean: 
36.89 
(9.90) 
 
Control 
group 
36.57 
(13.50) 
 
 
Study 
group 
F:15 
M: 20 
 
Control 
group 
F: 16 
M: 19 
 
Extremities No 
details 
provided 
No details 
provided 
Dermal 
burns: 
Superficial 
second 
degree-
deep 
second 
degree 
Spontaneo
us 
No details 
provided 
No details 
provided 
No details 
provided 
Included: 
18-60 years 
Spontaneous 
healed 
dermal burn 
wounds 
 
Excluded: 
Burn wounds 
requiring 
surgical 
repair 
Patients <18 
years 
Family 
history of 
HTS or 
keloid 
scarring 
Nimpoony
akampong 
2017 
 
Herbal 
extract in a 
silicone 
derivative 
gel vs 
Silicone gel 
vs Placebo 
gel 
Mean: 
36.33 
(11.55) 
years 
(Range: 
18-56yrs) 
Female: 8 
Male: 28 
(77.78%) 
No details 
provided 
No 
details 
provided 
Mean: 
37.52±10.
53% 
Second 
degree 
Spontaneo
us 
No details 
provided 
No details 
provided 
No details 
provided 
Included: 
20%TBSA, 
Second 
degree burns 
≤10 x 10cm2 
area 
 
Excluded: 
Wounds > 
10x10cm 
Wounds over 
joints 
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4.2 Pressure garment therapy 
 
First 
author 
Year 
 
Intervention Age Gender Location 
of scar-
site 
Skin type/ 
ethnicity 
%TBSA Maximum 
depth of 
injury 
Type of wound 
healing 
Time to 
wound 
healing 
Number of 
surgical 
procedures 
Comorbidity Inclusion/ 
exclusion 
Chang 
1995 
Pressure 
garment 
therapy vs no 
pressure 
garment 
therapy 
Treatment 
group 
Mean: 31 
(2.4) 
years 
 
Control 
group 
26 (2.6) 
years  
Treatment 
group 
F: 12 
M: 52 
 
Control 
group 
F: 7 
M: 51 
 
No details 
provided 
 
 
No details 
provided 
PG 
group 
21.7 
(2.2)% 
 
Control 
group 
19.1 
(1.8)% 
Full 
thickness 
Grafted and 
spontaneous 
healing >14 
days 
No details 
provided 
No details 
provided 
 
No details 
provided 
 
Included: 
Wounds 
requiring 14+ 
days to heal 
or grafting 
 
Excluded: 
Hands 
Face 
Van den 
Kerckhove 
2005 
 
Normal 
compression 
vs low 
compression 
Mean: 
37.5 
years 
(19 – 56 
years) 
F: 16 
M: 44 
Forearm 
or calf 
Caucasian Mean: 
8.5% 
Range:  
1-30% 
Partial 
thickness 
Spontaneously 
healed 
No details 
provided 
No details 
provided 
 
No details 
provided 
 
Included: 
Forearm or 
calf partial 
thickness 
burns, 
spontaneous 
healing 
 
Excluded: 
Infected 
wounds 
Engrav 
2010 
Normal 
compression 
vs low 
compression 
Mean: 36 
(14) years  
F: 8 
M: 46 
Forearm White: 37 
Non-white: 
15 
Not 
recorded: 2 
 
No 
details 
provided 
TBSA. 
Wounds 
≥4cm 
diameter 
No details 
provided 
Spontaneous: 
34 (63%) 
Grafted: 20 
(37%) 
Mean: 
21.9 
(12.4) 
days 
(Range = 
5 - 77 
days) 
No details 
provided 
No details 
provided 
Included: 
Forearm 
burns >4cm 
Required ≥ 3 
weeks to 
heal 
Required 
grafting 
 
Excluded: 
Injuries 
requiring 
fascial 
excision 
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Patients non 
-compliant 
with burn 
care 
Patients who 
could not 
return to the 
Burn Centre 
for follow up 
Lai 
2010 
High 
pressure vs 
low pressure 
High 
pressure 
group 
Mean: 
24.43 
(7.02) 
years 
 
 
Low 
pressure 
group 
Mean: 
28.24 
(8.22) 
years 
 
 
High 
pressure 
group 
F: 15 
M: 13 
 
 
 
Low 
pressure 
group 
F: 13 
M: 12 
 
High 
pressure 
group 
Upper 
limb: 12 
Lower 
limb: 13 
 
Low 
pressure 
group 
Upper 
limb: 14 
Lower 
limb: 14 
 
 
 
Chinese No 
details 
provided 
TBSA. 
Wounds 
≥4x4cm. 
No details 
provided 
No details 
provided 
Scar 
onset: 
 
High 
pressure 
group 
4.96 
(1.80) 
months  
 
Low 
pressure 
group 
5.48 
(2.02) 
months 
 
 
No details 
provided 
No details 
provided 
Included: 
Post-
traumatic 
hypertrophic 
scars on the 
extremities ≥ 
4x4cm, VSS 
≥1, 
compliant. 
 
Excluded: 
Open wound 
Other body 
locations 
Other 
treatments 
required 
Medical 
condition 
influencing 
wound 
healing 
Moiemen 
2018 
Pressure 
garment 
therapy vs no 
pressure 
garment 
therapy 
PG: 
Mean: 28 
years 
(6.5-52) 
 
No PGT: 
Mean: 31 
years  
(4.5-51.5) 
PG: 
F: 20 
M: 24 
 
No PGT: 
F: 19 
M: 25 
No details 
provided 
Fitzpatrick 
Scale: 
 
PG: (N) 
1a: 5 
1b: 2 
2: 6 
3: 17 
4: 10 
5: 1 
6: 3 
Unknown: 0 
PG: 
Median 
4%  
(1.8-8) 
 
No 
PGT: 
Median 
4%  
(1.8-7.5) 
Required 
split-
thickness 
skin graft; 
conservati
vely 
managed 
burn 
wounds 
or donor 
sites 
taking >2 
Those treated 
with split-
thickness skin 
grafts or 
conservatively 
managed burn 
wounds or 
donor sites 
that had taken 
>2 weeks to 
heal 
No details 
provided 
No details 
provided 
No details 
provided 
Included: 
Adults and 
children 
>1% TBSA 
burn 
requiring 
split-
thickness 
skin graft or 
taking >2 
weeks to 
heal  
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No PGT: (N) 
1a: 2 
1b: 0 
2: 7 
3: 21 
4: 9 
5: 1 
6: 2 
Unknown: 2 
 
weeks to 
heal 
 
Exclusions: 
Couldn’t 
understand 
English  
Pre-existing 
skin 
conditions 
affecting 
wound 
healing 
History of 
keloid 
scarring 
Allergy to 
Lycra or 
other 
component 
of pressure 
garments 
Other as 
per 
investigator 
opinion of 
suitability 
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4.3 Combined interventions 
 
First 
author 
Year 
 
Intervention Age Gender Location 
of scar-
site 
Skin type/ 
ethnicity 
%TBSA Max depth 
of injury 
Type of 
wound 
healing 
Time to 
wound 
healing 
Number of 
surgical 
procedures 
Comorbidities Inclusion/ 
exclusion 
Van den 
Kerckove 
2001 
Pressure 
garment 
therapy + 
occlusive 
plates 
Mean: 
30.8 
years 
(18-52 
years) 
F: 5 
M: 11 
Forearm 
and thigh 
Caucasian Mean: 
25.7% 
Range: 
3-60% 
Deep 
partial 
thickness 
Spontaneous No 
details 
provided 
No details 
provided 
No details 
provided 
Included: 
Thigh or 
forearm 
hypertrophic 
scarring 
Spontaneous 
healing deep 
partial burn 
wound 
 
Excluded: 
No details 
provided 
Harte 
2009  
 
 
 
 
 
 
Pressure 
garment 
therapy vs 
silicone 
sheeting + 
pressure 
garment 
therapy 
Group 1: 
Pressure 
garment 
only 
34.7 
(17.8) 
years 
(16-64 
years) 
 
Group 2: 
Pressure 
garment 
and 
silicone 
sheeting 
38.8 
(11.1) 
years 
Group 1 
F: 2 
M: 9  
 
Group 2 
F: 7 
M: 4 
 
Group 1 
Upper 
limb: 8 
Lower 
limb: 3 
 
Group 2 
Upper 
limb: 6 
Lower 
limb: 5  
 
 
Group 1 
Caucasian: 
11 
Other: 0 
 
Group 2 
Caucasian: 
11 
Other: 0 
 
Group 1 
16.2±8.
8% 
Range 
4-30 
 
Group 2 
13.8±18
.4% 
Range 
1-55 
 
Group 1 
No details 
provided 
 
Group 2 
No details 
provided 
 
Group 1 
Grafted: 11 
(100%) 
Not grafted: 
0 (0%) 
 
Group 2 
Grafted: 5 
45.5%) 
Not grafted: 
6 (54.5%) 
 
 
 
Group 1 
No 
details 
provided 
 
Group 2 
No 
details 
provided 
 
 
 
Group 1 
No details 
provided 
 
Group 2 
No details 
provided 
 
Group 1 
Smoker: 4 
(36.4%) 
Non-smoker: 7 
(63.6%) 
 
Group 2 
Smoker: 3 
(27.3%) 
Non-smoker: 8 
(72.7%) 
 
 
Included: 
Widespread, 
immature 
hypertrophic 
Located on 
limbs 
16-65 years 
of age 
Within 6 
months of 
injury 
 
Excluded: 
Skin infection 
or condition 
Keloid, 
surgical or 
concave 
scarring 
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(19-49 
years) 
Wounds 
taking <2 
weeks to 
heal 
Scars 
located over 
joints 
Li-Tsang 
2010 
Pressure 
garment 
therapy vs 
silicone gel 
sheeting vs 
pressure 
garment 
therapy + 
silicone gel 
sheeting 
Mean: 
21.8 
(18.7) 
years 
F: 41 
M: 63 
Upper 
limbs: 
44.2% 
Lower 
limbs: 
28.8% 
Other 
areas: 
26.9% 
Chinese No 
details 
provided 
Scar 
area 
≤16cm2 
No details 
provided 
Not all 
participants 
had burns 
No details 
provided 
No 
details 
provided 
No details 
provided 
No details 
provided 
Included: 
Active HTS 
Burn, scald 
or trauma 
mechanism 
Scar surface 
area <16cm2. 
 
Exclusions: 
Diabetes 
mellitus 
Steinstrae
sser 
2011 
 
Silicone gel 
sheet + 
pressure 
garment 
therapy vs 
pressure 
garment 
therapy 
 
vs 
 
Silicone 
spray + 
pressure 
garment 
therapy vs 
pressure 
garment 
therapy 
Silicone 
spray: 
42.3 
(13.3) 
 
Silicone 
gel sheet: 
43.1 
(13.7) 
Silicone 
spray: 
F: 5 
M: 14 
 
Silicone 
gel 
sheet: 
F:6 
M:13 
Silicone 
spray 
Anterior 
trunk: 
15.8% 
Upper 
extremity: 
42.1% 
Lower 
extremity: 
42.1% 
 
Silicone 
gel sheet 
Anterior 
trunk: 
15.8% 
Upper 
extremity: 
42.1% 
Fitzpatrick 
I-III 
No 
details 
provided 
Scar 
area 
>3x5cm 
Deep 
dermal 
Split skin 
graft 
No 
details 
provided 
No details 
provided 
No details 
provided 
Included: 
Aged ≥ 18 
years 
Fitzpatrick 
skin type I-III 
2 x 
comparable 
burn wounds 
that required 
split 
thickness 
grafting 2cm 
away from 
each other 
Deep dermal 
burns 
> 3 x 5cm 
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Lower 
extremity: 
42.1% 
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Appendix 5: Interventions of included studies 
5.1 Silicone therapy 
 
First Author  
Year 
Description of 
Intervention  
Frequency 
(session/week), 
intensity and 
duration 
Intervention 
commenced 
Intervention 
length 
(weeks/months) 
Who 
provided 
intervention 
and mode of 
delivery 
Modifications/ 
tailoring 
Adherence/ 
fidelity 
(planned 
and actual) 
Drop out/ 
switched 
allocated 
treatment 
group 
So  
2003 
Group 1: 
Enhanced 
education program 
consisted of the 
conventional 
education as well 
as an additional 5 
page handout and 
a 26 minute video 
on the use, 
potential benefits, 
and care of SGS as 
well as problem 
solving tips.   
SGS was secured 
beneath pressure 
garments for all 
participants. 
Product: Cica 
Care® (Smith and 
Nephew, Memphis, 
TN) 
Quantity: as much 
as needed 
 
Group 2: 
Conventional 
education of 1 page 
handout and 
standard verbal 
Group 1: 
Enhanced 
education program 
= Conventional 
education + 5pg 
handout and 26min 
instructional video 
 
Group 2: 
Conventional 
education = 1pg 
handout + standard 
verbal instructions 
 
Both groups: 
instructed to wear 
Cica Care silicone 
gel sheeting for 12 
hours, increasing to 
24 hour wear 
removing only for 
bathing. 
 
Group 1:  
14.9 (11.7) 
weeks 
 
Group 2:   
12.4 (12.6) 
weeks. 
One extended 
education 
session. Silicone 
gel sheeting 
used for 6 
months.  
Who: 
Attending 
physician and 
Occupational 
Therapist 
 
How: Verbal 
instructions 
by the 
Occupational 
Therapist, 
written 
handout 
according to 
randomisation 
and videotape 
if randomised 
to extended 
education 
group 
 
Where: The 
participating 
facility 
Education 
modified 
according to 
randomised 
intervention 
group. 
Planned: 
Self-reported 
adherence in 
a personal 
diary with 
record sheet 
 
Actual: self-
reported 
hours of 
daily wear. 
Extended 
education 
group = 21.8 
(3.0) hours 
of daily wear 
Conventional 
education 
group = 10.1 
(7.5) hours 
of daily wear. 
Drop out = 
3, all from 
control 
group 
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instructions. SGS 
was secured 
beneath pressure 
garments, 
ElastoGrip or 
secured by the Cica 
Care adhesive. 
Product: Cica 
Care® (Smith and 
Nephew, Memphis, 
TN) 
Quantity: as much 
as needed 
 
Li-Tsang  
2006 
Group 1: Silicone 
gel sheeting plus 
lanoline deep 
massage. Cica-
care held in place 
with micropore 
tape. 
Product: Cica Care, 
lanolin cream 
Quantity:  
 
Group 2: 15 minute 
lanoline deep 
massage 
Product: lanolin 
cream 
Quantity: 
Group 1: silicone 
gel sheeting 24 
hours/day + 15 
mins massage 2 x 
day.  
 
Group 2: 15mins 
massage 2 x day 
Scar greater 
than 3mm thick 
6 months Who: Two 
therapists 
 
How: No 
details 
provided 
 
Where: No 
details 
provided 
No details 
provided 
No details 
provided 
Drop out = 
3, all from 
control 
group 
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Momeni  
2009 
Within wound 
comparison 
 
Group 1: Silicone 
gel sheeting 
Product: Cica-Care 
semi-occlusive self-
adhesive sheeting 
made from medical-
grade silicone 
reinforced with 
silicone membrane 
backing. Overlay 
taping used as 
required 
Quantity: details not 
provided 
 
Group 2: Placebo 
Product: self-
adhesive propylene 
glycol and 
hydroxethyl 
cellulose sheeting. 
Overlay taping 
used as required 
Quantity: details not 
provided 
Both to be applied 
for 4hr/day at 
baseline, increasing 
by 4hrs/day until 
24hr/day wear. 
2-4 months 
after injury 
4 months Who: No 
details 
provided 
 
How: No 
details 
provided 
 
Where: No 
details 
provided 
No details 
provided – no 
adverse effects 
identified 
No details 
provided 
Lost to 
follow up = 
4 
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Karagoz  
2009 
Group 1: Silicone 
gel Product: 
Scarfade® 
Quantity: No 
information 
provided 
 
Group 2: Silicone 
gel sheet 
Product: Epi-
DermTM 
Quantity: No 
information 
provided 
 
Group 3: Topical 
onion extract (with 
Heparin and 
Allantoin) 
Product: 
Contractubex® 
Quantity: No 
information 
provided 
 
All groups: 
Used TubigripTM 
where possible 
 
Group 1:  
Applied 2 x/day 
 
 
 
 
 
Group 2:  
Applied 24hrs/day, 
removed for 
bathing 
 
 
 
 
Group 3:  
Applied 2 x/day 
 
Scars < 6 
months old 
 
6 months Who: No 
details 
provided 
 
How: No 
details 
provided 
 
Where: No 
details 
provided 
Head and neck 
scars were 
randomised to 
group 1 or 
group 3 only 
 
 
Two patients 
receiving 
Epiderm (group 
2) required a 
break from 
treatment for 1 
week due to 
adverse effects 
Planned: No 
details 
provided 
 
Actual: 
Reported 
wear of 
silicone gel 
sheet = at 
least 
12hrs/day. 
No details 
provided re: 
how 
adherence 
was 
measured. 
No details 
provided for 
other groups. 
Lost to 
follow up = 
0 
Van der Wal  
2010 
Group 1: Topical 
silicone gel 
Product: Dermatix 
Quantity: No details 
provided 
 
Group 2: placebo 
cream 
Product: not 
provided, however 
descriptor and 
ingredients of 
Both products 
applied 2 x/day to 
the respective 
scars 
Mean = 123 
days post-burn 
3-7 months 
Mean = 263 
days 
Who: Treating 
doctor 
 
How: No 
details 
provided 
 
Where: 
Participating 
clinic 
No adverse 
effects 
reportedly 
experienced 
Planned: no 
details 
provided 
 
Actual: Self-
reported 
adherence, 
no difference 
between the 
groups was 
reported. No 
details 
Participants 
advised not 
to switch 
product use 
on allocated 
scars. 
 
Drop out = 7 
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cream were listed. 
Cream contained 
sorbitol, cetiol, and 
cetostearyl-alcohol.  
Quantity: No details 
provided 
provided as 
to how data 
collected 
Keorochana  
2015 
Group 1: topical 
herbal extract plus 
silicone gel 
Product: Cybele® 
 
Group 2: aloe vera 
gel 
 
Products applied 
2x/day by rubbing 
gel gently into the 
wound 
100% wound 
re-
epithelialisation 
6 months Who: No 
details 
provided 
 
How: No 
details 
provided 
 
Where: No 
details 
provided 
Planned: 
Patient 
interviews 
conducted to 
determine 
adverse effects 
 
Actual: No 
adverse effects 
reportedly 
experienced 
Planned: no 
details 
provided 
 
Actual: no 
details 
provided 
No details 
provided 
Nimpoonyakampong 
2017 
Group 1: Herbal 
extract in a silicone 
derivative gel:  
Product: Cybele 
scagel® Bangkok 
Botanica Co., Ltd 
Quantity: no details 
provided 
 
Group 2: Silicone 
gel 
Product: Dermatix® 
Invida 
Pharmaceuticals 
Ltd 
Quantity: no details 
provided 
 
Group 3: Placebo 
gel 
Product: no details 
provided 
Quantity: no details 
provided 
Wound divided into 
three areas, each 
area received one 
of the three gels 2 x 
daily 
Full re-
epithelialisation 
6 months Who: “Well 
trained burn 
nurses” 
 
How: No 
details 
provided re: 
format of 
instructions 
 
Where: No 
details 
provided 
No details 
provided 
No details 
provided 
4 
participants 
removed 
from 
analyses 
due to loss 
of follow up: 
2 males, 2 
females 
253 
 
5.2 Pressure garment therapy 
 
First Author  
Year 
Description of 
Intervention  
Frequency 
(session/week), 
intensity and 
duration 
Intervention 
commenced 
Intervention 
length 
(weeks/months) 
Who 
provided 
intervention 
and mode of 
delivery 
Modifications/ 
tailoring 
Adherence/ 
fidelity 
(planned and 
actual) 
 
Drop out/ 
switched 
allocated 
treatment 
group 
Chang  
1995 
Group 1:  
Pressure garment 
therapy  
 
Group 2: No pressure 
garment therapy 
 
Product: No details 
provided 
Quantity: No details 
provided 
No details provided No details 
provided 
Until wound 
maturation 
Who: No 
details 
provided 
 
How: No 
details 
provided 
 
Where: No 
details 
provided 
No details 
provided 
Planned: 
No details 
provided 
 
Actual: 
No details 
provided 
Drop out = 8 
participants 
in the 
pressure 
garment 
group and 9 
participants 
in the no 
pressure 
garment 
group 
Van den 
Kerckhove  
2005 
Group 1: Normal 
compression 
initial mean pressure 
approx 20mmHg 
(19.75 (3.44) mmHg) 
 
Group 2: Low 
compression 
initial mean pressure of 
12mmHg  
(11.85 (2.41) mmHg) 
 
Product: Tricolast – 
weft knit garments 
Anvarex – power net 
garments 
 
Quantity: 2 
 
Patients instructed to 
wear garments 23hrs 
a day and each 
patient received two 
garments to alternate 
wear once both 
garments were 
received. First 
garment received at 
baseline, second 
garment received 
within one week of 
baseline. 
Washing instructions 
as per manufacturer 
requirements. 
Pressure 
started 2-
weeks after re-
epithelialisation 
3 months Who: No 
details 
provided 
 
How: No 
details 
provided 
 
Where: No 
details 
provided 
Pressure 
garment type 
differed by 
location 
Brussels = 
Weft knit 
garments 
(Tricolast®) 
Louvain – 
Power net 
garments 
(Anvarex®) 
Planned: 
No details 
provided 
 
Actual: 
No details 
provided 
No details 
provided 
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Engrav  
2010 
Group 1: Normal 
compression 
17-24mmHg 
 
Group 2: Low 
compression 
<5mmHg 
 
Product: Custom fit 
Medical Z Inc pressure 
garment, within person 
comparison 
 
Quantity: Unspecified 
 
Patients instructed to 
wear garments for 
23hrs a day. Pressure 
garments to be 
removed for bathing. 
Pressure 
therapy started 
within 2-weeks 
of re-
epithelisation 
1 year until 
clinical stability, 
lost to follow up 
or patient died 
Who: No 
details 
provided 
 
How: No 
details 
provided 
 
Where: No 
details 
provided 
No details 
provided 
Planned: Self-
completed 
form, daily 
hours of wear 
 
Actual: 50% 
completed 
forms. Mean 
hours of wear 
= 20.4 (3.9) 
Drop out = 
13 prior to 
data 
collection 
 
Lai 
2010 
Group 1: High 
compression 
20-25mmHg  
 
Group 2: Low 
compression 
10-15mmHg 
 
Product: Pressure 
garments fabricated by 
a therapist, 5% strain of 
limb circumference was 
applied. Tailor made 
padding (3mm, 6mm, 
9mm) was provided 
according to high/low 
pressure treatment 
allocation and were 
renewed every two 
months. 
 
Quantity: Two pressure 
garments 
 
Pressure garments 
were provided for 
alternating wear every 
day. Patients 
instructed to wear 
garments for 23hrs a 
day. Remove for 
hygiene. 
 
5.21 (1.94) 
months post 
injury 
5 months Who: No 
details 
provided 
 
How: No 
details 
provided 
 
Where: No 
details 
provided 
Tailored 
padding 
according to 
pressure level  
Planned: 
No details 
provided 
 
Actual: 
Self-report of 
daily hours of 
wear 
Drop out = 
8.62% 
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Moiemen 
2018 
Pressure garment 
therapy  
Standard supply route 
(either externally 
purchased garments or 
manufactured in house) 
+ silicone, massage, 
stretching and 
education 
 
No pressure garment 
therapy 
+ silicone, massage, 
stretching and 
education 
1 – 2 garments either 
externally purchased 
garments or 
manufactured in 
house provided and 
recommended to wear 
23 hours a day 
No details Up to 12 months Who: 
Completed by 
therapists at 
site (not 
blinded) 
 
How: No 
details 
provided 
 
Where: No 
details 
provided  
No details Patient 
reported 
adherence 
assessed at 
trial visit 
(complied,  
percentage 
level and 
hours/day) 
5/88 (6%) 
withdrew 
PG=1 
No PG=4  
 
14/88 (16%) 
lost to follow 
up 
PG=7 
No PG=7 
 
10 crossed 
over  
PG=5 
No PG=5 
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5.3 Combined interventions 
 
First Author 
Year 
Description of 
Intervention  
Frequency 
(session/week), 
intensity and 
duration 
Intervention 
commenced 
Intervention 
length 
(weeks/months) 
Who provided 
intervention 
and mode of 
delivery 
Modifications/ 
tailoring 
Adherence/ 
fidelity 
(planned and 
actual) 
Drop out/ 
switched 
allocated 
treatment 
group 
Van den 
Kerckhove  
2001 
Each scar divided 
into 4 x 1.5cm2 
round sites. 
Pressure garment 
therapy provided to 
all participants.  
Occlusive plates 
secured with 
polyurethane 
dressing 
Plates and test 
sites to be washed 
2 x day with mild 
soap/disinfectant. 
 
Group 1: silicone 
plates 
Product: Otto Bock 
Orthopaedic 
Industries 
 
Group 2: silicone 
elastomer 
 
Group 3: plastic 
plates 1mm thick 
 
Group 4: control 
 
Pressure garments 
and plates to be 
worn 23 hours/day. 
Removed 2x/day 
for hygiene. 
 
Pressure garment 
therapy begun 
immediately after 
re-
epithelialisation. 
Occlusive therapy 
begun 60.4 days 
(mean) after 
reepithelialisation. 
 
3 months Who: No 
details 
provided 
 
How: No 
details 
provided 
 
Where: No 
details 
provided 
No details 
provided 
No details 
provided  
 
Drop out = 6 
due to 
adverse 
events 
257 
 
Harte  
2009 
Group 1: Pressure 
garment therapy 
alone 
Product: 
Customised 
Jobskin pressure 
garments 
measured prior to 
randomisation 
 
Group 2: Pressure 
therapy + silicone 
gel sheeting   
Product: Jobskin 
customised 
pressure garment + 
Mepiform silicone 
gel sheeting 
overlapping onto 
normal skin by 1cm 
 
Quantity: 
Mepiform strip 
replaced every 7 
days. 
Pressure garments 
to be worn for 23 
hours/day. 
Mepiform to be 
worn for 23 
hours/day.  
111.6 (38.8) days 
b/w injury and 
commencing 
pressure therapy 
6 months Who: One 
Occupational 
therapist and 
one 
physiotherapist 
with 8+ years 
of experience. 
 
How: No 
details 
provided 
 
Where: No 
details 
provided 
Interventions 
to be removed 
24 hours prior 
to research 
assessments. 
Planned: Self 
completed 
diary of 
adherence to 
intervention 
(no details 
provided) and 
hygiene 
requirements.  
 
Actual: 4 
participants 
completed 
diaries 
Drop out = 8 
Li-Tsang  
2010 
Group 1: Pressure 
garment therapy + 
lanolin massage 
Product: Tailor 
made by treating 
Occupational 
Therapist with 
padding inserts, 
lanolin cream 
 
Group 2: Silicone 
gel sheet secured 
with micropore tape 
if required + lanolin 
massage 
Group 1: Tailor 
made pressure 
garment with 
padding  
Pressure garment 
wear: 24hrs/ day 
except bathing 
Massage: 
15mins/day 
 
Group 2:  
SGS: 24hrs/ day 
except bathing 
Massage: 15 mins/ 
day  
 
14.9 (30.8) 
months 
6 months Who: No 
details 
provided 
 
How: No 
details 
provided 
 
Where: No 
details 
provided 
No details 
provided 
Participants 
advised to 
adhere to 
their 
intervention 
Drop out = 
19.23% 
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Product: Cica Care, 
micropore tape, 
lanolin cream 
 
Group 3: Combined 
pressure and SGS 
therapy 
SGS worn under 
garment with same 
wear regime 
Product: Tailor 
made by treating 
Occupational 
Therapist with 
padding inserts, 
Cica Care, 
micropore tape, 
lanolin cream 
 
Group 4: Control 
Lanolin massage 
on scar  
 
 
 
 
Group 3:  
Pressure garment 
therapy wear: 
24hrs/ day except 
bathing 
SGS: 24hrs/ day 
except bathing 
Massage: 15 mins/ 
day  
 
 
 
 
 
 
Group 4:  
Control 
Massage: 15 mins/ 
day  
 
Steinstraesser 
2011 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Intraindividual 
comparison 
Group 1:  
a) Silicone gel 
sheet and pressure 
garment 
Product: Mepiform 
+ Jobskin, Jobst 
Quantity:  
b) Pressure 
garment alone  
Product: Jobskin, 
Jobst 
Quantity:  
 
Group 2:  
No details provided  No details 
provided 
12 months 
 
Who: No 
details 
provided 
 
How: No 
details 
provided 
 
Where: No 
details 
provided 
Adverse 
effects 
reported 
(31.5% of 
participants) 
but 
modifications 
to treatment as 
a result were 
not reported 
No details 
provided 
Drop out = 5 
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a) Silicone self-
drying spray and 
pressure garment  
Product: Dermatix  
+ Jobskin, Jobst 
Quantity: Not 
provided 
b) Pressure 
garment alone  
Product: Jobskin, 
Jobst 
Quantity: Not 
provided 
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Appendix 6: Therapist intervention fidelity checklist 
 
Item Action Instruction Completed 
General 
 
Discuss Scar maturation discussed Y / NA 
Clinical goals of scar management discussed Y / NA 
STRATADERM 
 
 
Education 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discuss Cross out this section if not relevant 
The effectiveness of topical silicone gel linked to 
occlusion and hydration. 
Y / NA 
To be used on clean, dry, healed skin Y / N 
Apply a thin layer of Strataderm and ensure full 
coverage of the scar 24hrs/ 7 days. Dries within 3-4 
minutes when using the appropriate amount. 
Y / N 
To be applied once daily after bath (but check for water 
beading after 8-10hours and increase to twice daily if 
water beading not present).  
Y / N 
Sun protection – if out in the sun >15mins, apply 
sunscreen over the Strataderm once the gel has dried 
(beneath pressure garment if applicable).  
Y / N 
Skin care – apply moisturiser to the area as required 
over the dried Strataderm. Apply small amounts 
frequently vs large amount once/day if skin dryness is 
present. 
Y / N 
Adverse effects: may include skin breakdown or skin 
irritation. If this occurs, caregiver to email as soon as 
possible after observing adverse effect, if reported in 
session therapist to refer to adverse effects flow chart 
and advise trial coordinator.  
Y / N 
Provide Trial handout for Strataderm provided 
 
Y / N 
Demonstrate Application of Strataderm Y / NA  
Product 
supply 
 
 
 
 
Provide  
 
 
 
 
 
One Strataderm 20g tube is enough to treat a 10-14cm 
scar for over 90 days 
One Strataderm 50g tube is enough to treat a scar 
area of 6x12cm for over 90 days 
Y / N 
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Number of tubes provided:____________20g 
 
                                          ____________50g 
 
For the time period of: ___________( month/s) 
Please 
record 
PRESSURE 
GARMENT 
 
 
 
Education 
Discuss Cross out this section if not relevant 
Effectiveness of pressure garment linked to hypoxia, 
which reduces oxygen and nutrient flow to the scar. 
Hypoxia is thought to break down collagen fibres in the 
scar and the mechanical pressure realigns collagen 
fibres. 
Y / NA 
Pressure garment to be worn 23hrs/day. Y / N 
Care of garment – wash daily on a gentle machine cold 
water cycle in a lingerie bag/ pillowcase, dry flat in 
shade. 
Y / N 
Sun protection – if out in the sun >15mins apply 
sunscreen. Wait until sunscreen absorbed before 
donning pressure garment, apply over Strataderm if 
applicable. 
Y / N 
Skin care –moisturiser to be applied to the area as 
required. Wait until moisturiser is absorbed before 
donning garment. Apply small amounts frequently vs 
large amount once/day if skin dryness is present. 
Y / N 
Adverse effects may include blistering, wounds on the 
skin beneath the pressure garment, rash, eczema, 
itching, discomfort, dissatisfaction with the 
appearance of the garment. Refer to adverse effects 
flowchart and advise trial coordinator. 
Y / N 
Provide Trial handout for pressure garments  Y / N 
Demonstrate Application of pressure garment  
Product 
supply  
            
Provide Have you discussed details regarding delivery and fit 
of pressure garment? 
Garments may need to be replaced every 2-3  months 
to maintain optimal pressure 
Y / N 
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Number of new garments provided:_____________ 
Number of garments in adequate condition to continue 
wearing: ___________________ 
Comment: 
 
Please 
record 
OTHER Discuss and 
Demonstrate 
Cross out this section if not relevant 
Massage  
Times/day: ________________ 
Y / NA 
ROM/ Exercises 
Times/day: ________________ 
Y / NA 
Functional activities/ play  
List: 
Y / NA 
Other:  Y / NA 
ADVERSE 
EFFECTS 
 Were any adverse effects experienced since last 
contact with OT? 
List:_______________________________________ 
 
 
 
Y / NA 
What action was taken? 
 
 
 
 
Was research coordinator advised at the time? Y / N 
Email primary investigator re: new adverse effects and 
action taken 
Y / N 
ASSESSMENT 
(follow up 
appointment) 
 On average, how many times/ day did the patient 
and/or caregiver report needing to moisturise their 
scar since their last review? 
No.:____ 
Does the family have any questions? Y / N 
Has a follow up appointment been scheduled for 1 
week post beginning scar management, 3 or 6 months 
(as appropriate)? 
Y / N 
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Did the patient and/or caregiver report sufficient 
Strataderm to maintain complete coverage of the scar 
24hrs/ 7 days since their last review? 
If not, what actions were taken? 
Y / N 
At time of review, are the garments in adequate 
condition to maintain optimal pressure 24hrs/ 7 days? 
If not, what actions were taken? 
Y / N 
OT follow up 
actions for 
BRIS trial 
  
Complete this checklist and put in trial communication box 
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Appendix 7: Social and clinical characteristics: declined participants 
 
Characteristic N (%)a 
No of participants 
  Declined 
  Withdrew 
86 
80 
   6 
Age 
Median (IQR)b 
 
5.05 (1.00, 9.00) 
Male Gender  54 (63%) 
Skin type  
  Type I – Always burn  1 (1%) 
  Type II – Tan with difficulty  7 (8%) 
  Type III – Tan about average 28 (33%) 
  Type IV – Tan more than average 28 (33%) 
  Type V – Brown skin 12 (14%) 
  Type VI – Black skin   0 (0%) 
    Missing 10 (11%) 
%TBSA of burn 
Median (IQR) 
 
1.50 (0.88, 5.00) 
  Missing 12 
Burn depth  
  Full thickness 24 (28%) 
  Deep Partial 33 (38%) 
  Superficial partial 18 (21%) 
    Missing 11 (13%) 
Mechanism of injury  
  Scald 33 (38%) 
  Contact 28 (33%) 
  Flame  3 (4%) 
  Friction  8 (9%) 
  Electrical  4 (5%) 
  Chemical  2 (2%) 
  Other  0 (0%) 
    Missing  8 (9%) 
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Surgical group  
  Spontaneous 28 (33%) 
  Grafted 18 (21%) 
  Reconstruction   7 (8%) 
    Missing   33 (38%) 
Caregiver education  
  Completed post school qualifications 66 (77%) 
  Completed senior high school  8 (9%) 
  Completed junior high school  0 (0%) 
  Other  2 (2%) 
    Missing 10 (12%) 
Reason for decline/withdrawal  
  Wanted therapists opinion 30 (35%) 
  Had a preferred intervention option 14 (16%) 
  Travel 14 (16%) 
  Miscellaneous 28 (33%) 
 
a Number (percentage) except where indicated 
b IQR = interquartile range 
 
Mann Whitney U Legacy test identified that children who did not participate in the study had 
darker skin types (skin type p=0.01), a younger median age (age p=0.02) and a greater 
frequency of caregiver post school qualifications (caregiver education p<0.001). Burn depth, 
%TBSA, burn mechanism, wound healing type and gender were not significantly different 
between the two groups (p>0.05). There is missing sociodemographic and clinical 
characteristic data for this cohort as not all caregivers consented to data collection. 
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Appendix 8: Per protocol mixed effects regression analyses for primary outcomes 
 
 Topical silicone 
gel 
Pressure 
garment therapy 
Combineda Topical silicone gel vs 
pressure garment therapy 
Topical silicone gel vs 
combined 
Combined vs pressure 
garment therapy 
 Mean (SD), 
n 
Mean (SD), 
n 
Mean (SD),  
n 
Mean difference (CI) p Mean difference (CI) p Mean difference (CI) p 
Baseline 
 
         
Scar thickness (cm) 
 
0.17 (0.08), 
60 
0.16 (0.08), 
49 
0.16 (0.08), 
60 
- - - - - - 
Scar itch intensity (NRS) 
 
4.51 (2.62), 
59 
4.91 (2.80), 
53 
4.16 (2.83), 
63 
- - - - - - 
One week 
 
         
Scar thickness (cm) 
 
0.17 (0.10), 
56 
0.16 (0.08), 
53 
0.17 (0.08), 
58 
0.02 (-0.02, 0.05) 0.33 0.00 (-0.03, 0.04) 0.82 0.01 (-0.02, 0.05) 0.45 
Scar itch intensity (NRS) 
 
3.21 (2.29), 
48 
3.48 (2.53), 
48 
3.25 (2.62), 
53 
-0.21 (-1.13, 0.71) 0.66 0.03 (-0.87, 0.93) 0.95 -0.24 (-1.13, 0.66) 0.61 
Three months 
 
         
Scar thickness (cm) 
 
0.18 (0.10), 
57 
0.17 (0.09), 
51 
0.18 (0.13), 
48 
0.00 (-0.03, 0.04) 0.88 -0.00 (-0.04, 0.03) 0.87 0.01 (-0.03, 0.04) 0.76 
Scar itch intensity (NRS) 2.78 (2.37), 
54 
2.27 (2.19), 
48 
1.98 (1.76), 
47 
0.58 (-0.32, 1.48) 0.21 0.59 (-0.31, 1.50) 0.20 -0.01 (-0.93, 0.91) 0.98 
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Six months 
 
Scar thickness (cm) 
 
0.18 (0.10), 
50 
0.19 (0.09), 
41 
0.21 (0.13), 
40 
-0.00 (-0.04, 0.03) 0.80 -0.03 (-0.07, 0.01) 0.12 0.03 (-0.01, 0.06) 0.20 
Scar itch intensity (NRS) 
 
1.78 (1.49), 
49 
1.77 (1.65), 
39 
1.78 (1.56), 
40 
0.05 (-0.91, 1.01) 0.92 0.03 (-0.93, 0.99) 0.96 0.02 (-0.98, 1.02) 0.96 
 
a Combined = topical silicone gel + pressure garment therapy 
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Appendix 9: Mixed effects regression analyses for primary outcomes stratified by surgical group 
 
9.1 Spontaneous wound healing 
 
 Topical 
silicone gel 
Pressure 
garment therapy 
Combineda Topical silicone gel vs 
pressure garment therapy 
Topical silicone gel vs 
combined 
Combined vs pressure 
garment therapy 
 Mean (SD),  
n 
Mean (SD),  
n 
Mean (SD),  
n 
Mean difference (CI) p Mean difference (CI) p Mean difference (CI) p 
Baseline          
Scar thickness (cm) 
 
0.15 (0.06), 
41 
0.17 (0.08), 
31 
0.17 (0.06), 
36 
- - - - - - 
Scar itch intensity (NRS) 
 
4.78 (2.60), 
41 
5.48 (2.87), 
33 
4.34 (2.97), 
38 
- - - - - - 
One week          
Scar thickness (cm) 
 
0.17 (0.11), 
37 
0.15 (0.07), 
33 
0.17 (0.07), 
35 
0.02 (-0.01, 0.06) 0.23 -0.00 (-0.04, 0.03) 0.89 0.03 (-0.01, 0.06) 0.19 
Scar itch intensity (NRS) 
 
2.79 (1.95), 
33 
2.93 (2.03), 
30 
3.19 (2.73), 
32 
-0.03 (-1.13, 1.08) 0.96 -0.29 (-1.37, 0.79) 0.60 0.26 (-0.85, 1.37) 0.64 
Three months          
Scar thickness (cm) 
 
0.16 (0.09), 
38 
0.16 (0.07), 
31 
0.17 (0.07), 
29 
0.00 (-0.04, 0.04) 0.95 -0.01 (-0.05, 0.03) 0.67 0.03 (-0.01, 0.07) 0.14 
Scar itch intensity (NRS) 
 
2.45 (2.30), 
38 
2.30 (2.17), 
30 
1.89 (1.85), 
28 
0.18 (-0.90, 1.27) 0.74 0.45 (-0.65, 1.54) 0.42 -0.26 (-1.41, 0.88) 0.65 
Six months          
Scar thickness (cm) 
 
0.16 (0.09), 
34 
0.17 (0.08), 
24 
0.20 (0.10), 
27 
-0.00 (-0.04, 0.04) 0.90 -0.03 (-0.07, 0.01) 0.13 0.03 (-0.01, 0.07) 0.20 
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Scar itch intensity (NRS) 
 
1.82 (1.66), 
34 
1.57 (1.34), 
23 
1.44 (1.15), 
27 
0.12 (-1.05, 1.29) 0.84 0.24 (-0.89, 1.37) 0.68 -0.12 (-1.34, 1.10) 0.85 
 
a Combined = topical silicone gel + pressure garment therapy 
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9.2 Grafted wound healing 
 Topical 
silicone gel 
Pressure 
garment therapy 
Combineda 
 
Topical silicone gel vs 
pressure garment therapy 
Topical silicone gel vs 
combined 
Combined vs pressure 
garment therapy 
  Mean (SD),  
n 
Mean (SD),  
n 
Mean (SD),  
n 
Mean difference (CI) p Mean difference (CI) p Mean difference (CI) p 
Baseline          
Scar thickness (cm) 
 
0.19 (0.08), 
16 
0.18 (0.07), 
13 
0.17 (0.10), 
18 
- - - - - - 
Scar itch intensity (NRS) 
 
3.75 (2.72), 
16 
4.21 (2.69), 
14 
4.00 (2.62), 
19 
- - - - - - 
One week          
Scar thickness (cm) 
 
0.18 (0.08), 
16 
0.18 (0.06), 
14 
0.17 (0.08), 
17 
0.00 (-0.08, 0.08) 1.00 0.01  (-0.06, 0.08) 0.78 -0.01 (-0.08, 0.06) 0.79 
Scar itch intensity (NRS) 
 
4.36 (2.71), 
14 
5.55 (3.11), 
11 
3.47 (2.50), 
15 
-1.11 (-2.92, 0.70) 0.23 0.98 (-0.71, 2.67) 0.26 -2.08 (-3.87, -0.30) 0.02 
Three months          
Scar thickness (cm) 
 
0.21 (0.10), 
16 
0.23 (0.09), 
13 
0.23 (0.20), 
15 
-0.03 (-0.11, 0.05) 0.42 -0.01 (-0.09, 0.06) 0.74 -0.02 (-0.10, 0.06) 0.63 
Scar itch intensity (NRS) 
 
3.56 (2.42), 
16 
2.31 (2.39), 
13 
2.53 (1.73), 
15 
1.47 (-0.24, 3.19) 0.09 0.88 (-0.78, 2.53) 0.30 0.60 (-1.14, 2.33) 0.50 
Six months          
Scar thickness (cm) 
 
0.22 (0.13), 
14 
0.23 (0.08), 
12 
0.29 (0.17), 
15 
-0.01 (-0.10, 0.07) 0.76 -0.09 (-0.16, -0.01) 0.03 0.07 (-0.01, 0.15) 0.08 
Scar itch intensity (NRS) 
 
2.07 (1.94), 
15 
2.27 (2.00), 
11 
2.27 (1.98), 
15 
0.03 (-1.78, 1.84) 0.97 -0.10 (-1.78, 1.59) 0.91 0.14 (-1.68, 1.95) 0.88 
 
a Combined = topical silicone gel + pressure garment therapy  
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9.3 Reconstruction surgery 
 
a Combined = topical silicone gel + pressure garment therapy 
  Topical 
silicone gel 
Pressure 
garment therapy 
Combineda Topical silicone gel vs 
pressure garment  therapy 
Topical silicone gel vs 
combined 
Combined vs pressure 
garment  therapy 
 Mean (SD),  
n 
Mean (SD),  
n 
Mean (SD),  
n 
Mean difference (CI) p Mean difference (CI) p Mean difference (CI) p 
Baseline          
Scar thickness (cm) 
 
0.26 (0.14), 
3 
0.10 (0.03), 
6 
0.12 (0.09), 
6 
- - - - - - 
Scar itch intensity (NRS) 
 
5.00 (1.41), 
2 
3.86 (2.12), 
7 
3.50 (2.88), 
6 
- - - - - - 
One week          
Scar thickness (cm) 
 
0.19 (0.10), 
3 
0.13 (0.14), 
6 
0.15 (0.10), 
6 
0.02 (-0.13, 0.17) 0.78 0.03 (-0.11, 0.18) 0.65 -0.01 (-0.14, 0.11) 0.84 
Scar itch intensity (NRS) 
 
1.00, 
1 
2.57 (1.99), 
7 
3.00 (2.68), 
6 
-2.34 (-6.06, 1.39) 0.22 -2.69 (-6.44, 1.05) 0.16 0.36 (-1.86, 2.57) 0.75 
Three months          
Scar thickness (cm) 
 
0.20 (0.13), 
3 
0.12 (0.12), 
7 
0.10 (0.06), 
6 
0.05 (-0.09, 0.20) 0.47 0.10 (-0.05, 0.25) 0.18 -0.05 (-0.17, 0.08) 0.47 
Scar itch intensity (NRS) 
 
 
0 
2.00 (2.24), 
5 
1.00 (0.00), 
6 
0.92 (-2.10, 3.94) 0.55 1.86 (-1.49, 5.22) 0.28 -0.95 (-3.25, 1.35) 0.42 
Six months          
Scar thickness (cm) 
 
0.19 (0.11), 
3 
0.15 (0.14), 
7 
0.11 (0.06), 
6 
0.01 (-0.13, 0.16) 0.88 0.08 (-0.07, 0.23) 0.29 -0.07 (-0.19, 0.06) 0.29 
Scar itch intensity (NRS) 
 
2.00, 
1 
2.00 (2.24), 
7 
1.00 (0.00), 
6 
-0.81 (-4.49, 2.88) 0.67 0.26 (-3.44, 3.96) 0.89 -1.07 (-3.29, 1.15) 0.34 
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Appendix 10: Mixed effects regression analyses for primary outcomes stratified by scar location  
 
10.1 Upper limb 
 Topical 
silicone gel 
Pressure 
garment therapy 
Combineda Topical silicone gel vs 
pressure garment therapy 
Topical silicone gel vs 
combined 
Combined vs pressure 
garment therapy 
 Mean (SD), 
n 
Mean (SD), 
n 
Mean (SD), 
n 
Mean difference (CI) p Mean difference (CI) p Mean difference (CI) p 
Baseline          
Scar thickness (cm) 
 
0.13 (0.06), 
29 
0.13 (0.08), 
22 
0.14 (0.06), 
33 
- - - - - - 
Scar itch intensity (NRS) 3.97 (2.73), 
29 
5.56 (2.71), 
25 
3.77 (2.76), 
35 
- - - - - - 
One week          
Scar thickness (cm) 
 
0.15 (0.12), 
27 
0.12 (0.08), 
24 
0.15 (0.08), 
32 
0.03 (-0.02, 0.08) 0.29 -0.00 (-0.05, 0.04) 0.88 0.03 (-0.02, 0.08) 0.21 
Scar itch intensity (NRS) 2.43 (1.63), 
21 
3.00 (2.41), 
21 
2.75 (2.41), 
28 
-0.41 (-1.68, 0.86) 0.53 -0.07 (-1.25, 1.11) 0.90 -0.33 (-1.53, 0.86) 0.58 
Three months          
Scar thickness (cm) 
 
0.13 (0.07), 
28 
0.13 (0.09), 
25 
0.15 (0.11), 
30 
-0.00 (-0.05, 0.05) 0.99 -0.02 (-0.07, 0.03) 0.41 0.02 (-0.03, 0.07) 0.44 
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Scar itch intensity (NRS) 2.15 (1.79), 
27 
2.18 (2.20), 
22 
1.70 (1.60), 
30 
0.05 (-1.16, 1.26) 0.93 0.43 (-0.69, 1.55) 0.45 -0.38 (-1.55, 0.79) 0.53 
Six months          
Scar thickness (cm) 
 
0.13 (0.08), 
25 
0.14 (0.10), 
23 
0.20 (0.15), 
29 
-0.01 (-0.06, 0.04) 0.76 -0.07 (-0.12, -0.02) 0.004 0.06 (0.01, 0.11) 0.01 
Scar itch intensity (NRS) 1.52 (1.08), 
25 
2.00 (1.86), 
23 
1.38 (1.15), 
29 
-0.39 (-1.61, 0.84) 0.54 0.16 (-0.99, 1.31) 0.79 -0.54 (-1.72, 0.64) 0.37 
 
a Combined = topical silicone gel + pressure garment therapy 
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10.2 Lower limb 
 Topical 
silicone gel 
Pressure 
garment therapy 
Combineda Topical silicone gel vs 
pressure garment therapy 
Topical silicone gel vs 
combined 
Combined vs pressure 
garment therapy 
 Mean (SD), 
n 
Mean (SD), 
n 
Mean (SD), 
n 
Mean difference (CI) p Mean difference (CI) p Mean difference (CI) p 
Baseline          
Scar thickness (cm) 
 
0.20 (0.08), 
20 
0.19 (0.07), 
22 
0.20 (0.08), 
24 
- - - - - - 
Scar itch intensity (NRS) 
 
4.55 (2.33), 
20 
4.70 (2.88), 
23 
4.50 (2.87), 
24 
- - - - - - 
 
One week          
Scar thickness (cm) 
 
0.20 (0.10), 
20 
0.17 (0.05), 
23 
0.20 (0.08), 
22 
0.03 (-0.03, 0.08) 0.31 0.00 (-0.05, 0.06) 0.92 0.02 (-0.03, 0.08) 0.34 
Scar itch intensity (NRS) 
 
3.33 (1.75), 
18 
4.14 (2.46), 
21 
3.71 (2.61), 
21 
-0.72 (-2.18, 0.75) 0.34 -0.36 (-1.83, 1.11) 0.63 
 
-0.36 (-1.76, 1.05) 0.62 
Three months          
Scar thickness (cm) 
 
0.22 (0.10), 
18 
0.22 (0.07), 
21 
0.24 (0.14), 
18 
0.00 (-0.05, 0.06) 0.93 -0.00 (-0.06, 0.05) 0.91 0.01 (-0.05, 0.06) 0.83 
Scar itch intensity (NRS) 
 
3.53 (2.98), 
17 
2.33 (2.20), 
21 
2.59 (1.94), 
17 
1.14 (-0.35, 2.63) 0.13 0.92 (-0.64, 2.47) 0.25 0.22 (-1.25, 1.70) 0.77 
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Six months          
Scar thickness (cm) 
 
0.22 (0.11), 
15 
0.22 (0.06), 
15 
0.24 (0.13), 
16 
0.00 (-0.06, 0.06) 0.93 -0.01 (-0.07, 0.05) 0.66 0.02 (-0.04, 0.07) 0.59 
Scar itch intensity (NRS) 
 
2.40 (2.41), 
15 
1.69 (1.65), 
13 
1.75 (1.39), 
16 
0.42 (-1.26, 2.11) 0.62 0.77 (-0.85, 2.40) 0.35 -0.35 (-2.01, 1.31) 0.68 
 
 
a Combined = topical silicone gel + pressure garment therapy 
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10.3 Torso 
 Topical 
silicone gel 
Pressure 
garment therapy 
Combineda Topical silicone gel vs 
pressure garment therapy 
Topical silicone gel vs 
combined 
Combined vs pressure 
garment therapy 
 Mean (SD), 
n 
Mean (SD), 
n 
Mean (SD), 
n 
Mean difference (CI) p Mean difference (CI) p Mean difference (CI) p 
Baseline          
Scar thickness (cm) 
 
0.20 (0.05), 
11 
0.21 (0.05), 
6 
0.20 (0.04), 
3 
- - - - - - 
Scar itch intensity (NRS) 6.00 (2.45), 
10 
3.33 (2.25), 
6 
5.50 (3.32), 
4 
- - - - - - 
 
One week          
Scar thickness (cm) 
 
0.20 (0.04), 
9 
0.24 (0.06), 
6 
0.17 (0.02), 
4 
-0.05 (-0.11, 0.02) 0.20 0.02  (-0.06, 0.10) 0.64 -0.06 (-0.15, 0.02) 0.15 
Scar itch intensity (NRS) 4.78 (3.63), 
9 
2.83 (3.13), 
6 
4.25 (3.95), 
4 
1.82 (-0.67, 4.31) 0.15 0.41 (-2.43, 3.25) 0.78 1.42 (-1.65, 4.48) 0.37 
Three months          
Scar thickness (cm) 
 
0.23 (0.09), 
11 
0.19 (0.06), 
5 
0.19 (0.00), 
2 
0.02 (-0.05, 0.09) 0.58 0.05 (-0.04, 0.13) 0.31 -0.03 (-0.12, 0.07) 0.60 
Scar itch intensity (NRS) 3.20 (2.35), 
10 
2.40 (2.61), 
5 
1.0 (0.00), 
2 
0.95 (-1.61, 3.51) 0.47 0.76 (-2.74, 4.25) 0.67 0.19 (-3.59, 3.96) 0.92 
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Six months          
Scar thickness (cm) 
 
0.23 (0.11), 
11 
0.25 (0.09), 
5 
0.25 (0.05), 
3 
-0.00 (-0.08, 0.07) 0.91 -0.01 (-0.10, 0.07) 0.81 0.01 (-0.09, 0.10) 0.90 
Scar itch intensity (NRS) 2.10 (1.73), 
10 
1.40 (0.89), 
5 
3.67 (3.06), 
3 
0.80 (-1.78, 3.38) 0.54 -1.87 (-4.98, 1.25) 0.24 2.67 (-0.78, 6.11) 0.13 
 
a Combined = topical silicone gel + pressure garment therapy 
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Appendix 11: Standardised mean differences for primary outcomes of scar thickness and itch intensity 
 
 Topical silicone gel vs pressure 
garment therapy 
Topical silicone gel vs combined a Combined a vs pressure garment 
therapy 
 SMD b (95% CI) Favours SMD b (95% CI) Favours SMD b (95% CI) Favours 
Three months       
Scar thickness 0.10 (-0.27, 0.48) Pressure 
garment 
therapy 
 
0.00 (-0.38, 0.38) - 0.09 (-0.30, 0.48) Pressure 
garment 
therapy 
Scar itch intensity 0.27 (-0.13, 0.66) Pressure 
garment 
therapy 
0.38 (-0.01, 0.77) Combined -0.15 (-0.54, 0.25) Combined 
Six months 
 
      
Scar thickness 0.00 (-0.41, 0.41) - -0.33 (-0.72, 0.07) Silicone 0.33 (-0.08, 0.75) Pressure 
garment 
therapy 
Scar itch intensity 0.04 (-0.37, 0.45) Pressure 
garment 
therapy 
0.16 (-0.24, 0.55) Combined -0.11 (-0.53, 0.30) Combined 
 
 
a Combined = topical silicone gel + pressure garment therapy 
b SMD = standardised mean difference 
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Appendix 12: Mixed effects regression analyses for primary outcomes at three months post-burn injury 
 
 Topical 
silicone gel 
Pressure 
garment therapy 
Combineda Topical silicone gel vs 
pressure garment therapy 
Topical silicone gel vs 
combined 
Combined vs pressure 
garment therapy 
 Mean (SD), 
n 
Mean (SD), 
n 
Mean (SD), 
n 
Mean difference (CI) p Mean difference (CI) p Mean difference (CI) p 
Scar thickness (cm)  0.18 (0.10), 
57 
 
0.17 (0.09), 
51 
 
0.18 (0.13), 
50 
 
0.00 (-0.03, 0.04) 0.88 -0.00 (-0.0, 0.0) 1.00 0.00 (-0.03, 0.04) 0.88 
Scar itch intensity (NRS)          
  Caregiver report 2.78 (2.37), 
54 
2.27 (2.19), 
48 
1.98 (1.74), 
49 
0.58 (-0.32, 1.48) 0.20 0.65 (-0.24, 1.55) 0.15 -0.07 (-0.98, 0.84) 0.87 
  Child self-report 
 
2.63 (2.91), 
19 
2.04 (2.23), 
25 
0.94 (1.55), 
18 
0.61 (-0.77, 2.00) 0.39 1.60 (0.11, 3.09) 0.04 -0.99 (-2.38, 0.40) 0.17 
 
a Combined = topical silicone gel + pressure garment therapy 
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Appendix 13: Mixed effects regression analyses for caregiver behavioural observation of itch 
 
 
a Toronto Pediatric Itch Scale 
b Combined = topical silicone gel + pressure garment therapy 
 
 
 Topical 
silicone gel 
Pressure garment 
therapy 
Combinedb Topical silicone gel vs 
pressure garment  therapy 
Topical silicone gel vs 
combined 
Combined vs pressure 
garment  therapy 
a Mean (SD), 
n 
Mean (SD), 
n 
Mean (SD), 
n 
Mean difference (CI) p Mean difference (CI) p Mean difference (CI) p 
Baseline 
 
1.03 (0.74), 
32 
0.95 (0.84), 
22 
0.63 (0.72), 
30 
- - - - - - 
One week 
 
0.76(0.83), 
29 
0.50 (0.51), 
22 
0.43 (0.69), 
28 
0.27 (-0.11, 0.65) 0.16 0.36 (0.01, 0.71) 0.04 -0.09 (-0.47, 0.29) 0.64 
Three months 
 
0.43 (0.69), 
28 
0.41 (0.85), 
22 
0.28 (0.68), 
25 
0.05 (-0.32, 0.43) 0.78 0.15 (-0.21, 0.51) 0.42 -0.09 (-0.48, 0.29) 0.64 
Six months 
 
0.39 (0.69), 
28 
0.12 (0.33), 
17 
0.25 (0.53), 
24 
0.18 (-0.22, 0.59) 0.37 0.12 (-0.25, 0.48) 0.54 0.07 (-0.35, 0.48) 0.75 
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Appendix 14: Mixed effects regression analyses for scar severity 
14.1 Caregiver report 
 
 Topical silicone 
gel 
Pressure 
garment therapy 
Combinedb Topical silicone gel vs 
pressure garment therapy 
Topical silicone gel vs 
combined 
Combined vs pressure 
garment therapy 
a Mean (SD), 
n 
Mean (SD), 
n 
Mean (SD), 
n 
Mean difference (CI) p Mean difference (CI) p Mean difference (CI) p 
Baseline          
Pain 
 
3.48 (2.53), 
50 
3.25 (2.23), 
48 
1.54 (1.64), 
52 
- - - - - - 
Itch 
 
4.50 (2.60), 
50 
4.69 (2.68), 
48 
4.37 (2.79), 
52 
- - - - - - 
Colour 
 
7.84 (2.57), 
50 
7.53 (2.73), 
49 
8.08 (2.09), 
52 
- - - - - - 
Stiffness 
 
5.26 (2.75), 
50 
5.10 (2.76), 
49 
5.39 (2.83), 
49 
- - - - - - 
Thickness 
 
5.44 (2.98), 
50 
5.35 (2.70), 
49 
5.65 (2.84), 
52 
- - - - - - 
Irregular 
 
6.24 (2.87), 
50 
6.55 (2.61), 
49 
6.26 (2.75), 
50 
- - - - - - 
Overall opinion 
 
7.25 (2.39), 
48 
6.90 (2.43), 
49 
6.61 (2.32), 
51 
- - - - - - 
Three months          
Pain 
 
1.72 (1.33), 
46 
1.58 (1.72), 
43 
1.78 (1.95) 
40 
0.17 (-0.63, 0.97) 0.67 -0.00 (-0.82, 0.82) 1.00 0.14 (-0.65, 1.00) 0.68 
Itch 2.73 (2.33), 2.26 (2.24), 2.05 (1.85), 0.51 (-0.43, 1.46) 0.29 0.66 (-0.30, 1.62) 0.18 -0.15 (-1.11, 0.82) 0.77 
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 45 43 40 
Colour 
 
6.07 (2.92), 
46 
5.79 (3.04), 
42 
6.18 (2.65), 
40 
0.34 (-0.79, 1.47) 0.55 0.03 (-1.11, 1.16) 0.97 0.32 (-0.84, 1.47) 0.59 
Stiffness 
 
4.85 (2.72), 
46 
4.26 (2.94), 
42 
4.50 (2.81), 
40 
0.56 (-0.57, 1.69) 0.33 0.41 (-0.72, 1.55) 0.48 0.15 (-1.00, 1.29) 0.80 
Thickness 
 
5.13 (2.80), 
46 
4.93 (3.10), 
43 
5.30 (2.70), 
40 
0.17 (-0.99, 1.33) 0.77 -0.11 (-1.28, 1.06) 0.85 0.28 (-0.90, 1.46) 0.64 
Irregular 
 
5.52 (2.73), 
46 
5.07 (3.11), 
43 
5.20 (3.03), 
40 
0.39 (-0.78, 1.56) 0.51 0.46 (-0.72, 1.64) 0.44 -0.07 (-1.26, 1.12) 0.91 
Overall opinion 
 
6.02 (2.64), 
45 
5.02 (2.92), 
42 
5.68 (2.45), 
40 
0.85 (-0.21, 1.92) 0.12 0.41 (-0.66, 1.48) 0.45 0.44 (-0.64, 1.53) 0.42 
Six months          
Pain 
 
1.46 (1.32), 
41 
1.54 (1.64), 
37 
1.43 (1.57) 
40 
-0.15 (-1.00, 0.70) 0.73 0.03 (-0.83, 0.84) 1.00 -0.15 (-1.01, 0.70) 0.73 
Itch 
 
2.15 (2.04), 
41 
1.95 (1.76), 
37 
1.65 (1.46), 
40 
0.16 (-0.83, 1.15) 0.75 0.44 (-0.54, 1.42) 0.38 -0.28 (-1.28, 0.71) 0.58 
Colour 
 
5.56 (3.16), 
41 
4.70 (3.11), 
37 
5.00 (2.92), 
40 
0.99 (-0.19, 2.16) 0.10 0.67 (-0.49, 1.84) 0.26 0.31 (-0.87, 1.50) 0.61 
Stiffness 
 
4.46 (2.83), 
41 
3.86 (2.83), 
37 
4.13 (2.50), 
40 
0.90 (-0.28, 2.07) 0.13 0.34 (-0.81, 1.50) 0.56 0.55 (-0.63, 1.73) 0.36 
Thickness 
 
4.80 (2.84), 
41 
4.08 (2.75), 
37 
4.80 (2.94), 
40 
0.89 (-0.33, 2.10) 0.15 -0.05 (-1.25, 1.15) 0.93 0.94 (-0.28, 2.16) 0.13 
Irregular 
 
4.90 (2.83), 
41 
4.38 (2.80), 
37 
4.75 (3.30), 
40 
0.69 (-0.53, 1.92) 0.27 0.17 (-1.03, 1.38) 0.78 0.52 (-0.71, 1.75) 0.41 
Overall opinion 
 
5.29 (2.83), 
41 
4.83 (2.95), 
36 
4.90 (2.75), 
40 
0.56 (-0.56, 1.67) 0.33 0.40 (-0.69, 1.49) 0.47 0.15 (-0.96, 1.27) 0.79 
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a Patient and Observer Scar Assessment Scale (POSAS) 
b Combined = topical silicone gel + pressure garment therapy 
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14.2 Observer report 
 Topical 
silicone gel 
Pressure 
garment therapy 
Combinedb Topical silicone gel vs 
pressure garment therapy 
Topical silicone gel vs 
combined 
Combined vs pressure 
garment therapy 
a Mean (SD), 
n 
Mean (SD), 
n 
Mean (SD), 
n 
Mean difference (CI) p Mean difference (CI) p Mean difference (CI) p 
Baseline 
 
         
Vascularity 4.97 (1.25), 
60 
4.89 (1.65), 
53 
4.55 (1.70), 
62 
- - - - - - 
Pigmentation 1.75 (1.08), 
60 
1.58 (0.86), 
53 
2.19 (1.86), 
62 
- - - - - - 
Thickness 1.93 (1.21), 
60 
1.77 (0.80), 
53 
1.79 (0.85), 
62 
- - - - - - 
Relief 2.78 (1.09), 
60 
2.85 (1.01), 
53 
3.00 (1.10), 
62 
- - - - - - 
Pliability 2.38 (1.49), 
60 
2.45 (1.03), 
53 
2.35 (0.98), 
62 
- - - - - - 
Overall opinion 
 
4.17 (1.12), 
60 
4.15 (1.18), 
53 
4.02 (1.17), 
62 
- - - - - - 
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Three months 
 
Vascularity 4.15 (1.74), 
55 
3.78 (1.58), 
50 
3.69 (1.96), 
48 
0.33 (-0.28, 0.94) 0.29 0.54 (-0.08, 1.15) 0.09 -0.21 (-0.84, 0.41) 0.51 
Pigmentation 1.96 (1.47), 
55 
2.04 (1.28), 
50 
2.58 (2.01), 
48 
-0.10 (-0.65, 0.44) 0.71 -0.54 (-1.09, 0.00) 0.05 0.44 (-0.12, 0.99) 0.12 
Thickness 2.71 (1.50), 
55 
2.16 (1.46), 
50 
2.29 (1.46), 
48 
0.51 (-0.03, 1.06) 0.07 0.50 (-0.05, 1.05) 0.07 0.01 (-0.54, 0.57) 0.96 
Relief 2.09 (0.87), 
55 
2.08 (0.90), 
50 
2.02 (0.86), 
48 
0.01 (-0.37, 0.39) 0.96 0.07 (-0.32, 0.45) 0.73 -0.06 (-0.45, 0.34) 0.78 
Pliability 2.75 (1.66), 
55 
2.52 (1.34), 
50 
2.50 (1.47), 
48 
0.21 (-0.36, 0.79) 0.47 0.34 (-0.24, 0.92) 0.26 -0.12 (-0.71, 0.47) 0.68 
Overall opinion 
 
3.89 (1.41), 
55 
3.58 (1.46), 
50 
3.71 (1.50), 
48 
0.26 (-0.27, 0.80) 0.34 0.29 (-0.25, 0.82) 0.30 -0.02 (-0.57, 0.52) 0.93 
Six months 
 
         
Vascularity 3.00 (1.53), 
52 
2.60 (1.35), 
43 
2.75 (1.56), 
48 
0.33 (-0.31, 0.96) 0.32 0.33 (-0.29, 0.95) 0.30 -0.01 (-0.65, 0.64) 0.99 
Pigmentation 2.06 (1.06), 
52 
1.98 (1.08), 
43 
2.23 (1.31), 
48 
0.14 (-0.42, 0.70) 0.62 -0.13 (-0.68, 0.42) 0.65 0.27 (-0.30, 0.84) 0.36 
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Thickness 2.33 (1.56), 
52 
2.26 (1.42), 
43 
2.69 (2.40), 
48 
0.12 (-0.44, 0.69) 0.67 -0.27 (-0.83, 0.28) 0.34 0.39 (-0.18, 0.97) 0.18 
Relief 1.98 (0.85), 
52 
2.02 (0.86), 
43 
2.23 (1.26), 
48 
-0.01 (-0.40, 0.39) 0.98 -0.23 (-0.62, 0.16) 0.25 0.22 (-0.18, 0.63) 0.28 
Pliability 2.44 (1.64), 
52 
2.60 (1.50), 
43 
2.75 (2.34), 
48 
-0.08 (-0.68, 0.52) 0.79 -0.24 (-0.83, 0.34) 0.42 0.16 (-0.44, 0.77) 0.60 
Overall opinion 3.10 (1.49), 
52 
2.84 (1.34), 
43 
3.33 (1.91), 
48 
0.30 (-0.25, 0.86) 0.28 -0.18 (-0.72, 0.37) 0.52 0.48 (-0.08, 1.04) 0.09 
 
a Patient and Observer Scar Assessment Scale (POSAS) 
b Combined = topical silicone gel + pressure garment therapy 
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14.3 Scar colour 
 
 Topical 
silicone gel 
Pressure garment 
therapy 
Combinedb Topical silicone gel vs 
pressure garment therapy 
Topical silicone gel vs 
combined 
Combined vs pressure 
garment therapy 
c Mean (SD), 
n 
Mean (SD), 
n 
Mean (SD), 
n 
Mean difference (CI) p Mean difference (CI) p Mean difference (CI) p 
Baseline          
  Erythema a* 34.83 (6.64), 
58 
33.23 (8.97), 
52 
31.42 (8.69), 
61 
- - - - - - 
  Pigmentation L* 
 
-15.40 (10.22), 
51 
-15.90 (8.74), 
47 
-12.84 (12.73), 
58 
- - - - - - 
Three months          
  Erythema a* 29.70 (6.72), 
57 
29.14 (5.73), 
50 
28.05 (8.21), 
49 
0.74 (-2.02, 3.49) 0.60 1.30 (-1.44, 4.05) 0.35 -0.57 (-3.38, 2.24) 0.69 
  Pigmentation L* 
 
-12.84 (10.31), 
53 
-12.41 (8.36), 
48 
-9.56 (8.34), 
44 
-0.52 (-4.36, 3.32) 0.79 -2.83 (-6.72, 1.06) 0.15 2.31 (-1.65, 6.26) 0.25 
Six months          
  Erythema a* 25.70 (4.48), 
52 
26.42 (5.33), 
42 
26.16 (8.06), 
48 
-0.56 (-3.42, 2.31) 0.70 -0.62 (-3.43, 2.18) 0.66 0.06 (-2.84, 2.97) 0.97 
  Pigmentation L* 
 
-8.00 (10.70), 
49 
-8.52 (9.51), 
41 
-7.87 (8.14), 
45 
0.51 (-3.50, 4.52) 0.80 0.87 (-3.08, 4.82) 0.67 -0.36 (-4.44, 3.72) 0.86 
 
b Combined = topical silicone gel + pressure garment therapy 
c DSMII ColorMeter® (Cortex Technology, Hadsund, Denmark) 
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Appendix 15: Mixed effects regression analyses for generic health-related quality of life 
 
 Topical 
silicone gel 
Pressure 
garment therapy 
Combinedb Topical silicone gel vs 
pressure garment therapy 
Topical silicone gel vs 
combined 
Combined vs pressure 
garment therapy 
a Mean (SD), 
n 
Mean (SD), 
n 
Mean (SD), 
n 
Mean difference (CI) p Mean difference (CI) p Mean difference (CI) p 
Baseline          
Caregiver report less than 
5 years of age 
0.78 (0.17), 
28 
0.82 (0.17), 
22 
0.82 (0.20), 
27 
- - - - - - 
Caregiver report greater 
than 5 years of age 
0.80 (0.18), 
21 
0.78 (0.19), 
27 
0.81 (0.22), 
24 
- - - - - - 
Child self-report from 5 
years of age 
0.80 (0.22), 
19 
0.79 (0.16), 
26 
0.80 (0.19), 
23 
- - - - - - 
Three months          
Caregiver report less than 
5 years of age 
0.89 (0.12), 
27 
0.90 (0.09), 
20 
0.89 (0.14), 
23 
-0.01 (-0.09, 0.08) 0.89 -0.00 (-0.08, 0.08) 0.98 -0.00 (-0.09, 0.08) 0.91 
Caregiver report greater 
than 5 years of age 
0.93 (0.09), 
18 
0.92 (0.12), 
23 
0.92 (0.10), 
16 
-0.00 (-0.09, 0.09) 0.10 -0.01 (-0.11, 0.09) 0.84 0.01 (-0.08, 0.10) 0.83 
Child self-report from 5 
years of age 
0.91 (0.12), 
19 
0.88 (0.14), 
26 
0.92 (0.10), 
18 
0.02 (-0.06, 0.11) 0.56 -0.03 (-0.12, 0.06) 0.49 0.06 (-0.03, 0.14) 0.18 
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Six months          
Caregiver report less than 
5 years of age 
0.92 (0.15), 
25 
0.91 (0.12), 
16 
0.93 (0.10), 
21 
0.01 (-0.08, 0.10) 0.86 -0.01 (-0.09, 0.08) 0.86 0.02 (-0.08, 0.11) 0.74 
Caregiver report greater 
than 5 years of age 
0.96 (0.06), 
0.06 
0.94 (0.08), 
21 
0.96 (0.07), 
18 
0.02 (-0.08, 0.11) 0.74 0.00 (-0.10, 0.10) 0.99 0.02 (-0.07, 0.10) 0.74 
Child self-report from 5 
years of age 
0.91 (0.13), 
16 
0.93 (0.07), 
18 
0.92 (0.11), 
18 
-0.03 (-0.12, 0.06) 0.51 -0.01 (-0.11, 0.08) 0.78 -0.02 (-0.11, 0.07) 0.69 
 
a Child Health Utility-9D (CHU-9D) 
b Combined = topical silicone gel + pressure garment therapy 
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Appendix 16: Mixed effects regression analyses for burn specific health-related quality of life 
16.1 Burn-specific health-related quality of life: caregivers of children < 8 years 
 
 
 
Topical 
silicone gel 
Pressure garment 
therapy 
Combinedb Topical silicone gel vs 
pressure garment therapy 
Topical silicone gel vs 
combined 
Combined vs pressure 
garment therapy 
a Mean (SD), 
n 
Mean (SD), 
n 
Mean (SD), 
n 
Mean difference (CI) p Mean difference (CI) p Mean difference (CI) p 
Baseline          
Overall impact of burn 
scar 
 
2.43 (0.83), 
36 
2.02 (0.53), 
23 
2.16 (0.89), 
32 
- - - - - - 
Sensory frequency 
 
2.17 (0.82), 
36 
1.86 (0.73), 
23 
1.92 (0.94), 
32 
- - - - - - 
Sensory sensitivityc 
 
1.86 (2.37), 
36 
2.22 (2.65), 
23 
2.31 (2.51), 
32 
- - - - - - 
Mobility 
 
1.67 (0.99), 
36 
1.68 (1.19), 
23 
1.63 (1.15), 
32 
- - - - - - 
Daily living 
 
1.96 (0.85), 
36 
1.92 (0.77), 
23 
1.98 (1.02), 
32 
- - - - - - 
Friendships and social 
interactions 
1.65 (0.92), 
33 
1.42 (0.85), 
23 
1.68 (1.08), 
31 
- - - - - - 
Appearance 
 
2.25 (1.29), 
35 
1.83 (0.89), 
23 
1.88 (1.19), 
32 
- - - - - - 
Emotional reactions 
 
1.52 (0.65), 
36 
1.37 (0.53), 
23 
1.39 (0.71), 
31 
- - - - - - 
Physical symptoms 2.00 (0.65), 2.02 (0.60), 1.88 (0.57), - - - - - - 
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 36 23 32 
Parent worry 
 
1.83 (0.95), 
36 
1.55 (0.53), 
23 
1.77 (0.89), 
32 
- - - - - - 
Parent impact 
 
2.04 (1.09), 
36 
1.79 (0.92), 
23 
1.78 (0.99), 
32 
- - - - - - 
Impact on daily routined 
 
2.18 (1.29), 
33 
1.67 (0.91), 
21 
1.87 (1.20), 
30 
- - - - - - 
Impact on developing new 
skills or independence? e 
 
1.79 (1.23), 
34 
1.65 (1.11), 
23 
1.71 (1.13), 
31 
- - - - - - 
Child bothered by 
appearance of their scarf 
 
1.74 (1.07), 
35 
1.30 (0.76), 
23 
1.55 (1.06), 
31 
- - - - - - 
Three months 
 
         
Overall impact of burn 
scar 
1.46 (0.44), 
33 
1.47 (0.59), 
22 
1.44 (0.52), 
26 
-0.03 (-0.37, 0.31) 0.86 0.01 (-0.31, 0.33) 0.96 -0.04 (-0.39, 0.32) 0.83 
Sensory frequency 
 
1.71 (0.89), 
33 
1.56 (0.96), 
22 
1.42 (0.79), 
26 
0.14 (-0.29, 0.57) 0.52 0.28 (-0.12, 0.68) 0.17 -0.14 (-0.59, 0.30) 0.53 
Sensory sensitivityc 
 
1.55 (2.48), 
33 
1.27 (2.16), 
22 
2.00 (2.59), 
26 
0.24 (-1.04, 1.51) 0.71 -0.62 (-1.82, 0.58) 0.31 0.86 (-0.47, 2.19) 0.21 
Mobility 
 
1.06 (0.22), 
33 
1.00 (0.00), 
22 
1.27 (0.82), 
26 
0.05 (-0.34, 0.45) 0.79 -0.25 (-0.63, 0.13) 0.19 0.30 (-0.11, 0.72) 0.15 
Daily living 
 
1.06 (0.12), 
33 
1.21 (0.40), 
22 
1.37 (0.70), 
26 
-0.17 (-0.51, 0.17) 0.32 -0.36 (-0.68, -0.04) 0.03 0.19 (-0.16, 0.54) 0.29 
Friendships and social 
interactions 
1.12 (0.42), 
33 
1.06 (0.17), 
22 
1.09 (0.24), 
26 
0.06 (-0.28, 0.40) 0.74 0.02 (-0.30, 0.34) 0.90 0.04 (-0.32, 0.40) 0.83 
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Appearance 
 
1.57 (0.81), 
33 
1.35 (0.61), 
22 
1.44 (0.67), 
26 
0.11 (-0.40, 0.63) 0.67 0.07 (-0.41, 0.56) 0.77 0.04 (-0.49, 0.57) 0.88 
Emotional reactions 
 
1.12 (0.24), 
33 
1.12 (0.38), 
22 
1.18 (0.28), 
25 
-0.02 (-0.27, 0.24) 0.90 -0.04 (-0.28, 0.20) 0.73 0.03 (-0.24, 0.29) 0.85 
Physical symptoms 
 
1.85 (0.53), 
33 
1.73 (0.69), 
22 
1.84 (0.63), 
26 
0.12 (-0.20, 0.44) 0.46 0.05 (-0.25, 0.35) 0.74 0.07 (-0.26, 0.40) 0.69 
Parent worry 
 
1.53 (0.79), 
33 
1.38 (0.56), 
22 
1.41 (0.45), 
26 
0.10 (-0.28, 0.48) 0.60 0.12 (-0.23, 0.48) 0.50 -0.02 (-0.41, 0.37) 0.92 
Parent impact 
 
1.11 (0.28), 
33 
1.11 (0.27), 
22 
1.25 (0.47), 
26 
-0.03 (-0.41, 0.35) 0.87 -0.14 (-0.50, 0.22) 0.43 0.11 (-0.29, 0.51) 0.58 
Impact on daily routined 
 
1.06 (0.25), 
32 
1.05 (0.21), 
22 
1.15 (0.37), 
26 
-0.00 (-0.41, 0.41) 1.00 -0.10 (-0.49, 0.29) 0.61 0.10 (-0.33, 0.53) 0.65 
Impact on developing new 
skills or independence? e 
 
1.06 (0.25), 
31 
1.00 (0.00), 
22 
1.15 (0.46), 
26 
0.07 (-0.36, 0.50) 0.75 -0.12 (-0.52, 0.29) 0.58 0.19 (-0.26, 0.63) 0.41 
Child bothered by 
appearance of their scarf 
 
1.16 (0.45), 
32 
1.05 (0.21), 
22 
1.15 (0.46), 
26 
0.10 (-0.29, 0.49) 0.62 -0.02 (-0.39, 0.34) 0.90 0.12 (-0.28, 0.53) 0.56 
Six months          
Overall impact of burn 
scar 
1.30 (0.52), 
29 
1.44 (0.48), 
19 
1.45 (0.54), 
25 
-0.15 (-0.50, 0.21) 0.42 -0.14 (-0.47, 0.18) 0.39 -0.00 (-0.37, 0.37) 1.00 
Sensory frequency 
 
1.39 (0.72), 
29 
1.30 (0.53), 
19 
1.40 (0.78), 
25 
0.06 (-0.39, 0.50) 0.81 0.01 (-0.41, 0.42) 0.97 0.05 (-0.41, 0.51) 0.84 
Sensory sensitivityc 
 
1.38 (2.35), 
29 
0.84 (1.61), 
19 
1.56 (2.62), 
25 
0.41 (-0.93, 1.75) 0.55 -0.25 (-1.49, 0.99) 0.69 0.66 (-0.71, 2.04) 0.35 
Mobility 
 
1.03 (0.09), 
29 
1.05 (0.23), 
19 
1.08 (0.20), 
25 
-0.02 (-0.45, 0.40) 0.91 -0.04 (-0.43, 0.35) 0.84 0.02 (-0.42, 0.45) 0.94 
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a Brisbane Burn Scar Impact Profile (BBSIP): total score for item groups were examined except where indicated 
b Combined = topical silicone gel + pressure garment therapy 
c Individual item: sensory sensitivity 
Daily living 
 
1.07 (0.19), 
29 
1.10 (0.20), 
19 
1.10 (0.26), 
25 
-0.08 (-0.43, 0.28) 0.67 -0.04 (-0.37, 0.29) 0.83 -0.04 (-0.41, 0.32) 0.83 
Friendships and social 
interactions 
1.08 (0.30), 
29 
1.16 (0.41), 
19 
1.03 (0.13), 
25 
-0.08 (-0.45, 0.28) 0.65 0.04 (-0.30, 0.38) 0.81 -0.12 (-0.50, 0.25) 0.51 
Appearance 
 
1.45 (0.94), 
29 
1.74 (1.09), 
19 
1.40 (0.70), 
25 
-0.29 (-0.83, 0.24) 0.28 0.051 (-0.44, 0.55) 0.84 -0.34 (-0.89, 0.21) 0.22 
Emotional reactions 
 
1.15 (0.42), 
29 
1.03 (0.08), 
19 
1.14 (0.30), 
25 
0.06 (-0.20, 0.33) 0.63 -0.01 (-0.25, 0.24) 0.96 0.07 (-0.20, 0.35) 0.61 
Physical symptoms 
 
1.73 (0.57), 
29 
1.72 (0.62), 
19 
1.83 (0.67), 
25 
0.09 (-0.24, 0.42) 0.60 -0.08 (-0.39, 0.23) 0.61 0.17 (-0.17, 0.51) 0.34 
Parent worry 
 
1.47 (0.80), 
29 
1.44 (0.58), 
19 
1.37 (0.49), 
25 
-0.01 (-0.40, 0.38) 0.96 0.08 (-0.28, 0.44) 0.67 -0.09 (-0.49, 0.31) 0.67 
Parent impact 
 
1.17 (0.52), 
29 
1.02 (0.06), 
19 
1.18 (0.42), 
25 
0.10 (-0.30, 0.50) 0.63 -0.00 (-0.37, 0.37) 1.00 0.10 (-0.31, 0.51) 0.64 
Impact on daily routined 
 
1.10 (0.31), 
29 
1.12 (0.33), 
17 
1.16 (0.37), 
25 
-0.01 (-0.45, 0.43) 0.98 -0.05 (-0.45, 0.35) 0.79 0.05 (-0.41, 0.50) 0.84 
Impact on developing new 
skills or independence? e 
 
1.17 (0.54), 
29 
1.26 (0.81), 
19 
1.08 (0.28), 
25 
-0.10 (-0.55, 0.35) 0.66 0.10 (-0.31, 0.52) 0.63 -0.20 (-0.66, 0.26) 0.39 
Child bothered by 
appearance of their scarf 
 
1.29 (0.81), 
28 
1.21 (0.54), 
19 
1.08 (0.28), 
24 
0.08 (-0.33, 0.49) 0.70 0.18 (-0.21, 0.56) 0.37 -0.10 (-0.52, 0.33) 0.66 
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d Individual item: your child’s daily routine 
e Individual item: developing new skills or becoming more independent 
f Individual item: how bothered has your child been by the appearance of their scars?
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16.2 Burn-specific health-related quality of life: caregivers of children > 8 years 
 
 Topical silicone 
gel 
Pressure garment 
therapy 
Combinedb Topical silicone gel vs 
pressure garment therapy 
Topical silicone gel vs 
combined 
Combined vs pressure 
garment therapy 
a Mean (SD), 
n 
Mean (SD), 
n 
Mean (SD), 
n 
Mean difference 
(CI) 
p Mean difference 
(CI) 
p Mean difference 
(CI) 
p 
Baseline          
Overall impact of burn scar 2.00 (0.61), 
14 
2.34 (0.82), 
26 
2.15 (0.94), 
20 
- - - - - - 
Sensory frequency 
 
2.26 (0.85), 
14 
2.27 (0.84), 
26 
2.43 (1.18), 
20 
- - - - - - 
Sensory sensitivityc 
 
1.86 (1.92), 
14 
2.92 (2.54), 
26 
2.67 (2.93), 
18 
- - - - - - 
Mobility  
 
1.55 (1.11), 
14 
1.66 (0.63), 
26 
1.38 (0.70), 
20 
- - - - - - 
Daily living 
 
1.83 (0.86), 
14 
1.87 (0.69), 
26 
1.85 (0.88), 
20 
- - - - - - 
Friendships and social 
interactions 
1.84 (0.82), 
14 
1.59 (0.74), 
26 
1.44 (0.72), 
20 
- - - - - - 
Appearance 
 
1.78 (0.71), 
13 
1.77 (0.97), 
26 
1.68 (1.11), 
20 
- - - - - - 
Emotional reactions 
 
1.65 (1.04), 
14 
1.55 (0.85), 
26 
1.52 (0.58), 
20 
- - - - - - 
Physical symptoms 2.00 (0.49), 
14 
1.95 (0.58), 
26 
2.06 (0.68), 
20 
- - - - - - 
Parent worry 1.62 (0.54), 1.77 (0.70), 1.62 (0.54), - - - - - - 
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14 26 20 
Parent impact 1.87 (1.37), 
14 
1.81 (0.97), 
26 
1.57 (0.61), 
20 
- - - - - - 
Bothered by appearance of 
child’s scar?d 
 
1.93 (1.14), 
14 
1.88 (0.77), 
26 
1.65 (1.04), 
20 
- - - - - - 
Three months          
Overall impact of burn scar 1.52 (0.48), 
12 
1.51 (0.45), 
21 
1.33 (0.27), 
14 
0.03 (-0.38, 0.45) 0.87 0.27 (-0.17, 0.72) 0.23 -0.24 (-0.63, 0.15) 0.23 
Sensory frequency 1.58 (0.53), 
12 
 
1.52 (0.63), 
21 
 
1.44 (0.55), 
13 
 
0.05 (-0.47, 0.58) 0.84 0.09 (-0.49, 0.66) 0.77 -0.03 (-0.54, 0.47) 0.90 
Sensory sensitivityc 
 
1.67 (2.31), 
12 
1.62 (2.71), 
21 
1.57 (1.74), 
14 
-0.05 (-1.56, 1.47) 0.95 0.15 (-1.48, 1.80) 0.85 -0.20 (-1.64, 1.23) 0.78 
Mobility 1.06 (0.16), 
12 
1.04 (0.12), 
21 
1.06 (0.15), 
13 
0.05 (-0.31, 0.42) 0.78 0.01 (-0.39, 0.41) 0.97 0.05 (-0.31, 0.40) 0.80 
Daily living 1.15 (0.33), 
12 
1.09 (0.12), 
21 
1.06 (0.11), 
14 
0.06 (-0.31, 0.43) 0.74 0.10 (-0.30, 0.49) 0.64 -0.03 (-0.38, 0.31) 0.85 
Friendships and social 
interactions 
 
1.19 (0.34), 
12 
1.18 (0.43), 
21 
1.06 (0.21), 
13 
0.01 (-0.36, 0.38) 0.96 0.11 (-0.29, 0.51) 0.59 -0.10 (-0.45, 0.26) 0.58 
Appearance 
 
1.25 (0.37), 
11 
1.43 (0.90), 
21 
1.31 (0.59), 
13 
-0.14 (-0.67, 0.40) 0.62 0.02 (-0.57, 0.60) 0.96 -0.15 (-0.66, 0.35) 0.55 
Emotional reactions 1.26 (0.38), 
12 
1.17 (0.30), 
21 
1.09 (0.17), 
13 
0.08 (-0.31, 0.47) 0.70 0.17 (-0.25, 0.60) 0.43 -0.09 (-0.47, 0.28) 0.62 
Physical symptoms 1.98 (0.51), 
12 
1.75 (0.51), 
21 
1.95 (0.58), 
13 
0.26 (-0.12, 0.64) 0.18 0.09 (-0.32, 0.50) 0.66 0.17 (-0.20, 0.53) 0.37 
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Parent worry 1.25 (0.32), 
12 
1.35 (0.34), 
21 
1.21 (0.25), 
14 
-0.11 (-0.44, 0.22) 0.52 0.05 (-0.31, 0.41) 0.78 -0.16 (-0.47, 0.15) 0.32 
Parent impact 1.05 (0.12), 
12 
1.11 (0.24), 
21 
1.04 (0.12), 
14 
0.02 (-0.43, 0.46) 0.94 0.04 (-0.45, 0.52) 0.89 -0.02 (-0.44, 0.40) 0.93 
Bothered by appearance of 
child’s scar?d 
1.17 (0.39), 
12 
1.62 (0.67), 
21 
1.43 (0.51), 
14 
-0.32 (-0.83, 0.20) 0.23 -0.07 (-0.63, 0.48) 0.80 -0.24 (-0.73, 0.24) 0.33 
 
Six months 
         
Overall impact of burn scar 1.23 (0.31), 
12 
1.37 (0.39), 
18 
1.21 (0.30), 
14 
-0.10 (-0.52, 0.32) 0.64 0.04 (-0.41, 0.49) 0.87 -0.14 (-0.54, 0.26) 0.50 
Sensory frequency 
 
1.53 (0.89), 
12 
1.30 (0.36), 
18 
1.17 (0.39), 
14 
0.16 (-0.38, 0.70) 0.56 0.24 (-0.33, 0.81) 0.41 -0.08 (-0.60, 0.43) 0.76 
Sensory sensitivityc 
 
1.17 (1.27), 
12 
0.94 (2.10), 
18 
0.50 (0.76), 
14 
0.20 (-1.36, 1.76) 0.80 0.42 (-1.23, 2.07) 0.62 -0.22 (-1.70, 1.26) 0.77 
Mobility  1.08 (0.29), 
12 
1.02 (0.06), 
16 
1.00 (0.00), 
14 
0.05 (-0.33, 0.43) 0.80 0.02 (-0.38, 0.42) 0.93 0.03 (-0.33, 0.40) 0.87 
Daily living 1.05 (0.14), 
12 
1.11 (0.24), 
18 
1.02 (0.05), 
14 
-0.06 (-0.44, 0.32) 0.77 0.02 (-0.38, 0.42) 0.92 -0.08 (-0.44, 0.28) 0.67 
Friendships and social 
interactions 
 
1.02 (0.07), 
12 
1.14 (0.27), 
16 
1.02 (0.07), 
14 
-0.04 (-0.43, 0.35) 0.84 -0.04 (-0.44, 0.37) 0.87 -0.01 (-0.37, 0.36) 0.98 
Appearance 
 
1.00 (0.00), 
12 
1.22 (0.45), 
18 
1.14 (0.36), 
14 
-0.19 (-0.73, 0.34) 0.48 -0.14 (-0.71, 0.42) 0.62 -0.05 (-0.56, 0.46) 0.84 
Emotional reactions 1.02 (0.06), 
12 
1.14 (0.32), 
18 
1.02 (0.06), 
14 
-0.14 (-0.54, 0.26) 0.50 -0.03 (-0.46, 0.39) 0.88 -0.10 (-0.48, 0.28) 0.60 
Physical symptoms 1.75 (0.66), 
12 
1.60 (0.39), 
18 
1.73 (0.60), 
14 
0.11 (-0.27, 0.50) 0.57 0.04 (-0.37, 0.45) 0.84 0.07 (-0.30, 0.44) 0.71 
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Parent worry 1.17 (0.30), 
12 
1.37 (0.50), 
18 
1.19 (0.31), 
14 
-0.18 (-0.52, 0.16) 0.31 0.01 (-0.36, 0.37) 0.97 -0.19 (-0.51, 0.14) 0.26 
Parent impact 1.05 (0.17), 
12 
1.00 (0.00), 
18 
1.01 (0.05), 
14 
0.09 (-0.37, 0.55) 0.70 0.04 (-0.44, 0.53) 0.86 0.05 (-0.39, 0.48) 0.83 
Bothered by appearance of 
child’s scar?d 
1.42 (0.67), 
12 
1.28 (0.57), 
18 
1.21 (0.43), 
14 
0.24 (-0.28, 0.77) 0.37 0.35 (-0.21, 0.90) 0.22 -0.11 (-0.61, 0.39) 0.67 
 
a Brisbane Burn Scar Impact Profile (BBSIP): total score for item groups were examined except where indicated 
b Combined = topical silicone gel + pressure garment therapy 
c Individual item: sensory sensitivity 
d Individual item: how bothered have you been by the appearance of your child’s scars 
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16.3 Burn-specific health-related quality of life: child self-report 8 to 18 years 
 Topical 
silicone gel 
Pressure 
garment therapy 
Combinedb Topical silicone gel vs 
pressure garment therapy 
Topical silicone gel vs 
combined 
Combined vs pressure 
garment therapy 
a Mean (SD), 
n 
Mean (SD), 
n 
Mean (SD), 
n 
Mean difference (CI) p Mean difference (CI) p Mean difference (CI) p 
Baseline          
Overall impact of burn 
scar 
 
1.90 (0.91), 
12 
2.02 (0.84), 
25 
1.95 (0.92), 
19 
- - - - - - 
Sensory frequency 
 
2.19 (1.13), 
12 
2.29 (0.87), 
25 
2.14 (0.72), 
19 
- - - - - - 
Sensory sensitivity 
 
2.08 (2.21), 
12 
2.00 (1.74), 
25 
2.49 (1.74), 
19 
- - - - - - 
Sensory impact 
 
1.47 (0.51), 
12 
1.61 (0.61), 
25 
1.43 (0.57), 
19 
- - - - - - 
Mobility 1.58 (0.98), 
12 
1.55 (0.78), 
25 
1.51 (0.98), 
19 
- - - - - - 
Daily living 
 
1.65 (0.73), 
12 
1.88 (0.76), 
25 
1.77 (0.67), 
19 
- - - - - - 
Friendships and social 
interactions 
2.17 (1.05), 
12 
1.77 (1.06), 
25 
1.74 (0.78), 
19 
- - - - - - 
Appearance 
 
1.65 (0.85), 
12 
1.79 (0.94), 
25 
1.64 (0.82), 
19 
- - - - - - 
Emotional reactions 1.46 (0.49), 
12 
1.44 (0.77), 
25 
1.31 (0.51), 
19 
- - - - - - 
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Physical symptoms 2.02 (0.59), 
12 
1.82 (0.51), 
25 
2.06 (0.58), 
19 
- - - - - - 
Three months          
Overall impact of burn 
scar 
1.22 (0.35), 
12 
1.44 (0.38), 
22 
1.10 (0.13), 
12 
-0.20 (-0.64, 0.24) 0.37 0.07 (-0.42, 0.55) 0.79 -0.27 (-0.69, 0.15) 0.21 
Sensory frequency 1.50 (0.48), 
12 
1.58 (0.66), 
22 
1.28 (0.49), 
12 
-0.05 (-0.53, 0.44) 0.86 0.19 (-0.36, 0.73) 0.50 -0.23 (-0.71, 0.24) 0.33 
Sensory sensitivity 
 
0.90 (1.20), 
12 
1.17 (1.32), 
22 
0.56 (0.95), 
12 
-0.23 (-1.28, 0.82) 0.67 0.20 (-0.96, 1.38) 0.73 -0.44 (-1.45, 0.57) 0.39 
Sensory impact 1.07 (0.16), 
12 
1.25 (0.38), 
22 
1.23 (0.63), 
12 
-0.16 (-0.48, 0.16) 0.32 -0.18 (-0.53, 0.17) 0.31 0.02 (-0.28, 0.32) 0.90 
Mobility 1.04 (0.14), 
12 
1.15 (0.31), 
22 
1.13 (0.31), 
12 
-0.10 (-0.52, 0.32) 0.64 -0.02 (-0.48, 0.45) 0.95 -0.09 (-0.49, 0.32) 0.68 
Daily living 1.08 (0.15), 
12 
1.20 (0.24), 
22 
1.12 (0.29), 
12 
-0.11 (-0.45, 0.24) 0.55 0.01 (-0.38, 0.39) 0.97 -0.11 (-0.45, 0.22) 0.51 
Friendships and social 
interactions 
1.72 (0.83), 
12 
1.49 (0.87), 
22 
1.64 (0.86), 
12 
0.18 (-0.45, 0.82) 0.57 0.06 (-0.65, 0.76) 0.88 0.13 (-0.48, 0.74) 0.68 
Appearance 1.33 (0.62), 
12 
1.40 (0.46), 
21 
1.15 (0.24), 
12 
-0.06 (-0.54, 0.42) 0.81 0.23 (-0.31, 0.77) 0.41 -0.29 (-0.76, 0.19) 0.24 
Emotional reactions 1.23 (0.38), 
12 
1.15 (0.26), 
22 
1.11 (0.21), 
12 
0.05 (-0.30, 0.40) 0.79 0.12 (-0.27, 0.50) 0.55 -0.07 (-0.40, 0.26) 0.69 
Physical symptoms 1.79 (0.54), 
12 
1.74 (0.44), 
22 
1.74 (0.48), 
12 
0.05 (-0.30, 0.40) 0.78 0.06 (-0.33, 0.45) 0.76 -0.01 (-0.35, 0.33) 0.95 
How much did 
treatments improve your 
scar 
4.09 (0.94), 
11 
3.32 (1.21), 
22 
4.64 (0.50), 
11 
0.77 (0.05, 1.49) 0.04 -0.54 (-1.38, 0.29) 0.20 1.32 (0.60, 2.04) 0.00 
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a Brisbane Burn Scar Impact Profile (BBSIP): total score for item groups were examined except where indicated 
b Combined = topical silicone gel + pressure garment therapy 
Six months 
Overall impact of burn 
scar 
1.27 (0.34), 
10 
1.18 (0.23), 
18 
1.05 (0.12), 
12 
0.07 (-0.39, 0.54) 0.76 0.14 (-0.36, 0.65) 0.58 -0.07 (-0.51, 0.37) 0.75 
Sensory frequency 1.39 (0.63), 
11 
1.35 (0.46), 
18 
1.20 (0.36), 
12 
-0.04 (-0.55, 0.47) 0.88 0.11 (-0.45, 0.67) 0.70 -0.15 (-0.64, 0.34) 0.55 
Sensory sensitivity  1.14 (1.59), 
11 
0.85 (1.26), 
18 
0.44 (0.82), 
12 
0.08 (-1.01, 1.17) 0.89 0.46 (-0.73, 1.65) 0.45 -0.38 (-1.42, 0.66) 0.47 
Sensory impact 1.09 (0.21), 
11 
1.09 (0.18), 
18 
1.13 (0.46), 
12 
-0.02 (-0.34, 0.31) 0.92 -0.08 (-0.44, 0.27) 0.64 0.07 (-0.24, 0.38) 0.67 
Mobility 1.02 (0.08), 
11 
1.07 (0.24), 
18 
1.06 (0.22), 
12 
-0.04 (-0.48, 0.39) 0.84 -0.03 (-0.51, 0.45) 0.90 -0.01 (-0.44, 0.41) 0.95 
Daily living 1.05 (0.10), 
11 
1.15 (0.23), 
18 
1.07 (0.18), 
12 
-0.09 (-0.45, 0.27) 0.63 -0.01 (-0.40, 0.39) 0.97 -0.08 (-0.43, 0.27) 0.65 
Friendships and social 
interactions 
1.79 (0.74), 
11 
1.98 (0.99), 
18 
1.83 (0.99), 
12 
-0.00 (-0.66, 0.66) 1.00 -0.06 (-0.78, 0.66) 0.87 0.06 (-0.57, 0.69) 0.86 
Appearance 1.41 (0.66), 
11 
1.31 (0.47), 
17 
1.21 (0.72), 
12 
0.14 (-0.37, 0.65) 0.58 0.20 (-0.36, 0.75) 0.49 -0.05 (-0.55, 0.44) 0.83 
Emotional reactions 1.26 (0.43), 
11 
1.28 (0.58), 
17 
1.06 (0.20), 
12 
-0.04 (-0.40, 0.32) 0.83 0.16 (-0.23, 0.55) 0.42 -0.20 (-0.54, 0.14) 0.25 
Physical symptoms 1.88 (0.57), 
11 
1.59 (0.57), 
18 
1.51 (0.32), 
12 
0.30 (-0.06, 0.67) 0.11 0.35 (-0.05, 0.75) 0.09 -0.05 (-0.40, 0.30) 0.79 
How much did 
treatments improve your 
scar 
4.43 (0.79), 
7 
4.31 (0.79), 
16 
3.70 (1.42), 
10 
0.12 (-0.76, 1.01) 0.79 0.73 (-0.23, 1.70) 0.14 -0.61 (-1.40, 0.18) 0.13 
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Appendix 17: Analysis of adverse effects 
17.1 Type and number of adverse effects 
 
 Topical silicone gel Pressure garment therapy Combined 
 n (%) n (%) n (%) 
Three months 48 45 42 
  Skin irritation 1 (2.0%) 3 (6.1%) 5 (9.4%) 
  Sensory symptoms 0 (0.0%) 1 (2.0%) 2 (3.8%) 
  Wound breakdown 3 (5.9%) 5 (10.2%) 1 (1.9%) 
  Swelling 0 (0.0%) 0 (0.0%) 2 (3.8%) 
  Bony changes 0 (0.0%) 0 (0.0%) 0 (0.0%) 
  Misplaced intervention 0 (0.0%) 1 (2.0%) 0 (0.0%) 
  Problems with intervention (e.g. ill fitting pressure garment, ran out of silicone) 1 (2.0%) 7 (14.3%) 7 (13.2%) 
Six months 43 37 39 
  Skin irritation 0 (0.0%) 5 (10.2%) 1 (1.9%) 
  Sensory symptoms 0 (0.0%) 1 (2.0%) 0 (0.0%) 
  Wound breakdown 0 (0.0%) 0 (0.0%) 0 (0.0%) 
  Swelling 0 (0.0%) 0 (0.0%) 0 (0.0%) 
  Bony changes 0 (0.0%) 0 (0.0%) 0 (0.0%) 
  Misplaced intervention 0 (0.0%) 0 (0.0%) 0 (0.0%) 
  Problems with intervention (e.g. ill fitting pressure garment, ran out of silicone) 2 (3.9%) 4 (8.2%) 3 (5.7%) 
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17.2 Mixed effects regression intention-to-treat analysis for adverse effects 
 
a Topical 
silicone gel 
Pressure 
garment therapy 
Combinedb Topical silicone gel vs 
pressure garment therapy 
Topical silicone gel vs 
combined 
Combined vs pressure 
garment therapy 
Total number of 
adverse effects 
n (%) n (%) n (%) Mean difference (CI) p Mean difference (CI) p Mean difference (CI) p 
Three months 48 45 42 -1.29 (-2.30, -0.28) 0.01 -1.36 (-2.37, -0.35) 0.01 0.07 (-0.62, 0.76) 0.84 
0 
1 
2 
44 (91.7%)  
  3 (6.2%) 
  1 (2.1%) 
29 (64.4%) 
15 (33.3%) 
  1 (2.2%) 
28 (66.7%) 
11 (26.2%)  
  3 (7.1%) 
      
Six months 43 37 39 -1.36 (-2.66, -0.06) 0.04 -0.40 (-1.90, 1.11) 0.61 -0.97 (-2.14, 0.20) 0.10 
0 
1 
2 
40 (93.0%)   
  3 (7.0%) 
  0 (0.0) 
28 (75.7%)  
  8 (21.6%) 
  1 (2.7%) 
35 (89.7%) 
  4 (10.3%) 
  0 (0.0%) 
      
 
a Poisson model 
b Combined = topical silicone gel + pressure garment therapy 
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17.3 Mixed effects regression per protocol analysis for adverse effects 
 
a Topical 
silicone gel 
Pressure garment 
therapy 
Combined† Topical silicone gel vs pressure 
garment therapy 
Topical silicone gel vs 
combined 
Combined vs pressure 
garment therapy 
Total number of 
adverse effects 
n (%) 
 
n (%) n (%) Mean difference (CI) p Mean difference (CI) p Mean difference (CI) p 
Three months 
 
48 45 40 -1.29 (-2.29, -0.28) 0.01 -1.35 (-2.36, -0.33) 0.01 0.06 (-0.64, 0.76) 0.87 
0 
1 
2 
 
44 (91.67) 
 3 (6.25) 
 1 (2.08) 
29 (64.44) 
15 (33.33) 
  1 (2.22) 
27 (67.50) 
10 (25.00) 
 3 (7.50) 
      
Six months 
 
42 34 32 -1.72 (-3.26, -0.18) 0.03 -0.97 (-2.68, 0.73) 0.26 -0.75 (-1.93, 0.44) 0.22 
0 
1 
2 
40 (95.24) 
 2 (4.76) 
 0 (0.00) 
26 (76.47) 
 7 (20.59) 
 1 (2.94) 
28 (87.50) 
 4 (12.50) 
 0 (0.00) 
      
 
a Poisson model 
b Combined = topical silicone gel + pressure garment therapy 
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Appendix 18: Mixed effects regression analyses for intervention fidelity 
 
 Topical 
silicone gel 
Pressure 
garment therapy 
Combinedb 
 
Topical silicone gel vs 
pressure garment therapy 
Topical silicone gel vs 
combined 
Combined vs pressure garment 
therapy 
a Mean (SD), 
n 
Mean (SD), 
n 
Mean (SD), 
n 
Mean difference (CI) p Mean difference (CI) p Mean difference (CI) p 
Baseline 
 
96.88 (10.24), 
44 
90.48 (21.95), 
36 
93.12 (14.41), 
44 
- - - - - - 
One week 
 
88.17 (27.68), 
32 
97.99 (4.48), 
45 
94.78 (13.91), 
43 
-9.65 (-20.04, 0.74) 0.07 -6.56 (-17.05, 3.93) 0.22 -3.09 (-12.67, 6.49) 0.53 
Three months 
 
76.30 (29.66), 
45 
79.22 (28.73), 
36 
70.22 (31.31), 
35 
-2.97 (-13.02, 7.08) 0.56 6.06 (-4.07, 16.19) 0.24 -9.03 (-19.69, 1.64) 0.10 
Six months 
 
79.17 (27.72), 
28 
76.51 (31.59), 
16 
67.34 (36.11), 
18 
3.01 (-11.07, 17.09) 0.68 12.09 (-1.48, 25.67) 0.08 -9.08 (-24.52, 6.36) 0.25 
 
a Paper-based intervention fidelity checklists 
b Combined = topical silicone gel + pressure garment therapy 
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Appendix 19: Mixed effects regression analyses for intervention burden at six months post-burn 
 
 Topical 
silicone gel 
Pressure 
garment therapy 
Combineda Topical silicone gel vs 
pressure garment therapy 
Topical silicone gel vs 
combined 
Combined vs pressure 
garment therapy 
 Mean (SD), 
n 
Mean (SD), 
n 
Mean (SD), 
n 
Mean difference (CI) p Mean difference (CI) p Mean difference (CI) p 
Caregivers of 
children < 8 yearsb 
1.30 (0.67), 
27 
1.83 (1.15), 
18 
1.54 (0.98), 
24 
-0.57 (-1.14, 0.00) 0.05 -0.18 (-0.71, 0.35) 0.51 -0.39 (-0.98, 0.20) 0.19 
Caregivers of 
children > 8 yearsb 
1.42 (0.67), 
12 
1.61 (1.04), 
18 
1.29 (0.61), 
14 
-0.18 (-0.72, 0.35) 0.50 0.13 (-0.44, 0.70) 0.66 -0.31 (-0.83, 0.20) 0.23 
Children 8-18 
yearsb 
1.43 (0.79), 
7 
1.81 (1.17), 
16 
1.30 (0.67), 
10 
-0.41 (-1.11, 0.28) 0.24 0.16 (-0.59, 0.91) 0.68 -0.57 (-1.19, 0.05) 0.07 
 
a Combined = topical silicone gel + pressure garment therapy  
b Single item on the Brisbane Burn Scar Impact Profile (BBSIP) 
307 
 
Appendix 20: Mixed effects regression analyses for interface pressure 
 Pressure garment therapy Combinedb Combined vs pressure garment therapy 
a Mean (SD), 
n 
Mean (SD), 
n 
Mean difference (CI) p 
Baseline 
 
    
Stationary interface pressure 
 
35.10 (32.49), 
44 
25.22 (23.04), 
42 
- - 
Dynamic interface pressure 
 
33.67 (31.15), 
44 
32.02 (26.45), 
41 
- - 
Three months 
 
    
Stationary interface pressure 
 
21.10 (28.66), 
36 
21.17 (29.95), 
19 
0.82 (-13.96, 15.59) 0.91 
Dynamic interface pressure 18.89 (15.68), 
36 
28.60 (31.56), 
18 
9.79 (-4.37, 23.95) 0.18 
Six months 
 
    
Stationary interface pressure 
 
29.97 (23.68), 
21 
21.70 (15.21), 
14 
-8.64 (-26.51, 9.24) 0.34 
Dynamic interface pressure 
 
28.50 (22.74), 
21 
32.55 (21.51), 
13 
6.00 (-11.05, 23.04) 0.49 
 
a Pliance X® (Novel Electronics, Munich, Germany) (mmHg) 
b Combined = topical silicone gel + pressure garment therapy 
